<SEC-DOCUMENT>0001628280-22-029906.txt : 20221114
<SEC-HEADER>0001628280-22-029906.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114171150
ACCESSION NUMBER:		0001628280-22-029906
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		221387544

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e0839ea3-e098-4f93-afa3-37d29c6655d1,g:ef7281af-56e2-4e26-9661-b3993287f2ab,d:9d8b5229cbe549cdb99425ffcfc909d0--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:cpix="http://www.cumberlandpharma.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGFibGU6N2VkOTMxZDJlOWRjNDQwMWFkODg1YjRlYjEzZTAzMmQvdGFibGVyYW5nZTo3ZWQ5MzFkMmU5ZGM0NDAxYWQ4ODViNGViMTNlMDMyZF81LTEtMS0xLTMxMjEz_9f06ffe2-3e9b-4e2c-baf5-4e15e3750758">2022</ix:nonNumeric><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGFibGU6N2VkOTMxZDJlOWRjNDQwMWFkODg1YjRlYjEzZTAzMmQvdGFibGVyYW5nZTo3ZWQ5MzFkMmU5ZGM0NDAxYWQ4ODViNGViMTNlMDMyZF82LTEtMS0xLTMxMjEz_c5040bd2-93d8-4032-8119-15e940b94a2b">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGFibGU6N2VkOTMxZDJlOWRjNDQwMWFkODg1YjRlYjEzZTAzMmQvdGFibGVyYW5nZTo3ZWQ5MzFkMmU5ZGM0NDAxYWQ4ODViNGViMTNlMDMyZF83LTEtMS0xLTMxMjEz_bfb2e8ad-b5b8-43d2-ba60-afe5e35e7aeb">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGV4dHJlZ2lvbjo3NTM1ZjY0NWY0MDQ0YmM2YjZkM2RiMjZiNzEzM2MzN183OA_c5c8ec39-3772-4644-baf3-748dce59d30f">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGV4dHJlZ2lvbjo3NTM1ZjY0NWY0MDQ0YmM2YjZkM2RiMjZiNzEzM2MzN183OQ_7d5f4636-7a87-495c-b4ba-d7694be2d487">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ecf59c7ee0f4ebf9430d47fc996630e_I20221107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i16ada3ab868247dd9574797af517d567_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if626e02bae5647008aa9c24841ba535a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c72ce76653b4c67a43289e60f381b45_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb4adb610e0487da3f871d1774882a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e37ca58de94c968783906ecbe91aed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i469879a126f645e6957c45bf0ffe9267_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8364ff2b3c64c9ba02d2282288d872c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816fdbe7cf00466da247a111463219bd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984b30ad550c466bb44529cda7dd3e4a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd66a8cd08ad466a871a154c19ab33e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f34225fa00b49d2886530446efba2bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bbe436ab9243bf9e8e1752ee7ba9c4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1d4b58df9742c4af8e0eb4e6838a85_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida381f36684e4a5eb6add6bc60925c59_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700befe6d648426db6fbc40ee5dcc1a0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedd290adc07485ca2c5f8e444d98b02_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af4ea0922c24564a827d627f319505b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0144f9dc224850955f0f39892c50b7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib91da5e323af4228a5d518ae9dfabe2b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218f7c05e38145d0a763437aa9f82a87_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i896ff8d34ff14381a728f65812de9237_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefeac04e34504adc9b365fe4ab275dda_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4385acb51a744d36a58b40ca8fc87ed8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb9253827ae4d4893eafb5d816d8f8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4e12a79e884084831efe27e493c0a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91dfb736e2c42719050801c83e8a3c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db23060227f4160ba28455c16b8b07f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3243bd8ec27a48e0af6fabfc07ac337c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35731f9de26c4c06af01f46bde90a9b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c80483524e94ce385b64322c7e6ebab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca7aed0a270443ab090d05d1305fb08_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic47373afe83f4d06b32efc31992a4bbf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6baec924b84624945c5bd58260a450_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ace87a0492248878926a8f03cd4a851_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04d0344712f4a1aafd6f9ba7a41df3c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2da3c3015846d4942e467930489296_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ad4d2d8d8444fbbd7d930a0a59e68c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49466fa28fb04d6cb5ce8a17a31d35a2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1457746c76430098d4ceb9d629e6dc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33219167c744508bf085d2ae2eba1dd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753dd913f191471e8a379e7fa42a7892_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib81209df23984304bd9299e97be9d76a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="idc8c19c661864883b36b04dc73597c1a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40fb787c5304021af13e3f348f7983b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d1ae337b8241eaa014de1e9b8f7c07_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e17b402c0f4e0288249a98d5c1ef67_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d6b3e6fa3b44c390043374bd0da6ab_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf9a2d719ce448809401f919889d8f43_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef2fd27ce9b4de6811b30262e109c4c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96dba68919a94185be0f2caa4d19fbd6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81107b4b859c48379106d400c932111b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie672054973a54d8b96a1429d7893b153_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c935e63cfe042c0b62e5ad1b3ffccc4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de578808568412b98f4258ca2a140d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5b9640c93e4f4787d4be2b043c3ae6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2423acefd847a9a84fc30460b5526a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aaf93c862d54ccb94779f62960f1d26_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3b5f2e4fb145d9951d563e234c5113_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0468ba36dc8c4f4e94efe1fce522a602_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378e8f356b7d41ea99ef9c631175c257_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebdfd0073023463d9f73789defb1bc95_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f0f1e915d743ea86de5bef24145fd2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef1b02b27044b4a842a41c51f0dda36_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a22798105d04ccf960042a44583bde5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb5fd089f1847c09d6b1565f351311b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc92d5aecc141899d9bbb33fece4352_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28345cf5e7864e4f88e1ad3783be1eb1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i393707a2f8e84e51aab9d9aa77ec97cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15d6ec26dd9148f19ebaf571b61a2b1b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i474d3830aff24d969ed6a7730701fff4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ea0bc96ecd4501a2dea5ae2bd2122b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ccd958b6a845348dde9c5a826d3f1d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2c178f155b4cd0a7df168033b61d35_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb4c673c94a4eebb2bb9cead80bf84a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87128d81de3b40f59ea5c6c5a4e7e490_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029c4ae96e134c18bb123cde8e3f3b46_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ff531cbef64ec99752b4a2832ce9b2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eba1c1c7837438686f9bbe8a1d81821_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65a4295cc5943d2bdca764eec17c7fc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica03638cc07848c3ad90c3dc523f5a6f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5029ffaf4ba44d2ebd77cf036dcb3394_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf738532e4694162b9ca0c676b7e2bfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i227ccd5f3c584c1f80be5a81980484aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a588281c96f412e8750a46d0cf78bff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f654c5250f1487a87a937cdbf000493_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie91cbfa298a24c6db40c5463641c9886_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i658044c887034a83bdb045b4fb42ca2b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie795a7e8b44749c2b64904584da6bf32_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ea0a5e1de9410b819fbb525f8f78e1_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewalterm"><xbrli:measure>cpix:renewalTerm</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i73e648d1756d4361ac4f73a357526bb6_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a5078dc2e454b1ba6c7f4e344e79a4b_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dfb60514b2a4bfba647a1772e5f8bad_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c5bbf3a46c412fbe0e400fa873a864_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f068611586b404c9e736da8397fb6d3_D20220401-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9a83dbeb504232888f1be955d3484a_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba3428fcf7b4d74a47c2ef785d2fa87_D20211227-20211227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-27</xbrli:startDate><xbrli:endDate>2021-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9a3f9de6fd74bcc977d7a494dfd0845_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26fc6a73ecc488bbe41fa9905a8441a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c80572bb63c43f3a1049c338dfc7e8e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia41636d373054e1b8b162bc68c25ba1c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d70987e1124eccabfc3d8e4dec7545_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie71841d6d5c24f758fab7ac85872aa45_I20220929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:NinthAmemdmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="q"><xbrli:measure>utr:Q</xbrli:measure></xbrli:unit><xbrli:context id="i357c94714cfb4fd08c6fffaa13a6c200_D20220401-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f82082fed14f898c9cf04f1b98af86_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39e421790ed488e946469a82c5d37a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SixthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88065d8df8544ba4bf056f4d71ec695a_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifedf271cc67e434abd3401e7acffd33c_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede01fe31ea346b4918f9f4d3d001891_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31108d31c0b44f30a2b52b23201aea12_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceae2fc3bfa449c5bb629a222d37c37f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866dc2144f804589a64b1eb2c037834c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a44e5571a0d436ca5db214ef0319e3e_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i319a720f5704435caf765b6497b99cd9_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5877b735a5424506a5da1c44d8a26339_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea269d83c37d448a868f5ac00213446b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9529ac6603c4a1f9da2fbbe9d90afe8_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767388330a25494b84c7b1f3f5e31ca9_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b15f1a6a0214d9db3c1f1b2e95e05e9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida016a3372fe4bd9999e6c19613c11af_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib33917577d8c413092ed9270c4c1e044_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba57519128a042e6bcc12053ad575901_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14fe005a15a14d999173b7903bf4a67e_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20273d5a5164f0589d2524268988a2a_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa76b73d21648f5a7205032b91c3205_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134a7c60cd4344ffbbd3642de16ac052_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16021fcc1ba042c6952a72b0e414e233_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe5febaa0764ac187ee7a439033f2cb_D20220103-20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7092e7f4631046c394046d8e01666761_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1475f8cb974dc2b812258f6b108a91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d73c406eebd400ab792cf31e23c80e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0213cec992ab4b93b597378f304014b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>cpix:installment</xbrli:measure></xbrli:unit><xbrli:context id="id09c93443a82400e9a283705c01948ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b3b7c2e16664c71bf1bf299d2abd068_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb344f54d56f4e8fa0bcc0e5e31b52e9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b37e261fb14120ab86fd7d766694c8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib806724dc82b467680c5d90135d516b1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98818e47614047d287fd5c789ac7559e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTcy_6de4c893-3bc6-4408-a42a-a90924f4ad92">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6NzlhM2M2NGM1NGZkNGZlOGJkNGMwZDcyYmY5OTdhOWIvdGFibGVyYW5nZTo3OWEzYzY0YzU0ZmQ0ZmU4YmQ0YzBkNzJiZjk5N2E5Yl8wLTAtMS0xLTMxMjEz_fe5203ec-16dd-41eb-9a08-2685c96fc560">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xMzA_a36d5c86-0329-429c-a830-7059184ec4e9">September 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MDFlYmYwZDYxM2YwNDAwNzllYzY1OTc4MzFiYzIwMDYvdGFibGVyYW5nZTowMWViZjBkNjEzZjA0MDA3OWVjNjU5NzgzMWJjMjAwNl8wLTAtMS0xLTMxMjEz_e5646a37-b084-496d-8032-234fd04b485a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTgw_4bfa1fac-f1be-49e2-b07e-0277af6b5d79">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc0_31cfd354-36b9-4b07-b09f-bdc409ec9a6c">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8wLTAtMS0xLTMxMjEz_2d460f6f-5e3a-460b-b1c5-6dcb92280ebe">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8wLTItMS0xLTMxMjEz_240d3379-39ef-4d8d-a5cc-424d5401154c">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfNQ_32087906-6314-498b-b743-bd87553815e9">1600 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfOQ_24743d02-8951-4f94-9874-77a9919964c8">Suite 1300</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfMTM_c58b8b0a-0851-474e-8571-b5c5d04c693e">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfMTc_2565528f-3f69-45a6-a59d-cd3d044cb44e">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTItMS0xLTMxMjEz_80882c03-c41d-4e38-9512-381e23740b64">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTgx_93791a6c-70bb-4eb4-9a82-1a2586e3333f">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc2_cf2d5c63-2ed8-40c3-be31-61ffa5f29eb2">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:31.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6OWQ3MWM1NDA3YThiNDExNjk5Y2Y2MjZiZWQwOTY4ODgvdGFibGVyYW5nZTo5ZDcxYzU0MDdhOGI0MTE2OTljZjYyNmJlZDA5Njg4OF8yLTAtMS0xLTMxMjEz_28990051-4028-4982-8808-1fbf93f7da0e">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6OWQ3MWM1NDA3YThiNDExNjk5Y2Y2MjZiZWQwOTY4ODgvdGFibGVyYW5nZTo5ZDcxYzU0MDdhOGI0MTE2OTljZjYyNmJlZDA5Njg4OF8yLTItMS0xLTMxMjEz_8159dcfa-a0e6-4af5-be2e-5913a8cfac02">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6OWQ3MWM1NDA3YThiNDExNjk5Y2Y2MjZiZWQwOTY4ODgvdGFibGVyYW5nZTo5ZDcxYzU0MDdhOGI0MTE2OTljZjYyNmJlZDA5Njg4OF8yLTQtMS0xLTMxMjEz_69fa5967-b507-48cd-975d-6754c5ba09d0">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc1_ddda0194-eb14-4c57-abac-a68f9d919124">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTcx_6db48c1b-ff30-446e-9328-ce79aff991b7">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MzVmZDgyZTQ0ZmEyNDc3Njk2YTk3ZTJhNjc5NmI3ZDQvdGFibGVyYW5nZTozNWZkODJlNDRmYTI0Nzc2OTZhOTdlMmE2Nzk2YjdkNF8xLTAtMS0xLTMxMjEz_a479840f-5f0b-42c1-9d2a-9febe8e2bbd7">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MzVmZDgyZTQ0ZmEyNDc3Njk2YTk3ZTJhNjc5NmI3ZDQvdGFibGVyYW5nZTozNWZkODJlNDRmYTI0Nzc2OTZhOTdlMmE2Nzk2YjdkNF8xLTUtMS0xLTMxMjEz_1334a4b8-a384-4891-9b5e-335f802033b8">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MzVmZDgyZTQ0ZmEyNDc3Njk2YTk3ZTJhNjc5NmI3ZDQvdGFibGVyYW5nZTozNWZkODJlNDRmYTI0Nzc2OTZhOTdlMmE2Nzk2YjdkNF8yLTItMS0xLTMxMjEz_04b2b157-9397-479f-b818-92cdb3b1cc1b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc3_dbbbed63-77ac-4252-bf68-ba4368a1681f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="i1ecf59c7ee0f4ebf9430d47fc996630e_I20221107" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTM2_8ab2c15a-2b6b-4fe2-99b6-b15dc9f70e88">14,464,127</ix:nonFraction> shares of common stock as of November&#160;7, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_25">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_61">16</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_82">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_82">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_85">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_88">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_88">32</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_91">32</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_94">32</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_97">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_97">32</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_100">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_100">33</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_103">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9d8b5229cbe549cdb99425ffcfc909d0_103">34</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMy0xLTEtMS0zMTIxMw_8b3603a6-17ca-449c-aa35-2eab55ddeb93">19,541,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMy0zLTEtMS0zMTIxMw_737c8e4b-4108-446a-bd13-640ddc06134d">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNS0xLTEtMS0zMTIxMw_89c3d149-ce76-4582-aba5-27648e7e2eb9">15,232,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNS0zLTEtMS0zMTIxMw_7cb42750-1855-4f86-b896-7814f4ba2bab">6,877,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNi0xLTEtMS0zMTIxMw_ff3e1113-a4ef-4ab9-8264-b513705217f6">10,647,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNi0zLTEtMS0zMTIxMw_a2872ab2-943e-474e-bf6e-56e684a2c66c">8,429,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNy0xLTEtMS0zMTIxMw_29bf0ab7-b91d-437f-a92d-0bd0a05ad871">3,738,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNy0zLTEtMS0zMTIxMw_0b9ca854-1aff-4870-a14e-5236e424a999">3,339,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOC0xLTEtMS0zMTIxMw_edc26c8b-371d-4859-9fa9-4793a7d383c1">49,160,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOC0zLTEtMS0zMTIxMw_4dd92d48-c7a4-4c4f-9ef6-7276619df6cf">45,688,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOS0xLTEtMS0zMTIxMw_3d90b762-e145-4a78-818e-f74730e40560">7,497,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOS0zLTEtMS0zMTIxMw_408534c3-d479-419e-8bd4-bcd0d6b8d8ba">9,048,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTAtMS0xLTEtMzEyMTM_0761a11d-ea1b-4a19-9d89-77c43878dbea">490,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTAtMy0xLTEtMzEyMTM_e085838b-0f5f-47be-89ad-182fbd8db378">442,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTEtMS0xLTEtMzEyMTM_cae56555-5d70-415d-80dd-e9a93a80f903">29,048,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTEtMy0xLTEtMzEyMTM_74bd2fdf-fae4-4988-bb32-b25093ca089f">23,954,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTItMS0xLTEtMzEyMTM_e201672a-68f1-449f-9811-18a41cb5c167">1,932,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTItMy0xLTEtMzEyMTM_95ee6bdd-bd90-4049-b25b-177618847c43">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTMtMS0xLTEtMzEyMTM_4c6be4f7-8d44-44c1-88f4-0f811571e047">219,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTMtMy0xLTEtMzEyMTM_50a1a127-27ab-4c27-869f-edb8da782546"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTMtMy0xLTEtMzEyMTM_94b25b70-349e-4dfc-91c4-a65aa019399b">1,024,200</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTQtMS0xLTEtMzEyMTM_45ccec88-644d-4fcc-b692-a4d2a6df64d0">2,426,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTQtMy0xLTEtMzEyMTM_00f61da9-6425-4f57-89d4-c11f080e2c37">3,419,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTUtMS0xLTEtMzEyMTM_f5266faf-7607-49a2-a300-b01aeff82a7c">90,776,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTUtMy0xLTEtMzEyMTM_1b2e901a-0115-4d8b-892b-385c82ba1096">84,459,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTgtMS0xLTEtMzEyMTM_b923590e-cca9-4942-91a2-0367c2ec7ed2">11,510,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTgtMy0xLTEtMzEyMTM_da25132a-17a1-416f-8b11-f9693d27fa0e">9,640,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTktMS0xLTEtMzEyMTM_fae870b7-88c0-4e2d-bccd-696b7b365908">229,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTktMy0xLTEtMzEyMTM_6bd4c061-9d46-4a31-9335-8006051693ec"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTktMy0xLTEtMzEyMTM_e4791503-bad7-4c73-a3ca-c6b9c40b6ef2">969,677</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjAtMS0xLTEtMzEyMTM_90301c5c-f980-45d7-9549-d1b3fa1cac22">13,565,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjAtMy0xLTEtMzEyMTM_2e842492-62b7-4e11-951d-99724f9d5f21">8,668,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjEtMS0xLTEtMzEyMTM_9d506153-8c7a-40bd-8c3b-8b5fd48a0f0f">25,306,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjEtMy0xLTEtMzEyMTM_e5b0dee3-66f7-46e6-a88f-a2b0f5cda2ad">19,278,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjItMS0xLTEtMzEyMTM_b08109a5-5b88-4ba5-a6aa-7e7ad4a5d047">17,700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjItMy0xLTEtMzEyMTM_acfbc7f5-e226-449b-97d0-e56df4b673d3">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjMtMS0xLTEtMzEyMTM_ee46a639-e498-4589-8366-1ec35f9fada5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjMtMy0xLTEtMzEyMTM_1bc6210e-fc2d-42ee-8bda-a97c92ca1368"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjMtMy0xLTEtMzEyMTM_2c34c072-4e86-43b8-ae5c-e6132f1201b6">90,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjQtMS0xLTEtMzEyMTM_dfbb948d-9170-48d0-8847-08434d21f7a4">9,279,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjQtMy0xLTEtMzEyMTM_e7ea173e-e22b-445e-8d54-8700c33c555a">7,488,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjUtMS0xLTEtMzEyMTM_bbfa6b2b-0df5-48af-8d11-b48d6fba4549">52,285,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjUtMy0xLTEtMzEyMTM_7c2b3807-855d-4552-bd45-23d45b8b21f3">41,857,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjYtMS0xLTEtMzEyMTM_fc2cf6cc-d378-4047-a2b0-a522f8cd5f11"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjYtMy0xLTEtMzEyMTM_bc3f7db0-576b-4604-80d6-511b301bd984"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8xNw_349115dc-d89f-459f-a68f-c56f2a6eb466"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8xNw_988af9e0-12dc-4193-b44c-80696c973b3b">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8zMQ_4f075ace-919d-4c37-ab95-910d0df2f9a3"><ix:nonFraction unitRef="shares" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8zMQ_a2875bb7-2d5a-4771-9c9e-4daf06e4e4d0">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV81Mw_0a2abd35-a62a-40d6-aa79-ab29daea019d"><ix:nonFraction unitRef="shares" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV81Mw_49ecae3a-b411-4e24-b516-a67846bbe251">14,436,583</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV82MA_47b99124-932a-418d-9c8e-b71c3576d086"><ix:nonFraction unitRef="shares" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV82MA_d64ea13d-e69e-4b87-85ff-00db6b706f7e">14,742,754</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2022 and December 31, 2021 , respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMS0xLTEtMzEyMTM_905ffc9d-ac45-461a-ac76-83c7429bb48f">47,532,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMy0xLTEtMzEyMTM_7ec6a86d-0bb5-4e5d-8687-639def58c69e">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzAtMS0xLTEtMzEyMTM_dcd139c5-1cae-47e2-b33a-de3e08897874">8,768,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzAtMy0xLTEtMzEyMTM_0a4f52dc-6fb2-4201-adf5-a916a360e347">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzEtMS0xLTEtMzEyMTM_4add7444-0d44-48f4-8723-8149c978ff4e">38,764,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzEtMy0xLTEtMzEyMTM_e707cf2f-749d-4121-a8f0-1b55a78bd1e3">42,814,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzItMS0xLTEtMzEyMTM_88570669-1b2f-4659-88cd-0677fe908c51">273,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzItMy0xLTEtMzEyMTM_62c5e4dd-9d81-40c6-b4cf-7e0b04282979">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzMtMS0xLTEtMzEyMTM_f90ccf94-bbf2-42ad-8e09-5df53a15db58">38,491,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzMtMy0xLTEtMzEyMTM_be7ebb33-f774-4cb0-8c75-a87b2edb87e0">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzQtMS0xLTEtMzEyMTM_7def717d-3b6b-4688-b028-13cb401afb90">90,776,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzQtMy0xLTEtMzEyMTM_e81b5c55-b315-4f3b-a7f2-714a65c8a072">84,459,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi0xLTEtMS0zMTIxMw_bb0475f5-adaf-439b-88a0-44176133d5dd">11,413,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi0zLTEtMS0zMTIxMw_e4a41170-d550-4947-a909-4aac9c2d9470">8,072,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi01LTEtMS0zMTIxMw_4254774e-c408-48ee-a908-1426a180cc05">32,887,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi03LTEtMS0zMTIxMw_e9f13c54-1aeb-40df-844a-fd7dd5e6f519">27,665,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC0xLTEtMS0zMTIxMw_22180e6f-13d4-40c3-b67a-42733b9eee57">2,224,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC0zLTEtMS0zMTIxMw_4038b2ae-1de2-470a-8551-0a53f91e2b8d">1,328,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC01LTEtMS0zMTIxMw_dc59c857-0c0c-4035-b957-7f49567bb5a3">6,468,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC03LTEtMS0zMTIxMw_f9e5548e-d04f-4dae-9512-78b202b5d4af">5,486,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS0xLTEtMS0zMTIxMw_d49acac3-7ced-49b4-a6fe-9beb6fba9f7a">4,110,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS0zLTEtMS0zMTIxMw_1e2aa132-9dde-461c-9c27-9ab3868b0ca5">3,800,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS01LTEtMS0zMTIxMw_e9ef9260-a542-4101-a0b2-f1f41277134f">13,281,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS03LTEtMS0zMTIxMw_7cd21c80-cd7e-4dc4-96b6-d44aed57a96b">11,709,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi0xLTEtMS0zMTIxMw_dcdb02a8-309e-4e49-8578-f232ff143ee5">1,714,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi0zLTEtMS0zMTIxMw_699c90f9-563a-4eb1-9c15-7bb05642d1df">1,453,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi01LTEtMS0zMTIxMw_6e8e862f-4372-4c59-915e-e78dcf4771d8">5,283,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi03LTEtMS0zMTIxMw_0630a397-019f-4e7b-93a6-6957fa933321">4,071,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy0xLTEtMS0zMTIxMw_93263af4-413d-4e74-81cf-0f6a4ee4669d">2,166,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy0zLTEtMS0zMTIxMw_f9ea06c6-220b-4d32-9b85-13991684cf34">2,039,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy01LTEtMS0zMTIxMw_438d6d24-2dfb-4f47-b37a-525258c06297">6,672,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy03LTEtMS0zMTIxMw_930ef420-6239-4f36-af3e-d1a1bc536bfa">6,367,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC0xLTEtMS0zMTIxMw_69663639-a706-486d-bcbe-1c96585c6efa">1,486,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC0zLTEtMS0zMTIxMw_74271984-4634-4271-b7d0-beef5ef8c01a">1,013,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC01LTEtMS0zMTIxMw_958aac80-21b2-4c63-9ef2-003fa252a049">4,609,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC03LTEtMS0zMTIxMw_2ef616b2-f957-4d83-a65c-5b9126aca798">3,354,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS0xLTEtMS0zMTIxMw_420d6843-41e8-4b6f-b432-e3b412824950">11,701,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS0zLTEtMS0zMTIxMw_aac2f0e2-aede-4f8c-8ac7-2ba002b22f44">9,635,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS01LTEtMS0zMTIxMw_226c4698-2c7c-491f-b77f-cabe2b2a7d68">36,314,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS03LTEtMS0zMTIxMw_f2c4e284-44fd-4e93-a30f-11b0a6363d6b">30,988,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtMS0xLTEtMzEyMTM_de53ceff-adcc-4409-a5f0-edb35209d27c">288,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtMy0xLTEtMzEyMTM_20620874-e9f0-4e2f-a93b-85880e1db080">1,563,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtNS0xLTEtMzEyMTM_98919d7c-e82e-425c-8db4-9a29e8a6c002">3,427,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtNy0xLTEtMzEyMTM_edd4dc68-fd2f-4683-973a-4a972284eb65">3,323,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtMS0xLTEtMzEyMTM_8e2aef15-4af0-4d8b-b765-30f52f609785">21,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtMy0xLTEtMzEyMTM_029a9688-7672-41d3-9ceb-5861456eb9fa">7,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtNS0xLTEtMzEyMTM_ab5eccca-5786-46b8-a077-b8441e93c634">52,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtNy0xLTEtMzEyMTM_64872455-d976-4b85-bf85-aac12865cc50">19,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItMS0xLTEtMzEyMTM_f3bbaacf-f773-4dc8-b2ad-11ba1771f757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItMy0xLTEtMzEyMTM_e84add83-13d2-4be2-88c5-039a1331a1ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItNS0xLTEtMzEyMTM_a618a3f9-5030-4c04-8303-52423af12c72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItNy0xLTEtMzEyMTM_598a33cc-0221-4b39-86cd-2cb0c65c8abf">2,187,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - gain on insurance proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtMS0xLTEtMzEyMTM_72171565-6586-442c-9c79-6c91537dbb3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtMy0xLTEtMzEyMTM_feb7fb8f-ebc6-4432-a3ec-c8205de199ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtNS0xLTEtMzEyMTM_72779df9-8b03-413b-b09d-ac1620195f75">611,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtNy0xLTEtMzEyMTM_083aead9-1556-427a-949d-a6cf5b4520ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtMS0xLTEtMzEyMTM_5cbab2e4-1e26-44eb-b8a3-c632bb34f929">149,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtMy0xLTEtMzEyMTM_e05f6d72-6faa-49b1-ab08-b8c6871bf937">20,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtNS0xLTEtMzEyMTM_6d1e050c-1844-40d9-8f81-8eed50dbcc4c">406,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtNy0xLTEtMzEyMTM_6a9a5323-04b5-4082-80ec-30bbab30b275">70,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtMS0xLTEtMzEyMTM_04296c8a-ff8a-417d-8ad7-bd38799e0a1a">416,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtMy0xLTEtMzEyMTM_06acfc8a-c659-4f3d-af26-8fa916ad8692">1,576,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtNS0xLTEtMzEyMTM_2878eb96-8827-4752-ba34-ed350be64243">3,169,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtNy0xLTEtMzEyMTM_4017e317-73e1-4f2f-ae1b-d9fba298a76b">1,187,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtMS0xLTEtMzEyMTM_71230639-eb4e-41a1-abf2-266d481fc7fe">6,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtMy0xLTEtMzEyMTM_c90df69e-5c4d-445a-9dd6-aed29b05d0b4">7,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtNS0xLTEtMzEyMTM_c4c31589-55a7-4adb-8494-fe458e3ae612">20,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtNy0xLTEtMzEyMTM_29215c70-7a7c-4d23-9a07-a6e5e1dc2d14">22,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctMS0xLTEtMzEyMTM_cd306f8d-7a23-4447-b7b8-fd1ed163ebe6">423,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctMy0xLTEtMzEyMTM_a42c9fc0-5fd8-493d-91db-9bf0dc7eda56">1,583,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctNS0xLTEtMzEyMTM_0845a259-2c09-4f78-84dd-d140ff304e97">3,190,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctNy0xLTEtMzEyMTM_d20ec557-09a0-4330-b526-f582b79a03c1">1,209,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtMS0xLTEtMzEyMTM_a366bf5a-6c37-4c1d-9d11-3a1aa767af75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtMy0xLTEtMzEyMTM_fb028702-2690-4ef2-bee4-8184ef6fc3c4">496,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtNS0xLTEtMzEyMTM_5ceaead0-f754-4cc5-afe8-90c915a6320f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtNy0xLTEtMzEyMTM_e6c4ce79-b1ed-43e7-9e29-5b9a601883b9">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktMS0xLTEtMzEyMTM_d3412bce-2f41-4b65-b8ae-ac4c5c1ca3c2">423,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktMy0xLTEtMzEyMTM_29feac07-dd66-4e8f-a0f1-698a89fa4c55">1,086,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktNS0xLTEtMzEyMTM_9816b8c3-83b7-4ef3-8b55-3b904b8d3e27">3,190,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktNy0xLTEtMzEyMTM_34daef80-f076-4020-b559-5f998325dfe3">281,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtMS0xLTEtMzEyMTM_eff198a1-5c67-4bcf-b459-92c3cb42f19d">14,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtMy0xLTEtMzEyMTM_0f71b9d1-df41-4bd8-a060-2a9c06c3021f">31,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtNS0xLTEtMzEyMTM_3556da5d-f8ce-4ed1-a523-271022aeb086">60,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtNy0xLTEtMzEyMTM_c2cd2dda-1d4a-4fd8-b5a7-cc6db09e1b1f">58,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtMS0xLTEtMzEyMTM_9ba2e104-59ca-4a7b-aaaa-ef9261e93f1d">408,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtMy0xLTEtMzEyMTM_1989e941-bd1f-49f8-b313-fd904fcdfa69">1,055,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtNS0xLTEtMzEyMTM_0c77e351-abc9-47d1-a10d-1e1a793bfd6b">3,129,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtNy0xLTEtMzEyMTM_e57038d3-13c0-4d1a-9270-9f0f2e05a65b">340,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtMS0xLTEtMzEyMTM_360fd5f1-051f-4ecd-b206-babf78f3fb56">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtMy0xLTEtMzEyMTM_d4146cf7-1d2c-4562-9d60-7cacbc2aedbb">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtNS0xLTEtMzEyMTM_7ccaa803-c69d-4bd1-b377-d637be6ae3eb">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtNy0xLTEtMzEyMTM_e9939922-d47a-4565-a407-ef22ac2df6f8">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtMS0xLTEtMzEyMTM_9fa8ae8d-6744-49c4-83c9-6c9b3dee2c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtMy0xLTEtMzEyMTM_1ec8f047-b20d-407a-8a9f-8e22cb25d3ec">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtNS0xLTEtMzEyMTM_6f7ac40e-5028-4cd4-bfdd-040a6cd54bab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtNy0xLTEtMzEyMTM_d4be1b70-a454-4e01-84b5-7493f50930d9">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtMS0xLTEtMzEyMTM_f574c2ad-0ec4-4411-8b0c-8e1a935fc3dc">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtMy0xLTEtMzEyMTM_be0b5fd7-e4fb-407d-bf5b-ea118d5335c4">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtNS0xLTEtMzEyMTM_9fe99f2d-ab42-44a9-97fb-156434fa172d">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtNy0xLTEtMzEyMTM_309013cb-fa34-4635-9ecf-1ad335b6cb35">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctMS0xLTEtMzEyMTM_28640a1c-6842-433c-88f7-8cd308a8b5d0">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctMy0xLTEtMzEyMTM_45b187fa-82ab-43ea-8949-137f8582b31b">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctNS0xLTEtMzEyMTM_63f385ad-a0d9-4241-b9f7-535bf369ced2">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctNy0xLTEtMzEyMTM_e9b7d2cd-ebf0-4bca-8227-c488119d069a">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtMS0xLTEtMzEyMTM_f7f4cede-c4e3-4aa9-9298-37b3638e006b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtMy0xLTEtMzEyMTM_d8d3fe42-d17a-45f8-aef7-0a1e46eea1f5">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtNS0xLTEtMzEyMTM_bc4e876a-50e8-4c2f-8a63-4cbf28e9bf38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtNy0xLTEtMzEyMTM_8fca3c1b-7a61-4098-965c-f2c0a7faca98">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktMS0xLTEtMzEyMTM_53f3ff8a-99e9-4388-b9d4-98c9e3e6d61b">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktMy0xLTEtMzEyMTM_130f7f61-b18f-42b8-ad8e-616e5b27a7ef">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktNS0xLTEtMzEyMTM_fb53d72f-5489-49c8-a384-5f52bbae9286">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktNy0xLTEtMzEyMTM_6ed0e09e-f3a3-425c-82d5-bc1e5ce0be74">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtMS0xLTEtMzEyMTM_e1a1f4d8-f81d-440d-9872-1a42f4ddf3b7">14,477,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtMy0xLTEtMzEyMTM_554afac6-e827-4b81-a7d9-18a391f6ffce">14,880,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtNS0xLTEtMzEyMTM_6d99a7e9-647b-4d61-ad56-13ccbbc226b9">14,618,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtNy0xLTEtMzEyMTM_b89fbfa8-61f9-43b7-9b98-54351347df72">14,939,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItMS0xLTEtMzEyMTM_4ded4125-9700-4ad7-8826-967d5c1c164d">14,477,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItMy0xLTEtMzEyMTM_daf4f1d3-863b-4d08-8948-0d7cb971ca51">14,880,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItNS0xLTEtMzEyMTM_0b230d13-d390-4094-8abb-06e6aab4e27a">14,618,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItNy0xLTEtMzEyMTM_4ce3dc71-5705-43d4-9194-c3cb7ddd1298">15,139,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMy0xLTEtMS0zMTIxMw_41a57610-f6d6-4fd1-bdfd-52f3192e7d46">3,190,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMy0zLTEtMS0zMTIxMw_58fde146-01d1-4d6d-8af6-5df0b7a59869">281,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNC0xLTEtMS0zMTIxMw_665159ac-f879-4356-ae53-1a26e0337e27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNC0zLTEtMS0zMTIxMw_1e9b1438-513b-429e-8463-f90e4f39819d">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNS0xLTEtMS0zMTIxMw_35b98dda-78f6-4a4b-bc0d-ebc89646976e">3,190,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNS0zLTEtMS0zMTIxMw_6c3e40fa-dbf2-4a95-93e4-281902c2965a">1,209,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNy0xLTEtMS0zMTIxMw_3517ce5f-2b74-4048-8d96-333a044d8cd5">4,816,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNy0zLTEtMS0zMTIxMw_a2d0cb15-38fe-4f5d-8ec3-f4d13bb7d83b">3,529,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOC0xLTEtMS0zMTIxMw_e0b4c639-ec56-4a33-b0ed-c0858a91a55b">320,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOC0zLTEtMS0zMTIxMw_dc905ef3-1572-40be-8afe-201c79422930">517,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOS0xLTEtMS0zMTIxMw_9669b089-1049-4c3b-b659-3049d8a33204">1,051,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOS0zLTEtMS0zMTIxMw_82e6d69f-7708-4c4b-ae7c-ddbf3f9635f7">632,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTAtMS0xLTEtMzEyMTM_cf02051f-ad94-444c-99e4-5ebbc375a84f">708,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTAtMy0xLTEtMzEyMTM_1e30dd35-1619-4982-8ef6-823198279faa">52,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTItMS0xLTEtMzEyMTM_9175560c-47b2-427d-a972-b9959f152a84">7,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTItMy0xLTEtMzEyMTM_eb13cdf3-25c0-4448-a7e7-7df30f569196">33,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMS0xLTEtMzEyMTM_a5bda9ca-1914-4ec0-bbfd-aefb254b625c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMy0xLTEtMzEyMTM_fb83ad2e-990d-4b2a-a01d-49832610b597">2,187,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on receivable of life insurance policy proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMS0xLTEtMzM2MjQ_728f5a8e-c460-4e13-927f-ad06d3bb631d">611,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMy0xLTEtMzM2MjQ_ebae8bfa-4b00-4fe2-8450-140212bb98f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTUtMS0xLTEtMzEyMTM_7947b9ac-2760-4103-b105-b9d902beb625">8,184,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTUtMy0xLTEtMzEyMTM_f5fc9a35-e8e4-4c7b-be62-73ae7942eacb">2,527,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTYtMS0xLTEtMzEyMTM_0f09e1b1-d7c9-4c84-a9a1-6018a55e7181">1,338,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTYtMy0xLTEtMzEyMTM_5f99c2bf-c382-4c11-b6be-2494f8fb82f3">2,555,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTctMS0xLTEtMzEyMTM_eac338d3-aa6b-4e90-a9a5-48e98b8157df">4,355,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTctMy0xLTEtMzEyMTM_5f2a5935-c506-44ab-a8da-354c5ceb061e">1,627,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTgtMS0xLTEtMzEyMTM_f5c590b2-2aea-4efd-b76b-09193c04366a">8,778,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTgtMy0xLTEtMzEyMTM_646966e0-86ce-4e99-b407-9f8952180f33">2,873,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTktMS0xLTEtMzEyMTM_5b3a8be6-e651-45e6-8d48-3d67667b6592">2,472,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTktMy0xLTEtMzEyMTM_7f7c8336-ebdb-4036-bed3-7fa1711741bd">943,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjAtMS0xLTEtMzEyMTM_86354614-3369-42dd-ab64-8cec51d1f351">4,815,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjAtMy0xLTEtMzEyMTM_160a372c-c6cf-45c7-bad7-59bca06d2b11">2,891,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjEtMS0xLTEtMzEyMTM_f2e9fa97-32c2-4a2f-b108-a0d6e956548e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjEtMy0xLTEtMzEyMTM_49e45a55-fa92-4355-8f45-7dc6ca8482a4">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjItMS0xLTEtMzEyMTM_85a26056-ba37-4818-81bf-c24cbebd318b">4,815,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjItMy0xLTEtMzEyMTM_01a18a75-aad0-4f5a-85f6-3ef728853e95">4,382,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjQtMS0xLTEtMzEyMTM_d340075a-d5ce-4eeb-83a0-41e7119a81e1">255,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjQtMy0xLTEtMzEyMTM_e47d31e5-a6c6-4a67-aa48-77ec8ec6de24">94,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of patent litigation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="cpix:ProceedsFromSettlementOfPatentLitigation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjUtMS0xLTEtMzEyMTM_da3239b1-1255-42d6-9911-80e9999da698">21,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="cpix:ProceedsFromSettlementOfPatentLitigation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjUtMy0xLTEtMzEyMTM_a4c1345c-3586-4b8c-a04b-62bc11529a70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance policy proceeds received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:ProceedsFromLifeInsurancePolicies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjYtMS0xLTEtMzEyMTM_048d17bd-5329-48e5-b11e-16cf3f0c6e32">877,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ProceedsFromLifeInsurancePolicies" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjUtMy0xLTEtMzM1NTA_824cfa09-c0e8-45eb-b42e-78701c4ffaae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjctMS0xLTEtMzEyMTM_e7f1dd3f-7950-4d28-88d2-0ba9d237a8c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjctMy0xLTEtMzEyMTM_3897ea1b-e0bb-4098-a71e-d9fd267ebd60">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjgtMS0xLTEtMzEyMTM_692fb8be-02d3-4883-83a8-9be4a5c06418">13,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjgtMy0xLTEtMzEyMTM_879753eb-ce36-41c4-b6fa-d66e97dce70b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjktMS0xLTEtMzEyMTM_9eb64414-0250-46a3-bf74-6faf5ae3f27c">177,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjktMy0xLTEtMzEyMTM_a4c2c386-2d44-400a-ae53-a8139deae466">180,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzAtMS0xLTEtMzEyMTM_e4670111-77f6-4ff3-8553-5a71b78b9568">13,033,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzAtMy0xLTEtMzEyMTM_5bde2286-d17d-4e5c-94a9-b6e0c1227670">475,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzMtMS0xLTEtMzEyMTM_332a6517-b716-4066-92c3-0d40b66100da">46,700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzMtMy0xLTEtMzEyMTM_5693e1d4-7ca1-4d04-9737-58c7f2b9168e">45,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzQtMS0xLTEtMzEyMTM_36ed24bc-16ae-40a9-a1fc-e3abbfb606cd">44,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzQtMy0xLTEtMzEyMTM_91e1e686-7a0f-44bb-8c87-a94b99824d66">45,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzUtMS0xLTEtMzEyMTM_b1dcd068-9325-4735-a9ea-e9827fb2f36a">1,117,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzUtMy0xLTEtMzEyMTM_ca5adf20-4fc5-463b-85ad-3573058ea265">1,792,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzYtMS0xLTEtMzEyMTM_7852a3be-77f8-4fa6-9371-0ef2139b89d1">863,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzYtMy0xLTEtMzEyMTM_a9b056ee-c90a-4992-81b5-4178f8db6109">1,025,657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzctMS0xLTEtMzEyMTM_94da312e-c0be-44d7-942b-a8b13445e05d">719,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzctMy0xLTEtMzEyMTM_87ef5fe1-7f99-41f9-b612-b8c1a7dc5ac8">2,818,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzgtMS0xLTEtMzEyMTM_1e9ff420-25e7-4ed1-b2d2-c764b640bfea">7,499,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzgtMy0xLTEtMzEyMTM_ef3703ff-89e8-40c6-99a6-636104f58915">1,089,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzktMS0xLTEtMzEyMTM_8db953d3-27f0-4a5c-b114-c3a9b88f0b50">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if626e02bae5647008aa9c24841ba535a_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzktMy0xLTEtMzEyMTM_58891743-b0e4-4c36-ad7d-39a49a4dea68">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNDAtMS0xLTEtMzEyMTM_35e59e1a-1c2f-4376-bebb-94052f4d4b5d">19,541,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c72ce76653b4c67a43289e60f381b45_I20210930" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNDAtMy0xLTEtMzEyMTM_94d6a797-c2b6-46dc-8f3c-f1adec249273">25,843,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_25"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeb4adb610e0487da3f871d1774882a5_I20201231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi0xLTEtMS0zMTIxMw_80ffaca0-87bf-4d9a-95b4-9b58b1e1b36f">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb4adb610e0487da3f871d1774882a5_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi0zLTEtMS0zMTIxMw_7948ff11-1dc3-4527-8546-2504bd59f513">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e37ca58de94c968783906ecbe91aed_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi01LTEtMS0zMTIxMw_220cfd94-0d50-4c07-9aaf-009bcdae1f1b">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i469879a126f645e6957c45bf0ffe9267_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi03LTEtMS0zMTIxMw_ae070f0c-81d9-4020-9c5c-d5ff07dc6f1a">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if626e02bae5647008aa9c24841ba535a_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi05LTEtMS0zMTIxMw_b32bfd5c-b178-40e6-bc97-871da0b3e6b2">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMy0xLTEtMS0zMTIxMw_efda9f4f-bc8a-45f2-9b33-e1580956f580">187,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMy0zLTEtMS0zMTIxMw_449fa34b-05ed-4653-a41d-3f7d7f5d2243">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMy05LTEtMS0zMTIxMw_8130a0a7-f3dc-4663-ac63-aa5939ab6d50">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNC0xLTEtMS0zMTIxMw_575fcaa2-0084-4460-8a6b-f4b2e26c78a0">91,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNC0zLTEtMS0zMTIxMw_408ddf9a-3d7c-4342-9c9b-b85f0717087c">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNC05LTEtMS0zMTIxMw_1f892adf-b9fd-4681-bd8c-6873e0a0907c">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8364ff2b3c64c9ba02d2282288d872c_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNS01LTEtMS0zMTIxMw_65df64b3-d5d4-4f2d-a1c0-646c1c466042">166,828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i816fdbe7cf00466da247a111463219bd_D20210101-20210331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNS03LTEtMS0zMTIxMw_4e9f07b9-4d2a-4df8-847c-be1db1498ed2">22,167</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNS05LTEtMS0zMTIxMw_71a9e48e-148f-4258-9af8-9f56680861ae">144,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi0xLTEtMS0zMTIxMw_8c74aefa-b018-490c-8015-38317ad11bd1">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi0zLTEtMS0zMTIxMw_db03e667-98c3-4d57-a576-57399155d904">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd66a8cd08ad466a871a154c19ab33e0_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi01LTEtMS0zMTIxMw_bad0dde3-8535-4d65-a36e-6e9ed73d8a73">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f34225fa00b49d2886530446efba2bd_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi03LTEtMS0zMTIxMw_73737f9f-1e52-408e-bda8-f1b77175985d">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bbe436ab9243bf9e8e1752ee7ba9c4_I20210331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi05LTEtMS0zMTIxMw_cd233151-0f5f-4fb7-b436-437f64255800">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS0xLTEtMS0zMTIxMw_ba8f70db-aa99-43d3-aa2b-a2d60e0f7098">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS0zLTEtMS0zMTIxMw_c9e2d578-d795-423c-b34a-615cb0c2bba4">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd66a8cd08ad466a871a154c19ab33e0_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS01LTEtMS0zMTIxMw_0b1c6ef1-d684-4f16-97d2-d6e492ee61f8">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f34225fa00b49d2886530446efba2bd_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS03LTEtMS0zMTIxMw_0d632786-0aa3-4c16-8b4f-5c4f4d3e2800">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bbe436ab9243bf9e8e1752ee7ba9c4_I20210331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS05LTEtMS0zMTIxMw_dad57672-c970-465d-8ca2-c3021367b6bc">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMi0zLTEtMS0zMzY4Mw_9e7c4877-5a24-4a4d-b9a5-7cbb3db5a8f1">191,954</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMi05LTEtMS0zMzY4Mw_5be51635-2c67-48ae-9f49-396d82ed2076">191,954</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMy0xLTEtMS0zMzY4NQ_572759b4-456a-4336-beab-092d542dc349">158,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMy0zLTEtMS0zMzY4Mw_afd63585-ae9f-438e-bb49-7d786a4c5270">484,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMy05LTEtMS0zMzY4Mw_03b70ac5-bc73-472f-af67-2ea524eb6853">484,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1d4b58df9742c4af8e0eb4e6838a85_D20210401-20210630" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNC01LTEtMS0zMzY4Mw_d5101416-1ff3-4684-a3bc-e7ea81c9ecb8">1,228,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida381f36684e4a5eb6add6bc60925c59_D20210401-20210630" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNC03LTEtMS0zMzY4Mw_246e5e4a-2791-4358-8969-932a02b4d1d0">5,069</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNC05LTEtMS0zMzY4Mw_f3fae1dc-8781-46de-b211-488fefa7f3f7">1,223,491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS0xLTEtMS0zMTIxMw_22a7c590-ecc5-46bf-b4c1-e85ebdf837a0">14,926,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS0zLTEtMS0zMTIxMw_c57f1803-48f2-4a0b-81e5-5b8f8868f218">48,688,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaedd290adc07485ca2c5f8e444d98b02_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS01LTEtMS0zMTIxMw_8882e4ec-44da-493c-abb5-93db7a9ce3a4">735,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9af4ea0922c24564a827d627f319505b_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS03LTEtMS0zMTIxMw_061ed500-2497-4250-bbbe-7a6c76664d13">144,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0144f9dc224850955f0f39892c50b7_I20210630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS05LTEtMS0zMTIxMw_a2aa6911-42af-4c4f-894a-b4f8ff292502">47,808,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS0xLTEtMS0zMTYwNg_2983a7bc-ac6b-4a16-a3b0-800e358e3566">14,926,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS0zLTEtMS0zMTYwNg_a98a6170-1bea-42d7-ba69-0d361e3ffc69">48,688,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaedd290adc07485ca2c5f8e444d98b02_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS01LTEtMS0zMTYwNg_890f2b3e-bb50-407e-b0bb-2bbb9d128abb">735,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9af4ea0922c24564a827d627f319505b_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS03LTEtMS0zMTYwNg_8b0ecd16-f775-4f77-a516-96d7e10c5af5">144,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0144f9dc224850955f0f39892c50b7_I20210630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS05LTEtMS0zMTYwNg_9830a122-1741-4e6f-81f2-0bf2683b7ed4">47,808,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMi0xLTEtMS0zMTYxNA_0e013ef5-97c7-42e4-a414-70cc5cbac868">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMi0zLTEtMS0zMTYxNA_d10ba79f-4a6e-4c56-8a64-3276b06db7fc">162,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMi05LTEtMS0zMTYxNA_3e67bfcf-2643-40bd-8770-b9fa0bb8e351">162,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNS0xLTEtMS0zMTYyMg_b61e421a-b083-43d9-aa2d-a073dd39c3f5">76,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNS0zLTEtMS0zMTYyMg_2063a4a0-9d54-495d-9f9d-fbafa2fbc16c">237,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNS05LTEtMS0zMTYyMg_f0c84711-03da-4856-96a4-f39733c28a8a">237,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib91da5e323af4228a5d518ae9dfabe2b_D20210701-20210930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNi01LTEtMS0zMTYzMg_034d1d0c-2c9c-462b-b43e-b7dbf8f7aae5">1,055,278</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i218f7c05e38145d0a763437aa9f82a87_D20210701-20210930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNi03LTEtMS0zMTYzMg_977686b9-85d6-4f55-b00e-ab72decc4274">31,415</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNi05LTEtMS0zMTYzMg_71383744-a59e-4a1d-b40c-807eeefd736f">1,086,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i896ff8d34ff14381a728f65812de9237_I20210930" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy0xLTEtMS0zMTIxMw_02754412-d258-4f5a-ad54-1989eb37110f">14,850,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i896ff8d34ff14381a728f65812de9237_I20210930" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy0zLTEtMS0zMTIxMw_d2257290-7592-42f2-97ff-05a5ede95d58">48,612,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefeac04e34504adc9b365fe4ab275dda_I20210930" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy01LTEtMS0zMTIxMw_4606c2e9-32e9-4363-88c2-36ce3b204b12">1,790,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4385acb51a744d36a58b40ca8fc87ed8_I20210930" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy03LTEtMS0zMTIxMw_f80abcba-83af-4ca3-aa60-37fd29fbf889">175,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c72ce76653b4c67a43289e60f381b45_I20210930" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy05LTEtMS0zMTIxMw_5160cd19-6b38-431e-b1af-5f6c9ae91f9a">46,646,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbb9253827ae4d4893eafb5d816d8f8d_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi0xLTEtMS0zMTIxMw_62e7583e-3ae0-4d29-8dc9-2374ba4d6057">14,742,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb9253827ae4d4893eafb5d816d8f8d_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi0zLTEtMS0zMTIxMw_36f3dc96-006a-4bee-8e7e-19274fbab3a5">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife4e12a79e884084831efe27e493c0a7_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi01LTEtMS0zMTIxMw_71009273-7e1f-4de3-9245-b079da2c8131">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia91dfb736e2c42719050801c83e8a3c7_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi03LTEtMS0zMTIxMw_2be5e9bd-56d0-4dff-8cff-99a113c0b5d4">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi05LTEtMS0zMTIxMw_d6bd1b0e-8406-4995-beb1-6a480f5bf07e">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMy0xLTEtMS0zMTIxMw_c1476b6f-6c77-4e0b-a93f-aa685cba4f9c">162,155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMy0zLTEtMS0zMTIxMw_436d7044-4cb8-4527-b8b3-45afe6016769">159,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMy05LTEtMS0zMTIxMw_e3a632b8-4312-4c57-b409-6cefd3f2a4ad">159,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNC0xLTEtMS0zMTIxMw_ed323c90-c2e2-41ca-a33b-0cd7a947057a">174,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNC0zLTEtMS0zMTIxMw_85e82730-7e9f-43f1-a44a-06538ea31ca9">566,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNC05LTEtMS0zMTIxMw_6c5d2e13-f6c3-4c1a-a8e9-a81f8f2f9695">566,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db23060227f4160ba28455c16b8b07f_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNS01LTEtMS0zMTIxMw_b0ff0265-943c-42e1-807c-6ea4e6850d8a">1,385,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3243bd8ec27a48e0af6fabfc07ac337c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNS03LTEtMS0zMTIxMw_b922b8a4-15a1-4c5c-a1f1-41cc028186af">17,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNS05LTEtMS0zMTIxMw_f03cbaaa-4ba7-49b1-bd5f-0b9a2343b76d">1,402,433</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi0xLTEtMS0zMTIxMw_4d82762e-9e3f-4f16-96f7-38d21260762c">14,730,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi0zLTEtMS0zMTIxMw_081e60a1-3b45-4bf7-9601-3dff5442f471">48,046,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c80483524e94ce385b64322c7e6ebab_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi01LTEtMS0zMTIxMw_e85b8cec-f9d9-4863-a8e5-a695f59219ea">7,023,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca7aed0a270443ab090d05d1305fb08_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi03LTEtMS0zMTIxMw_be8ca2c1-46e8-4b9f-9389-73574436b4b3">229,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47373afe83f4d06b32efc31992a4bbf_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi05LTEtMS0zMTIxMw_d0a0ad74-ecc5-4d84-ae4c-8b459fdcf80d">40,793,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS0xLTEtMS0zMTIxMw_4d82762e-9e3f-4f16-96f7-38d21260762c">14,730,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS0zLTEtMS0zMTIxMw_081e60a1-3b45-4bf7-9601-3dff5442f471">48,046,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c80483524e94ce385b64322c7e6ebab_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS01LTEtMS0zMTIxMw_e85b8cec-f9d9-4863-a8e5-a695f59219ea">7,023,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca7aed0a270443ab090d05d1305fb08_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS03LTEtMS0zMTIxMw_be8ca2c1-46e8-4b9f-9389-73574436b4b3">229,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47373afe83f4d06b32efc31992a4bbf_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS05LTEtMS0zMTIxMw_d0a0ad74-ecc5-4d84-ae4c-8b459fdcf80d">40,793,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMi0xLTEtMS0zMTIxMw_d476bd77-d5c5-40f1-b0ab-14478ac84234">2,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMi0zLTEtMS0zMTIxMw_d96b83f4-5cb6-43a2-a131-e504585f574a">27,753</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMi05LTEtMS0zMTIxMw_5a79871c-f6ae-4960-b6de-da3fe9f000e6">27,753</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMy0xLTEtMS0zMTIxMw_1bad1df8-50eb-4270-a2c8-2f9087344f41">83,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMy0zLTEtMS0zMTIxMw_ad18fda6-1cf5-4255-a165-92e90683b291">196,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMy05LTEtMS0zMTIxMw_c60f308c-0c07-404c-aeeb-1bf2fd19cf81">196,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice6baec924b84624945c5bd58260a450_D20220401-20220630" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNC01LTEtMS0zMTIxMw_f66b0bc8-82c8-42cc-bdd3-0865fb041438">1,335,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ace87a0492248878926a8f03cd4a851_D20220401-20220630" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNC03LTEtMS0zMTIxMw_c7a06006-cd90-497c-bb77-d48737bbbe97">29,046</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNC05LTEtMS0zMTIxMw_8747594e-01e5-40ea-8b86-1b3c8fff9fd4">1,364,666</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS0xLTEtMS0zMTIxMw_4715eb16-62bc-4834-955d-dcb63259e5c4">14,649,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS0zLTEtMS0zMTIxMw_372b3bf4-2130-43e8-a826-08a3fbc6f0ae">47,822,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id04d0344712f4a1aafd6f9ba7a41df3c_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS01LTEtMS0zMTIxMw_6f1e5908-da81-48c9-aa2f-9580125faa0f">8,359,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd2da3c3015846d4942e467930489296_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS03LTEtMS0zMTIxMw_61c56c3c-0f95-40bd-a135-63eb3170460e">258,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ad4d2d8d8444fbbd7d930a0a59e68c_I20220630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS05LTEtMS0zMTIxMw_4bade462-f624-4dc2-9958-f474c7de1078">39,204,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS0xLTEtMS0zMTIxMw_a26b0352-fcc9-476e-9bb2-9ce3f5445232">14,649,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS0zLTEtMS0zMTIxMw_f0bc2b41-f471-43d9-a000-89bab5a0fd09">47,822,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id04d0344712f4a1aafd6f9ba7a41df3c_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS01LTEtMS0zMTIxMw_6e94a865-ee49-4af2-983f-3635fa9e34e9">8,359,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd2da3c3015846d4942e467930489296_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS03LTEtMS0zMTIxMw_f89659be-f81f-4973-b773-a130178bca97">258,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ad4d2d8d8444fbbd7d930a0a59e68c_I20220630" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS05LTEtMS0zMTIxMw_78851de5-8d5a-4b74-bd3e-4cfec85ddd24">39,204,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi0xLTEtMS0zMjM2MA_909f969e-1e6a-4cce-b2ad-5ae08817697b">180,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi0zLTEtMS0zMjM2MA_9a94138d-163b-41c7-b215-908952b2aebc">399,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi05LTEtMS0zMjM2MA_785ab2a7-eae1-4f0e-937d-2deac30b4736">399,600</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi0zLTEtMS0zMTIxMw_178c1f9c-2a8f-4eb1-beba-358375f2f633">188,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi05LTEtMS0zMTIxMw_130536a3-4aa4-495b-a461-177fc8bafea6">188,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMy0xLTEtMS0zMTIxMw_ed45258a-b2b7-4347-8264-4fb0e20f425f">33,110</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMy0zLTEtMS0zMTIxMw_a11a9c09-208e-4491-8303-e4c5d666dae3">78,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMy05LTEtMS0zMTIxMw_a60d7bcb-1e98-487a-b3a2-b4813d4de0ae">78,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49466fa28fb04d6cb5ce8a17a31d35a2_D20220701-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNC01LTEtMS0zMTIxMw_507bd996-2ee6-405b-b5bc-e6b58de70bf0">408,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c1457746c76430098d4ceb9d629e6dc_D20220701-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNC03LTEtMS0zMTIxMw_cdfc10e0-56d6-4bac-a409-98d70257bd77">14,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNC05LTEtMS0zMTIxMw_5b58e695-2218-43cf-9039-f1c929c45d7c">423,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic33219167c744508bf085d2ae2eba1dd_I20220930" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS0xLTEtMS0zMTIxMw_121de7e3-9bf1-4211-9fcd-e60c9d2c4372">14,436,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33219167c744508bf085d2ae2eba1dd_I20220930" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS0zLTEtMS0zMTIxMw_8a8b9149-9b05-4fa1-98f6-665acefbc19a">47,532,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i753dd913f191471e8a379e7fa42a7892_I20220930" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS01LTEtMS0zMTIxMw_de7cfafe-fc9f-4f2b-a83f-b98e068ab955">8,768,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81209df23984304bd9299e97be9d76a_I20220930" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS03LTEtMS0zMTIxMw_3e0b29f5-6f1d-4146-a5de-d7eb14e25d27">273,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS05LTEtMS0zMTIxMw_92266611-e39e-4cfe-8117-1c745c93bdbd">38,491,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_31"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUyMQ_a4a9d187-bcba-4e2e-b45a-d9d119bca9cd" continuedAt="i80273960c1df4c279480f7be49f99aa1" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i80273960c1df4c279480f7be49f99aa1" continuedAt="i1255c9528e894e35a4a083ed413a8a4b"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its hospital, field and oncology sales teams and its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Annual Report on Form 10-K&#8221;). The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 10, for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, 2021 and the nine months ended September 30, 2022,  we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i1255c9528e894e35a4a083ed413a8a4b" continuedAt="i6216a728dd874d0495f064eb80b3ce94"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUyMw_712a490d-d2e7-4597-8789-7246527fc5a6" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUxNw_6582bed1-f92d-4f4a-9457-72e174270f84" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUxOA_0762b239-417d-4120-b29d-723aa1834a1b" continuedAt="i0e1561d9344c4377b150f433ee71f554" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6216a728dd874d0495f064eb80b3ce94"><ix:continuation id="i0e1561d9344c4377b150f433ee71f554">The Company has <ix:nonFraction unitRef="segment" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfODcxMQ_4fe877b9-b30c-4f9a-b581-2d38d7f66a80">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfNDE1_d14aef8b-cf3a-49dd-9f3d-449ad10522e8" continuedAt="ia0dbaaafd2724f5e971e4a91c7570d6c" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ia0dbaaafd2724f5e971e4a91c7570d6c"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfNDE3_66a1d82d-d9ac-4ce5-92ce-9eb511bace04" continuedAt="i704d7c052b1540e8afb57669676dbae0" escape="true">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><ix:continuation id="i704d7c052b1540e8afb57669676dbae0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNC0xLTEtMS0zMTIxMw_cd306f8d-7a23-4447-b7b8-fd1ed163ebe6">423,226</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNC0zLTEtMS0zMTIxMw_a42c9fc0-5fd8-493d-91db-9bf0dc7eda56">1,583,480</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNS0xLTEtMS0zMTIxMw_a366bf5a-6c37-4c1d-9d11-3a1aa767af75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNS0zLTEtMS0zMTIxMw_fb028702-2690-4ef2-bee4-8184ef6fc3c4">496,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNi0xLTEtMS0zMTIxMw_1f19ad60-40f5-4905-b627-517a854d4eec">423,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNi0zLTEtMS0zMTIxMw_269e53c2-3bd4-4661-8558-77ffa6a4cb7c">1,086,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNy0xLTEtMS0zMTIxMw_eff198a1-5c67-4bcf-b459-92c3cb42f19d">14,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNy0zLTEtMS0zMTIxMw_0f71b9d1-df41-4bd8-a060-2a9c06c3021f">31,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfOC0xLTEtMS0zMTIxMw_9ba2e104-59ca-4a7b-aaaa-ef9261e93f1d">408,639</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfOC0zLTEtMS0zMTIxMw_1989e941-bd1f-49f8-b313-fd904fcdfa69">1,055,278</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTAtMS0xLTEtMzEyMTM_e1a1f4d8-f81d-440d-9872-1a42f4ddf3b7">14,477,478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTAtMy0xLTEtMzEyMTM_554afac6-e827-4b81-a7d9-18a391f6ffce">14,880,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTEtMS0xLTEtMzEyMTM_3dfabb03-1010-4ee7-a086-e506e13a9446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTEtMy0xLTEtMzEyMTM_bcec73c9-f789-4d7b-b19e-13a30fd2663f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTItMS0xLTEtMzEyMTM_4ded4125-9700-4ad7-8826-967d5c1c164d">14,477,478</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTItMy0xLTEtMzEyMTM_daf4f1d3-863b-4d08-8948-0d7cb971ca51">14,880,887</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNC0xLTEtMS0zMTIxMw_0845a259-2c09-4f78-84dd-d140ff304e97">3,190,325</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNC0zLTEtMS0zMTIxMw_d20ec557-09a0-4330-b526-f582b79a03c1">1,209,545</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNS0xLTEtMS0zMTIxMw_5ceaead0-f754-4cc5-afe8-90c915a6320f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNS0zLTEtMS0zMTIxMw_e6c4ce79-b1ed-43e7-9e29-5b9a601883b9">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNi0xLTEtMS0zMTIxMw_b168c6ff-209c-4019-9743-2bab2dc85742">3,190,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNi0zLTEtMS0zMTIxMw_95940213-cb76-4546-9974-fe4a1c98f04e">281,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNy0xLTEtMS0zMTIxMw_3556da5d-f8ce-4ed1-a523-271022aeb086">60,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNy0zLTEtMS0zMTIxMw_c2cd2dda-1d4a-4fd8-b5a7-cc6db09e1b1f">58,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfOC0xLTEtMS0zMTIxMw_0c77e351-abc9-47d1-a10d-1e1a793bfd6b">3,129,512</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfOC0zLTEtMS0zMTIxMw_e57038d3-13c0-4d1a-9270-9f0f2e05a65b">340,110</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTAtMS0xLTEtMzEyMTM_6d99a7e9-647b-4d61-ad56-13ccbbc226b9">14,618,975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTAtMy0xLTEtMzEyMTM_b89fbfa8-61f9-43b7-9b98-54351347df72">14,939,919</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTEtMS0xLTEtMzEyMTM_910272fa-cf8a-4d36-98b1-dad4aabe54b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTEtMy0xLTEtMzEyMTM_5aa9a374-70a5-44f1-9eaa-c591cdafda56">199,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTItMS0xLTEtMzEyMTM_0b230d13-d390-4094-8abb-06e6aab4e27a">14,618,975</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTItMy0xLTEtMzEyMTM_4ce3dc71-5705-43d4-9194-c3cb7ddd1298">15,139,904</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfMjM5_859ce511-e81d-40b5-bd9c-8a4d7558f6db">233,750</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfMjQ2_93e22efd-7f4a-46fa-930c-3e988c1bf7b2">158,900</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i9d8b5229cbe549cdb99425ffcfc909d0_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzI0MQ_59555243-6f34-4e29-9e7c-1780a8844897" continuedAt="i5e2c04145e834b16aeea1fb9eb3d2b23" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i5e2c04145e834b16aeea1fb9eb3d2b23"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzI0Mg_336ac9dc-1b87-4bc2-a602-ea2b5bcdf7f1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc8c19c661864883b36b04dc73597c1a_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy0xLTEtMS0zMTIxMw_efb08e05-14b8-4cd4-a786-af0d7cbcff39">3,903,305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib40fb787c5304021af13e3f348f7983b_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy0zLTEtMS0zMTIxMw_7983ab91-8b1d-4c28-adbe-827e96601836">4,012,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d1ae337b8241eaa014de1e9b8f7c07_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy01LTEtMS0zMTIxMw_53afaf62-9c0f-44fe-9e10-a67ec8b561b7">11,418,673</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e17b402c0f4e0288249a98d5c1ef67_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy03LTEtMS0zMTIxMw_3934238d-5ab0-46e6-9856-200403fd8cb5">12,286,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d6b3e6fa3b44c390043374bd0da6ab_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC0xLTEtMS0zMTIxMw_731bde77-7e49-40b1-9fc2-2b3e746967a7">3,960,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9a2d719ce448809401f919889d8f43_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC0zLTEtMS0zMTIxMw_c4408ac3-8e63-4460-a71a-67cdbf1fb5bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef2fd27ce9b4de6811b30262e109c4c_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC01LTEtMS0zMTIxMw_3cf00b1c-17e5-4bd0-8829-14d779254635">10,756,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96dba68919a94185be0f2caa4d19fbd6_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC03LTEtMS0zMTIxMw_9c1b844a-d6f5-4522-ad5a-5dd7d2d9d03b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81107b4b859c48379106d400c932111b_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS0xLTEtMS0zMTIxMw_c81b168a-c54f-4b97-86e9-f8d30c671a3b">1,909,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie672054973a54d8b96a1429d7893b153_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS0zLTEtMS0zMTIxMw_d2b311db-dfa8-4681-a8a7-ad2e5f92c906">1,896,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c935e63cfe042c0b62e5ad1b3ffccc4_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS01LTEtMS0zMTIxMw_dec601e0-ad53-4390-a283-4c9523b16f2a">6,008,005</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de578808568412b98f4258ca2a140d4_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS03LTEtMS0zMTIxMw_1ef19ab5-e9dd-46cc-b156-b69574833d41">8,799,891</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b9640c93e4f4787d4be2b043c3ae6_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi0xLTEtMS0zMTIxMw_8c3c3f9e-3fb7-4d03-ac2a-79d7f3dfb927">921,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2423acefd847a9a84fc30460b5526a_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi0zLTEtMS0zMTIxMw_a3b40028-3ee2-43c5-a29d-9a3af6726784">1,255,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aaf93c862d54ccb94779f62960f1d26_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi01LTEtMS0zMTIxMw_b66ab6ce-eea5-436f-9344-071d2eff2d34">3,075,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3b5f2e4fb145d9951d563e234c5113_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi03LTEtMS0zMTIxMw_c74bf698-1791-454e-8945-abab0dbb1fc0">3,734,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0468ba36dc8c4f4e94efe1fce522a602_D20220701-20220930" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy0xLTEtMS0zMTIxMw_45084d6b-be77-4bab-940c-68bfbd3aecae">436</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378e8f356b7d41ea99ef9c631175c257_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy0zLTEtMS0zMTIxMw_f32b8943-6aa4-4b79-ae4e-5995c5b61900">325,774</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebdfd0073023463d9f73789defb1bc95_D20220101-20220930" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy01LTEtMS0zMTIxMw_0bdf5053-816e-4bf8-adfd-761c17fd112a">252,059</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f0f1e915d743ea86de5bef24145fd2_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy03LTEtMS0zMTIxMw_5be112bc-a292-485e-aa11-6d6c33900734">1,861,130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef1b02b27044b4a842a41c51f0dda36_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC0xLTEtMS0zMTIxMw_19a3baeb-3bbc-4a06-9439-3b5a5560007b">99,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a22798105d04ccf960042a44583bde5_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC0zLTEtMS0zMTIxMw_0d42ba93-a71e-4b37-a4cc-329a4296ef12">368,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb5fd089f1847c09d6b1565f351311b_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC01LTEtMS0zMTIxMw_22210f34-1f85-4fbf-95d2-e017edd9dc6e">337,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc92d5aecc141899d9bbb33fece4352_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC03LTEtMS0zMTIxMw_060dc9ca-0961-4772-809f-b6f0bb81696f">638,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28345cf5e7864e4f88e1ad3783be1eb1_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS0xLTEtMS0zMTIxMw_0f8104b9-bfc1-4d86-925f-1ae58d07af3c">35,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i393707a2f8e84e51aab9d9aa77ec97cd_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS0zLTEtMS0zMTIxMw_8fb8c6f4-2686-4a57-87ed-4cadb21faef5">22,689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d6ec26dd9148f19ebaf571b61a2b1b_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS01LTEtMS0zMTIxMw_be275c9c-c0b3-48c6-8394-c94c4eeda862">31,925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i474d3830aff24d969ed6a7730701fff4_D20210101-20210930" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS03LTEtMS0zMTIxMw_06386565-34a2-4a91-acb0-ffd767c1a410">451,683</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ea0bc96ecd4501a2dea5ae2bd2122b_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtMS0xLTEtMzEyMTM_bc4a6fa1-1eb9-47d7-9448-6c2b4a8c51e8">85,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ccd958b6a845348dde9c5a826d3f1d_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtMy0xLTEtMzEyMTM_f78adffe-4ca8-4d4e-8f9b-e5fa027fc7c4">11,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2c178f155b4cd0a7df168033b61d35_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtNS0xLTEtMzEyMTM_d6d35946-ad0a-46cb-8ce1-51bdc287f168">238,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb4c673c94a4eebb2bb9cead80bf84a_D20210101-20210930" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtNy0xLTEtMzEyMTM_b3573952-f8fe-4612-bf14-81fde9a90ed1">13,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87128d81de3b40f59ea5c6c5a4e7e490_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtMS0xLTEtMzEyMTM_2467f835-f79e-42a3-a634-3c5cd77dac41">496,789</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029c4ae96e134c18bb123cde8e3f3b46_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtMy0xLTEtMzEyMTM_1a104261-53aa-4e38-b04e-62db4cef1b9c">178,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ff531cbef64ec99752b4a2832ce9b2_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtNS0xLTEtMzEyMTM_2f8d968d-99d7-497e-a651-41da92cadfc8">1,272,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eba1c1c7837438686f9bbe8a1d81821_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtNy0xLTEtMzEyMTM_5f9bb108-c13e-4d09-a47e-7427431d23e5">809,429</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItMS0xLTEtMzEyMTM_1c12680d-70f2-4c66-8e62-f3fcae53334a">11,413,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItMy0xLTEtMzEyMTM_a30704b4-14c8-4df0-a7e9-d339aed842b0">8,072,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItNS0xLTEtMzEyMTM_3854177d-6b96-484f-b502-b67586be803d">32,887,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItNy0xLTEtMzEyMTM_bb7a3f1f-86c7-488e-9892-d11da5858be0">27,665,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the third quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the third quarter of 2022, the amounts noted were normal adjustments by channel partners.  Net revenue was positively impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022.  Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval.  Net revenue was negatively impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="-5" name="cpix:RevenueRecognitionMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMjU0Mg_c3cc3dbf-6ee7-4006-82ba-438d65850bfc">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="-5" name="cpix:RevenueRecognitionMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMjU0OQ_4ccef4d7-72ed-46eb-bca0-6ac4ba5cfbfe">0.6</ix:nonFraction> million, respectively, for milestone and international licensee payments as part of other revenue.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant  programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ia65a4295cc5943d2bdca764eec17c7fc_D20220701-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzE1MQ_3eec6faa-e982-47d4-8e35-535eeb649025">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ica03638cc07848c3ad90c3dc523f5a6f_D20210701-20210930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfNTQ5NzU1ODE3NDMy_20780b03-fc2a-4522-ad2b-37f41d8f5277">0.02</ix:nonFraction> million for the three months ended September 30, 2022 and 2021, respectively, and approximately $<ix:nonFraction unitRef="usd" contextRef="i5029ffaf4ba44d2ebd77cf036dcb3394_D20220101-20220930" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzE5OA_54e15a53-0eb8-42d7-9d9d-ae8a5fb38208">0.3</ix:nonFraction> million each for the nine months ended September 30, 2022 and 2021.</span></div></ix:continuation><div id="i9d8b5229cbe549cdb99425ffcfc909d0_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjMxMA_b1175a78-8938-4bb0-9202-658665858fae" continuedAt="icfa062de8514425ca88a1b8db8997a87" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="icfa062de8514425ca88a1b8db8997a87"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTAzOQ_9c8b4c6a-3c58-402b-a6e7-47b3ea64c2d4">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTA0Ng_fbd0241b-87ed-43b2-b082-f3a29182f9ec">1.4</ix:nonFraction> million, respectively.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2022 and December 31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="iaf738532e4694162b9ca0c676b7e2bfe_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTYzOQ_40d93cb4-f979-451d-b4a2-1d53bd014124">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  For the Sancuso acquisition, Cumberland acquired $<ix:nonFraction unitRef="usd" contextRef="i227ccd5f3c584c1f80be5a81980484aa_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTc4Mg_3b8d3b79-a16d-4be3-8db9-1632a67e939b">3.0</ix:nonFraction> million of work in progress non-current inventory.  At September 30, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTk0Mg_d75b9012-aff3-4e4e-bd33-a88b6047999b">7.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTk0OQ_3296865c-4403-48c1-8a72-6da692ac3804">9.0</ix:nonFraction> million, respectively. The Company had no Vibativ finished goods included in non-current inventory at September 30, 2022, and $<ix:nonFraction unitRef="usd" contextRef="iaf738532e4694162b9ca0c676b7e2bfe_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjA1NA_529e2a1c-1d7c-4f15-a927-aa0c3525804d">0.5</ix:nonFraction> million included at December 31, 2021.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="i0a588281c96f412e8750a46d0cf78bff_I20220930" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjEwNA_04404f34-f8bf-4555-aa0c-d17c22d69a07">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f654c5250f1487a87a937cdbf000493_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjExMQ_a66b7dc5-06d5-445d-af6c-3cef9fb7a94c">0.4</ix:nonFraction>&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjMxMw_931f64a2-5c55-4aa5-b8a8-7e08b1a9bdcc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMi0yLTEtMS0zMTIxMw_69c0c450-f24d-4689-8a6e-321da92f2fdd">11,738,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMi00LTEtMS0zMTIxMw_06849e8d-5d40-4f5a-a8fd-1bcc780a6a14"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMi00LTEtMS0zMTIxMw_3220e695-4e04-41eb-b175-6e5702651c14">12,374,983</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMy0yLTEtMS0zMTIxMw_ddd102f3-9b39-4f74-85e1-5ffab49dde50">128,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMy00LTEtMS0zMTIxMw_8d3493e1-c881-450f-80b0-fca7e76df105"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMy00LTEtMS0zMTIxMw_d4fc08c7-5f48-4dc2-82b6-0b145294eff8">164,378</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNC0yLTEtMS0zMTIxMw_51331cbf-5c91-440a-9dcb-ea07a77597c8">6,277,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNC00LTEtMS0zMTIxMw_2f65b052-e3d0-4f80-8e62-411c350814ff"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNC00LTEtMS0zMTIxMw_ebbf2965-409e-4c5c-afef-24f690e2cb07">4,939,088</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNS0yLTEtMS0zMTIxMw_c310ebb0-043a-4fc1-8964-33f3f3594725">18,144,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNS00LTEtMS0zMTIxMw_fae64f53-db61-4798-8e1b-3706edef91af">17,478,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNi0yLTEtMS0zMTIxMw_08de56f8-9996-4fd9-a325-107aa5392ed9">7,497,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNi00LTEtMS0zMTIxMw_d19a1ca9-b20b-41bd-9864-d4ca7040761f">9,048,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNy0yLTEtMS0zMTIxMw_aa2cbf65-e907-4da6-9d41-512a24f06971">10,647,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNy00LTEtMS0zMTIxMw_2396e96f-a9ea-438d-ac18-eba96e55b0ca">8,429,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i9d8b5229cbe549cdb99425ffcfc909d0_43"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg1MA_9530b94a-65b8-42d2-9ce5-b3d049a38843" continuedAt="icb6422b629bc4c3da52589fa7b857742" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="icb6422b629bc4c3da52589fa7b857742" continuedAt="i92c2f5a740f44c629889e3cecbc0597e"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="ie91cbfa298a24c6db40c5463641c9886_I20220930" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfOTQ_efede379-9dda-4d19-b140-095137968688">25,500</ix:nonFraction> square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease expired in October 2022.  The Company's operating leases also include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i658044c887034a83bdb045b4fb42ca2b_I20220930" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMzAw_cf004c99-389e-4c83-a355-13e335396e10">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTI0OA_d2b69b16-8a66-44a6-b82e-12ed283f88eb">7.42</ix:nonFraction>%. The weighted-average remaining lease term at September 30, 2022 is <ix:nonNumeric contextRef="i16ada3ab868247dd9574797af517d567_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTMwMw_395dc84a-67f8-4ce1-a1a9-9aa10db9b672">0.4</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i92c2f5a740f44c629889e3cecbc0597e"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately <ix:nonFraction unitRef="sqft" contextRef="ie795a7e8b44749c2b64904584da6bf32_I20211115" decimals="0" name="cpix:LesseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTQxNw_76fa705a-a887-4468-9507-92f5565259a1">16,631</ix:nonFraction> rentable square feet of space (the &#8220;Leased Premise&#8221;) at the new Broadwest development located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (<ix:nonNumeric contextRef="ie795a7e8b44749c2b64904584da6bf32_I20211115" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTcxMg_e458e5a3-46dc-4aed-a39d-18afba9dd828">157</ix:nonNumeric>) months, with <ix:nonFraction unitRef="renewalterm" contextRef="i89ea0a5e1de9410b819fbb525f8f78e1_I20211115" decimals="INF" name="cpix:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTcyOQ_9166e799-d06e-497d-82af-2d5a14a76c8e">two</ix:nonFraction> consecutive options to renew for a period of <ix:nonNumeric contextRef="i89ea0a5e1de9410b819fbb525f8f78e1_I20211115" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTc3Nw_3ee98b6d-992f-4bc9-b790-16672ab54213">five years</ix:nonNumeric> each.  The Broadwest lease calls for monthly base rent, operating expense and parking payments. In year 1, the base rent starts at $<ix:nonFraction unitRef="usdPerSqft" contextRef="ie795a7e8b44749c2b64904584da6bf32_I20211115" decimals="2" name="cpix:LesseeOperatingLeaseBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTA5OTUxMTYzMTc5OA_9cff46b2-2337-40dd-9d99-6effbe9ef0f3">33.06</ix:nonFraction> per square foot of rentable area. The lease also provides for several months of free rent plus a tenant improvement allowance.  Cumberland received approval for its building permit and began construction on the Leased Premise in June 2022.  On October 25, 2022,  Cumberland received final building approval and a certificate of occupancy for the Leased Premise.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg1MQ_041c233f-60b3-47b2-a237-3c90f400dd3c" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjMzNzgzM2UxYTkxNTQ5MDNiMjA4NjQxZjNjYTMxY2NkL3RhYmxlcmFuZ2U6MzM3ODMzZTFhOTE1NDkwM2IyMDg2NDFmM2NhMzFjY2RfMS0yLTEtMS0zMTIxMw_4c6be4f7-8d44-44c1-88f4-0f811571e047">219,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjMzNzgzM2UxYTkxNTQ5MDNiMjA4NjQxZjNjYTMxY2NkL3RhYmxlcmFuZ2U6MzM3ODMzZTFhOTE1NDkwM2IyMDg2NDFmM2NhMzFjY2RfMS00LTEtMS0zMTIxMw_50a1a127-27ab-4c27-869f-edb8da782546"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjMzNzgzM2UxYTkxNTQ5MDNiMjA4NjQxZjNjYTMxY2NkL3RhYmxlcmFuZ2U6MzM3ODMzZTFhOTE1NDkwM2IyMDg2NDFmM2NhMzFjY2RfMS00LTEtMS0zMTIxMw_94b25b70-349e-4dfc-91c4-a65aa019399b">1,024,200</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMS0yLTEtMS0zMTIxMw_fae870b7-88c0-4e2d-bccd-696b7b365908">229,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMS00LTEtMS0zMTIxMw_6bd4c061-9d46-4a31-9335-8006051693ec"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMS00LTEtMS0zMTIxMw_e4791503-bad7-4c73-a3ca-c6b9c40b6ef2">969,677</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMy0yLTEtMS0zMTIxMw_ee46a639-e498-4589-8366-1ec35f9fada5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMy00LTEtMS0zMTIxMw_1bc6210e-fc2d-42ee-8bda-a97c92ca1368"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMy00LTEtMS0zMTIxMw_2c34c072-4e86-43b8-ae5c-e6132f1201b6">90,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfNC0yLTEtMS0zMTIxMw_aec57555-ef44-4ded-8f53-79eab4436262">229,605</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfNC00LTEtMS0zMTIxMw_4afedfdc-3433-4aa2-a25c-363312b22c0c">1,059,693</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjM0Ng_8519010c-8647-4dd8-9b3b-24e649891526">0.2</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg1Mg_0289bf2f-d2c4-447d-be8d-c5a66ed84ec6" continuedAt="i4c3c46d6338644e287d4e9a2679d50b0" escape="true">Excluding the Broadwest lease agreement, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i4c3c46d6338644e287d4e9a2679d50b0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfMS0yLTEtMS0zMTIxMw_bfe6192f-1904-4467-b73a-33c84db78d22">150,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfMi0yLTEtMS0zMTIxMw_f1659c70-368b-42ff-936d-8552f7ea29ee">92,477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfMy0yLTEtMS0zMTIxMw_0826d265-5071-415c-86b2-2c8e0edefa60">243,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfNC0yLTEtMS0zMTIxMw_3e5d16f3-765c-46b5-bda4-9ceead9babe0">13,405</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfNS0yLTEtMS0zMTIxMw_6863efc4-1646-4636-8d03-7243b08685ec">229,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg0OQ_13cde049-ec10-4323-9b1d-ce2a6fbcdca9" continuedAt="id3a581db221841a6bdc60c1c3521e3be" escape="true">Rent expense and sublease income were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="id3a581db221841a6bdc60c1c3521e3be"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfMi0yLTEtMS0zMTIxMw_6a8fbbee-7dd0-4471-9a15-d62bdd7e9845">861,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfMi00LTEtMS0zMTIxMw_d880fbe6-552f-4a0c-bacc-3743dc018383">910,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfNC0yLTEtMS0zMTIxMw_5f20ad41-3915-4fd2-b929-315e4f73618b">424,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfNC00LTEtMS0zMTIxMw_f259dfcc-6bbe-4561-b5f1-cc430ac18025">526,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i9d8b5229cbe549cdb99425ffcfc909d0_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNjE3OQ_c9151383-0b52-478a-baa1-402ba9ced7f7" continuedAt="i47dfbcb323a541788efe8e38c395939b" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i47dfbcb323a541788efe8e38c395939b" continuedAt="i3dd7fd5299924223a3871b314dff5e2a"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i73e648d1756d4361ac4f73a357526bb6_I20100513" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTMw_98901114-7c93-49e2-a7ff-997101cee93a">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i9a5078dc2e454b1ba6c7f4e344e79a4b_I20160131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjkx_d0b9dec1-f587-4f91-bbb1-62a7e8ca5767">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2022 and September 30, 2021, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i0dfb60514b2a4bfba647a1772e5f8bad_D20220101-20220930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzk3_8c503148-bb3d-4033-a5e2-7026ebe74f1f">290,576</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ib2c5bbf3a46c412fbe0e400fa873a864_D20210101-20210930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDEx_ec3392e4-920e-4c4a-8960-3a102ba999e7">326,537</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i0dfb60514b2a4bfba647a1772e5f8bad_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDcw_dde0d428-95ca-430f-a65c-e81fa305bbc9">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib2c5bbf3a46c412fbe0e400fa873a864_D20210101-20210930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTQ5NzU1ODIxMDc4_808bdb6d-be9e-472b-8eb8-d281bf063f68">1.0</ix:nonFraction> million, respectively.  At September 30, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="ic33219167c744508bf085d2ae2eba1dd_I20220930" decimals="0" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTA4_b006f79b-116b-4fd8-86b7-c9b9e847ecdf">3.9</ix:nonFraction> million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  These purchases began in April 2022 and as of September 30, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="i9f068611586b404c9e736da8397fb6d3_D20220401-20220930" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTQ5NzU1ODIxMDA5_3b07d29f-b743-45d7-871d-d7010ef5b7da">27,698</ix:nonFraction> shares have been purchased through this trading plan.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i8b9a83dbeb504232888f1be955d3484a_D20171101-20171130" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTA4MA_0361aa11-8e23-4ee0-85ec-7ed1f63759b5">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $<ix:nonFraction unitRef="usd" contextRef="icba3428fcf7b4d74a47c2ef785d2fa87_D20211227-20211227" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTY1OA_c4568b81-0d37-4d1d-a784-4dd776fe7ad8">19</ix:nonFraction> million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the nine months ended September 30, 2022 or September 30, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and September 30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ia9a3f9de6fd74bcc977d7a494dfd0845_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTk2Nw_d1688aaa-e0bb-4097-af9d-6f0be357c6ec">65,225</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="if26fc6a73ecc488bbe41fa9905a8441a_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTk4MQ_5c459b8d-4c02-4045-948c-e323b5880054">36,850</ix:nonFraction> shares of restricted stock to employees, advisors and directors, respectively. Restricted stock issued to employees and advisors generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i7c80572bb63c43f3a1049c338dfc7e8e_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNjE3NA_cf0e0c1d-5a32-4cb5-958c-a186b560d7f1">one-year</ix:nonNumeric> anniversary of the date of grant.  During the nine months ended September 30, 2022 and 2021, the Company also issued <ix:nonFraction unitRef="shares" contextRef="ia41636d373054e1b8b162bc68c25ba1c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjI5Ng_c82b8c9b-7eec-4885-a87e-f546dab37bbd">172,300</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i94d70987e1124eccabfc3d8e4dec7545_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjMwMw_cfe21664-29a3-446e-8d8d-6c33ddc23986">174,800</ix:nonFraction> incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in 2032 and 2031, respectively. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.  For the nine months ended September 30, 2022, we recorded a credit of $<ix:nonFraction unitRef="usd" contextRef="ia9a3f9de6fd74bcc977d7a494dfd0845_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjY1NA_37dd7089-ef40-4676-b84b-eb7c322f82a5">0.1</ix:nonFraction>&#160;million to share-based compensation related to the forfeiture of unvested restricted stock awards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $<ix:nonFraction unitRef="usd" contextRef="ie71841d6d5c24f758fab7ac85872aa45_I20220929" decimals="0" name="cpix:DebtInstrumentCovenantUnrestrictedCashThreshold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTA5OTUxMTYzNTE3Nw_58a6be3c-2d43-4323-a34c-486c3bd72b0c">8,500,000</ix:nonFraction>, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (<ix:nonFraction unitRef="q" contextRef="ie71841d6d5c24f758fab7ac85872aa45_I20220929" decimals="0" name="cpix:DebtInstrumentCovenantEvaluationFrequency" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTA5OTUxMTYzNTE4OQ_73f34a73-997c-46fd-89c2-acfc9d400736">4</ix:nonFraction>) quarter basis.  For the quarter ended September 30, 2022, we were in compliance with the Funded Debt Ratio financial covenant.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than <ix:nonFraction unitRef="number" contextRef="i357c94714cfb4fd08c6fffaa13a6c200_D20220401-20220930" decimals="0" name="cpix:DebtInstrumentCovenantFundedDebtRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzAyMQ_50ed9649-9b8c-4045-9377-2e4c7a739abd">3.00</ix:nonFraction> to 1.00 for the second and third quarters of 2022 and <ix:nonFraction unitRef="number" contextRef="i13f82082fed14f898c9cf04f1b98af86_D20220101-20221231" decimals="2" name="cpix:DebtInstrumentCovenantFundedDebtRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzA3OA_884d1be7-eea6-459c-b6d4-267b53c94699">2.50</ix:nonFraction> to 1.00 for each quarter thereafter.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $<ix:nonFraction unitRef="usd" contextRef="ie39e421790ed488e946469a82c5d37a3_I20211231" decimals="-6" name="cpix:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzg5NA_d1370502-95ed-45d2-ac53-3bc2e2805b9e">15</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ie39e421790ed488e946469a82c5d37a3_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzkwMA_0d02bd45-8f6a-41eb-8f9a-0983407df914">20</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i3dd7fd5299924223a3871b314dff5e2a" continuedAt="ide5388815d544a7e8a38893c5e4d45c4"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement.  The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i88065d8df8544ba4bf056f4d71ec695a_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDY2Ng_5bfd8995-fd16-4476-96aa-dd2c4f04e0ee">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifedf271cc67e434abd3401e7acffd33c_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDY3Mg_d0850c94-e37c-4590-a85f-666a57e503e7">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="iede01fe31ea346b4918f9f4d3d001891_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDcxMQ_f784b0c8-8bd7-431a-b248-c511bc83a216">0.90</ix:nonFraction>%. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="i31108d31c0b44f30a2b52b23201aea12_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDc3Nw_2d96bbf0-68c4-4c52-b349-297b84feac52">5.25</ix:nonFraction>% at September 30, 2022.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="iceae2fc3bfa449c5bb629a222d37c37f_D20220101-20220930" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDgxMA_22cfc065-f8bf-4753-93a5-61948ac4344a">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i866dc2144f804589a64b1eb2c037834c_I20220930" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTEyOQ_47cb8fff-52a4-4f08-9541-5317bd9bbed2">17.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTEzNg_acfbc7f5-e226-449b-97d0-e56df4b673d3">15.0</ix:nonFraction> million, respectively, in borrowings outstanding under its revolving credit facility.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><ix:continuation id="ide5388815d544a7e8a38893c5e4d45c4" continuedAt="i87c82bacb24848289f03ca6f1ee8054e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87c82bacb24848289f03ca6f1ee8054e">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i7a44e5571a0d436ca5db214ef0319e3e_I20200831" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTc3Ng_bcf48797-9479-4ccf-bc56-4fc748920e23">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of a $<ix:nonFraction unitRef="usd" contextRef="i319a720f5704435caf765b6497b99cd9_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTg1OA_874892c2-7ff4-4350-b386-8a73b34ffa3b">0.2</ix:nonFraction>&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.</ix:continuation>   </span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_49"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80OS9mcmFnOmI3MzRmMDRiNzQ5ODQyZTc4Zjk3MjQ4MDFlZTFkZDBmL3RleHRyZWdpb246YjczNGYwNGI3NDk4NDJlNzhmOTcyNDgwMWVlMWRkMGZfNjM1_17e4fe66-2526-442c-9b43-96aa068c4825" continuedAt="if00b690d990347bfa2805d7c8a098c51" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if00b690d990347bfa2805d7c8a098c51" continuedAt="i2f682f0c75c64d048c8971e8245443c8">As of September 30, 2022, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i5877b735a5424506a5da1c44d8a26339_I20220930" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80OS9mcmFnOmI3MzRmMDRiNzQ5ODQyZTc4Zjk3MjQ4MDFlZTFkZDBmL3RleHRyZWdpb246YjczNGYwNGI3NDk4NDJlNzhmOTcyNDgwMWVlMWRkMGZfNjI_a5f207f4-f533-45a7-a848-4c8ec207f9b6">56.6</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="i16ada3ab868247dd9574797af517d567_I20220930" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80OS9mcmFnOmI3MzRmMDRiNzQ5ODQyZTc4Zjk3MjQ4MDFlZTFkZDBmL3RleHRyZWdpb246YjczNGYwNGI3NDk4NDJlNzhmOTcyNDgwMWVlMWRkMGZfMTMz_978a6266-f197-4242-bec0-4595fa420c6f">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f682f0c75c64d048c8971e8245443c8">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_52"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81Mi9mcmFnOjJiYjMyMzY3MzNhMzQxZDhiMjE5NDAyNDMwOTk1MmFiL3RleHRyZWdpb246MmJiMzIzNjczM2EzNDFkOGIyMTk0MDI0MzA5OTUyYWJfMTU4_e945900f-05f3-47a1-b97e-943f83b3fede" continuedAt="i7277ee5e8148472e8ad1cbe299f9fde4" escape="true">OTHER INCOME</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7277ee5e8148472e8ad1cbe299f9fde4">The Company realized a $<ix:nonFraction unitRef="usd" contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630" decimals="-5" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81Mi9mcmFnOjJiYjMyMzY3MzNhMzQxZDhiMjE5NDAyNDMwOTk1MmFiL3RleHRyZWdpb246MmJiMzIzNjczM2EzNDFkOGIyMTk0MDI0MzA5OTUyYWJfNDU_ecc6cff7-f8f5-43f1-9f01-9ddd11a41636">0.6</ix:nonFraction>&#160;million gain in the second quarter of 2022 from insurance proceeds for a Company owned executive life insurance policy.</ix:continuation>  </span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_55"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81NS9mcmFnOmU5NzI3ZjYyMjU4MTQzODVhOTQyMWIyOTBjYjYzZjBjL3RleHRyZWdpb246ZTk3MjdmNjIyNTgxNDM4NWE5NDIxYjI5MGNiNjNmMGNfMTAyNw_36ffbcc6-49a6-4ff1-8d9c-955685de309d" continuedAt="i5c4b6ce85c964fdfab78263a5f2c2f05" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><ix:continuation id="i5c4b6ce85c964fdfab78263a5f2c2f05"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_58"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwOQ_5297fc34-efb1-47b0-ae0b-f4b0dd44e17d" continuedAt="ie1c6cb9ededa474f86efb074ac8aa45f" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="ie1c6cb9ededa474f86efb074ac8aa45f" continuedAt="i1005c53f9ae14619a518a9b4c436f56b"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTY5_342c9a25-d8e5-45a8-85e1-185a80c42713">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTAxMg_0197f4fd-4b51-4b8d-aac5-4ceec8b9838d">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTExNQ_1442895e-f619-457d-9811-80fca5a5d673">20</ix:nonFraction>% of on-going net sales of the product after the $<ix:nonFraction unitRef="usd" contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130" decimals="-5" name="cpix:TieredRoyaltyPaymentsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTE2NQ_56d9ac58-a21f-4de8-b8c9-237e6370b435">2.5</ix:nonFraction>&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwNA_c958c243-48b8-45f2-816c-9cb18dcca1ae" continuedAt="iaa0d518c277d4b4ea8e493c32d79ce0b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf738532e4694162b9ca0c676b7e2bfe_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfOS0xLTEtMS0zMTIxMw_9230aaf3-68cc-4b9c-85bd-8eb287fd1dd9">6,515,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTAtMS0xLTEtMzEyMTM_ed5c7c8c-8e7c-4d00-bb49-b75a748669a0">777,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTEtMS0xLTEtMzEyMTM_4c0da4f3-21b9-461f-8d62-24cc0206129b">1,550,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTItMS0xLTEtMzEyMTM_c3a6a76b-ee18-4831-b7ca-a8ef191addcd">631,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea269d83c37d448a868f5ac00213446b_I20220930" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTMtMS0xLTEtMzEyMTM_d47cd6da-87ac-4d32-a5b3-bfc3018cdc7e">4,819,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="iea269d83c37d448a868f5ac00213446b_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTg5MQ_4b8833d2-5db4-4aad-a335-b5c9136e5acb">4.8</ix:nonFraction> million was accounted for as $<ix:nonFraction unitRef="usd" contextRef="iea269d83c37d448a868f5ac00213446b_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTkxNQ_b11f9444-770b-478f-b662-1743a3060e53">1.9</ix:nonFraction> million of other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="iea269d83c37d448a868f5ac00213446b_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTk1MQ_2278b9aa-4861-42d5-a80b-8cc14a8547b8">3.0</ix:nonFraction> million of other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2022.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="if9529ac6603c4a1f9da2fbbe9d90afe8_D20161101-20161130" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMjQ0MA_f4a01342-a274-4efd-bd5a-cee4a077fae3">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="if9529ac6603c4a1f9da2fbbe9d90afe8_D20161101-20161130" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMjQ3Nw_68f265a4-9724-42c1-a719-cf3a7f72e03d">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="i767388330a25494b84c7b1f3f5e31ca9_D20161101-20161130" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMjUxNg_a437a9f0-e9f7-45ac-8905-21c3e1b7766c">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="i767388330a25494b84c7b1f3f5e31ca9_D20161101-20161130" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzEyNw_59e445d1-5e16-4da6-b202-ac2a5ad12904">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i1b15f1a6a0214d9db3c1f1b2e95e05e9_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzI0NQ_216350a2-19be-4773-9581-db1c63da6697">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="ida016a3372fe4bd9999e6c19613c11af_I20200731" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzMwNQ_d2e924f1-2a26-44e9-9b31-78c7812d09db">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 resulted in a $<ix:nonFraction unitRef="usd" contextRef="ib33917577d8c413092ed9270c4c1e044_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzQ1Ng_0fee642f-d093-4f08-bf41-9a89e5a8bece">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i1005c53f9ae14619a518a9b4c436f56b" continuedAt="i0714092a456c4dab9970a25d9e37e541"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after March 31, 2023. Cumberland will continue to distribute and support the product until then.  In accordance with the terms of the amendment, Nordic has agreed to return the <ix:nonFraction unitRef="shares" contextRef="iba57519128a042e6bcc12053ad575901_I20220712" decimals="0" name="cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzkxMg_4e121989-9cf2-4d1e-9608-7221a12673c7">180,000</ix:nonFraction> restricted Cumberland shares we previously issued to Nordic which will be cancelled, refund to Cumberland the milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i14fe005a15a14d999173b7903bf4a67e_I20220712" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNDAyMA_3359400b-27f0-462f-94e7-8275b5133e9e">1.0</ix:nonFraction>&#160;million we made associated with the brand's U.S. approval and issue a credit note in favor of the Company in the amount of $<ix:nonFraction unitRef="usd" contextRef="i14fe005a15a14d999173b7903bf4a67e_I20220712" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNDEzOA_828df07d-2e28-4ab6-a53d-c97cd636ca90">1.0</ix:nonFraction>&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Acquisition</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id20273d5a5164f0589d2524268988a2a_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNTc1NQ_4456987f-5d44-4b61-a2c9-67a542d39e6c">13.5</ix:nonFraction>&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="id20273d5a5164f0589d2524268988a2a_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNTg0NQ_6e87838f-953f-45fd-844f-c7f0d3a5074b">3.5</ix:nonFraction>&#160;million based on the attainment of various approvals and sales performance. The Company believes that $<ix:nonFraction unitRef="usd" contextRef="idfa76b73d21648f5a7205032b91c3205_D20220101-20220930" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNTk0Mg_939c8fb3-e9b6-48a2-bc8d-30bf790e6e6b">1.5</ix:nonFraction>&#160;million of the milestone payments will be earned and paid.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i134a7c60cd4344ffbbd3642de16ac052_I20220103" decimals="2" name="cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjA1Nw_667844c6-aaf1-40d6-9703-f6a06e3b85d8">10</ix:nonFraction>% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.  The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year.  The estimates of fair value for the more significant assets and liabilities assumed were as follows: prepaid expenses $<ix:nonFraction unitRef="usd" contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjg3OA_f6a6df6e-d219-4ac8-98a9-8a26d3fc0dee">0.3</ix:nonFraction>&#160;million, inventory $<ix:nonFraction unitRef="usd" contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjg5Mg_5573a9b1-a362-4ca1-bf94-a5a6d75ed128">5.2</ix:nonFraction>&#160;million, goodwill $<ix:nonFraction unitRef="usd" contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjkwNQ_306d6aa5-0a48-4a43-8fef-f43c1d0bffee">1.0</ix:nonFraction>&#160;million, intangible assets $<ix:nonFraction unitRef="usd" contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjkyNw_8f8117b0-2002-4bec-ba7f-fdc35790b48b">12.1</ix:nonFraction>&#160;million, milestone payable $<ix:nonFraction unitRef="usd" contextRef="ibbe5febaa0764ac187ee7a439033f2cb_D20220103-20220103" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjk0OQ_edbedcba-6698-4a6d-96be-427ae20aa6a0">1.2</ix:nonFraction>&#160;million and contingent liability $<ix:nonFraction unitRef="usd" contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjk3Nw_38d185c1-b2df-41ee-a1ba-34c8c13307ec">3.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="iaa0d518c277d4b4ea8e493c32d79ce0b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfOS0xLTEtMS0zMTIxMw_4568b627-a815-4067-b405-d8524601216a">3,946,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTAtMS0xLTEtMzEyMTM_ba08683c-de08-4a9f-9ce3-e137f75f451f">339,721</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTEtMS0xLTEtMzEyMTM_d9d7c436-bdfd-4186-bfa7-80e731173762">498,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTItMS0xLTEtMzEyMTM_f9dbfaf4-3fff-495b-8ef7-e842f8e31753">430,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7092e7f4631046c394046d8e01666761_I20220930" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTMtMS0xLTEtMzEyMTM_a64858d8-8c8f-4fe1-9397-f041cc4046bb">4,535,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i7092e7f4631046c394046d8e01666761_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNzI4MQ_b1d4feb0-4c25-467a-a2f3-5e2ea127f21d">4.5</ix:nonFraction> million was accounted for as $<ix:nonFraction unitRef="usd" contextRef="i7092e7f4631046c394046d8e01666761_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNzMwNQ_af430b14-f6da-49e1-b5c1-80e3362d8270">1.9</ix:nonFraction> million of current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i7092e7f4631046c394046d8e01666761_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNzMzNQ_35619baf-18b7-403e-8a55-da56c8711e65">2.6</ix:nonFraction> million of other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2022.  </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i0714092a456c4dab9970a25d9e37e541"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $<ix:nonFraction unitRef="usd" contextRef="i2f1475f8cb974dc2b812258f6b108a91_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODU3Nw_36e59a0a-e9ce-4649-a011-5c683d16f9ae">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the <ix:nonNumeric contextRef="i5d73c406eebd400ab792cf31e23c80e5_D20190101-20191231" name="cpix:FinancialConsiderationPaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwNg_46e6d26c-7dcb-48d1-bd96-bdac3e0b2557">two-years</ix:nonNumeric> following the transition date. Cumberland recorded the first <ix:nonFraction unitRef="installment" contextRef="i0213cec992ab4b93b597378f304014b2_D20200101-20201231" decimals="INF" name="cpix:FinancialConsiderationNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODcxNw_22fa8341-0f56-4bbc-a1e2-4c892f1ef838">four</ix:nonFraction> quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i0213cec992ab4b93b597378f304014b2_D20200101-20201231" decimals="-5" name="cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODc1Mg_6d3adfd4-1c6f-4d1f-a06d-759ec9d1ca22">3.0</ix:nonFraction> million during 2020 and the final <ix:nonFraction unitRef="installment" contextRef="id09c93443a82400e9a283705c01948ba_D20210101-20211231" decimals="INF" name="cpix:FinancialConsiderationNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODc4MQ_cd29ce93-b970-4cb3-8e34-f4f8badb32cc">four</ix:nonFraction> installments totaling $<ix:nonFraction unitRef="usd" contextRef="i0b3b7c2e16664c71bf1bf299d2abd068_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODgwNg_d6a9646e-499a-474b-969d-98f58c8a2b67">2.0</ix:nonFraction> million during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><ix:nonNumeric contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwNw_74a62f51-2dc5-4076-bb17-6494088cb006" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi0yLTEtMS0zMTIxMw_a366bf5a-6c37-4c1d-9d11-3a1aa767af75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi00LTEtMS0zMTIxMw_fb028702-2690-4ef2-bee4-8184ef6fc3c4">496,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi01LTEtMS0zMTIxMw_5ceaead0-f754-4cc5-afe8-90c915a6320f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi03LTEtMS0zMTIxMw_e6c4ce79-b1ed-43e7-9e29-5b9a601883b9">1,491,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb344f54d56f4e8fa0bcc0e5e31b52e9_D20220701-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy0yLTEtMS0zMTIxMw_0c09155e-a4f9-4dd0-90ec-c5a86fca511d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b37e261fb14120ab86fd7d766694c8_D20210701-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy00LTEtMS0zMTIxMw_ce0b151a-08bc-4b95-8b41-a31c7b09650d">496,787</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib806724dc82b467680c5d90135d516b1_D20220101-20220930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy01LTEtMS0zMTIxMw_17ace65c-60cc-4926-a28f-2387c1c1f7f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98818e47614047d287fd5c789ac7559e_D20210101-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy03LTEtMS0zMTIxMw_d21b0546-7c36-4218-9bce-b9a1b4290117">1,491,004</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_64"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target sectors are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, oncology and field sales forces in the United States.  We have also established partnerships in Puerto Rico and the Middle East for our Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product  and are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands includes:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">granisetron)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates for patients with cardiomyopathy associated with 1) Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a fatal, genetic neuromuscular disease; 2) Systemic Sclerosis (&#8220;SSc&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs; and 3)  Aspirin-Exacerbated Respiratory Disease (&#8220;AERD&#8221;), a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in the acquisition, development and commercialization of pharmaceutical products in the U.S. - and we believe we can leverage this existing infrastructure to support our continued growth both domestically and internationally. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GROWTH STRATEGY</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s growth strategy involves maximizing the success of our existing brands while continuing to build a portfolio of differentiated products. We currently feature eight products approved by the FDA in the United States. We are also continuing to explore international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support of select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier-stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland could further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long-term sustainable growth by:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Supporting and expanding the use of our marketed products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. For example, we have secured pediatric approval of Acetadote and Caldolor and are expanding the labeling for both brands accordingly. We also recently further expanded the labeling for Caldolor to allow its use prior to surgery. We will continue to explore such opportunities to bring our products to new patient populations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Selectively adding complementary brands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisitions of Vibativ and Sancuso are examples of this strategy.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Progressing our clinical pipeline and incubating future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, as we are doing though our ifetroban Phase II development programs. We are also supplementing our acquisitions and late-stage development activities with early-stage drug development activities with CET. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Leveraging our infrastructure through co-promotion partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand the support for Kristalose and Sancuso across the U.S.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Building an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including three sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Managing our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues to deliver cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Headquarters Location </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently announced the relocation of our headquarters into new offices located on the Broadwest campus in the Vanderbilt/West End corridor of Nashville in late October 2022. We are delighted to continue our presence and participation in the Nashville healthcare community, which represents the largest concentration of healthcare companies in the country. Our new, state-of-the-art headquarters keeps us close to the Vanderbilt University Medical Center, enabling our continued collaboration, as we work to develop new medicines for the future.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broadwest is a 1.2 million-square-foot urban, mixed-use complex and business park &#8211; with office space, a Conrad Hilton hotel and supportive retail space. Our move allows us to accommodate recent growth and better serve our international base of customers and partners. Following this relocation, our organization is expected to grow to over 100 individuals, with a majority employed at our Nashville headquarters.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International Agreements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we signed a new agreement with PiSA Pharmaceutical ("PiSA") for the exclusive supply and distribution of our ibuprofen injection product in Mexico. Cumberland will be responsible for sharing the U.S. dossier and providing product supply, while PiSA will be responsible for obtaining the regulatory approval and then commercializing the product in Mexico. PiSA expects to provide the product in both 400- and 800-milligram vials.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the third quarter of 2022, we entered into an agreement with Phebra PTY Ltd. ("Phebra") to market and distribute Caldolor in Australia. Caldolor was registered and launched by CSL Seqirus in Australia, with the marketing authorization and distribution now shifted to Phebra who also distributes our Acetadote product in that country.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor, our proprietary, intravenously delivered formulation of ibuprofen, can be a key component in cost-effective </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Enhanced Recovery After Surgery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multimodal treatment protocols. When administered immediately prior to surgery, the non-narcotic pain reliever enables patients to wake in significantly less pain and to suffer significantly less pain during their recovery. Ibuprofen delivered through intravenous injection can also considerably reduce the need for post-operative opioids and improve recovery by reducing the side effects associated with those narcotics.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sancuso Acquisition and Promotion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. We largely completed the transition of Sancuso to Cumberland during the third quarter of 2022. Cumberland has assumed commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support Sancuso we formed a specialty sales division, Cumberland Oncology. To augment those efforts we also entered into a co-promotion agreement with Verity Pharmaceuticals (&#8220;Verity&#8221;) to feature Sancuso through their national oncology sales organization. Verity completed training of its sales force and in July 2022 launched their promotion of Sancuso. Verity will promote the product across the U.S. market for an initial three-year term, with an option to extend for an additional two years. Verity and Cumberland will share in the incremental contribution margin resulting from Verity&#8217;s efforts.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nordic Pharma Arrangements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an amendment to our agreement with Nordic Pharma (&#8220;Nordic&#8221;) that addresses the responsibilities and financial arrangements regarding our license to Nordic&#8217;s methotrexate line of products for the U.S. (the &#8220;License&#8221;). Our line of prefilled methotrexate syringes, marketed under the brand name RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., is covered by the License.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the amendment, Nordic may assume responsibility for commercializing the methotrexate products in the U.S. after March 31, 2023. We will continue to distribute and support the RediTrex product line during a transition period until then. Following the return of the License, Nordic will provide us with a royalty on their future sales of the products through April 2035. The companies will continue to collaborate on any transition and the ongoing commercialization of the product line.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland will transfer the marketing authorization associated with the RediTrex product line to Nordic. Nordic has agreed to return the 180,000 shares we issued to Nordic associated with the License and will refund the $1 million we paid to Nordic following the brand&#8217;s approval in the U.S. Nordic has also issued a credit note in favor of Cumberland in the amount of $1 million for the unpaid milestone payment due from us which was associated with our launch of the product line.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Clinical Studies</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate, a selective thromboxane-prostanoid receptor (&#8220;TPr&#8221;) antagonist, in a series of clinical studies. It has been dosed in nearly 1,400 subjects and has been found to be safe and well tolerated in healthy volunteers and various patient populations. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is currently sponsoring three Phase II clinical programs to evaluate ifetroban in patients with:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1) Aspirin-Exacerbated Respiratory Disease, ("AERD") a severe form of asthma; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, which we believe has the potential to help many patients.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also designing a fourth Phase II program to evaluate the use of ifetroban to treat patients with Progressive Fibrosing Interstitial Lung Diseases and we are currently preparing an application to the FDA to support the new program.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our Company-sponsored studies, researchers at Brigham and Women&#8217;s Hospital have completed an investigator-initiated study evaluating the impact of ifetroban on the aspirin desensitization process in patients with AERD. This single center study closed early due to poor patient accrual and exhausted funding. The researchers found no statistical difference in the dose of aspirin needed to provide an increase in an extended version of the patient&#8217;s total nasal symptom score. A publication by the researchers with the full study results will be forthcoming.. It should be noted that the results from this investigator study were inconsistent with the previously published preclinical findings that demonstrated ifetroban blockade inhibited all features of aspirin reactions in a model of AERD.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaprisol Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are transitioning to a new manufacturer for our Vaprisol product. During 2021, we shipped all remaining inventory of the product and notified the FDA that supplies of the product were then not currently available. We have transferred manufacturing to a new facility and await the submission and FDA approval for that plant before resuming shipments. During the second quarter of 2022, the new manufacturer was issued an FDA Form 483 followed by a warning letter in the fourth quarter, after an inspection of their facility. The FDA notified us that our application to manufacture Vaprisol at the new facility would need to be resubmitted once those 483 issues are satisfactorily resolved. Our new manufacturing partner is working with the FDA to address those issues on a timely basis. Meanwhile, we plan to provide an interim supply of compounded product to the market while awaiting the needed facility approval.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for our Omeclamox-Pak product has been unable to provide us with supplies of the product, having encountered difficulties and therefore suspending operations during the pandemic. We are currently awaiting the facility&#8217;s packaging to resume, while also exploring other alternatives to restart the product&#8217;s packaging before we seek to resupply the market.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Adjustment </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After announcing preliminary earnings on November 8, 2022, Cumberland identified a balance sheet adjustment, which is reflected in the financial results included in this Quarterly Report on Form 10-Q.  As a result of this adjustment, accounts receivable were increased by $0.15 million, property and equipment were reduced by $0.8 million and current liabilities were reduced by $0.65 million from the amounts reported in the earnings release as of September 30, 2022. This adjustment only affected the balance sheet and the statement of cash flows but did not change net loss for the period. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland remains committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We are working to fulfill this mission by building a portfolio of innovative and differentiated products through a multifaceted strategy that includes the development of new candidates as well as the acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges while our team remains responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission throughout the remainder of the year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended September 30, 2022 compared to the three months ended September 30, 2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,340,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,110,397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,660&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635,935&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065,725&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,588)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,563,395)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416,326)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,576,022)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,340,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Net revenues for the three months ended September 30, 2022, were $11.4 million compared to $8.1 million for the three months ended September 30, 2021.  As detailed in the table above, net revenue increased during the quarter for two of our marketed products: RediTrex and Vibativ.  We also continued significant shipments of Sancuso which we launched earlier in the year.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue of $3.9 million for the third quarter of 2022, represented a decrease of $0.1 million when compared to the prior year period.  The decrease was primarily the result of timing of shipments to one of our co-promotion partners.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a decrease in the branded product's revenue due to sales adjustments related to expired product returns.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no Vaprisol revenue for the third quarter of 2022, a decrease of $0.3 million compared to the same period last year. This decrease is primarily due to the lack of inventory of the product, as we await FDA approval on a new manufacturer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $0.9 million for the third quarter of 2022, a decrease of $0.3 million, compared to the third quarter of 2021. The decrease was due to the timing of international shipments of the product in 2021 and 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $1.9 million for the three months ended September 30, 2022, which is comparable to the product's revenue in 2021.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso revenue was $4.0 million for the third quarter of 2022, which was $1.1 million higher than the third quarter of 2021 U.S. results reported by Kyowa Kirin, from whom Cumberland acquired the U.S. rights to Sancuso on January 3, 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the third quarter of 2022, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties, and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  Net revenue for the three months ended September 30, 2022, was positively impacted by various revenue adjustments.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the third quarter of 2022 and 2021 were $2.2 million and $1.3 million, respectively. Cost of products sold, as a percentage of net revenues, were 19.5% during the three months ended September 30, 2022, compared to 16.5% during the three months ended September 30, 2021. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the third quarter of 2022 increased $0.3 million compared to the same period last year.  This increase is primarily attributable to an increase in marketing expenses associated with the Sancuso acquisition, including royalty costs, promotional spending and the costs associated with our new oncology sales division. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the third quarter of 2022 and 2021 were $1.7 million and $1.5 million, respectively.  A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline product candidates.     </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense increased to $2.2 million for the third quarter of 2022, compared to $2.0 million for the third quarter of 2021, an increase of  $0.1 million. The increase was primarily attributable to increases in compensation expenses.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103,581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,384&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Sancuso:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Sancuso</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,535&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648,103&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In the third quarter of 2022, net revenue includes a $100,000 payment to Cumberland required under a new sales representation agreement.</span></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended September 30, 2022 and 2021, totaled approximately $1.5 million and $1.0 million, respectively.  The increase in amortization expense is due to the acquisition of Sancuso.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended September 30, 2022, was comparable to the income tax expense for the three months ended September 30, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had approximately $56.6 million in federal net operating loss carryforwards including approximately  $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_73"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the nine months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,887,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,468,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,486,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,281,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,283,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672,442&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,367,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,314,394&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,988,606&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,325,788&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,427,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,323,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,298&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - gain on debt forgiveness</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,187,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - gain on insurance proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,169,625)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,982,455)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,190,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,980,780)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,286,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,756,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,756,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,008,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,791,886)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,075,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658,918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,059)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,113,189)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,887,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the nine months ended September 30, 2022, were $32.9 million compared to $27.7 million for the nine months ended September 30, 2021, an increase of $5.2 million. The addition of our newest product Sancuso contributed to an overall 18.9% revenue increase.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue was $11.4 million during the first nine months of 2022, compared to $12.3 million for the prior year period.  Revenue decreased due to slightly lower sales volume associated with one of our co-promotion partners in 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $6.0 million for the nine months ended September 30, 2022, compared to $8.8 million for the same period last year.  The decrease in net revenue was a result of higher sales volume for the product during the nine months ended September 30, 2021.  The decline was also a result of increased purchases in 2021 associated in part with wholesaler stocking of our new packaged product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $(0.3) million for the first nine months of 2022 as Cumberland is currently out of commercial inventory of the product.  Net revenue was negatively impacted by various sales adjustments.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the nine months ended September 30, 2022, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. There was a decrease in the product's year to date revenue for the nine months ended September 30, 2022, when compared to the prior year period as a result of an increase in expired product returns in 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $3.1 million for the first three quarters of 2022, a decrease of $0.7 million compared to the same period last year due to the timing of international shipments.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the first nine months of 2022 were $6.5 million, an increase of $1.0 million compared to the same period last year due to the addition of Sancuso to the product mix.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the nine months ended September 30, 2022, increased $1.6 million compared to the prior year period.  This increase is primarily attributable to an increase in marketing expenses associated with the Sancuso acquisition including royalty costs, promotional spending and the costs associated with our new oncology sales division.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $5.3 million for the first nine months of  2022 compared to  $4.1 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline product candidates.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the nine months ended September 30, 2022, remained consistent with $6.7 million compared to $6.4 million during the nine months ended September 30, 2021.  In 2022, we experienced a slight increase in compensation expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,158,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433,061&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,240,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,531,654&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Since Acquisition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,279,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,622,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,718,609&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Sancuso:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Sancuso</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,106,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2022 net revenue includes a $250,000 payment to Cumberland required under the terms of a new licensee agreement and a $100,000 payment to Cumberland required under a sales representation agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the nine months ended September 30, 2022, and nine months ended September 30, 2021, totaled approximately $4.6 million and $3.4 million, respectively.  The increase was attributable to the Sancuso acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the nine months ended September 30, 2022, as a percentage of income (loss) from continuing operations before income taxes, was 0.7% compared to 1.9% for the nine months ended September 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recognized a gain on insurance proceeds of $0.6 million.</span></div><div><span><br/></span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash equivalents, cash flows from operations and the amounts borrowed under our line of credit. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of September 30, 2022 and December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,541,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,040,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,854,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,409,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300,000&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the nine months ended September 30, 2022 and September 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,382,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,033,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,041&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,818,230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,499,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $7.5 million decrease in cash and cash equivalents for the nine months ended September 30, 2022, was primarily attributable to cash used in investing and partially offset by cash provided by operating and financing activities.  Cash provided by operating activities of $4.8 million was primarily the result of a decreases in inventory of $1.3 million, decrease in other assets of $4.4 million and increases in accounts payable and other liabilities of $8.8 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $5.1 million.  This was partially offset by accounts receivable increasing by $8.2 million, mainly from the addition of Sancuso sales and the increase in long-term liabilities of $2.5 million. Cash used in investing activities was the result of the acquisition of Sancuso. Our financing activities included the increase in our line of credit of $2.7 million partially offset by the $0.9 million in cash used to repurchase shares of our common stock as well as the $1.1 million used for the payment of royalties for sales of Vibativ and Sancuso.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.1 million increase in cash and cash equivalents for the nine months ended September 30, 2021, was primarily attributable to cash provided by operating activities, partially offset by cash used in investing and financing activities.  Cash provided by operating activities of $4.4 million was positively impacted by decreases in inventory of $2.6 million and accounts receivable of $2.5 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $4.0 million.  Operating activities were also offset by the decrease in accounts payable of $2.9 million and the forgiveness of our PPP Loan of $2.2 million.  Cash used in investing activities was the result of additions to intangibles of $0.2 million and the payment of $0.2 million to the WHC JV.  Our financing activities included the $1.0 million in cash used to repurchase shares of our common stock as well as the $1.8 million used for the payment of royalties to Theravance for sales of Vibativ. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.   For the quarter ended September 30, 2022, we were in compliance with the Funded Debt Ratio financial covenant.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 5.25% at September 30, 2022.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company had $17.7 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. </span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_79"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, we did not engage in any off-balance sheet arrangements.</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_82"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at September 30, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 5.25% at September 30, 2022.   As of September 30, 2022, we had $17.7 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the nine months ended September 30, 2022 and 2021.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_85"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_91"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material developments with regard to the legal proceedings previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_94"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to the effects of a rising rate of inflation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation rates have increased recently to levels not seen in decades.  If our costs, in particular costs related to clinical trial expenses and/or employee-related expenses, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition. In addition, the United States Federal Reserve has raised, and is expected to continue to raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue to rise) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with COVID-19 and the ongoing conflict between Russia and Ukraine, and employee availability and wage increases.</span></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_97"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended September 30, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:37.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares or Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased, which were also Part of the Publicly Announced Plans or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,066</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,995,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,713</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,110</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend9tolo.htm">Ninth Amendment to Revolving Credit Loan Agreement, dated as of September 29, 2022, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i9d8b5229cbe549cdb99425ffcfc909d0_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 14, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Duly Authorized Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>pinnaclebank-cpiamend9tolo.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idcc29d02c65e4af5a746af01a6e42d5b_1"></div><div style="min-height:92.88pt;width:100%"><div style="margin-bottom:0.11pt;padding-left:0.02pt;text-align:justify;text-indent:0.35pt"><font><br></font></div></div><div style="margin-bottom:15pt;padding-left:1.45pt;padding-right:1.45pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">NINTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT</font></div><div style="margin-bottom:10.2pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS NINTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this &#34;Amendment&#34;) is entered into as of September 29, 2022 by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (&#34;Borrower&#34;), and PINNACLE BANK, a Tennessee banking corporation (the &#34;Lender&#34;).</font></div><div style="margin-bottom:10.45pt;padding-left:2.4pt;padding-right:2.4pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">RECITALS&#58;</font></div><div style="margin-bottom:11.55pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower and the Lender entered into that certain Revolving Credit Loan Agreement dated as of July 31, 2017, as amended by that certain First Amendment to Revolving Credit Loan Agreement dated August 14, 2018, as amended by that certain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018, as amended by that certain Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement dated May 10, 2019, as amended by that certain Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement dated October 7, 2020, as amended by that certain Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement dated as of October 28, 202 1, as amended by that certain Fifth Amendment to Revolving Credit Note and Sixth Amendment to Revolving Credit Loan Agreement dated as of December 31, 2021, as amended by that certain Seventh Amendment to Revolving Credit Loan Agreement dated as of March 31, 2022, and as amended by that certain Eighth Amendment to Revolving Credit Loan Agreement dated as of June 30, 2022 (the &#34;Loan Agreement&#34;). Capitalized terms not otherwise defined therein have the same meaning as set forth in the Loan Agreement.</font></div><div style="margin-bottom:11.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;Borrower and the Lender desire to amend the Loan Agreement as provided herein.</font></div><div style="margin-bottom:11.55pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:11.55pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:29.05pt">The definition of &#34;Funded Debt Ratio&#34; set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Loan Agreement is hereby amended and restated as follows&#58;</font></div><div style="margin-bottom:13.2pt;padding-left:35.3pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;Funded Debt Ratio&#34; means the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.</font></div><div style="margin-bottom:10.85pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:29.05pt">The following is hereby added as a new definition to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> of the Loan Agreement&#58;</font></div><div style="margin-bottom:13.85pt;padding-left:35.05pt;padding-right:2.6pt;text-align:justify;text-indent:39.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;Unrestricted Cash&#34; means, on any date of determination, the aggregate amount of all cash of the Borrower and its Subsidiaries held with Lender, not subject to any Lien or restriction (except for Liens or restrictions in favor of, or imposed by, Lender).</font></div><div style="margin-bottom:13.55pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:29.05pt">As a condition precedent to the effectiveness of this Amendment, Borrower shall pay to Lender all fees and expenses incurred by Lender in connection herewith, including without limitation a $2,000 amendment fee and reasonable legal fees.</font></div><div style="margin-bottom:50.9pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:29.05pt">The Loan Agreement is not amended in any other respect.</font></div><div style="padding-left:0.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">105639-301010</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.11pt;padding-left:0.02pt;text-align:justify;text-indent:0.35pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="margin-bottom:0.11pt;padding-left:0.02pt;text-align:justify;text-indent:0.35pt"><font><br></font></div></div><div style="margin-bottom:10.3pt;padding-left:0.45pt;padding-right:2.6pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:29.05pt">Borrower reaffirms the terms and provisions of the Loan Documents and agrees that such are valid and binding, enforceable in accordance with their terms and provisions, and subject to no defense, counterclaim, or objection.</font></div><div style="margin-bottom:0.15pt;padding-left:33.72pt;padding-right:33.72pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;signatures commence on following page&#93;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.11pt;padding-left:0.02pt;text-align:justify;text-indent:0.35pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="margin-bottom:0.11pt;padding-left:0.02pt;text-align:justify;text-indent:0.35pt"><font><br></font></div></div><div style="margin-bottom:10.3pt;padding-left:38.4pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ENTERED INTO as of the date first written above.</font></div><div style="margin-bottom:10.15pt;padding-left:17.52pt;padding-right:17.52pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">BORROWER&#58;</font></div><div style="margin-bottom:5.1pt;padding-left:210.25pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="margin-bottom:4.95pt;padding-left:87.72pt;padding-right:87.72pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58;</font><img alt="image_1.jpg" src="image_1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:253px"></div><div style="padding-left:210.25pt;padding-right:145.2pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:223%">LENDER&#58; PINNACLE BANK</font></div><div style="margin-bottom:0.15pt;padding-left:87.25pt;padding-right:87.25pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">By&#58;</font><img alt="image_2.jpg" src="image_2.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:253px"></div><div style="margin-bottom:71.85pt;padding-right:38.4pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Mark D. Mattson, Senior Vice President</font></div><div style="margin-bottom:0.15pt;padding-left:34.92pt;padding-right:34.92pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;Signature Page to Ninth Amendment to Revolving Credit Loan Agreement&#93;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.11pt;padding-left:0.02pt;text-align:justify;text-indent:0.35pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2022q3-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib4a61cf28f1c402785ca06df31ba2f1e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 14, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2022q3-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i74d55825ef434b8a94cb34ec9a2a5cda_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Hamm, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 14, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2022q3-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3d91123defc54aefa019d499c2dfe902_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended September 30, 2022 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 14, 2022</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 14, 2022</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cpix-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e0839ea3-e098-4f93-afa3-37d29c6655d1,g:ef7281af-56e2-4e26-9661-b3993287f2ab-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000007 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>0000008 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>0000009 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>0000010 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>0000011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>0000012 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>0000013 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncome" roleURI="http://www.cumberlandpharma.com/role/OtherIncome">
        <link:definition>0000014 - Disclosure - Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>0000015 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>0000016 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>0000017 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>0000018 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>0000019 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>0000020 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>0000021 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>0000022 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>0000023 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>0000024 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>0000025 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofRevenueDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails">
        <link:definition>0000026 - Disclosure - Revenues - Schedule of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesAdditionalInformationDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails">
        <link:definition>0000027 - Disclosure - Revenues - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>0000028 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000029 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>0000030 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>0000031 - Disclosure - Leases - Lease Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>0000032 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>0000032 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRentExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails">
        <link:definition>0000033 - Disclosure - Leases - Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>0000034 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>0000035 - Disclosure - Shareholders' Equity and Debt - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>0000036 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDetails" roleURI="http://www.cumberlandpharma.com/role/OtherIncomeDetails">
        <link:definition>0000037 - Disclosure - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails">
        <link:definition>0000039 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails">
        <link:definition>0000040 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
        <link:definition>0000041 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_KyowaKirinMember" abstract="true" name="KyowaKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdMember" abstract="true" name="WinHealthInvestmentSingaporeLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RevenueRecognitionMilestonePayments" abstract="false" name="RevenueRecognitionMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FinancialConsiderationPaymentPeriod" abstract="false" name="FinancialConsiderationPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NinthAmemdmentMember" abstract="true" name="NinthAmemdmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_EightAmendmentMember" abstract="true" name="EightAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_BroadwestLeaseFiveYearRenewalOptionMember" abstract="true" name="BroadwestLeaseFiveYearRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SixthAmendmentMember" abstract="true" name="SixthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" abstract="false" name="DebtInstrumentCovenantFundedDebtRatioMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantEvaluationFrequency" abstract="false" name="DebtInstrumentCovenantEvaluationFrequency" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsThreshold" abstract="false" name="TieredRoyaltyPaymentsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_SancusoMember" abstract="true" name="SancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:monetaryPerAreaItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" abstract="false" name="DebtInstrumentCovenantUnrestrictedCashThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_FinancialConsiderationNumberOfInstallments" abstract="false" name="FinancialConsiderationNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" abstract="false" name="ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProceedsFromSettlementOfPatentLitigation" abstract="false" name="ProceedsFromSettlementOfPatentLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLeasedArea" abstract="false" name="LesseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cpix-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e0839ea3-e098-4f93-afa3-37d29c6655d1,g:ef7281af-56e2-4e26-9661-b3993287f2ab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4cc8cafd-4520-439b-8a84-524473043add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_c1e7e7af-8259-4e9a-b5de-76f86799a5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4cc8cafd-4520-439b-8a84-524473043add" xlink:to="loc_us-gaap_LongTermLineOfCredit_c1e7e7af-8259-4e9a-b5de-76f86799a5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39cd990b-1700-42a2-8e07-81ab08b06ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4cc8cafd-4520-439b-8a84-524473043add" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39cd990b-1700-42a2-8e07-81ab08b06ad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27671f8c-fe85-447c-838e-5521b768a32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4cc8cafd-4520-439b-8a84-524473043add" xlink:to="loc_us-gaap_LiabilitiesCurrent_27671f8c-fe85-447c-838e-5521b768a32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_0ec344a5-c093-4d6d-8744-6ff87f619aba" xlink:href="cpix-20220930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4cc8cafd-4520-439b-8a84-524473043add" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_0ec344a5-c093-4d6d-8744-6ff87f619aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a62fe1e5-df36-49ad-8f64-067314e5f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fc95ad84-275c-4faa-9174-ab29b8df8528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a62fe1e5-df36-49ad-8f64-067314e5f0c8" xlink:to="loc_us-gaap_Liabilities_fc95ad84-275c-4faa-9174-ab29b8df8528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0d94b9b6-f1fa-478f-98dd-b6fdf7f08000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a62fe1e5-df36-49ad-8f64-067314e5f0c8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0d94b9b6-f1fa-478f-98dd-b6fdf7f08000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cae1c1c3-c176-48ad-9717-3edd8cf8190a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a62fe1e5-df36-49ad-8f64-067314e5f0c8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cae1c1c3-c176-48ad-9717-3edd8cf8190a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3ff616f-d237-40a8-8216-716b8dbd2ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8295e6b0-77ef-4102-abeb-2cadb3e1013f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e3ff616f-d237-40a8-8216-716b8dbd2ee9" xlink:to="loc_us-gaap_CommonStockValue_8295e6b0-77ef-4102-abeb-2cadb3e1013f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f6740b0-ae93-4336-8da7-f50344dc90cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e3ff616f-d237-40a8-8216-716b8dbd2ee9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f6740b0-ae93-4336-8da7-f50344dc90cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c11f3c5e-e57d-493a-b419-b7bd3191addc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_871070d7-e20d-4631-b22f-54c6d7f9bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c11f3c5e-e57d-493a-b419-b7bd3191addc" xlink:to="loc_us-gaap_StockholdersEquity_871070d7-e20d-4631-b22f-54c6d7f9bf00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ff4a82d2-1de4-4ec1-a850-226d443999f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c11f3c5e-e57d-493a-b419-b7bd3191addc" xlink:to="loc_us-gaap_MinorityInterest_ff4a82d2-1de4-4ec1-a850-226d443999f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b35d636-b1fe-4d7b-8f8e-eaa219fa5469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2559ad21-4cb8-40e1-8a43-a6568b94e315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b35d636-b1fe-4d7b-8f8e-eaa219fa5469" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2559ad21-4cb8-40e1-8a43-a6568b94e315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0cd8f3ed-7265-4f01-b3cb-b174bd495e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b35d636-b1fe-4d7b-8f8e-eaa219fa5469" xlink:to="loc_us-gaap_AccountsPayableCurrent_0cd8f3ed-7265-4f01-b3cb-b174bd495e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2fd0b22c-cd78-4743-8448-27fe88ce45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b35d636-b1fe-4d7b-8f8e-eaa219fa5469" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2fd0b22c-cd78-4743-8448-27fe88ce45d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dff3e3f7-b081-4053-b97c-a489fcd1f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dff3e3f7-b081-4053-b97c-a489fcd1f4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_186916ad-301e-4555-8b22-5ad3e8c6077d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_Goodwill_186916ad-301e-4555-8b22-5ad3e8c6077d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ee724d8a-a71a-434b-9cc7-e9090a1e7a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_InventoryNoncurrent_ee724d8a-a71a-434b-9cc7-e9090a1e7a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7b40dfa2-8323-4ba1-b0bb-fd076c260e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_AssetsCurrent_7b40dfa2-8323-4ba1-b0bb-fd076c260e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6cb7d166-275b-464f-88f1-3de215b30991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6cb7d166-275b-464f-88f1-3de215b30991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_00ed547b-cd49-443e-b5e6-090cc9c22753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_00ed547b-cd49-443e-b5e6-090cc9c22753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_65f2ea43-52c5-4030-9470-eee2176268ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a43a98ca-a9a3-4b1f-993b-67f1327f4c0b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_65f2ea43-52c5-4030-9470-eee2176268ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_984dd392-b161-4196-ae98-abc6215f00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c70b945-198e-4287-a68b-94f186672a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_984dd392-b161-4196-ae98-abc6215f00a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c70b945-198e-4287-a68b-94f186672a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c1cd60e1-61bd-4514-826f-42c3c44e7a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_984dd392-b161-4196-ae98-abc6215f00a3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c1cd60e1-61bd-4514-826f-42c3c44e7a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c2a9de59-0962-4dae-b1fd-0ef8f17219b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_984dd392-b161-4196-ae98-abc6215f00a3" xlink:to="loc_us-gaap_OtherAssetsCurrent_c2a9de59-0962-4dae-b1fd-0ef8f17219b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_75dd27a9-0c91-468f-b6f6-233ff5c562b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_984dd392-b161-4196-ae98-abc6215f00a3" xlink:to="loc_us-gaap_InventoryNet_75dd27a9-0c91-468f-b6f6-233ff5c562b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8d5614ee-03f5-4fa1-b78a-d03be767e7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa97665b-3716-4e65-b341-a4da10d39bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8d5614ee-03f5-4fa1-b78a-d03be767e7ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa97665b-3716-4e65-b341-a4da10d39bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cbf03167-fdbb-4596-be57-9fb5fbb0c356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8d5614ee-03f5-4fa1-b78a-d03be767e7ce" xlink:to="loc_us-gaap_CostsAndExpenses_cbf03167-fdbb-4596-be57-9fb5fbb0c356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a6a1e7e9-58d5-4626-b34d-7baebc28d671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd2352c-9e9f-4957-bfe1-4bbbe15a3de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a6a1e7e9-58d5-4626-b34d-7baebc28d671" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd2352c-9e9f-4957-bfe1-4bbbe15a3de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eafe5583-e1c7-4a83-8240-647975641e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a6a1e7e9-58d5-4626-b34d-7baebc28d671" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eafe5583-e1c7-4a83-8240-647975641e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432be398-7743-4072-b685-088dcd1f26f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9ce7e2bc-7e10-4045-9ce8-79d829c00af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432be398-7743-4072-b685-088dcd1f26f7" xlink:to="loc_us-gaap_InterestExpense_9ce7e2bc-7e10-4045-9ce8-79d829c00af9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_85bbaf99-f6e1-40cb-be31-7937383075bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432be398-7743-4072-b685-088dcd1f26f7" xlink:to="loc_us-gaap_InsuredEventGainLoss_85bbaf99-f6e1-40cb-be31-7937383075bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a8b1ee81-8b7d-44c1-8862-82e75d902c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432be398-7743-4072-b685-088dcd1f26f7" xlink:to="loc_us-gaap_OperatingIncomeLoss_a8b1ee81-8b7d-44c1-8862-82e75d902c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_bc4fd52f-4f26-497b-a8d7-1cbcb7bd3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432be398-7743-4072-b685-088dcd1f26f7" xlink:to="loc_us-gaap_OtherIncome_bc4fd52f-4f26-497b-a8d7-1cbcb7bd3bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_89dd4dda-5566-4b61-a67a-e347fa42eed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432be398-7743-4072-b685-088dcd1f26f7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_89dd4dda-5566-4b61-a67a-e347fa42eed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bf610f31-3c0e-4fb8-a776-549f146368d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c234820f-c085-4e6f-90bc-6f699fad5dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bf610f31-3c0e-4fb8-a776-549f146368d1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c234820f-c085-4e6f-90bc-6f699fad5dbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_bdd50464-63ef-4e81-b4d3-5d0ba23e89fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bf610f31-3c0e-4fb8-a776-549f146368d1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_bdd50464-63ef-4e81-b4d3-5d0ba23e89fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7efa33d7-b1d5-44c3-846d-27ecd2de4fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bf610f31-3c0e-4fb8-a776-549f146368d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7efa33d7-b1d5-44c3-846d-27ecd2de4fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_30c31be1-4805-474c-89cf-f9ed682ac869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bf610f31-3c0e-4fb8-a776-549f146368d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_30c31be1-4805-474c-89cf-f9ed682ac869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eed39e7c-b132-4945-9611-a92427675696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bf610f31-3c0e-4fb8-a776-549f146368d1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eed39e7c-b132-4945-9611-a92427675696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_47bcb68a-1e7d-4d17-a7e3-895f9a98085e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ea9e697b-6a63-44f8-9707-b9248c9dd1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_47bcb68a-1e7d-4d17-a7e3-895f9a98085e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ea9e697b-6a63-44f8-9707-b9248c9dd1fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_49d6d3d1-d82b-4771-9704-01e0d1bc7101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_47bcb68a-1e7d-4d17-a7e3-895f9a98085e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_49d6d3d1-d82b-4771-9704-01e0d1bc7101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecd9e761-5575-4fca-be28-6334888d335d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8372e83a-67a3-450d-83d0-df7f2de03513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ecd9e761-5575-4fca-be28-6334888d335d" xlink:to="loc_us-gaap_ProfitLoss_8372e83a-67a3-450d-83d0-df7f2de03513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4e29f324-02c5-42e0-8a25-06a4e1a4c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ecd9e761-5575-4fca-be28-6334888d335d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4e29f324-02c5-42e0-8a25-06a4e1a4c7d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1605af0a-0902-4338-ada1-d3c357875808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43f1d776-6736-46a4-bdbe-469ee23e412f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1605af0a-0902-4338-ada1-d3c357875808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43f1d776-6736-46a4-bdbe-469ee23e412f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cc04df9-b8d8-4599-bb78-21ec1cf156c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1605af0a-0902-4338-ada1-d3c357875808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cc04df9-b8d8-4599-bb78-21ec1cf156c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09123f3f-d248-4b6d-9e40-502850c4c002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1605af0a-0902-4338-ada1-d3c357875808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09123f3f-d248-4b6d-9e40-502850c4c002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_68871a5e-943e-4392-b1ab-ab722542b50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_60a7c145-b771-4017-924c-1c94d1be345f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_68871a5e-943e-4392-b1ab-ab722542b50a" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_60a7c145-b771-4017-924c-1c94d1be345f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_12465efc-9296-47da-8a9f-89ffc0233155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_68871a5e-943e-4392-b1ab-ab722542b50a" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_12465efc-9296-47da-8a9f-89ffc0233155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_71ad4096-e888-4a32-a85b-3147b1638a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_68871a5e-943e-4392-b1ab-ab722542b50a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_71ad4096-e888-4a32-a85b-3147b1638a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_55eebb28-2a7b-4f29-be71-147c4402f0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_68871a5e-943e-4392-b1ab-ab722542b50a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_55eebb28-2a7b-4f29-be71-147c4402f0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e43e1162-dedc-4fce-94c0-7dbaed604dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_6bebf245-572b-4d2e-b732-b47275534557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e43e1162-dedc-4fce-94c0-7dbaed604dbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_6bebf245-572b-4d2e-b732-b47275534557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c8f35eb6-87d6-49ab-bbe8-42cb829f10cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e43e1162-dedc-4fce-94c0-7dbaed604dbd" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c8f35eb6-87d6-49ab-bbe8-42cb829f10cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_16f0d7c3-1ce8-42c3-9a4a-cd799295ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_16f0d7c3-1ce8-42c3-9a4a-cd799295ce69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation_f3f118d4-2b3c-4f84-826a-4a16beb14f31" xlink:href="cpix-20220930.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:to="loc_cpix_ProceedsFromSettlementOfPatentLitigation_f3f118d4-2b3c-4f84-826a-4a16beb14f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_02dda8c6-0400-479a-8c17-15d96ff7dfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_02dda8c6-0400-479a-8c17-15d96ff7dfcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ef59d1a9-0c23-4bb5-b6cb-96cd1119b460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ef59d1a9-0c23-4bb5-b6cb-96cd1119b460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_284247da-4426-4e6c-a7a4-a3f5e291b815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_284247da-4426-4e6c-a7a4-a3f5e291b815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5233522-14b8-4c30-af1d-d6e475422c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcbff5a4-ee9d-4d94-a5ac-69b9e78d2ae3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5233522-14b8-4c30-af1d-d6e475422c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1771bbe1-25c9-4fe6-b0d5-07252eb15503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1771bbe1-25c9-4fe6-b0d5-07252eb15503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5142f059-971a-4e6b-aaec-741545dd6412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_ShareBasedCompensation_5142f059-971a-4e6b-aaec-741545dd6412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1791597a-b000-4c4b-971e-f7e3f3bf18a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1791597a-b000-4c4b-971e-f7e3f3bf18a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3d08725a-176b-4a48-8ebb-127e1482e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3d08725a-176b-4a48-8ebb-127e1482e42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_11c18633-256c-4f95-b93b-77990c6eb59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_11c18633-256c-4f95-b93b-77990c6eb59d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cf781fa8-b2a2-4247-adf8-1410418acaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cf781fa8-b2a2-4247-adf8-1410418acaa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2a48a41f-79e9-4694-9413-fd173cc85004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2a48a41f-79e9-4694-9413-fd173cc85004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bf638ee0-d91b-4b66-b9d2-4554f3df9932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bf638ee0-d91b-4b66-b9d2-4554f3df9932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_56da0760-11e7-4765-bd5d-aac8dd18d63f" xlink:href="cpix-20220930.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_56da0760-11e7-4765-bd5d-aac8dd18d63f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_95f9070d-fedc-4565-be66-8ef4f8321111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_InsuredEventGainLoss_95f9070d-fedc-4565-be66-8ef4f8321111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cd8b2a69-d017-4764-bf91-a60f2c940d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cd8b2a69-d017-4764-bf91-a60f2c940d41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_d1745221-fe63-42e5-a61c-22a975294744" xlink:href="cpix-20220930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_d1745221-fe63-42e5-a61c-22a975294744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_00dfb14e-ebe0-4ab9-9cb9-ff1e05d4302f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e9b6b780-a798-445d-b6cb-30c073bb03ef" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_00dfb14e-ebe0-4ab9-9cb9-ff1e05d4302f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c44dd94d-52f0-49fb-9d5d-e1af9020ebc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ac016c2-9b80-4d98-b723-0b6d7ba41d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c44dd94d-52f0-49fb-9d5d-e1af9020ebc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ac016c2-9b80-4d98-b723-0b6d7ba41d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_241c4483-26dc-48c4-99c7-b9e8f7532113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c44dd94d-52f0-49fb-9d5d-e1af9020ebc9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_241c4483-26dc-48c4-99c7-b9e8f7532113" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7da26bca-2db4-455b-97b5-1c2f3dca3054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2a83da77-b92b-4f94-add1-80dfc0b229fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7da26bca-2db4-455b-97b5-1c2f3dca3054" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2a83da77-b92b-4f94-add1-80dfc0b229fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_946b9719-0770-4492-92dc-3a5fdc47b1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7da26bca-2db4-455b-97b5-1c2f3dca3054" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_946b9719-0770-4492-92dc-3a5fdc47b1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a34f7a04-549a-4e57-86e4-9410f2d0c0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7da26bca-2db4-455b-97b5-1c2f3dca3054" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a34f7a04-549a-4e57-86e4-9410f2d0c0cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1307ab3b-6527-4370-9430-6db0b89d4543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_948fca80-26b7-44f0-9eed-d2bc94dab8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1307ab3b-6527-4370-9430-6db0b89d4543" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_948fca80-26b7-44f0-9eed-d2bc94dab8c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_80f1b3f6-d3fa-41f7-9251-66363b04f491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1307ab3b-6527-4370-9430-6db0b89d4543" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_80f1b3f6-d3fa-41f7-9251-66363b04f491" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4849c372-c081-4350-8991-a04674b8cf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a0fba40-add2-47f3-8668-3aa367dd3d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4849c372-c081-4350-8991-a04674b8cf07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5a0fba40-add2-47f3-8668-3aa367dd3d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_66abdf2d-f280-44b0-8c21-5fdac4a3d07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4849c372-c081-4350-8991-a04674b8cf07" xlink:to="loc_us-gaap_OperatingLeaseLiability_66abdf2d-f280-44b0-8c21-5fdac4a3d07a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cpix-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e0839ea3-e098-4f93-afa3-37d29c6655d1,g:ef7281af-56e2-4e26-9661-b3993287f2ab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i976306f048264b759d13c7a0dab26d9c_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_553a5a9a-1b3b-4489-ad3e-a42625d8253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_553a5a9a-1b3b-4489-ad3e-a42625d8253e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f8fd22fa-4435-4b88-9fc6-65d18a61a2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f8fd22fa-4435-4b88-9fc6-65d18a61a2b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21c6bab2-13bb-425b-8c0d-b5f785930a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21c6bab2-13bb-425b-8c0d-b5f785930a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9d18fb7c-fb32-4ebd-bd70-eb827824030e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9d18fb7c-fb32-4ebd-bd70-eb827824030e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_621dd2c4-1665-40e8-a724-dfedb4ec856a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_621dd2c4-1665-40e8-a724-dfedb4ec856a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_8bdad16e-66f8-48dd-a213-bd8799acacff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_8bdad16e-66f8-48dd-a213-bd8799acacff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_a332038a-9e51-471a-b247-b0d589346c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_a332038a-9e51-471a-b247-b0d589346c9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2d6d41ae-21cd-4834-9fa8-c9175bec10a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2d6d41ae-21cd-4834-9fa8-c9175bec10a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_3c6b81fc-d425-4b22-9c23-012de862c075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_3c6b81fc-d425-4b22-9c23-012de862c075" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5a5053f4-5db2-4667-9cae-24d4c22c55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_ProfitLoss_5a5053f4-5db2-4667-9cae-24d4c22c55ba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b7db971d-1265-4502-9d62-14b798ef1e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64950262-e57a-4416-ac5f-a74255ad51e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_553a5a9a-1b3b-4489-ad3e-a42625d8253e" xlink:to="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6829acb-20aa-4972-bf5f-a284227ff0ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:to="loc_us-gaap_EquityComponentDomain_e6829acb-20aa-4972-bf5f-a284227ff0ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:to="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0232e171-4156-4123-a39f-8bed1a47875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:to="loc_us-gaap_CommonStockMember_0232e171-4156-4123-a39f-8bed1a47875f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dc205af0-dcb0-44d1-9ea6-f94b6c73d46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:to="loc_us-gaap_RetainedEarningsMember_dc205af0-dcb0-44d1-9ea6-f94b6c73d46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_bc2e78a9-edd8-4410-9146-f41b2494d2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:to="loc_us-gaap_NoncontrollingInterestMember_bc2e78a9-edd8-4410-9146-f41b2494d2e1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#RevenuesScheduleofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="extended" id="ibe1cc4ec41c746eea17eec8ba33acaa6_RevenuesScheduleofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1985f6b7-7421-4fc3-b908-170aa3652e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f09362d6-71d0-42b0-ab98-91c9e1018b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1985f6b7-7421-4fc3-b908-170aa3652e2e" xlink:to="loc_us-gaap_RevenuesAbstract_f09362d6-71d0-42b0-ab98-91c9e1018b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_19dbd858-d05c-4512-8c4b-b6092fecd348" xlink:href="cpix-20220930.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f09362d6-71d0-42b0-ab98-91c9e1018b6c" xlink:to="loc_cpix_ProductsAbstract_19dbd858-d05c-4512-8c4b-b6092fecd348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8933ff21-e078-4abf-953e-aa1a876ba0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_19dbd858-d05c-4512-8c4b-b6092fecd348" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8933ff21-e078-4abf-953e-aa1a876ba0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1985f6b7-7421-4fc3-b908-170aa3652e2e" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:to="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4d55118-9021-49cb-86b8-21bd416b97d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:to="loc_srt_ProductsAndServicesDomain_a4d55118-9021-49cb-86b8-21bd416b97d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:to="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_56362aac-bc7a-48fb-8b3e-42c7c06db390" xlink:href="cpix-20220930.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_KristaloseMember_56362aac-bc7a-48fb-8b3e-42c7c06db390" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_5acd8a76-519f-4421-8c30-36389a3cab14" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_SancusoMember_5acd8a76-519f-4421-8c30-36389a3cab14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_c44f41d1-1a10-4382-8214-31e6543c59cf" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_VIBATIVMember_c44f41d1-1a10-4382-8214-31e6543c59cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_6cbd69c4-ccbc-426f-8ac1-198446e50dac" xlink:href="cpix-20220930.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_CaldolorMember_6cbd69c4-ccbc-426f-8ac1-198446e50dac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_ee5c653d-613a-4897-ba27-36e4cf7ac63d" xlink:href="cpix-20220930.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_VaprisolMember_ee5c653d-613a-4897-ba27-36e4cf7ac63d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_fae5c131-17f2-4c81-9e4c-e94c46d5ac38" xlink:href="cpix-20220930.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_AcetadoteMember_fae5c131-17f2-4c81-9e4c-e94c46d5ac38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_41cd9137-f3ec-41ae-af9b-6992b3bc8fd0" xlink:href="cpix-20220930.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_OmeclamoxPakMember_41cd9137-f3ec-41ae-af9b-6992b3bc8fd0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_67231971-215e-4d5c-a961-da8fba13173d" xlink:href="cpix-20220930.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_RediTrexMember_67231971-215e-4d5c-a961-da8fba13173d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_472e0173-2c64-46a7-9b15-c9eb4df89ac2" xlink:href="cpix-20220930.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_OtherProductsMember_472e0173-2c64-46a7-9b15-c9eb4df89ac2" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#RevenuesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended" id="i8a58e3c18a6d4412abcbc04d0601ab3e_RevenuesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_de7f30d2-95ba-4da9-8419-cfe96813ff01" xlink:href="cpix-20220930.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_de7f30d2-95ba-4da9-8419-cfe96813ff01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64c2d345-4670-45f9-bff0-da6eeef3e450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64c2d345-4670-45f9-bff0-da6eeef3e450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:to="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34fb546c-69cf-4648-8681-872939bf4b53_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:to="loc_srt_ProductsAndServicesDomain_34fb546c-69cf-4648-8681-872939bf4b53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd09fa66-c0ae-4afa-ba11-b7dd25b677a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:to="loc_srt_ProductsAndServicesDomain_dd09fa66-c0ae-4afa-ba11-b7dd25b677a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_310e059c-35f9-439f-9aad-9ddc71be92f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dd09fa66-c0ae-4afa-ba11-b7dd25b677a4" xlink:to="loc_us-gaap_GrantMember_310e059c-35f9-439f-9aad-9ddc71be92f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i8fa3d2fbbcbc4d499ff5ed8d206b7982_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_788489b4-7f69-4d4b-b9e8-cb6f6f936c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryValuationReserves_788489b4-7f69-4d4b-b9e8-cb6f6f936c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_37fb8a61-8c9c-4446-8b34-8a258b8f8a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryNoncurrent_37fb8a61-8c9c-4446-8b34-8a258b8f8a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9801914d-996b-4a46-8912-8702ac89bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryFinishedGoods_9801914d-996b-4a46-8912-8702ac89bc1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c0b426e-d6db-409d-9583-a082e056ca8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c0b426e-d6db-409d-9583-a082e056ca8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_9a9b2a65-19cb-4e92-b616-51cd86d07274" xlink:href="cpix-20220930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:to="loc_cpix_IfetrobanClinicalMember_9a9b2a65-19cb-4e92-b616-51cd86d07274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_99c4ebd6-208e-4be3-aa74-443319012d1e" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:to="loc_cpix_VIBATIVMember_99c4ebd6-208e-4be3-aa74-443319012d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_dc53f81d-28cd-4e14-9af6-2e086dd1e073" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:to="loc_cpix_SancusoMember_dc53f81d-28cd-4e14-9af6-2e086dd1e073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ee204d5c-83ff-46fb-a10e-e48cda6892ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ee204d5c-83ff-46fb-a10e-e48cda6892ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c3cdac16-1d72-4715-bd5f-fae76b97c988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c3cdac16-1d72-4715-bd5f-fae76b97c988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_a5ef8d06-3ae9-4609-8d04-22970b66c8b7" xlink:href="cpix-20220930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c3cdac16-1d72-4715-bd5f-fae76b97c988" xlink:to="loc_cpix_IfetrobanClinicalMember_a5ef8d06-3ae9-4609-8d04-22970b66c8b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i7e161de4926e49b2a5136e98c92ab9ad_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_a6556cbe-db2d-449b-a106-1d7c23aa3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_a6556cbe-db2d-449b-a106-1d7c23aa3e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_06ddb871-36bb-4c3c-9769-0a2b57a4cab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_06ddb871-36bb-4c3c-9769-0a2b57a4cab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8a5b51d3-3b16-4405-9dd2-bc80ee8962e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8a5b51d3-3b16-4405-9dd2-bc80ee8962e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_257db194-301a-4b4b-aad2-b9dc2b03c697" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_257db194-301a-4b4b-aad2-b9dc2b03c697" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_537775bd-218d-41e9-9895-178571711728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_537775bd-218d-41e9-9895-178571711728" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_2e9854ef-66ad-4381-87be-8a4b4c59b9cc" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_2e9854ef-66ad-4381-87be-8a4b4c59b9cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_87fc2248-545e-4117-8d34-84d91a9cd854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_87fc2248-545e-4117-8d34-84d91a9cd854" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_02033ff5-bde6-46f2-9250-cab9479a7017" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_02033ff5-bde6-46f2-9250-cab9479a7017" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eafcaefe-eaf0-4ed8-8a5f-553b40270915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eafcaefe-eaf0-4ed8-8a5f-553b40270915" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1636bdd5-9196-465c-993d-04ffbe094139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:to="loc_us-gaap_BuildingMember_1636bdd5-9196-465c-993d-04ffbe094139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_e0e0eef0-9737-4d78-aa85-0aa4a8a5fda2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:to="loc_srt_OfficeBuildingMember_e0e0eef0-9737-4d78-aa85-0aa4a8a5fda2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_68a5b195-9e78-4b17-a2ac-b68eb0aea685_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:to="loc_us-gaap_LeaseContractualTermDomain_68a5b195-9e78-4b17-a2ac-b68eb0aea685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_14004d2e-2068-4ce1-a3b7-e17cad59d606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:to="loc_us-gaap_LeaseContractualTermDomain_14004d2e-2068-4ce1-a3b7-e17cad59d606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_7c162d9b-01b2-41c8-bc82-39af3873e690" xlink:href="cpix-20220930.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_14004d2e-2068-4ce1-a3b7-e17cad59d606" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_7c162d9b-01b2-41c8-bc82-39af3873e690" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="icbeb95fdd14741d19884c0c21df64f96_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ebf9eec-7441-4f1d-b648-de9e96b18c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:href="cpix-20220930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ebf9eec-7441-4f1d-b648-de9e96b18c95" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_77866b72-e8db-49fb-9995-3b557b9a94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_77866b72-e8db-49fb-9995-3b557b9a94ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_469eaa6e-2a18-420a-bc56-10b7149745c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_469eaa6e-2a18-420a-bc56-10b7149745c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_fb359459-714c-4e2d-a28e-d5a7566c5e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_fb359459-714c-4e2d-a28e-d5a7566c5e3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_af7fc565-7017-4f4f-94be-5b8dfc51ffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_af7fc565-7017-4f4f-94be-5b8dfc51ffd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_fea16d82-bf99-4f1b-bd7e-36865622c044" xlink:href="cpix-20220930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_fea16d82-bf99-4f1b-bd7e-36865622c044" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_534e034c-0189-4412-8eb5-f79827ab4034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_534e034c-0189-4412-8eb5-f79827ab4034" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3eda8bc-be53-4b42-b0b1-27d33a8d61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3eda8bc-be53-4b42-b0b1-27d33a8d61a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dcad2b81-be32-4cd7-9f1b-e360fca4fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dcad2b81-be32-4cd7-9f1b-e360fca4fd6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ebf9eec-7441-4f1d-b648-de9e96b18c95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:to="loc_us-gaap_EquityComponentDomain_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9b183d6-def3-49aa-87dc-549b3e88d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:to="loc_us-gaap_EquityComponentDomain_a9b183d6-def3-49aa-87dc-549b3e88d6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8b5141f-79c3-4ea4-9ddd-0e4e2bc66e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9b183d6-def3-49aa-87dc-549b3e88d6dc" xlink:to="loc_us-gaap_CommonStockMember_f8b5141f-79c3-4ea4-9ddd-0e4e2bc66e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_89263de0-3346-4392-b737-24f773fd1ae2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_89263de0-3346-4392-b737-24f773fd1ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_147ade9c-ec95-4cc4-a287-90c0b6b5e8ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_89263de0-3346-4392-b737-24f773fd1ae2" xlink:to="loc_srt_DirectorMember_147ade9c-ec95-4cc4-a287-90c0b6b5e8ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b90d9823-3cb1-42d7-9757-bbf0622078ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b90d9823-3cb1-42d7-9757-bbf0622078ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c0dce23c-c8c9-45ba-84dc-34d95f687a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:to="loc_us-gaap_RestrictedStockMember_c0dce23c-c8c9-45ba-84dc-34d95f687a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_3a23ccc6-a8a6-4258-8e9b-065efa61b096" xlink:href="cpix-20220930.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:to="loc_cpix_IncentiveStockOptionsMember_3a23ccc6-a8a6-4258-8e9b-065efa61b096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_e6aa8d22-d895-4a26-ad7b-1eb213082f67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_e6aa8d22-d895-4a26-ad7b-1eb213082f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_76d8de2d-f3fc-43bb-8d51-a14cf8bea64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_76d8de2d-f3fc-43bb-8d51-a14cf8bea64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_9982b366-b3b0-431b-af53-28c361298ea3" xlink:href="cpix-20220930.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_76d8de2d-f3fc-43bb-8d51-a14cf8bea64f" xlink:to="loc_cpix_PinnacleBankMember_9982b366-b3b0-431b-af53-28c361298ea3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="iff8faf983a2e46359c4170468381fcc5_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_a5c99bab-ee8e-4d07-b5ba-a6500d3d8ef5" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_a5c99bab-ee8e-4d07-b5ba-a6500d3d8ef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_b4dc795c-3127-44f0-9f01-639e8ed43017" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantEvaluationFrequency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_b4dc795c-3127-44f0-9f01-639e8ed43017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_1b6db5db-7eb3-492d-a15b-181e081a32e7" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantFundedDebtRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_1b6db5db-7eb3-492d-a15b-181e081a32e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_f8357cf9-150c-42d5-831d-dccec75cdecd" xlink:href="cpix-20220930.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_f8357cf9-150c-42d5-831d-dccec75cdecd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_8c6e9268-1c7c-49a9-9d63-8a6897d78480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_8c6e9268-1c7c-49a9-9d63-8a6897d78480" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5385a77e-2309-47e8-b371-72e790303cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5385a77e-2309-47e8-b371-72e790303cdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95d4c4f9-cbc4-487d-9ac6-90415b3c8de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95d4c4f9-cbc4-487d-9ac6-90415b3c8de6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_779b7d03-1722-49a1-bb09-adf1a6826c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_779b7d03-1722-49a1-bb09-adf1a6826c8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_c70b5373-d763-49c3-b515-6e198f24e726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LongTermLineOfCredit_c70b5373-d763-49c3-b515-6e198f24e726" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_268e894f-4eca-4f62-8d70-6d7b6b706545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_268e894f-4eca-4f62-8d70-6d7b6b706545" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d10f9e0f-4aa6-4149-9b9b-4a2d42464129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d10f9e0f-4aa6-4149-9b9b-4a2d42464129" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1fa0b091-e714-4ec7-a777-5b364a9a46cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1fa0b091-e714-4ec7-a777-5b364a9a46cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_fc7c0da3-4b50-4e57-8b25-77743bfdb97d" xlink:href="cpix-20220930.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1fa0b091-e714-4ec7-a777-5b364a9a46cd" xlink:to="loc_cpix_PinnacleBankMember_fc7c0da3-4b50-4e57-8b25-77743bfdb97d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_725430a2-291f-4c4f-ae39-d9f23e6770ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_725430a2-291f-4c4f-ae39-d9f23e6770ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2feb6f1d-8ee2-4cb1-ac8f-e7a85e7047ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_us-gaap_LineOfCreditMember_2feb6f1d-8ee2-4cb1-ac8f-e7a85e7047ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SixthAmendmentMember_26fb5c2a-62b1-498b-bbee-4298de3a713d" xlink:href="cpix-20220930.xsd#cpix_SixthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_cpix_SixthAmendmentMember_26fb5c2a-62b1-498b-bbee-4298de3a713d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EightAmendmentMember_4fe76e62-8eff-428d-b418-c3ada5c3326c" xlink:href="cpix-20220930.xsd#cpix_EightAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_cpix_EightAmendmentMember_4fe76e62-8eff-428d-b418-c3ada5c3326c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember_0eb9ec4e-b13e-4518-8852-eb2c0490be9d" xlink:href="cpix-20220930.xsd#cpix_NinthAmemdmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_cpix_NinthAmemdmentMember_0eb9ec4e-b13e-4518-8852-eb2c0490be9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d59f0ea0-ac6a-469e-9051-ec636f43ffff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:to="loc_us-gaap_CreditFacilityDomain_d59f0ea0-ac6a-469e-9051-ec636f43ffff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f9f502fe-f284-4ac5-aa78-158a67329c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:to="loc_us-gaap_CreditFacilityDomain_f9f502fe-f284-4ac5-aa78-158a67329c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a68f3bb0-a50d-49ef-8288-40e7d8a9f915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f9f502fe-f284-4ac5-aa78-158a67329c36" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a68f3bb0-a50d-49ef-8288-40e7d8a9f915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7bcec839-1def-4073-b86d-ca0129eca87c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:to="loc_srt_RangeMember_7bcec839-1def-4073-b86d-ca0129eca87c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:to="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d2bff9e5-cc5e-422e-b4aa-59e102280b34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:to="loc_srt_MinimumMember_d2bff9e5-cc5e-422e-b4aa-59e102280b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6e3b27a-602a-453c-b654-dbcd13284167" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:to="loc_srt_MaximumMember_c6e3b27a-602a-453c-b654-dbcd13284167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_33fe629e-3654-4065-981c-0fa3405570ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:to="loc_us-gaap_VariableRateDomain_33fe629e-3654-4065-981c-0fa3405570ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7a7a1c63-f973-41d9-8eee-fce397eaef12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:to="loc_us-gaap_VariableRateDomain_7a7a1c63-f973-41d9-8eee-fce397eaef12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_368f93d0-b70e-4aca-a016-d653b9d4368d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7a7a1c63-f973-41d9-8eee-fce397eaef12" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_368f93d0-b70e-4aca-a016-d653b9d4368d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dbce260c-bf43-4803-9c52-bf5cb7bc08f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dbce260c-bf43-4803-9c52-bf5cb7bc08f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e72827ad-f6ea-42bd-9617-28e9d40970aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e72827ad-f6ea-42bd-9617-28e9d40970aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0c781b45-a25f-404d-97ec-956dd760868e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e72827ad-f6ea-42bd-9617-28e9d40970aa" xlink:to="loc_us-gaap_ConvertibleDebtMember_0c781b45-a25f-404d-97ec-956dd760868e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da423112-ab4e-43c2-9b2f-cf9e02048665_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da423112-ab4e-43c2-9b2f-cf9e02048665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b8aeadb-dac7-4e44-9d5b-583ffe678b5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b8aeadb-dac7-4e44-9d5b-583ffe678b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_af230f7d-fe55-40be-b8f2-b7d2cfefe2dd" xlink:href="cpix-20220930.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b8aeadb-dac7-4e44-9d5b-583ffe678b5f" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_af230f7d-fe55-40be-b8f2-b7d2cfefe2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1a0661f1-c0e1-430e-8ee9-a4fee188e222_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1a0661f1-c0e1-430e-8ee9-a4fee188e222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1a27a452-bc5f-477f-84be-d7c07fd6927f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1a27a452-bc5f-477f-84be-d7c07fd6927f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_477f6d19-464d-48c2-8a5e-d107d6046247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1a27a452-bc5f-477f-84be-d7c07fd6927f" xlink:to="loc_srt_ScenarioForecastMember_477f6d19-464d-48c2-8a5e-d107d6046247" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20220930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="icca7dfbca3bc4a51bab4fa9b49d9b0cf_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_65fbd368-5a8f-4e9d-a2cb-f0df361c58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_52e112ee-ddd8-41a0-826a-de74360399fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_65fbd368-5a8f-4e9d-a2cb-f0df361c58ca" xlink:to="loc_us-gaap_OperatingLossCarryforwards_52e112ee-ddd8-41a0-826a-de74360399fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_65fbd368-5a8f-4e9d-a2cb-f0df361c58ca" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_eb98837a-8068-4e6f-9591-04097953ad50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_eb98837a-8068-4e6f-9591-04097953ad50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1fbee9ec-31ca-4c26-b995-96b5fc63dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1fbee9ec-31ca-4c26-b995-96b5fc63dfbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_da15e87b-bfec-4241-8236-99513e0f852b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1fbee9ec-31ca-4c26-b995-96b5fc63dfbe" xlink:to="loc_us-gaap_DomesticCountryMember_da15e87b-bfec-4241-8236-99513e0f852b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i5f2a654c16614880845a4c675c6c7f87_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c0379ce-254f-44b8-9471-b7128689a473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c0379ce-254f-44b8-9471-b7128689a473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_341bc901-5f9c-42f2-8e73-57dd6fec29d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_341bc901-5f9c-42f2-8e73-57dd6fec29d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_3d2af002-7c58-4e25-9c1f-ba009aaca4ce" xlink:href="cpix-20220930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_3d2af002-7c58-4e25-9c1f-ba009aaca4ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_0cdf0868-e4ce-42cf-9fbb-e75d839f4281" xlink:href="cpix-20220930.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_0cdf0868-e4ce-42cf-9fbb-e75d839f4281" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e5875cde-5181-4eee-b73d-7b1b4a8e91c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e5875cde-5181-4eee-b73d-7b1b4a8e91c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_451ebe1d-75f5-49f8-ab0a-74ef95e2b411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_451ebe1d-75f5-49f8-ab0a-74ef95e2b411" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3e9db82b-00f2-467f-a6b7-2bc1409fbe03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3e9db82b-00f2-467f-a6b7-2bc1409fbe03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_59ff9e4a-a5b6-4d46-86c0-a5fddd30cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_59ff9e4a-a5b6-4d46-86c0-a5fddd30cf06" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f5e59475-2d39-469f-b12b-c732d2a7d498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f5e59475-2d39-469f-b12b-c732d2a7d498" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3e2e8a36-8e1a-4745-a145-9dde73a01a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3e2e8a36-8e1a-4745-a145-9dde73a01a2c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_056cd0ac-5294-4218-b3e9-fd8c192e5bbb" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_056cd0ac-5294-4218-b3e9-fd8c192e5bbb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_48e82fab-f470-4fb7-a88f-89b604e2610f" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_48e82fab-f470-4fb7-a88f-89b604e2610f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_ffb15b23-507a-47cd-b562-5c652ee8cc31" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_ffb15b23-507a-47cd-b562-5c652ee8cc31" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_00f4b9ba-bb20-4323-ae81-1ee6c6904a73" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_00f4b9ba-bb20-4323-ae81-1ee6c6904a73" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_6f2c3b67-06e1-4942-8ce9-da694e6db6a0" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_6f2c3b67-06e1-4942-8ce9-da694e6db6a0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_384c4eb4-ef95-4a17-be6a-9ba11e180597" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_384c4eb4-ef95-4a17-be6a-9ba11e180597" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_d8dcaacd-bff1-4bb3-a33d-cbbe6d13fa0d" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_d8dcaacd-bff1-4bb3-a33d-cbbe6d13fa0d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_82fcba06-0f3c-49fd-ad2d-b09279b90925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_82fcba06-0f3c-49fd-ad2d-b09279b90925" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db1e21ba-9a48-45b9-81b5-1560e13d4ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db1e21ba-9a48-45b9-81b5-1560e13d4ad8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4bda6212-3e74-48e2-b1d1-38b24845f776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_Goodwill_4bda6212-3e74-48e2-b1d1-38b24845f776" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dc717de-1f7d-4fcc-8112-4d1e3802cbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dc717de-1f7d-4fcc-8112-4d1e3802cbd3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f077753f-e901-4594-b13e-d973513fb10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f077753f-e901-4594-b13e-d973513fb10e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_362e73f4-2923-4c53-b02b-1508800fa846" xlink:href="cpix-20220930.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_362e73f4-2923-4c53-b02b-1508800fa846" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments_84e37c89-5106-4dea-8fc0-a5f077fa73af" xlink:href="cpix-20220930.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_FinancialConsiderationNumberOfInstallments_84e37c89-5106-4dea-8fc0-a5f077fa73af" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_7726c724-fb89-4de0-87f7-e03152f07c9e" xlink:href="cpix-20220930.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_7726c724-fb89-4de0-87f7-e03152f07c9e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_49c1a0a0-d896-4817-b526-5dbee62356dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_49c1a0a0-d896-4817-b526-5dbee62356dc" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1336436-25e6-43e9-9a31-d1c7b092f1fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1336436-25e6-43e9-9a31-d1c7b092f1fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_3aadb6f1-f7a3-4ce0-88d7-c9425e8d1896" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:to="loc_cpix_VIBATIVMember_3aadb6f1-f7a3-4ce0-88d7-c9425e8d1896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_4bb3e816-c0aa-4e47-9fad-d0ae5b7e0ead" xlink:href="cpix-20220930.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:to="loc_cpix_MethotrexateMember_4bb3e816-c0aa-4e47-9fad-d0ae5b7e0ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_32bcc3d1-3c12-4aa9-84f4-09517db64c10" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:to="loc_cpix_SancusoMember_32bcc3d1-3c12-4aa9-84f4-09517db64c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c1d5b6f-23df-4548-a884-8030ef0746bc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c1d5b6f-23df-4548-a884-8030ef0746bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_12332736-347d-4c23-b83f-cfba9670ecba" xlink:href="cpix-20220930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_12332736-347d-4c23-b83f-cfba9670ecba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_c7586f98-c712-4bc6-84e3-d6ba372f48cd" xlink:href="cpix-20220930.xsd#cpix_KyowaKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:to="loc_cpix_KyowaKirinMember_c7586f98-c712-4bc6-84e3-d6ba372f48cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_f0799284-d9fd-4469-95e0-cfcaf6ffa94d" xlink:href="cpix-20220930.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:to="loc_cpix_NordicGroupBVMember_f0799284-d9fd-4469-95e0-cfcaf6ffa94d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e820f9c3-9d32-4312-9b2a-0331c5388157_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e820f9c3-9d32-4312-9b2a-0331c5388157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a0731a-67e9-44f5-bf0a-3c4068ac64d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a0731a-67e9-44f5-bf0a-3c4068ac64d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_092993d9-8bb8-4258-acc3-749481d8b182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a0731a-67e9-44f5-bf0a-3c4068ac64d0" xlink:to="loc_us-gaap_RestrictedStockMember_092993d9-8bb8-4258-acc3-749481d8b182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a7b2971-218a-49d8-ab45-2a9e9091f21a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8a7b2971-218a-49d8-ab45-2a9e9091f21a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0619ceb-242c-4b1b-9d52-ceab67919481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0619ceb-242c-4b1b-9d52-ceab67919481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_452d6f76-5977-4b00-9aa1-58051192f362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0619ceb-242c-4b1b-9d52-ceab67919481" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_452d6f76-5977-4b00-9aa1-58051192f362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5284a028-c84e-4989-96e4-ad634c779c67_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:to="loc_srt_RangeMember_5284a028-c84e-4989-96e4-ad634c779c67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b013dd3-b810-4aca-897c-5112592f148b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:to="loc_srt_RangeMember_9b013dd3-b810-4aca-897c-5112592f148b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1f118dd-b890-489e-88cd-d662e46aa686" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b013dd3-b810-4aca-897c-5112592f148b" xlink:to="loc_srt_MaximumMember_d1f118dd-b890-489e-88cd-d662e46aa686" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="extended" id="ic0163355d8d543699832522f66ba8189_AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_16e93fe8-5f3f-451e-862b-4d14ec4e8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_16e93fe8-5f3f-451e-862b-4d14ec4e8ab9" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a34f15cc-3ce2-4123-95b5-b9569222e6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a34f15cc-3ce2-4123-95b5-b9569222e6cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_7efa16f8-20ee-4e85-8777-1d533b3790f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_PaymentsForRoyalties_7efa16f8-20ee-4e85-8777-1d533b3790f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cdd63e35-c640-46e1-95ac-c28f1e13557f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cdd63e35-c640-46e1-95ac-c28f1e13557f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5358cd7c-8982-4ca0-90ca-347489a415ee" xlink:href="cpix-20220930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5358cd7c-8982-4ca0-90ca-347489a415ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d419493-86ba-42f0-ba69-f531dcf7d6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_16e93fe8-5f3f-451e-862b-4d14ec4e8ab9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cda9b32-e604-4203-8680-b570c353535a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cda9b32-e604-4203-8680-b570c353535a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e6e09b0-a722-46a7-bb28-a39476fc7f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e6e09b0-a722-46a7-bb28-a39476fc7f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_10cfe68c-005b-4ee3-a60c-b58242a5fc35" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e6e09b0-a722-46a7-bb28-a39476fc7f2a" xlink:to="loc_cpix_VIBATIVMember_10cfe68c-005b-4ee3-a60c-b58242a5fc35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="extended" id="i276ee13c582544ea97b4ba84e16875bf_AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dd7897a6-ebe2-4800-ad12-e1f627d2a630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dd7897a6-ebe2-4800-ad12-e1f627d2a630" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_789b0b3e-20b0-4d7c-bee0-fb692c9143e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_789b0b3e-20b0-4d7c-bee0-fb692c9143e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_ac9abd5c-ad57-473c-bfc7-ddca9d865ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_PaymentsForRoyalties_ac9abd5c-ad57-473c-bfc7-ddca9d865ae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_038c9752-e605-4c14-90a9-21ec4251c304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_038c9752-e605-4c14-90a9-21ec4251c304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_fa6800f1-41b8-42eb-9aed-e427809094ac" xlink:href="cpix-20220930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_fa6800f1-41b8-42eb-9aed-e427809094ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_781ff0ad-d694-4523-8183-417dd790162b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dd7897a6-ebe2-4800-ad12-e1f627d2a630" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b8fcad3-aa10-401b-881c-03bd5c585f2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b8fcad3-aa10-401b-881c-03bd5c585f2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78ea5aee-b825-4cdc-becd-fe85431cc064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78ea5aee-b825-4cdc-becd-fe85431cc064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_9208d42c-f85e-4f89-8c34-3d35a81de40b" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78ea5aee-b825-4cdc-becd-fe85431cc064" xlink:to="loc_cpix_SancusoMember_9208d42c-f85e-4f89-8c34-3d35a81de40b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended" id="i903fdea709644a63b143197790ef096f_AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_97351859-5274-4075-b498-5b464f935c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_97351859-5274-4075-b498-5b464f935c60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_28000d1d-6d10-4cd9-b15d-fa16086db6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_28000d1d-6d10-4cd9-b15d-fa16086db6bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:to="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_154fb27c-f56e-4c91-af05-bebac37b416d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_154fb27c-f56e-4c91-af05-bebac37b416d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2a68f81-f3c2-49ad-bce0-6edfd203a77c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2a68f81-f3c2-49ad-bce0-6edfd203a77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_60ca1349-4ab1-42a0-a3d0-ed8be41d66c6" xlink:href="cpix-20220930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2a68f81-f3c2-49ad-bce0-6edfd203a77c" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_60ca1349-4ab1-42a0-a3d0-ed8be41d66c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cpix-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e0839ea3-e098-4f93-afa3-37d29c6655d1,g:ef7281af-56e2-4e26-9661-b3993287f2ab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_859d1726-de70-4464-9f4f-0ebdc3bcee1c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_68ab4790-67b5-4230-9a2a-a7928ee66fd4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_8ea7c389-8c21-4c1c-b586-e67910e62d87_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_dbdf7143-3466-43bd-8ed4-cb190fe49f2e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_5edebbe4-a4f0-43fa-a20f-4c700b902862_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20220930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_5d9a5f87-17ce-4d24-84cd-ed3ee18aff24_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fab099a1-03f4-48c5-931c-b44b1ba7fba0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb513238-46ae-4458-8bb3-d00ef8e7c009_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b05728ad-f141-4e75-aac4-e72e83f4d35d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_50dfb682-a41f-4ee0-92cf-5ea5e9a769e9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_fe6d313c-2412-4d4a-9d73-9196061be218_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_799c6ad2-a096-46c0-a11a-dea0e0a52396_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_90fc289a-3d49-4e7f-b357-fb9135b236bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dffbcdd7-716f-480e-b97b-8957df5084d2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_badd02ae-99d0-4f3e-a47c-937abbd0772b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e3944017-90d6-439b-889b-d6320b2c0fd4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_79a28ab5-2569-46fa-b16a-56f5d27fb570_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet of office space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_fe26970a-d416-4c9d-8760-03087e6d4aca_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20220930.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f6d07166-e726-466c-af36-e4c58b5ec6f4_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ed06c03-7e20-44d6-8e3c-195637b69d62_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58ad9889-b2b1-42f7-8f9a-399d1ab89e95_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fb4cb0f0-af5e-4fcb-8ad2-99f7113b1586_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_80514bf9-49bc-4b43-be11-91c33578acc1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_f8725634-2c7d-444b-a8c6-fdeb83ae9803_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20220930.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_595491f7-5047-45d5-8065-2970e75eceac_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20220930.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aaa5c035-eeca-42e7-b2f1-0b86dcfadf6f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_bf8eefca-c7be-4b61-84f7-66937bbdb1fb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_885ea681-7acd-40d9-b0e4-a0a7183065d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_b96c29ed-b743-46c6-ba48-dd60fe3f9154_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_161049ab-5fb5-4823-8a55-a727a442162d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_b3b849af-c991-4491-a170-a549721af672_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20220930.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_dcd0600e-e270-45c8-ac59-6aa3f1c5cc16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8085a8c3-c1a5-4be6-8b83-7f3cc569ed32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_18d0d51e-7734-4287-9ed4-90d55edcfc8c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eb15de13-5129-470f-ba92-44f060d22c14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_18fb39d8-bf12-44e2-84dd-a3af4155c068_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional borrowing capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="cpix-20220930.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d5fb44a9-4fbd-484b-a9a8-0c39542e47d2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_29274540-91fe-486b-9e01-7c9a01554531_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ebe0776b-e20a-43ec-bc7e-4d869e4baca6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_34a1bfa9-50e6-4f5e-a720-463673925649_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_d623c6ff-c6c9-4f8a-aa05-5f8bed9484a9_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20220930.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_296f3644-609d-4ae7-84d3-cb0dfa73936e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_2428821a-1f58-4a89-916e-6e8a5063159c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_cdd33163-1fcf-4da7-ab2e-3e919a7f2db1_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent per square foot</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:to="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca2cd4a2-433b-4875-a01e-4cb82d496062_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_927a6c6e-d0cb-455b-be02-f11bd3a2a24d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4d3a9fed-49ff-4d83-b640-22f3fe2361ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_1a6ef0f2-97ac-424c-9940-04ed59dde165_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e9455558-4bcb-4b84-b2f2-824677c308e2_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ef8dcfea-c3a4-4dd3-a178-592c543b9a4d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_20453ca1-301e-48da-9047-9604ecbb1f0d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_5202b6e8-7111-41a0-ae8b-055e66fd2974_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payment, threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:href="cpix-20220930.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:to="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_508d38ac-6725-4aed-9df2-c60a86a75db0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4fb140b5-264e-4304-915b-e63f52178c5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_4ed21ed7-c720-407c-85d0-03a7e6840d3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4c865e12-c495-4466-902c-f5af8ae57713_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_6d47046a-1e6f-4ab6-aeeb-2fae912b6516_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EightAmendmentMember_57ed4ec7-1903-45b1-9ea9-4f6be342ea25_terseLabel_en-US" xlink:label="lab_cpix_EightAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Amendment</link:label>
    <link:label id="lab_cpix_EightAmendmentMember_label_en-US" xlink:label="lab_cpix_EightAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Amendment [Member]</link:label>
    <link:label id="lab_cpix_EightAmendmentMember_documentation_en-US" xlink:label="lab_cpix_EightAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eight Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EightAmendmentMember" xlink:href="cpix-20220930.xsd#cpix_EightAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EightAmendmentMember" xlink:to="lab_cpix_EightAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_cba6595a-d488-4480-a1b0-ad21f766ea3c_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights, installment payments</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_label_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:href="cpix-20220930.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:to="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_16aa2365-05f9-4b5c-a1ff-5f9e65b52716_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities at September 30, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_81da1344-1b2c-4b41-9081-56a79b6d960e_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20220930.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c28d5577-f81f-444c-a9bb-9329f1d0aef4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_90789799-1abe-498b-99de-de050c9b3191_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_583ebf18-c89d-4820-9f73-b428d4a46f62_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5845c7e5-d5d3-4d61-be1f-9df7f6e5bb19_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_20ec6883-2029-4f01-b319-91636a89d74f_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20220930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d5740640-d557-4394-bd49-02c6d89a1515_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_efe772c3-b70c-4538-97fd-b8d82dde7c38_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_0fc3d25e-85c9-4227-b3fa-9bdba6963c0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1ca3f0e3-9327-4783-98a9-b7fa59ebd104_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_45ba81ce-bcf7-4203-b5be-3fde3119e428_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, payment period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_label_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:href="cpix-20220930.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:to="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8f50418d-99c6-4098-8dd1-1e9084892507_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3f3cb7c0-3d31-4ae6-b788-7a6e49e9aa7b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_67ff687b-3ec8-443d-8d81-bad8e1be76f8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_df05a178-8018-4e2e-865b-4491d63f842b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9fb3e825-8c89-4699-a347-74759339f277_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_121114e5-8a88-46aa-bb1b-fc86c9d6ad0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_69b9a414-8200-4c11-9dfc-b2d36e70e83a_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5691bd14-8ecc-4858-bcea-c976b68bd71b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_31fe7171-d290-4c21-95eb-3de5ec75d9ff_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_af69ed98-55d2-4289-88d2-394c8f2fd0b3_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty, percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_7fd1fcaa-6dc7-4022-8f2e-a622cf9fb57a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_eb4633fb-af64-4c64-8de6-6fb5e8888163_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0d0cfab7-1119-420f-b5c9-6e8303758070_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ccebb2c5-389e-4630-bad7-0fd71bf46694_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_af1cbeca-7a95-41ea-a1f9-338cb2c115b4_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20220930.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_8c6fd78d-97d8-4bc5-a2e3-3984fd5cba95_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_e0bd11e3-d049-4203-864d-0487c58caaad_terseLabel_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_label_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option [Member]</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_documentation_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:href="cpix-20220930.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:to="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1bd1b485-4bff-4b35-a1df-3bc8bf73775f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NinthAmemdmentMember_a1a9fca4-feae-4a6a-9cd3-1a44963023b8_terseLabel_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment</link:label>
    <link:label id="lab_cpix_NinthAmemdmentMember_label_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment [Member]</link:label>
    <link:label id="lab_cpix_NinthAmemdmentMember_documentation_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember" xlink:href="cpix-20220930.xsd#cpix_NinthAmemdmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NinthAmemdmentMember" xlink:to="lab_cpix_NinthAmemdmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_f9e6ae2d-dfcc-434d-8346-7772fbda73a1_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20220930.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a6a93087-2aa8-4d32-873c-2ceda792680f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_c163b2ba-3b93-4c9a-bceb-9cb77a521c64_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20220930.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_59a07260-45f6-464b-9e71-78e05e53274f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1f9c4a68-0a13-4151-b1dc-9fa4a960bf4d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0885e480-8e66-4e82-ab33-7efdfbbe4acf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4f6db3fe-6650-4a46-8f55-672626a3b766_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_0afaed0a-6f2d-48ef-8bb5-cf53aad3ba71_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20220930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0edda9a5-b497-41fd-81e4-508b8f2cbace_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c4c2d055-6489-4b61-b3d4-a363303d020e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_3af04bc7-ad79-4c89-9dab-15eb54762c24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_02ce25c3-6be9-4e24-8132-4d474e9e624f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantEvaluationFrequency_22b101c6-2f54-4d9d-88dc-10a15d0638b1_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant evaluation frequency</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantEvaluationFrequency_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Evaluation Frequency</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantEvaluationFrequency_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Evaluation Frequency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantEvaluationFrequency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:to="lab_cpix_DebtInstrumentCovenantEvaluationFrequency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5c81555c-1536-44ab-ba93-213f3c3ca912_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_9a3fd822-88c8-4f1a-940f-1748b3eac41d_terseLabel_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember" xlink:href="cpix-20220930.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncentiveStockOptionsMember" xlink:to="lab_cpix_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b3678183-8009-401f-8ca1-ca4cf6e1ff47_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_94e9269b-41d1-45ec-b6ff-c81b1392b0cf_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e122dc3-d7a5-4320-88cb-2772057e1e72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf184750-2e90-4257-b401-448f6688ac7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7a0e507d-05d7-44f2-bcb7-776e9072c7ad_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2bb1cbf-b8bd-4658-9eed-40c3dd4a0190_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_80eb4fe3-32c4-4ee3-ac91-ac06a5b5f527_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_dfbcd474-2a2a-4514-a3de-797b887b6cce_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_0ea045f8-5fa5-4950-b4bc-8264bb57fe9a_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20220930.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7e4e1e2a-5e09-4db1-a606-70d09b439a15_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee59f8bb-3966-4c3a-9b2f-92b4ea7b11a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_eca4c6ff-3582-4101-ab2d-adbac18e5f4b_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_30ef056f-ce66-437b-bc29-e234c3994966_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_ae9ba154-5b17-4179-a432-a126bd50d64a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1daea724-89bd-4823-b3b7-5c7136da9b80_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_61494d5b-084b-4625-ab4c-312b6126be0b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fc2b47c8-9407-4474-ac94-0831320272d9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_48580382-80ec-46a5-8adb-b5872b20adae_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f6ddc57f-84e6-4e6a-965e-a3d41d995db6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3ce4f67d-014b-4684-89bb-2159dc3d950d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_28143972-7d30-4a23-9c62-b333b4c5f68b_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_79a176be-6332-4e20-986f-1794d22d755d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6e32c3eb-ba24-4cef-9c8b-3406c729dc6e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f3256292-d6fb-409a-a98b-9cad1a575ccd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e26ff68f-f9c4-46a5-ae68-a017f6d4a264_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f3dc8773-2072-4da5-a859-a6101db25adb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_3ee61088-1416-4dc9-8fe9-efcf66b8c807_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9bdcd9d4-c645-4d11-9101-aa71520fce37_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_28ca0bd5-202d-437a-bc66-c137ccdfdf17_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_955e6390-1a21-4cb9-857f-b7e3032f3860_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_ed9bff29-d461-43be-844d-c58e326b0179_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09272c66-6631-4958-b22a-65cdc7e81123_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_92508dbd-9031-4c66-836b-6edb72c18386_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_cd7ae9f7-9b95-4c6e-b532-667d19cd14e9_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20220930.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9f427965-f997-4625-8528-8bba7a436a98_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_524913fd-fe86-4cd4-a850-5256cf36842c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_43b85439-09b2-4ac9-8a65-bae6539ca021_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_968eadbc-bfcd-41b8-aed1-f4fc45afb348_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5e27661f-36f8-4d3d-8bf4-9d2045cd113f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5668c513-e036-46b6-84a6-00db0e545cc5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_efba4797-5ac2-426c-be6f-2476f24f29c6_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20220930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_ae644686-b743-4aef-ac1f-54b49e79f6ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SixthAmendmentMember_f77f3a05-9854-4223-8439-ddf19bd64cf7_terseLabel_en-US" xlink:label="lab_cpix_SixthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixth Amendment</link:label>
    <link:label id="lab_cpix_SixthAmendmentMember_label_en-US" xlink:label="lab_cpix_SixthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixth Amendment [Member]</link:label>
    <link:label id="lab_cpix_SixthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SixthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SixthAmendmentMember" xlink:href="cpix-20220930.xsd#cpix_SixthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SixthAmendmentMember" xlink:to="lab_cpix_SixthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3a8d545f-1786-4ae0-b636-9c419e7dc8cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_ab1d9aab-8f18-4046-b68a-ee097c68f531_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funded debt ratio</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Funded Debt Ratio, Maximum</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Funded Debt Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantFundedDebtRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:to="lab_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b5414636-6491-472c-8474-489a4d7db6a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a9ee72e9-102f-4fd7-9dca-63cbeb643e14_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_41b715fc-878d-4218-9f2d-79c02f231a62_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_25cdf93f-ceb6-4d0b-99c2-16c25ff6d502_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_0beb3fc1-8c83-46f9-be22-cfd7e41180df_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_f437758b-5835-4241-823d-4849468162ad_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, number of installments</link:label>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_label_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Number of Installments</link:label>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Number of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments" xlink:href="cpix-20220930.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationNumberOfInstallments" xlink:to="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18020204-dff9-4e07-aa4f-1a56da7717e9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_ba9a7dc8-5eeb-4ae9-bf6c-4682f1e3ba10_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1c21b82-aa26-409e-9f58-5622d8c076c9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14882f02-661b-4587-9042-ed306384f176_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_51bac583-f0dc-48d8-ab05-52212c15fbc1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_80c9233f-68a2-4c3c-9a5c-d802aa01816f_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20220930.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_c89ec74f-6d2f-47b9-968a-4cd26497d37b_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0693d50f-0161-43b9-9c3e-c51a17e424ae_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3ba3cc62-46ac-489a-b84e-cfcc00a75558_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_7fe202d4-05da-4091-aa3d-9d2658f9b9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_85f3d0e7-b9bc-4d6e-8352-61a92f21c635_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6b1a6f08-8fc9-4109-b5da-e405955beeed_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_52f02f2e-54bf-4d07-8c44-5bc636f75c6b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9797fe60-8e28-4141-a4c9-484ff857964b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8fc3eb73-a0f1-401c-b242-53fa523fba2d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9eb9207c-b895-438b-88b4-ab25e96a7b6f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6856db55-df5a-4fbf-a456-217a0b259d98_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_52e9e9ee-625f-442c-8a4b-a58df52e28f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_e1e88195-f5ff-488b-bef5-03039ebc2b35_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20220930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_95fc8511-84e3-4553-8534-50a3cac3754a_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20220930.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_00ead50e-0e8d-49d5-88a6-8758667ab699_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1b8a3ddc-b113-40b7-aec0-b347a53570bf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_43b52a03-4393-4c9a-ad38-4adecbd8f246_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e405623a-7f8a-47c6-83ee-512f2d859a5b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bff3534b-7a6f-4ff8-8b3d-c680027aacc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ae8e6f63-703e-4f1f-9c1e-c43654f6ac7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_8788596b-b707-4645-b53c-af8872c70607_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_65242d1b-193b-4dfc-ac29-c014c6447414_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares receivable (in shares)</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_988e4ccc-0f97-41da-beb6-176e3c822da4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4b3fc8ab-3b14-46f0-aaa5-c858db0c7d09_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_13e35e50-fb73-4ab6-98c2-1d5bc2ba9a01_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_22cd74a1-6f60-4a3d-a7dc-117c8ad8b8ae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f800261b-8615-4b50-b325-872f3c792cd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation credit</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2adb9bae-10a0-4619-b627-e196cf182f96_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fed014d5-112b-4aeb-b1a3-5eb1139ff73a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2b0513be-e227-46d9-a56b-35ffd111d2a9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_bcd7a9fb-f51c-477f-aaed-72deccc997fa_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20220930.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_829c63d0-d61a-40c4-9cbb-0ba93b0539cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_648bd185-83d5-44b7-b7af-3ffbe6cf24c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of common shares</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Redeemed or Called During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4afe5b72-e1fe-4320-9b51-e8af0b5b5fc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_ec5d650b-1c67-4ba9-8ba7-c29305764567_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7b6e1697-0d78-4b20-beb1-207440c3b877_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_e1f62409-ae95-407c-9c82-675c8c183917_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_9a98bca3-3fb8-4086-9478-96fbbcd65783_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wet Laboratory and Office Space</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_868b3dec-ce13-4e9d-9492-698e4e477de3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0938ec5-6b4e-4e18-b63c-6da7ab02751f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_daf4d759-b16c-4cc5-98b6-17ad66c79442_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7696322-e754-4602-95af-cefc25846a16_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_844aed3a-e3e0-4885-869f-32494bfcf190_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0c65bf7b-4d07-4d40-aec4-b4b165e2d864_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_222cc9e1-824d-4dc1-b6d6-b7df0eaa57d3_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Member]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:href="cpix-20220930.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_87ab3dff-4c76-4fec-85c5-01404133767b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life insurance policy proceeds received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:to="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a97a1eb3-9b03-48b0-8694-b6ec571a85aa_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_69e4b375-7a16-4ce6-9a12-c8e112b3815f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f87b93d5-f979-4df8-9d65-325e2132d21d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_626c6932-1403-45fa-93a8-18f27efafe6b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b7347ffe-6a41-496e-aab2-04c1c14cce4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_94b13133-1a92-4fcc-8a18-3c777b356563_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20220930.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c9f36243-6359-49a2-bf4a-a9f581a9273a_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_868c3f64-37c2-484c-9bd5-e42f8d0a1830_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_22a0a262-9d03-4362-9bb2-a7b37c228ed6_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_ee184f07-a96a-41b2-a348-e4a7a35b4f85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f6c6a3a8-592f-45f8-8edf-6f502291fe33_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_43ce77a3-f5a9-462c-b7e1-4626b844e3e3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_100e538b-95b9-471e-bfa0-c73870f2896d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_1485c72f-ffd1-4395-a868-8e9fd1d7ff84_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash threshold</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Threshold</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:to="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_474b3359-1b70-4cf3-b862-f723120f83a5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_88f1ab19-c6cc-45bc-82c0-fd7bdfd9b326_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4895068c-ed4d-4cc2-a992-a7f8f5d76172_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_53b3f3a8-498d-46a8-9d00-b0863f4c31b6_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:to="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_19d88ca4-fbd3-4e5b-b736-3d0eb7da9393_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares left to repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_a38e0a90-c616-46c6-8b4a-c26ae165d814_verboseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income - gain on insurance proceeds</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_0ceb8250-9e1e-4ba2-be71-9d7aba0c3c5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on receivable of life insurance policy proceeds</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_a59d231c-c767-4965-a28c-78b198631867_terseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on receivable of life insurance policy proceeds</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_label_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insured Event, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuredEventGainLoss" xlink:to="lab_us-gaap_InsuredEventGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1de226ea-f3ac-4bc5-af99-48e72946861e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_c5228305-0544-4d56-bfef-3d91666d2d29_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85ff7bf8-abc8-4e62-a2b2-2b454f50cc85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_ce35a2bb-e3e1-48ee-827d-b095559f78b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable investment funding</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0f82c2da-6fd5-4cc0-b863-33143dbc3890_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f91814dd-0853-4d0d-8391-114fbcaeab19_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7b29174f-454e-4e25-8467-c68a6a15dcde_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_29698091-0271-437a-b227-2be82f8e2930_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SancusoMember_56fc2f19-c012-4b19-8922-753e7b657075_terseLabel_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:label id="lab_cpix_SancusoMember_label_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso [Member]</link:label>
    <link:label id="lab_cpix_SancusoMember_documentation_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SancusoMember" xlink:to="lab_cpix_SancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f9d331e8-60ff-4f8a-86f5-0968ca957001_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_daf1bfbf-ec36-4cb7-817b-e7131ee5ac6e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dafa04ad-c71d-4c24-a0d1-1a067ea0c2ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_13b1946b-9592-4c5d-994d-277a7b19f5e6_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1d1cb7b0-d34b-4df3-bdd4-620b4eee7502_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_7974c66f-cc94-4643-b011-88aaffdc3292_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e81fb8b7-7ddb-4e3a-baa2-da224100db2c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_8308b421-ce1f-4315-afd6-2f4f3f7dea5e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_00ed10f5-7681-4abd-b42d-9e62d4bbeced_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a0c44bf4-d201-4fce-aa1c-0631e6e87634_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6d756538-3e71-4364-b81d-c1ba7e011e33_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a012a0fb-148d-47bd-b342-34a8c6437c37_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f67d3540-7358-4955-b4a2-000a98f459cd_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_9ec8835b-890b-4677-bc50-361276ed1611_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_label_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments" xlink:href="cpix-20220930.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionMilestonePayments" xlink:to="lab_cpix_RevenueRecognitionMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a16ec3d7-d156-4fbb-9392-9a9cc293dc0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0d3ebf5f-febd-48f5-83e6-3ef55a49ca43_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dee36867-d4d0-4233-908e-7379a0aacac7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2e0f4656-153e-4a72-af6b-9857fc6cdb80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2596829b-5ba5-45f6-bb83-6667481aa1a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_93d6c6c0-801e-4519-8ef4-297c1b91616e_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment credit due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9bf4299f-d8c9-4162-8617-94b6c7dcde49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0110e633-939e-48b7-8905-24a6e9ffe3da_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_1763b930-e029-4050-bc85-c31ad9283fb4_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_639d82c6-9ffa-4563-8041-ed6a81533322_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KyowaKirinMember_d703c93d-9eae-4565-a925-a71821933e81_terseLabel_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_label_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin [Member]</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_documentation_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember" xlink:href="cpix-20220930.xsd#cpix_KyowaKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KyowaKirinMember" xlink:to="lab_cpix_KyowaKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_98083be3-b276-4770-b115-0c5b751c5ad8_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9603d2e1-f513-4fb1-9262-49f882647413_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_2ece7055-b216-4de7-b31f-cada2044ace7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_59371175-4bd4-43db-af62-fa115fe90b70_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_58123a89-ca46-4ded-91bf-4cbae1a64079_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20220930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_f99a507e-da23-41f2-942d-e8ef4f72dd54_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_773b0217-8c27-4674-addb-27fddfd0d45f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_9a70686d-6f14-43ec-8537-cdc105ec0abd_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20220930.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2e1f1276-85fd-402f-af1e-ee6803eba0e3_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b0ad6319-7b1f-4be9-bb80-b18bf6ac0bfd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a4023495-b4f7-4fd2-976d-6a15d09da550_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_106a12ef-e265-4e71-9fe5-4eec7126ab08_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_84732769-c9bf-4da3-9e9d-0a8804170e8a_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd52cdb8-2a78-476f-9dcd-ebb91c63e290_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_3593fecd-7011-47f5-aeba-3e62bd2d7894_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obsolescence and discontinuance losses</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a20af64b-ece2-4dac-923b-2cfd996cb610_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_63e9a5dd-0dc2-4a37-b74b-3f01d7338cba_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of patent litigation</link:label>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_label_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Settlement of Patent Litigation</link:label>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Settlement of Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:href="cpix-20220930.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:to="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a6af0baa-a7c5-40df-a980-422421c3c5f8_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_cd342f54-624d-4116-96dd-2d20032aa7e5_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_20210583-5273-4a26-b8df-28e740fbdd8a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f8eb7f98-7838-45ed-b4ed-991f706b3e65_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_991c4392-ec67-4331-ab79-93848639d5cf_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79844e70-83bd-4a72-a42d-73d001b2f98b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_4752caae-c40c-4125-a96d-40e223beff23_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares_010f3a6d-2a34-4f61-95a0-b74e26ff75e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_271d426f-f61b-493c-a255-2b63820519c1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e72a4065-373f-4dd7-934a-ebf1f7ff9d8c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a538e607-8a57-4606-b320-d4f2fd46227b_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_fc81d0fa-cb32-4e6d-9049-ab2c4a2aebbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3124acdc-d3a9-4479-8531-eaffebe4b691_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6d0ebb0a-fc27-4e85-b098-ff5e2b345d5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dissolution Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_87f74c29-0893-4fbd-a66d-acc3dfebafb0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_574ab966-fdd5-4486-8d94-95b26657bff1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d2fa0575-3793-4b3b-859a-55be505b91dc_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4f012d1e-677d-4462-afe1-58f28d94ad66_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_01be8036-27d8-4d99-97fb-7a6d0cc20ca0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20220930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_bdc78227-f7f4-465b-a0ac-dddf0affcd12_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_531165e6-a97d-46f9-8d0c-013e55233ae6_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a17e0f9d-954a-44c2-a6cc-72ae50445679_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45f45fa2-0dfc-4dec-844f-0bdb17579802_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_429ef6cc-ddf7-4324-ba70-8046d08dd69c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_210841b7-c17f-4932-ae45-2344270d0480_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b800d57e-1627-4826-bd91-dedf93d3976d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ab3a4490-5b14-4e57-a507-48d815392d00_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_05ba2feb-3f42-437a-b2d4-dfcd39fce70c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_49893ec2-9013-40f9-b6b6-4594181d7cfd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d1230bc9-2036-4c9d-81b4-a534cd3c35e9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_e55c3760-c07a-4b95-9534-79f2277fee39_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a85836c4-9cb9-436b-b59f-e2f9cdbaeebf_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_f6196662-95b8-4a92-8ea3-299456c4d701_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20220930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e8376d-526a-4963-822f-62a6030e24ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_03884911-e17b-4a7e-ba80-d203b741658a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3b339996-e42e-45c5-8dd1-3606b0d6a3e0_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d3ad9c3d-bf40-4e86-a72e-8eff7d246b66_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08c79198-d6f1-411e-b144-96be9268c6c0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bfde52b8-313b-43b9-9924-90eb1f559ecc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1c442bee-c53e-41dd-919d-4719738afaa5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ea0adcbd-aed1-4c96-918d-b92c7dbea2a0_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6ec41a6a-655b-4bc8-9f46-9e4f243a860a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_10df342c-5a36-4a4d-88e3-222c8463b8b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b174391b-4287-47f2-865e-3e38be444c53_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_6ad7ef9f-b77e-43a0-a271-ed0b7c59679f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_24b03cf6-46f6-4856-bb8d-6a36a9d2b296_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_da864901-c57c-42e1-9c9c-26ec575c0625_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f31e5621-5a4a-49d0-abbc-dbf4ac2b5fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8262bdb8-a075-4200-a703-21e4f6b0c01e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_d8dc26ae-89bf-4aa4-9042-04152221b1f8_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_be50427f-5d80-4fbe-bab1-3f536db90a89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b0fd065a-8431-4c8d-a878-1486f7811369_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_54d3ce98-ccfb-4e73-9b43-9574b0902445_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_8f65e528-fa77-4067-831c-e12def8a4288_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_0589353c-e24d-4489-a920-f10dcd45a4e1_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20220930.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_c5d2b060-430f-46e0-b60c-50ba7c869475_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a2a0d1fc-a613-4231-8e83-5ba4dba10bc4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_98b3d664-2eb7-4132-a9cc-c361b649336e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eae67526-7b89-471c-9864-a34f805c17a5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d5ecae01-3b65-4fa5-b8b4-abe5ad33da66_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d3415ed9-fad2-4d42-ad00-001d287a1a24_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0d619f52-eff5-45a5-b48b-6ccad30bd585_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fecd1ad9-ec3b-4a18-977e-a7bcd5544e01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_af053381-5af1-4c96-83da-20c33489cf47_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_d88ce4fb-6e62-43bf-a4ba-50e87674c2e0_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20220930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b828508b-cbae-4d3d-9cda-8f5ddf370f0a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d44e1fdb-20ea-48e3-ab0b-8a65f8b88750_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_044d6dd0-28c1-4296-a60f-17172a6dc8b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b83f7396-a1e8-4615-87e4-bca1c2ea567a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_96aa373d-e375-4452-baa1-a8ad47baf3d1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_da8e66cc-3f07-40d0-875f-b8b32049aca0_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cpix-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e0839ea3-e098-4f93-afa3-37d29c6655d1,g:ef7281af-56e2-4e26-9661-b3993287f2ab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f86a826a-925e-43ea-aa40-fa66d3983ead" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_DocumentType_f86a826a-925e-43ea-aa40-fa66d3983ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4a3909d7-a29d-49f7-ac84-fd5396328e97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_DocumentQuarterlyReport_4a3909d7-a29d-49f7-ac84-fd5396328e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4688d021-1bd0-451a-ae3b-a21da389ee01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_DocumentPeriodEndDate_4688d021-1bd0-451a-ae3b-a21da389ee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_60c86b95-f816-4cfb-901e-3dbbe859e5e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_DocumentTransitionReport_60c86b95-f816-4cfb-901e-3dbbe859e5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_76341c5e-22e8-4cef-a002-dc4184e12693" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityFileNumber_76341c5e-22e8-4cef-a002-dc4184e12693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_42642058-fc4f-485f-a3ed-41561f1113bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityRegistrantName_42642058-fc4f-485f-a3ed-41561f1113bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c56f0626-a9e0-48ff-a6c7-668a249be4a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c56f0626-a9e0-48ff-a6c7-668a249be4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ac5618c1-d483-4206-a96a-d9ca99d956e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityTaxIdentificationNumber_ac5618c1-d483-4206-a96a-d9ca99d956e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_59c9b7c8-6365-4025-9267-995292e47185" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityAddressAddressLine1_59c9b7c8-6365-4025-9267-995292e47185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f2b83bae-ed27-4516-a731-8936fdbc5cb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityAddressAddressLine2_f2b83bae-ed27-4516-a731-8936fdbc5cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eca0c99b-1ad8-4e12-9201-5c56c536a1e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityAddressCityOrTown_eca0c99b-1ad8-4e12-9201-5c56c536a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e6bf90bd-c920-4c2c-bb3c-2eafb28f9e60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityAddressStateOrProvince_e6bf90bd-c920-4c2c-bb3c-2eafb28f9e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_86ef2bb8-32c3-4c8a-9243-eab9ccda3827" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityAddressPostalZipCode_86ef2bb8-32c3-4c8a-9243-eab9ccda3827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_04c14daa-833b-4f52-b684-cddd1e7fb809" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_CityAreaCode_04c14daa-833b-4f52-b684-cddd1e7fb809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5ddfe70c-47cd-4a6b-8825-539f5d158ed5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_LocalPhoneNumber_5ddfe70c-47cd-4a6b-8825-539f5d158ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_38396d71-1903-40eb-9640-0e2f8ba26f77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_Security12bTitle_38396d71-1903-40eb-9640-0e2f8ba26f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cd4c32f3-851f-4f47-b0dd-6c93ed85656e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_TradingSymbol_cd4c32f3-851f-4f47-b0dd-6c93ed85656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6f1667a4-eeb0-45d1-8fc7-70e57464b457" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_SecurityExchangeName_6f1667a4-eeb0-45d1-8fc7-70e57464b457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_89b20f0b-d171-4a63-9055-fda8dfc2a8f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityCurrentReportingStatus_89b20f0b-d171-4a63-9055-fda8dfc2a8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0ebfc4aa-fdaa-477a-8c39-59e8ff40b51d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityInteractiveDataCurrent_0ebfc4aa-fdaa-477a-8c39-59e8ff40b51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ff97c6bc-54fa-46f4-9df4-9ca4a3fb91cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityFilerCategory_ff97c6bc-54fa-46f4-9df4-9ca4a3fb91cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d5e5c0b6-db11-41d0-af9e-489395a9523f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntitySmallBusiness_d5e5c0b6-db11-41d0-af9e-489395a9523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6fbbbb4b-8220-4f02-905a-114dd844811c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityEmergingGrowthCompany_6fbbbb4b-8220-4f02-905a-114dd844811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7a20eb38-6cce-4222-9ce7-d5aded31ee1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityShellCompany_7a20eb38-6cce-4222-9ce7-d5aded31ee1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7942a869-c979-4955-8ddb-75dfeb5b2c73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7942a869-c979-4955-8ddb-75dfeb5b2c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_04d513b3-b7b1-4a06-8683-e5a1418de2b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_DocumentFiscalYearFocus_04d513b3-b7b1-4a06-8683-e5a1418de2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_755eefb7-6cbf-496e-82de-72769db99f05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_755eefb7-6cbf-496e-82de-72769db99f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2f3e87d5-2209-4952-be94-faeb466cbb77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_AmendmentFlag_2f3e87d5-2209-4952-be94-faeb466cbb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0b108b77-03a1-478a-971a-e308e71fd005" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_EntityCentralIndexKey_0b108b77-03a1-478a-971a-e308e71fd005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_79566676-91ce-4663-ac1c-8b3348869e84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_52ec412f-8398-4877-8c9a-64984a8a1bed" xlink:to="loc_dei_CurrentFiscalYearEndDate_79566676-91ce-4663-ac1c-8b3348869e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3760c36e-7f39-4b2e-bcaf-1c46f1f87450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3760c36e-7f39-4b2e-bcaf-1c46f1f87450" xlink:to="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7662ac97-729c-481d-94cd-bbdf5d5a31ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7662ac97-729c-481d-94cd-bbdf5d5a31ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5a82c2b7-58f7-4a93-ae64-3e1ba47f115b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5a82c2b7-58f7-4a93-ae64-3e1ba47f115b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_96071b05-0846-4f37-9a64-8601bcc46b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:to="loc_us-gaap_InventoryNet_96071b05-0846-4f37-9a64-8601bcc46b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ec0ccfcb-3939-4090-89c8-6748a31f7716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:to="loc_us-gaap_OtherAssetsCurrent_ec0ccfcb-3939-4090-89c8-6748a31f7716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1d1eb86e-b703-4387-ac59-67e18e9c04a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1994710a-b10e-440e-a19f-60041520b5d5" xlink:to="loc_us-gaap_AssetsCurrent_1d1eb86e-b703-4387-ac59-67e18e9c04a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_472a872a-d664-415d-8e54-baa0f38adb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_InventoryNoncurrent_472a872a-d664-415d-8e54-baa0f38adb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19e8a23c-e9de-4552-bfa2-4071ddaf1dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19e8a23c-e9de-4552-bfa2-4071ddaf1dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f2dbdf7-2b10-4b65-8976-cf4388cbe400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f2dbdf7-2b10-4b65-8976-cf4388cbe400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b1b3d60d-faed-455a-bfb7-1bb1faa8bf36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_Goodwill_b1b3d60d-faed-455a-bfb7-1bb1faa8bf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7223688-a668-406d-9c53-63254dfdaf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7223688-a668-406d-9c53-63254dfdaf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_037f25ca-50b2-4b4d-9f57-72badcb51cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_037f25ca-50b2-4b4d-9f57-72badcb51cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ca86c07f-02bb-434d-93ee-372388878e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e00de329-fcd9-40d1-b368-6c1b3921cefd" xlink:to="loc_us-gaap_Assets_ca86c07f-02bb-434d-93ee-372388878e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3760c36e-7f39-4b2e-bcaf-1c46f1f87450" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8ab9a3ee-53a3-429e-bbd1-ed3fbe678f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8ab9a3ee-53a3-429e-bbd1-ed3fbe678f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_95e0e6c4-41c0-4a7d-9a04-f8ac205f1f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ab9a3ee-53a3-429e-bbd1-ed3fbe678f7a" xlink:to="loc_us-gaap_AccountsPayableCurrent_95e0e6c4-41c0-4a7d-9a04-f8ac205f1f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cab32d1a-c665-4439-8260-0f3ffe056c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ab9a3ee-53a3-429e-bbd1-ed3fbe678f7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cab32d1a-c665-4439-8260-0f3ffe056c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8e8dc6ac-4ca9-46c3-9397-d491a7481bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ab9a3ee-53a3-429e-bbd1-ed3fbe678f7a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8e8dc6ac-4ca9-46c3-9397-d491a7481bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16bd5458-4362-48b3-b5d3-849595a14e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ab9a3ee-53a3-429e-bbd1-ed3fbe678f7a" xlink:to="loc_us-gaap_LiabilitiesCurrent_16bd5458-4362-48b3-b5d3-849595a14e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_9ca95ce7-6d5c-4546-9057-264a46960a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_LongTermLineOfCredit_9ca95ce7-6d5c-4546-9057-264a46960a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aed1027c-94b2-4386-8343-173cd584f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aed1027c-94b2-4386-8343-173cd584f97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_9e9cd69d-79a5-4b9e-aa4b-e78cd7fe3cf8" xlink:href="cpix-20220930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_9e9cd69d-79a5-4b9e-aa4b-e78cd7fe3cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_197b8f5e-a264-4304-8d9a-c2e6d678f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_Liabilities_197b8f5e-a264-4304-8d9a-c2e6d678f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ec6ca1ac-4a9e-4c1c-8e3a-e453c8f68a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ec6ca1ac-4a9e-4c1c-8e3a-e453c8f68a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bdb8497b-07fe-4c5b-bdad-0f43e4392d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bdb8497b-07fe-4c5b-bdad-0f43e4392d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c0efd63d-890c-48bc-8a1c-40a1ebabc23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bdb8497b-07fe-4c5b-bdad-0f43e4392d8c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c0efd63d-890c-48bc-8a1c-40a1ebabc23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0281e916-f58d-4a86-bf66-e68d8a04e4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0efd63d-890c-48bc-8a1c-40a1ebabc23b" xlink:to="loc_us-gaap_CommonStockValue_0281e916-f58d-4a86-bf66-e68d8a04e4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_41dbd20b-7280-48a0-9b6a-702e279ae4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0efd63d-890c-48bc-8a1c-40a1ebabc23b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_41dbd20b-7280-48a0-9b6a-702e279ae4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61ac3133-cdc5-4d30-8d9b-a3f00300bdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c0efd63d-890c-48bc-8a1c-40a1ebabc23b" xlink:to="loc_us-gaap_StockholdersEquity_61ac3133-cdc5-4d30-8d9b-a3f00300bdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6f0ef9db-0857-422a-92cf-b89f6f906aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bdb8497b-07fe-4c5b-bdad-0f43e4392d8c" xlink:to="loc_us-gaap_MinorityInterest_6f0ef9db-0857-422a-92cf-b89f6f906aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c36ded9-19bd-43e4-9109-87bcc33628e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bdb8497b-07fe-4c5b-bdad-0f43e4392d8c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c36ded9-19bd-43e4-9109-87bcc33628e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aedbb5b6-feed-41bf-87ce-f82938a5c556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_834a5958-ae02-4a2b-bc77-e563bdb84f56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_aedbb5b6-feed-41bf-87ce-f82938a5c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_137b4d5e-821a-4371-bdaa-c81128d2ee93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_36f2de6e-cdf8-4a1d-afa8-fd82b5632234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_137b4d5e-821a-4371-bdaa-c81128d2ee93" xlink:to="loc_us-gaap_CommonStockNoParValue_36f2de6e-cdf8-4a1d-afa8-fd82b5632234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ea2f57c8-6788-4969-8fc6-9058149553c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_137b4d5e-821a-4371-bdaa-c81128d2ee93" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ea2f57c8-6788-4969-8fc6-9058149553c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3fc857a1-9a20-4017-b720-a0b503b42267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_137b4d5e-821a-4371-bdaa-c81128d2ee93" xlink:to="loc_us-gaap_CommonStockSharesIssued_3fc857a1-9a20-4017-b720-a0b503b42267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fbeb307b-802c-4846-891b-6f0192db94dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_137b4d5e-821a-4371-bdaa-c81128d2ee93" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fbeb307b-802c-4846-891b-6f0192db94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c1cf456-8740-4459-a32c-9a68e6ad80c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c1cf456-8740-4459-a32c-9a68e6ad80c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d015ae93-4768-42e2-b8eb-3c294a5c38af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d015ae93-4768-42e2-b8eb-3c294a5c38af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_55be27d8-f9e3-49c0-8622-512a4ae42406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_SellingAndMarketingExpense_55be27d8-f9e3-49c0-8622-512a4ae42406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c2789606-ceba-4465-bd81-bb86c9125fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c2789606-ceba-4465-bd81-bb86c9125fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b38c59dc-b547-40a9-9be2-8e59eca8cc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b38c59dc-b547-40a9-9be2-8e59eca8cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b5d455e4-27d6-4efd-bd4b-ce71d57dd585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b5d455e4-27d6-4efd-bd4b-ce71d57dd585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7847e59d-8c39-47b7-89c5-15974f6091d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_CostsAndExpenses_7847e59d-8c39-47b7-89c5-15974f6091d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b3c35eff-cddd-4676-ad4d-8d98036d8f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2edde835-47a0-4bf3-9b8a-a68c770ccc61" xlink:to="loc_us-gaap_OperatingIncomeLoss_b3c35eff-cddd-4676-ad4d-8d98036d8f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_23f771b2-448d-49d0-9e3f-3b2e95a6d311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_23f771b2-448d-49d0-9e3f-3b2e95a6d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_af8f7b78-4561-4633-bb57-0c5e8e60645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_OtherIncome_af8f7b78-4561-4633-bb57-0c5e8e60645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_774539dd-6fc7-43ee-bf4d-89f300dcf5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_InsuredEventGainLoss_774539dd-6fc7-43ee-bf4d-89f300dcf5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8ccd9e03-e9b3-49ac-93be-ec03d7de7602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_InterestExpense_8ccd9e03-e9b3-49ac-93be-ec03d7de7602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_656200f3-3dee-4db6-b07b-2186f215c4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_656200f3-3dee-4db6-b07b-2186f215c4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b08eb2c8-03dd-49da-a7f1-e20cf7a9bd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b08eb2c8-03dd-49da-a7f1-e20cf7a9bd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0d4f2e87-73fb-4c3d-a14b-c42000d151cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0d4f2e87-73fb-4c3d-a14b-c42000d151cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_86a2f4a7-e3c8-40d8-9979-e23f11eb206a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_86a2f4a7-e3c8-40d8-9979-e23f11eb206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5b7e5220-69dc-4b2b-ae33-85cdba074578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_ProfitLoss_5b7e5220-69dc-4b2b-ae33-85cdba074578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fbcc4434-7d68-4673-9fc2-748d24cd38ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fbcc4434-7d68-4673-9fc2-748d24cd38ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91587715-7c89-4a45-ab21-56796b226266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_NetIncomeLoss_91587715-7c89-4a45-ab21-56796b226266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_05862744-47b7-40c5-b209-d07b779f52bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_05862744-47b7-40c5-b209-d07b779f52bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_ab128e7b-5bc1-42b0-bdc0-a2d67d945ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_ab128e7b-5bc1-42b0-bdc0-a2d67d945ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_41c2a972-e981-47ac-a4cd-cdd5a3267971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:to="loc_us-gaap_EarningsPerShareBasic_41c2a972-e981-47ac-a4cd-cdd5a3267971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_36261a1e-c032-45de-8f47-36bbb05d1c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_36261a1e-c032-45de-8f47-36bbb05d1c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_258d1f4a-6c7d-4cf7-89ba-e0deff184392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_258d1f4a-6c7d-4cf7-89ba-e0deff184392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_db8df206-a57a-474c-8440-55ec85aa15e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d567c17-7281-4e2c-9220-332d9aed1e5d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_db8df206-a57a-474c-8440-55ec85aa15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_103cdfd0-4581-4cb6-8785-95aa26939096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fa1fa07-6625-4753-993d-f024b64badc0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_103cdfd0-4581-4cb6-8785-95aa26939096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a5c46b5-e357-41a5-a560-21e094aeb8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_103cdfd0-4581-4cb6-8785-95aa26939096" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a5c46b5-e357-41a5-a560-21e094aeb8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61591251-00ca-4da6-b27b-ac9a4d39af95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_103cdfd0-4581-4cb6-8785-95aa26939096" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61591251-00ca-4da6-b27b-ac9a4d39af95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_418e33bb-6a94-4d0b-8e1f-00e7e661b110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_418e33bb-6a94-4d0b-8e1f-00e7e661b110" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_95acaba1-4174-4a6a-b44b-82aa7335856e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_ProfitLoss_95acaba1-4174-4a6a-b44b-82aa7335856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f00af9d2-3e48-4006-9391-7262fca97510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f00af9d2-3e48-4006-9391-7262fca97510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_afd7516a-2815-412c-b4af-aadcd5eb70eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_afd7516a-2815-412c-b4af-aadcd5eb70eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_54169385-83ad-444e-be72-4000998f997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_54169385-83ad-444e-be72-4000998f997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_753acefb-9a2f-4659-bf78-9c97011b61d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_ShareBasedCompensation_753acefb-9a2f-4659-bf78-9c97011b61d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_14c9ab90-d9ca-4397-bd70-acc30ef3a222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_14c9ab90-d9ca-4397-bd70-acc30ef3a222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_067f617b-222c-40ac-a7e3-3885aa6ba311" xlink:href="cpix-20220930.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_067f617b-222c-40ac-a7e3-3885aa6ba311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_648fe8ff-9f0a-4fa5-af2e-a4fd91d1439a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_648fe8ff-9f0a-4fa5-af2e-a4fd91d1439a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e387c0c-042d-4d6c-bd2c-c65bc5fd9408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e387c0c-042d-4d6c-bd2c-c65bc5fd9408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_46c41090-3ab9-46c0-b752-b44132e52368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_InsuredEventGainLoss_46c41090-3ab9-46c0-b752-b44132e52368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1cf69660-ab70-4500-b65f-f90428b30e4f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_374ca7d8-12b5-4205-88d6-c0377d6a6dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_374ca7d8-12b5-4205-88d6-c0377d6a6dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2f88cf2b-05c1-4865-8e40-d79b97c8d11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2f88cf2b-05c1-4865-8e40-d79b97c8d11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cc921b73-c8fb-4e9b-9681-3eb08f42c2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cc921b73-c8fb-4e9b-9681-3eb08f42c2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_787df176-b43c-445c-8267-fb6318057a44" xlink:href="cpix-20220930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_787df176-b43c-445c-8267-fb6318057a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_237105df-759f-4486-9a16-b5c4fd86e668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b12ac50-ee25-469d-b6f5-2da39c7bc7fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_237105df-759f-4486-9a16-b5c4fd86e668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_625678bb-34ce-4045-8d95-3005f8c9976f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_625678bb-34ce-4045-8d95-3005f8c9976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7d7fa5e6-7c84-4ba0-8357-03c28fe5d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_7d7fa5e6-7c84-4ba0-8357-03c28fe5d51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20146f50-d8f6-4d56-8fb1-570fe517710d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3566996f-c928-4985-8f51-f203e3f0d7c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20146f50-d8f6-4d56-8fb1-570fe517710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_418e33bb-6a94-4d0b-8e1f-00e7e661b110" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_593434d5-bef6-45dd-9826-2fb2d81981d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_593434d5-bef6-45dd-9826-2fb2d81981d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation_fc4ce59e-a379-4be9-ba0e-7fa9dfdea3ba" xlink:href="cpix-20220930.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_cpix_ProceedsFromSettlementOfPatentLitigation_fc4ce59e-a379-4be9-ba0e-7fa9dfdea3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_055f1871-decb-43c1-b583-2827b00936f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_055f1871-decb-43c1-b583-2827b00936f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_39a092bb-dc4e-47dc-a973-183fb3fc6437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_39a092bb-dc4e-47dc-a973-183fb3fc6437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f361304a-dad3-4dbb-8613-efe0c0aad751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f361304a-dad3-4dbb-8613-efe0c0aad751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a69dee1d-a21b-4337-a0ca-a31e840e3ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a69dee1d-a21b-4337-a0ca-a31e840e3ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55de8992-6c85-4afb-b55b-33f4a3bdbc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02e3837f-f82e-4b98-b098-57a8c3b306b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55de8992-6c85-4afb-b55b-33f4a3bdbc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_418e33bb-6a94-4d0b-8e1f-00e7e661b110" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1322b976-2f50-4c67-a860-d2e552e69b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1322b976-2f50-4c67-a860-d2e552e69b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_3d889e5b-2092-4274-8479-fb4cb879f489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_3d889e5b-2092-4274-8479-fb4cb879f489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_45a61ae3-74e8-45ad-9dc7-61b140b9c5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_45a61ae3-74e8-45ad-9dc7-61b140b9c5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d87f0a9a-7eb8-4cf1-b68d-f706b9634cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d87f0a9a-7eb8-4cf1-b68d-f706b9634cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_adee4a0e-0571-42e1-8f4f-ce06ce843cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_adee4a0e-0571-42e1-8f4f-ce06ce843cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60c8c17b-26f8-480a-8971-66bc7729c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60c8c17b-26f8-480a-8971-66bc7729c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e8f942e-271a-43eb-986c-39f3062eecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e8f942e-271a-43eb-986c-39f3062eecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6751561a-805b-4a71-80af-787b06af1dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f1baf58-24d3-457a-a33a-89ab12a93054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6751561a-805b-4a71-80af-787b06af1dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20220930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_400ffd72-f1cc-4a9b-bba1-9a4f3d8d82b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_400ffd72-f1cc-4a9b-bba1-9a4f3d8d82b2" xlink:to="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6829acb-20aa-4972-bf5f-a284227ff0ad" xlink:to="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0232e171-4156-4123-a39f-8bed1a47875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:to="loc_us-gaap_CommonStockMember_0232e171-4156-4123-a39f-8bed1a47875f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dc205af0-dcb0-44d1-9ea6-f94b6c73d46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:to="loc_us-gaap_RetainedEarningsMember_dc205af0-dcb0-44d1-9ea6-f94b6c73d46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_bc2e78a9-edd8-4410-9146-f41b2494d2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8595b87-5333-48d7-9e34-146a5a22d815" xlink:to="loc_us-gaap_NoncontrollingInterestMember_bc2e78a9-edd8-4410-9146-f41b2494d2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_553a5a9a-1b3b-4489-ad3e-a42625d8253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0de6a310-26ed-4086-8440-4af2a80ed0dd" xlink:to="loc_us-gaap_StatementLineItems_553a5a9a-1b3b-4489-ad3e-a42625d8253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_553a5a9a-1b3b-4489-ad3e-a42625d8253e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f8fd22fa-4435-4b88-9fc6-65d18a61a2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f8fd22fa-4435-4b88-9fc6-65d18a61a2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21c6bab2-13bb-425b-8c0d-b5f785930a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21c6bab2-13bb-425b-8c0d-b5f785930a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9d18fb7c-fb32-4ebd-bd70-eb827824030e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9d18fb7c-fb32-4ebd-bd70-eb827824030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_621dd2c4-1665-40e8-a724-dfedb4ec856a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_621dd2c4-1665-40e8-a724-dfedb4ec856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_8bdad16e-66f8-48dd-a213-bd8799acacff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_8bdad16e-66f8-48dd-a213-bd8799acacff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_a332038a-9e51-471a-b247-b0d589346c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_a332038a-9e51-471a-b247-b0d589346c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_2d6d41ae-21cd-4834-9fa8-c9175bec10a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_2d6d41ae-21cd-4834-9fa8-c9175bec10a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_3c6b81fc-d425-4b22-9c23-012de862c075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_3c6b81fc-d425-4b22-9c23-012de862c075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5a5053f4-5db2-4667-9cae-24d4c22c55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_ProfitLoss_5a5053f4-5db2-4667-9cae-24d4c22c55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b7db971d-1265-4502-9d62-14b798ef1e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b7db971d-1265-4502-9d62-14b798ef1e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64950262-e57a-4416-ac5f-a74255ad51e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c10f822-5c62-45ae-85b6-6f4b40f09f13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64950262-e57a-4416-ac5f-a74255ad51e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20220930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08b0c33f-b179-4136-ad30-c37781e86265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e84d6fcc-0729-4d26-a390-e6d3e5006fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08b0c33f-b179-4136-ad30-c37781e86265" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e84d6fcc-0729-4d26-a390-e6d3e5006fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20220930.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0def96d2-5c41-45d1-be5e-f7253301f975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9925315f-2990-469a-b440-26b0504b72b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0def96d2-5c41-45d1-be5e-f7253301f975" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9925315f-2990-469a-b440-26b0504b72b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20220930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_be7535ec-520c-44c5-a228-292db4518382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_575aa814-9312-47c3-ab10-0ebb46709f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_be7535ec-520c-44c5-a228-292db4518382" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_575aa814-9312-47c3-ab10-0ebb46709f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20220930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_748cfec4-cacd-4cd3-adf8-24442f180edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_22b177d1-9f78-4342-9ab6-ce9d3bc2c245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_748cfec4-cacd-4cd3-adf8-24442f180edb" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_22b177d1-9f78-4342-9ab6-ce9d3bc2c245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_906d95f6-5401-4e1c-a40f-af829b6e8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_833c78a5-7b65-4425-8125-f05b96d9f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_906d95f6-5401-4e1c-a40f-af829b6e8e77" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_833c78a5-7b65-4425-8125-f05b96d9f8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20220930.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_b70d6876-03fc-4142-a7b7-fb82ab85f2b1" xlink:href="cpix-20220930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ccfa3837-4c0a-4f44-9e72-817dbf84ffac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_b70d6876-03fc-4142-a7b7-fb82ab85f2b1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ccfa3837-4c0a-4f44-9e72-817dbf84ffac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ba9eb69a-4223-454d-b18c-182198b8091b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5dc6d2be-02c8-413b-8b7b-c238d1cdd9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba9eb69a-4223-454d-b18c-182198b8091b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5dc6d2be-02c8-413b-8b7b-c238d1cdd9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherIncome" xlink:type="simple" xlink:href="cpix-20220930.xsd#OtherIncome"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_f5751f68-c616-40d9-9b4e-095d62887e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_5e95c674-abb2-4b3f-b70d-e300f6ab5d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f5751f68-c616-40d9-9b4e-095d62887e54" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_5e95c674-abb2-4b3f-b70d-e300f6ab5d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20220930.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff3f61f7-d2c6-499a-87a2-56134c65fbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c50b8f75-ffdf-4fd8-8020-4b750e83ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff3f61f7-d2c6-499a-87a2-56134c65fbec" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c50b8f75-ffdf-4fd8-8020-4b750e83ac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_98400ae9-bee5-4d72-9941-d3e0d02de781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_fb39e931-0bed-4611-a070-a71edb386d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_98400ae9-bee5-4d72-9941-d3e0d02de781" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_fb39e931-0bed-4611-a070-a71edb386d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20220930.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e8ca5ad-59f0-4882-afdf-ebdcb8570689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_978dcebf-eaf9-4565-a17e-7cc90b9d5cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e8ca5ad-59f0-4882-afdf-ebdcb8570689" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_978dcebf-eaf9-4565-a17e-7cc90b9d5cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_06429b02-4c73-42b0-bebb-e5ffa6f2666c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e8ca5ad-59f0-4882-afdf-ebdcb8570689" xlink:to="loc_us-gaap_UseOfEstimates_06429b02-4c73-42b0-bebb-e5ffa6f2666c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0090403d-333a-4e7c-b0e5-2b9a1cc35c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e8ca5ad-59f0-4882-afdf-ebdcb8570689" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0090403d-333a-4e7c-b0e5-2b9a1cc35c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20220930.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_324a00e4-8bf6-4d63-9978-c1f7a80a7958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be5ad60b-6457-4c62-9c30-d4600cbfc109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_324a00e4-8bf6-4d63-9978-c1f7a80a7958" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_be5ad60b-6457-4c62-9c30-d4600cbfc109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20220930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_87ccc19d-60f8-48f1-8aff-94eef9374572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e1e9181b-24c0-4298-a5cb-0511604679c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_87ccc19d-60f8-48f1-8aff-94eef9374572" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e1e9181b-24c0-4298-a5cb-0511604679c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20220930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ba9525a3-d9a3-4bbf-baac-30ee7bfc53c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5409ed47-8c27-4b81-a33c-4d2c7d7a6670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ba9525a3-d9a3-4bbf-baac-30ee7bfc53c7" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5409ed47-8c27-4b81-a33c-4d2c7d7a6670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f364ae0d-3345-4b13-8ff1-059a0865e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_a4c6ad3a-c957-41e0-a7ed-12d8e7f8873f" xlink:href="cpix-20220930.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f364ae0d-3345-4b13-8ff1-059a0865e0aa" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_a4c6ad3a-c957-41e0-a7ed-12d8e7f8873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6041024-b416-4563-8c3c-091b345c2ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f364ae0d-3345-4b13-8ff1-059a0865e0aa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6041024-b416-4563-8c3c-091b345c2ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_21a831ef-fa81-4f84-a934-eb5e33ce0a3b" xlink:href="cpix-20220930.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f364ae0d-3345-4b13-8ff1-059a0865e0aa" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_21a831ef-fa81-4f84-a934-eb5e33ce0a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7c5e0924-47bf-4c38-9345-cb77bec0b1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_8f6910da-5adc-48e5-af61-8f4cad3917be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7c5e0924-47bf-4c38-9345-cb77bec0b1dd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_8f6910da-5adc-48e5-af61-8f4cad3917be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_964c4ac1-8d84-4167-aeb0-8c2ef4d73870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7c5e0924-47bf-4c38-9345-cb77bec0b1dd" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_964c4ac1-8d84-4167-aeb0-8c2ef4d73870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46bca789-c965-411b-a8a5-056816acea34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_29effe78-c3d3-4617-a9e1-02c4eb6affc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46bca789-c965-411b-a8a5-056816acea34" xlink:to="loc_us-gaap_NumberOfOperatingSegments_29effe78-c3d3-4617-a9e1-02c4eb6affc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_141f58c5-600f-4def-980b-528da79c440a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:href="cpix-20220930.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_141f58c5-600f-4def-980b-528da79c440a" xlink:to="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3309b7ae-470b-4c40-bd4c-cbfde6b8b293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3309b7ae-470b-4c40-bd4c-cbfde6b8b293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_67e5a11b-6775-49dc-89ba-c8e7c32082dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_67e5a11b-6775-49dc-89ba-c8e7c32082dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8a6cd7fc-7b29-4fbd-81a0-4591a38be2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:to="loc_us-gaap_ProfitLoss_8a6cd7fc-7b29-4fbd-81a0-4591a38be2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c63bcd3d-07db-4639-acb0-97051349e5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c63bcd3d-07db-4639-acb0-97051349e5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d3c1e94-3bec-47d4-ba13-954f63eb059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_4bd80cb0-2e25-4d9d-b0c6-560b4de70a38" xlink:to="loc_us-gaap_NetIncomeLoss_3d3c1e94-3bec-47d4-ba13-954f63eb059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_3366be1c-b353-4d15-b643-65fa8f100c1f" xlink:href="cpix-20220930.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_141f58c5-600f-4def-980b-528da79c440a" xlink:to="loc_cpix_DenominatorAbstract_3366be1c-b353-4d15-b643-65fa8f100c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c563332f-fc03-4563-8aaf-d43f1142bd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_3366be1c-b353-4d15-b643-65fa8f100c1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c563332f-fc03-4563-8aaf-d43f1142bd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3bcfa6b9-736b-422f-bb79-4f0dc9c8eefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_3366be1c-b353-4d15-b643-65fa8f100c1f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3bcfa6b9-736b-422f-bb79-4f0dc9c8eefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4987b19-327c-4e27-b632-a27248bd7d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_3366be1c-b353-4d15-b643-65fa8f100c1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4987b19-327c-4e27-b632-a27248bd7d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20220930.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d418eb4f-6ccf-4845-b0ac-babd24315657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6934da3f-40ab-480c-b7d1-86f2b79d2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d418eb4f-6ccf-4845-b0ac-babd24315657" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6934da3f-40ab-480c-b7d1-86f2b79d2c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#RevenuesScheduleofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_790bdb64-9dbb-4749-9a16-046484f07964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_790bdb64-9dbb-4749-9a16-046484f07964" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:to="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a4d55118-9021-49cb-86b8-21bd416b97d2" xlink:to="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_56362aac-bc7a-48fb-8b3e-42c7c06db390" xlink:href="cpix-20220930.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_KristaloseMember_56362aac-bc7a-48fb-8b3e-42c7c06db390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_5acd8a76-519f-4421-8c30-36389a3cab14" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_SancusoMember_5acd8a76-519f-4421-8c30-36389a3cab14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_c44f41d1-1a10-4382-8214-31e6543c59cf" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_VIBATIVMember_c44f41d1-1a10-4382-8214-31e6543c59cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_6cbd69c4-ccbc-426f-8ac1-198446e50dac" xlink:href="cpix-20220930.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_CaldolorMember_6cbd69c4-ccbc-426f-8ac1-198446e50dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_ee5c653d-613a-4897-ba27-36e4cf7ac63d" xlink:href="cpix-20220930.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_VaprisolMember_ee5c653d-613a-4897-ba27-36e4cf7ac63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_fae5c131-17f2-4c81-9e4c-e94c46d5ac38" xlink:href="cpix-20220930.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_AcetadoteMember_fae5c131-17f2-4c81-9e4c-e94c46d5ac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_41cd9137-f3ec-41ae-af9b-6992b3bc8fd0" xlink:href="cpix-20220930.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_OmeclamoxPakMember_41cd9137-f3ec-41ae-af9b-6992b3bc8fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_67231971-215e-4d5c-a961-da8fba13173d" xlink:href="cpix-20220930.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_RediTrexMember_67231971-215e-4d5c-a961-da8fba13173d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_472e0173-2c64-46a7-9b15-c9eb4df89ac2" xlink:href="cpix-20220930.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6862a1a2-817b-4007-beb4-3357715be5c8" xlink:to="loc_cpix_OtherProductsMember_472e0173-2c64-46a7-9b15-c9eb4df89ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1985f6b7-7421-4fc3-b908-170aa3652e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_fc908b98-fd5c-4127-b16b-5956c01dca14" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1985f6b7-7421-4fc3-b908-170aa3652e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f09362d6-71d0-42b0-ab98-91c9e1018b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1985f6b7-7421-4fc3-b908-170aa3652e2e" xlink:to="loc_us-gaap_RevenuesAbstract_f09362d6-71d0-42b0-ab98-91c9e1018b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_19dbd858-d05c-4512-8c4b-b6092fecd348" xlink:href="cpix-20220930.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f09362d6-71d0-42b0-ab98-91c9e1018b6c" xlink:to="loc_cpix_ProductsAbstract_19dbd858-d05c-4512-8c4b-b6092fecd348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8933ff21-e078-4abf-953e-aa1a876ba0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_19dbd858-d05c-4512-8c4b-b6092fecd348" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8933ff21-e078-4abf-953e-aa1a876ba0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#RevenuesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_84ebd1a9-0a3b-4047-b7a6-37466f4ddbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_84ebd1a9-0a3b-4047-b7a6-37466f4ddbb5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:to="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd09fa66-c0ae-4afa-ba11-b7dd25b677a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_34fb546c-69cf-4648-8681-872939bf4b53" xlink:to="loc_srt_ProductsAndServicesDomain_dd09fa66-c0ae-4afa-ba11-b7dd25b677a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_310e059c-35f9-439f-9aad-9ddc71be92f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dd09fa66-c0ae-4afa-ba11-b7dd25b677a4" xlink:to="loc_us-gaap_GrantMember_310e059c-35f9-439f-9aad-9ddc71be92f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c394ea89-8bec-47b6-81fe-b00676a7e9c1" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_de7f30d2-95ba-4da9-8419-cfe96813ff01" xlink:href="cpix-20220930.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_de7f30d2-95ba-4da9-8419-cfe96813ff01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64c2d345-4670-45f9-bff0-da6eeef3e450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_860e304f-595b-4cfe-be31-4c3e3efb63ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_64c2d345-4670-45f9-bff0-da6eeef3e450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5f7be3ff-5a63-48ea-925e-87a71b140dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5f7be3ff-5a63-48ea-925e-87a71b140dce" xlink:to="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8c0b426e-d6db-409d-9583-a082e056ca8b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_9a9b2a65-19cb-4e92-b616-51cd86d07274" xlink:href="cpix-20220930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:to="loc_cpix_IfetrobanClinicalMember_9a9b2a65-19cb-4e92-b616-51cd86d07274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_99c4ebd6-208e-4be3-aa74-443319012d1e" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:to="loc_cpix_VIBATIVMember_99c4ebd6-208e-4be3-aa74-443319012d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_dc53f81d-28cd-4e14-9af6-2e086dd1e073" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f0ae9ec-3850-451d-bf06-94c005b38816" xlink:to="loc_cpix_SancusoMember_dc53f81d-28cd-4e14-9af6-2e086dd1e073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c3cdac16-1d72-4715-bd5f-fae76b97c988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_ee204d5c-83ff-46fb-a10e-e48cda6892ed" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c3cdac16-1d72-4715-bd5f-fae76b97c988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_a5ef8d06-3ae9-4609-8d04-22970b66c8b7" xlink:href="cpix-20220930.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_c3cdac16-1d72-4715-bd5f-fae76b97c988" xlink:to="loc_cpix_IfetrobanClinicalMember_a5ef8d06-3ae9-4609-8d04-22970b66c8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cea2df36-12df-469a-8d1d-904fbf9df515" xlink:to="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_788489b4-7f69-4d4b-b9e8-cb6f6f936c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryValuationReserves_788489b4-7f69-4d4b-b9e8-cb6f6f936c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_37fb8a61-8c9c-4446-8b34-8a258b8f8a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryNoncurrent_37fb8a61-8c9c-4446-8b34-8a258b8f8a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9801914d-996b-4a46-8912-8702ac89bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e5ff1640-eba6-4a55-87ba-7d3b4f32658f" xlink:to="loc_us-gaap_InventoryFinishedGoods_9801914d-996b-4a46-8912-8702ac89bc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_caaa3ae8-c1d8-4e30-b578-2d78508c42d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_caaa3ae8-c1d8-4e30-b578-2d78508c42d9" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_afaf7009-3220-4db7-94fc-3c5b92e8525c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_afaf7009-3220-4db7-94fc-3c5b92e8525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_9afd3005-b48a-4f4e-9273-6babf26f85da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_9afd3005-b48a-4f4e-9273-6babf26f85da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c26118db-4b4b-4c5a-b328-889874d659b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c26118db-4b4b-4c5a-b328-889874d659b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_66a8b7d6-2e43-417e-894d-fa3b3816bbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:to="loc_us-gaap_InventoryGross_66a8b7d6-2e43-417e-894d-fa3b3816bbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_82a0edec-faef-4630-99f4-7a99ab95743d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:to="loc_us-gaap_InventoryNoncurrent_82a0edec-faef-4630-99f4-7a99ab95743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_64bd45cc-51d0-47a4-98fc-7f592e5e662e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_9d19d452-3cfb-4b74-ab18-ce408b0b6199" xlink:to="loc_us-gaap_InventoryNet_64bd45cc-51d0-47a4-98fc-7f592e5e662e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ab8e4b97-d247-423f-a38b-83e02f30272c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab8e4b97-d247-423f-a38b-83e02f30272c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903bd6f5-3ba5-4d01-90e9-b90ac58fd21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1636bdd5-9196-465c-993d-04ffbe094139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:to="loc_us-gaap_BuildingMember_1636bdd5-9196-465c-993d-04ffbe094139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_e0e0eef0-9737-4d78-aa85-0aa4a8a5fda2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_78e200b8-a39d-43b8-ba2a-3fc123f2acbd" xlink:to="loc_srt_OfficeBuildingMember_e0e0eef0-9737-4d78-aa85-0aa4a8a5fda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_14004d2e-2068-4ce1-a3b7-e17cad59d606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_68a5b195-9e78-4b17-a2ac-b68eb0aea685" xlink:to="loc_us-gaap_LeaseContractualTermDomain_14004d2e-2068-4ce1-a3b7-e17cad59d606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_7c162d9b-01b2-41c8-bc82-39af3873e690" xlink:href="cpix-20220930.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_14004d2e-2068-4ce1-a3b7-e17cad59d606" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_7c162d9b-01b2-41c8-bc82-39af3873e690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d53bce95-3332-45ad-8146-9502cde5159f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_a6556cbe-db2d-449b-a106-1d7c23aa3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_a6556cbe-db2d-449b-a106-1d7c23aa3e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_06ddb871-36bb-4c3c-9769-0a2b57a4cab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_06ddb871-36bb-4c3c-9769-0a2b57a4cab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8a5b51d3-3b16-4405-9dd2-bc80ee8962e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8a5b51d3-3b16-4405-9dd2-bc80ee8962e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_257db194-301a-4b4b-aad2-b9dc2b03c697" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_257db194-301a-4b4b-aad2-b9dc2b03c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_537775bd-218d-41e9-9895-178571711728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_537775bd-218d-41e9-9895-178571711728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_2e9854ef-66ad-4381-87be-8a4b4c59b9cc" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_2e9854ef-66ad-4381-87be-8a4b4c59b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_87fc2248-545e-4117-8d34-84d91a9cd854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_87fc2248-545e-4117-8d34-84d91a9cd854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_02033ff5-bde6-46f2-9250-cab9479a7017" xlink:href="cpix-20220930.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_02033ff5-bde6-46f2-9250-cab9479a7017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eafcaefe-eaf0-4ed8-8a5f-553b40270915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00bf7e75-46be-4a6d-8421-fba0a3258731" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eafcaefe-eaf0-4ed8-8a5f-553b40270915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_169bd26d-7964-4534-b949-af5b71eee7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4ac567c5-c889-48b2-8806-573aef6f04ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_169bd26d-7964-4534-b949-af5b71eee7b1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4ac567c5-c889-48b2-8806-573aef6f04ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ea50c80a-aae5-4b3b-b30f-1cf0ab83bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_169bd26d-7964-4534-b949-af5b71eee7b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ea50c80a-aae5-4b3b-b30f-1cf0ab83bbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abf4baac-0b86-4535-ad6b-67a34b8ee21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_169bd26d-7964-4534-b949-af5b71eee7b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abf4baac-0b86-4535-ad6b-67a34b8ee21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_b31d302d-6fd6-4374-ab32-5be6adae2f65" xlink:href="cpix-20220930.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_169bd26d-7964-4534-b949-af5b71eee7b1" xlink:to="loc_cpix_LeaseLiability_b31d302d-6fd6-4374-ab32-5be6adae2f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9d4d4064-bc51-403c-a6be-ac47794157ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9d4d4064-bc51-403c-a6be-ac47794157ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b1a174b-e100-4ca2-bd28-569b7d135ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b1a174b-e100-4ca2-bd28-569b7d135ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e054cd37-4795-48a2-b909-8f2e095fc49e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e054cd37-4795-48a2-b909-8f2e095fc49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afc8fe2b-53a2-4b60-adbf-bb1c42fd0294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afc8fe2b-53a2-4b60-adbf-bb1c42fd0294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0810988-0299-43a6-a518-c6db6b9fc279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0810988-0299-43a6-a518-c6db6b9fc279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_acdf2acb-24f3-4f97-a736-8ac4d071d2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4b378133-058d-478b-8187-189b013df8fd" xlink:to="loc_us-gaap_OperatingLeaseLiability_acdf2acb-24f3-4f97-a736-8ac4d071d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#LeasesRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bfdb9c37-ae2a-4312-8699-485a21425e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_61897b5b-72fc-46da-b472-1b492986b8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfdb9c37-ae2a-4312-8699-485a21425e22" xlink:to="loc_us-gaap_OperatingLeaseExpense_61897b5b-72fc-46da-b472-1b492986b8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_95f33076-77bd-48d0-b389-31db24139244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfdb9c37-ae2a-4312-8699-485a21425e22" xlink:to="loc_us-gaap_SubleaseIncome_95f33076-77bd-48d0-b389-31db24139244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_7d06fb3e-a885-4060-b246-63335aef90a8" xlink:href="cpix-20220930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_7d06fb3e-a885-4060-b246-63335aef90a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9b183d6-def3-49aa-87dc-549b3e88d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4e0bfda8-fce3-4e0f-a3fc-f32938ddeace" xlink:to="loc_us-gaap_EquityComponentDomain_a9b183d6-def3-49aa-87dc-549b3e88d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8b5141f-79c3-4ea4-9ddd-0e4e2bc66e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9b183d6-def3-49aa-87dc-549b3e88d6dc" xlink:to="loc_us-gaap_CommonStockMember_f8b5141f-79c3-4ea4-9ddd-0e4e2bc66e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_89263de0-3346-4392-b737-24f773fd1ae2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a6f1481d-cf40-41a8-a46a-cefdcbfd1f54" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_89263de0-3346-4392-b737-24f773fd1ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_147ade9c-ec95-4cc4-a287-90c0b6b5e8ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_89263de0-3346-4392-b737-24f773fd1ae2" xlink:to="loc_srt_DirectorMember_147ade9c-ec95-4cc4-a287-90c0b6b5e8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b90d9823-3cb1-42d7-9757-bbf0622078ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c0dce23c-c8c9-45ba-84dc-34d95f687a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:to="loc_us-gaap_RestrictedStockMember_c0dce23c-c8c9-45ba-84dc-34d95f687a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_3a23ccc6-a8a6-4258-8e9b-065efa61b096" xlink:href="cpix-20220930.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91d15b-c2e9-4a24-abc9-c5b8ed352582" xlink:to="loc_cpix_IncentiveStockOptionsMember_3a23ccc6-a8a6-4258-8e9b-065efa61b096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_76d8de2d-f3fc-43bb-8d51-a14cf8bea64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e6aa8d22-d895-4a26-ad7b-1eb213082f67" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_76d8de2d-f3fc-43bb-8d51-a14cf8bea64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_9982b366-b3b0-431b-af53-28c361298ea3" xlink:href="cpix-20220930.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_76d8de2d-f3fc-43bb-8d51-a14cf8bea64f" xlink:to="loc_cpix_PinnacleBankMember_9982b366-b3b0-431b-af53-28c361298ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ebf9eec-7441-4f1d-b648-de9e96b18c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a90719-f854-4b36-93f4-716e84e00200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ebf9eec-7441-4f1d-b648-de9e96b18c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:href="cpix-20220930.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ebf9eec-7441-4f1d-b648-de9e96b18c95" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_77866b72-e8db-49fb-9995-3b557b9a94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_77866b72-e8db-49fb-9995-3b557b9a94ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_469eaa6e-2a18-420a-bc56-10b7149745c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_469eaa6e-2a18-420a-bc56-10b7149745c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_fb359459-714c-4e2d-a28e-d5a7566c5e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_fb359459-714c-4e2d-a28e-d5a7566c5e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_af7fc565-7017-4f4f-94be-5b8dfc51ffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_af7fc565-7017-4f4f-94be-5b8dfc51ffd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_fea16d82-bf99-4f1b-bd7e-36865622c044" xlink:href="cpix-20220930.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_fea16d82-bf99-4f1b-bd7e-36865622c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_534e034c-0189-4412-8eb5-f79827ab4034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_534e034c-0189-4412-8eb5-f79827ab4034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3eda8bc-be53-4b42-b0b1-27d33a8d61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3eda8bc-be53-4b42-b0b1-27d33a8d61a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dcad2b81-be32-4cd7-9f1b-e360fca4fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_857d6bba-bca9-4d5a-9be0-d8a2d09f128f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dcad2b81-be32-4cd7-9f1b-e360fca4fd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_c2eee8db-2766-4038-9321-9d8f63122184" xlink:href="cpix-20220930.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_c2eee8db-2766-4038-9321-9d8f63122184" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1fa0b091-e714-4ec7-a777-5b364a9a46cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_33d7dacf-f53c-4a4d-9874-cf55ba77c0e0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1fa0b091-e714-4ec7-a777-5b364a9a46cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_fc7c0da3-4b50-4e57-8b25-77743bfdb97d" xlink:href="cpix-20220930.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1fa0b091-e714-4ec7-a777-5b364a9a46cd" xlink:to="loc_cpix_PinnacleBankMember_fc7c0da3-4b50-4e57-8b25-77743bfdb97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_725430a2-291f-4c4f-ae39-d9f23e6770ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2feb6f1d-8ee2-4cb1-ac8f-e7a85e7047ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_us-gaap_LineOfCreditMember_2feb6f1d-8ee2-4cb1-ac8f-e7a85e7047ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SixthAmendmentMember_26fb5c2a-62b1-498b-bbee-4298de3a713d" xlink:href="cpix-20220930.xsd#cpix_SixthAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_cpix_SixthAmendmentMember_26fb5c2a-62b1-498b-bbee-4298de3a713d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EightAmendmentMember_4fe76e62-8eff-428d-b418-c3ada5c3326c" xlink:href="cpix-20220930.xsd#cpix_EightAmendmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_cpix_EightAmendmentMember_4fe76e62-8eff-428d-b418-c3ada5c3326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember_0eb9ec4e-b13e-4518-8852-eb2c0490be9d" xlink:href="cpix-20220930.xsd#cpix_NinthAmemdmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6e3bf34-cbbd-45f8-9c6a-c425e8c75076" xlink:to="loc_cpix_NinthAmemdmentMember_0eb9ec4e-b13e-4518-8852-eb2c0490be9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f9f502fe-f284-4ac5-aa78-158a67329c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d59f0ea0-ac6a-469e-9051-ec636f43ffff" xlink:to="loc_us-gaap_CreditFacilityDomain_f9f502fe-f284-4ac5-aa78-158a67329c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a68f3bb0-a50d-49ef-8288-40e7d8a9f915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f9f502fe-f284-4ac5-aa78-158a67329c36" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a68f3bb0-a50d-49ef-8288-40e7d8a9f915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7bcec839-1def-4073-b86d-ca0129eca87c" xlink:to="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d2bff9e5-cc5e-422e-b4aa-59e102280b34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:to="loc_srt_MinimumMember_d2bff9e5-cc5e-422e-b4aa-59e102280b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6e3b27a-602a-453c-b654-dbcd13284167" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49a9c5b1-b98a-40e2-a07b-0a0a3ad0ad8e" xlink:to="loc_srt_MaximumMember_c6e3b27a-602a-453c-b654-dbcd13284167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7a7a1c63-f973-41d9-8eee-fce397eaef12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_33fe629e-3654-4065-981c-0fa3405570ae" xlink:to="loc_us-gaap_VariableRateDomain_7a7a1c63-f973-41d9-8eee-fce397eaef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_368f93d0-b70e-4aca-a016-d653b9d4368d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7a7a1c63-f973-41d9-8eee-fce397eaef12" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_368f93d0-b70e-4aca-a016-d653b9d4368d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e72827ad-f6ea-42bd-9617-28e9d40970aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dbce260c-bf43-4803-9c52-bf5cb7bc08f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e72827ad-f6ea-42bd-9617-28e9d40970aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0c781b45-a25f-404d-97ec-956dd760868e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e72827ad-f6ea-42bd-9617-28e9d40970aa" xlink:to="loc_us-gaap_ConvertibleDebtMember_0c781b45-a25f-404d-97ec-956dd760868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b8aeadb-dac7-4e44-9d5b-583ffe678b5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_da423112-ab4e-43c2-9b2f-cf9e02048665" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b8aeadb-dac7-4e44-9d5b-583ffe678b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_af230f7d-fe55-40be-b8f2-b7d2cfefe2dd" xlink:href="cpix-20220930.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b8aeadb-dac7-4e44-9d5b-583ffe678b5f" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_af230f7d-fe55-40be-b8f2-b7d2cfefe2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1a27a452-bc5f-477f-84be-d7c07fd6927f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1a0661f1-c0e1-430e-8ee9-a4fee188e222" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1a27a452-bc5f-477f-84be-d7c07fd6927f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_477f6d19-464d-48c2-8a5e-d107d6046247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1a27a452-bc5f-477f-84be-d7c07fd6927f" xlink:to="loc_srt_ScenarioForecastMember_477f6d19-464d-48c2-8a5e-d107d6046247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d1579dfe-a039-48c8-9a3a-5f7e71bbac44" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_a5c99bab-ee8e-4d07-b5ba-a6500d3d8ef5" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_a5c99bab-ee8e-4d07-b5ba-a6500d3d8ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_b4dc795c-3127-44f0-9f01-639e8ed43017" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantEvaluationFrequency"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_DebtInstrumentCovenantEvaluationFrequency_b4dc795c-3127-44f0-9f01-639e8ed43017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_1b6db5db-7eb3-492d-a15b-181e081a32e7" xlink:href="cpix-20220930.xsd#cpix_DebtInstrumentCovenantFundedDebtRatioMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum_1b6db5db-7eb3-492d-a15b-181e081a32e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_f8357cf9-150c-42d5-831d-dccec75cdecd" xlink:href="cpix-20220930.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_f8357cf9-150c-42d5-831d-dccec75cdecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_8c6e9268-1c7c-49a9-9d63-8a6897d78480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_8c6e9268-1c7c-49a9-9d63-8a6897d78480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5385a77e-2309-47e8-b371-72e790303cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5385a77e-2309-47e8-b371-72e790303cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95d4c4f9-cbc4-487d-9ac6-90415b3c8de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95d4c4f9-cbc4-487d-9ac6-90415b3c8de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_779b7d03-1722-49a1-bb09-adf1a6826c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_779b7d03-1722-49a1-bb09-adf1a6826c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_c70b5373-d763-49c3-b515-6e198f24e726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_LongTermLineOfCredit_c70b5373-d763-49c3-b515-6e198f24e726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_268e894f-4eca-4f62-8d70-6d7b6b706545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_268e894f-4eca-4f62-8d70-6d7b6b706545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d10f9e0f-4aa6-4149-9b9b-4a2d42464129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abf8d3af-a0a6-4efe-9ae5-8309a60f53ed" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d10f9e0f-4aa6-4149-9b9b-4a2d42464129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20220930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85a76381-43e2-4bc1-a424-08ffbba97315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85a76381-43e2-4bc1-a424-08ffbba97315" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1fbee9ec-31ca-4c26-b995-96b5fc63dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_eb98837a-8068-4e6f-9591-04097953ad50" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1fbee9ec-31ca-4c26-b995-96b5fc63dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_da15e87b-bfec-4241-8236-99513e0f852b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1fbee9ec-31ca-4c26-b995-96b5fc63dfbe" xlink:to="loc_us-gaap_DomesticCountryMember_da15e87b-bfec-4241-8236-99513e0f852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_65fbd368-5a8f-4e9d-a2cb-f0df361c58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_42935435-2670-4f20-92d5-1e0674c26b7b" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_65fbd368-5a8f-4e9d-a2cb-f0df361c58ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_52e112ee-ddd8-41a0-826a-de74360399fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_65fbd368-5a8f-4e9d-a2cb-f0df361c58ca" xlink:to="loc_us-gaap_OperatingLossCarryforwards_52e112ee-ddd8-41a0-826a-de74360399fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherIncomeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#OtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1a35e3f1-0f44-44a2-bec8-be73904da30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_62bd0586-40b6-4220-a919-ebd243cca414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1a35e3f1-0f44-44a2-bec8-be73904da30c" xlink:to="loc_us-gaap_InsuredEventGainLoss_62bd0586-40b6-4220-a919-ebd243cca414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_28094e7d-4352-44c4-a576-587b02484fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_28094e7d-4352-44c4-a576-587b02484fce" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a1336436-25e6-43e9-9a31-d1c7b092f1fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_3aadb6f1-f7a3-4ce0-88d7-c9425e8d1896" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:to="loc_cpix_VIBATIVMember_3aadb6f1-f7a3-4ce0-88d7-c9425e8d1896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_4bb3e816-c0aa-4e47-9fad-d0ae5b7e0ead" xlink:href="cpix-20220930.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:to="loc_cpix_MethotrexateMember_4bb3e816-c0aa-4e47-9fad-d0ae5b7e0ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_32bcc3d1-3c12-4aa9-84f4-09517db64c10" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76f0a679-dc5d-4683-be24-88c27975e944" xlink:to="loc_cpix_SancusoMember_32bcc3d1-3c12-4aa9-84f4-09517db64c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2c1d5b6f-23df-4548-a884-8030ef0746bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_12332736-347d-4c23-b83f-cfba9670ecba" xlink:href="cpix-20220930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_12332736-347d-4c23-b83f-cfba9670ecba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_c7586f98-c712-4bc6-84e3-d6ba372f48cd" xlink:href="cpix-20220930.xsd#cpix_KyowaKirinMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:to="loc_cpix_KyowaKirinMember_c7586f98-c712-4bc6-84e3-d6ba372f48cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_f0799284-d9fd-4469-95e0-cfcaf6ffa94d" xlink:href="cpix-20220930.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e7d8b5a-e25f-4783-ae13-2025e916925d" xlink:to="loc_cpix_NordicGroupBVMember_f0799284-d9fd-4469-95e0-cfcaf6ffa94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a0731a-67e9-44f5-bf0a-3c4068ac64d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e820f9c3-9d32-4312-9b2a-0331c5388157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a0731a-67e9-44f5-bf0a-3c4068ac64d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_092993d9-8bb8-4258-acc3-749481d8b182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a0731a-67e9-44f5-bf0a-3c4068ac64d0" xlink:to="loc_us-gaap_RestrictedStockMember_092993d9-8bb8-4258-acc3-749481d8b182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0619ceb-242c-4b1b-9d52-ceab67919481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8a7b2971-218a-49d8-ab45-2a9e9091f21a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0619ceb-242c-4b1b-9d52-ceab67919481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_452d6f76-5977-4b00-9aa1-58051192f362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0619ceb-242c-4b1b-9d52-ceab67919481" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_452d6f76-5977-4b00-9aa1-58051192f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b013dd3-b810-4aca-897c-5112592f148b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5284a028-c84e-4989-96e4-ad634c779c67" xlink:to="loc_srt_RangeMember_9b013dd3-b810-4aca-897c-5112592f148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1f118dd-b890-489e-88cd-d662e46aa686" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b013dd3-b810-4aca-897c-5112592f148b" xlink:to="loc_srt_MaximumMember_d1f118dd-b890-489e-88cd-d662e46aa686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_800f72e1-768d-4af5-b1a2-6a6f729a3d76" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c0379ce-254f-44b8-9471-b7128689a473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c0379ce-254f-44b8-9471-b7128689a473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_341bc901-5f9c-42f2-8e73-57dd6fec29d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_341bc901-5f9c-42f2-8e73-57dd6fec29d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_3d2af002-7c58-4e25-9c1f-ba009aaca4ce" xlink:href="cpix-20220930.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_3d2af002-7c58-4e25-9c1f-ba009aaca4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_0cdf0868-e4ce-42cf-9fbb-e75d839f4281" xlink:href="cpix-20220930.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_0cdf0868-e4ce-42cf-9fbb-e75d839f4281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e5875cde-5181-4eee-b73d-7b1b4a8e91c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e5875cde-5181-4eee-b73d-7b1b4a8e91c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_451ebe1d-75f5-49f8-ab0a-74ef95e2b411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_451ebe1d-75f5-49f8-ab0a-74ef95e2b411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3e9db82b-00f2-467f-a6b7-2bc1409fbe03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3e9db82b-00f2-467f-a6b7-2bc1409fbe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_59ff9e4a-a5b6-4d46-86c0-a5fddd30cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_59ff9e4a-a5b6-4d46-86c0-a5fddd30cf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f5e59475-2d39-469f-b12b-c732d2a7d498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f5e59475-2d39-469f-b12b-c732d2a7d498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3e2e8a36-8e1a-4745-a145-9dde73a01a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3e2e8a36-8e1a-4745-a145-9dde73a01a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_056cd0ac-5294-4218-b3e9-fd8c192e5bbb" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_056cd0ac-5294-4218-b3e9-fd8c192e5bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_48e82fab-f470-4fb7-a88f-89b604e2610f" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_48e82fab-f470-4fb7-a88f-89b604e2610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_ffb15b23-507a-47cd-b562-5c652ee8cc31" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_ffb15b23-507a-47cd-b562-5c652ee8cc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_00f4b9ba-bb20-4323-ae81-1ee6c6904a73" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_00f4b9ba-bb20-4323-ae81-1ee6c6904a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_6f2c3b67-06e1-4942-8ce9-da694e6db6a0" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_6f2c3b67-06e1-4942-8ce9-da694e6db6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_384c4eb4-ef95-4a17-be6a-9ba11e180597" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_384c4eb4-ef95-4a17-be6a-9ba11e180597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_d8dcaacd-bff1-4bb3-a33d-cbbe6d13fa0d" xlink:href="cpix-20220930.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_d8dcaacd-bff1-4bb3-a33d-cbbe6d13fa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_82fcba06-0f3c-49fd-ad2d-b09279b90925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_82fcba06-0f3c-49fd-ad2d-b09279b90925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db1e21ba-9a48-45b9-81b5-1560e13d4ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_db1e21ba-9a48-45b9-81b5-1560e13d4ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4bda6212-3e74-48e2-b1d1-38b24845f776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_Goodwill_4bda6212-3e74-48e2-b1d1-38b24845f776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dc717de-1f7d-4fcc-8112-4d1e3802cbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dc717de-1f7d-4fcc-8112-4d1e3802cbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f077753f-e901-4594-b13e-d973513fb10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f077753f-e901-4594-b13e-d973513fb10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_362e73f4-2923-4c53-b02b-1508800fa846" xlink:href="cpix-20220930.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_362e73f4-2923-4c53-b02b-1508800fa846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments_84e37c89-5106-4dea-8fc0-a5f077fa73af" xlink:href="cpix-20220930.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_FinancialConsiderationNumberOfInstallments_84e37c89-5106-4dea-8fc0-a5f077fa73af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_7726c724-fb89-4de0-87f7-e03152f07c9e" xlink:href="cpix-20220930.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_7726c724-fb89-4de0-87f7-e03152f07c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_49c1a0a0-d896-4817-b526-5dbee62356dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_842e7fcf-6d3b-40d4-8ba2-580c1505f5ee" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_49c1a0a0-d896-4817-b526-5dbee62356dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2e7086a0-cc52-4fa3-916a-1e006794d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2e7086a0-cc52-4fa3-916a-1e006794d600" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e6e09b0-a722-46a7-bb28-a39476fc7f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cda9b32-e604-4203-8680-b570c353535a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e6e09b0-a722-46a7-bb28-a39476fc7f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_10cfe68c-005b-4ee3-a60c-b58242a5fc35" xlink:href="cpix-20220930.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e6e09b0-a722-46a7-bb28-a39476fc7f2a" xlink:to="loc_cpix_VIBATIVMember_10cfe68c-005b-4ee3-a60c-b58242a5fc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_16e93fe8-5f3f-451e-862b-4d14ec4e8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1ddf6ad5-7e9a-441f-b8e2-d95bdc9e7ee4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_16e93fe8-5f3f-451e-862b-4d14ec4e8ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_16e93fe8-5f3f-451e-862b-4d14ec4e8ab9" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a34f15cc-3ce2-4123-95b5-b9569222e6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a34f15cc-3ce2-4123-95b5-b9569222e6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_7efa16f8-20ee-4e85-8777-1d533b3790f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_PaymentsForRoyalties_7efa16f8-20ee-4e85-8777-1d533b3790f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cdd63e35-c640-46e1-95ac-c28f1e13557f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cdd63e35-c640-46e1-95ac-c28f1e13557f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5358cd7c-8982-4ca0-90ca-347489a415ee" xlink:href="cpix-20220930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5358cd7c-8982-4ca0-90ca-347489a415ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d419493-86ba-42f0-ba69-f531dcf7d6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_822c0739-e643-4fa2-9f87-241d11991c8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d419493-86ba-42f0-ba69-f531dcf7d6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d32a3520-77c1-491d-a05c-e498b3a3c729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d32a3520-77c1-491d-a05c-e498b3a3c729" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78ea5aee-b825-4cdc-becd-fe85431cc064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b8fcad3-aa10-401b-881c-03bd5c585f2e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78ea5aee-b825-4cdc-becd-fe85431cc064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_9208d42c-f85e-4f89-8c34-3d35a81de40b" xlink:href="cpix-20220930.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78ea5aee-b825-4cdc-becd-fe85431cc064" xlink:to="loc_cpix_SancusoMember_9208d42c-f85e-4f89-8c34-3d35a81de40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dd7897a6-ebe2-4800-ad12-e1f627d2a630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6182be96-5673-4381-b854-f880e805b967" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dd7897a6-ebe2-4800-ad12-e1f627d2a630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dd7897a6-ebe2-4800-ad12-e1f627d2a630" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_789b0b3e-20b0-4d7c-bee0-fb692c9143e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_789b0b3e-20b0-4d7c-bee0-fb692c9143e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_ac9abd5c-ad57-473c-bfc7-ddca9d865ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_PaymentsForRoyalties_ac9abd5c-ad57-473c-bfc7-ddca9d865ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_038c9752-e605-4c14-90a9-21ec4251c304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_038c9752-e605-4c14-90a9-21ec4251c304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_fa6800f1-41b8-42eb-9aed-e427809094ac" xlink:href="cpix-20220930.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_fa6800f1-41b8-42eb-9aed-e427809094ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_781ff0ad-d694-4523-8183-417dd790162b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_c1c40000-5455-448f-ab1c-ccba8f86c777" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_781ff0ad-d694-4523-8183-417dd790162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20220930.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_45c0e7cf-5d89-48cb-8581-bf7b052af343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_45c0e7cf-5d89-48cb-8581-bf7b052af343" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:to="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2a68f81-f3c2-49ad-bce0-6edfd203a77c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_154fb27c-f56e-4c91-af05-bebac37b416d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2a68f81-f3c2-49ad-bce0-6edfd203a77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_60ca1349-4ab1-42a0-a3d0-ed8be41d66c6" xlink:href="cpix-20220930.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2a68f81-f3c2-49ad-bce0-6edfd203a77c" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_60ca1349-4ab1-42a0-a3d0-ed8be41d66c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acac2b15-779c-4426-9100-ca3c8ec7383d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_97351859-5274-4075-b498-5b464f935c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_97351859-5274-4075-b498-5b464f935c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_28000d1d-6d10-4cd9-b15d-fa16086db6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4a634350-4cac-446f-be0d-bf6f8ffa82a0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_28000d1d-6d10-4cd9-b15d-fa16086db6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "] Q@# 2(  A$! Q$!_\0
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M.IJTM(M9=38=1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4F:*:1W-2V US6/X@\06/AS3;B_U*YBLK*WC
M:6:XG<(D:*,EF)/  J]/=+"DDCNL<:#<S,< #N2:_/C]ICX_/^T9XDT_X6>
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M^_7O0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*CF8[)+0^M:*^1&_:H_:*5L']E2+_P .5I?_ ,;J1?VH?VC9%)7]E*/ Z_\
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M_P!&J1?^'-TK_P"(H_X:<_:-;_FU6,?]U.TK_P"(H ^N*2OD-_VJ?VBH^/\
MAE6/_P .5IA_E'3H?VI/VB[C.W]E2,;?^JE:6O\ ./F@#ZZHS7R._P"U)^T7
M&.?V4X__  Y>EG_VG40_:K_:)_Z-24_[OQ'TW_XW0!]?4F:^0_\ AJK]HK_H
MU'_S(^F__&J1OVK/VB%Z_LI*/][XD:;_ /&Z /KW</6C(]:^0?\ AJ[]H?\
MZ-4C_P##D:9_\;H_X:M_:(/3]E2/_P .1IG_ ,;H ^OZ*^1D_:D_:+D''[*<
M?_AR]+'\XZ;+^U)^T7;XW?LJQ_-T_P"+EZ6W\DH ^NLT9KY"_P"&K/VB/^C5
M(_\ PY.F?_&Z/^&K/VB/^C5(_P#PY.F?_&Z /KW-+7R#_P -6?M$?]&J1_\
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M#_ON^_\ E;1_P\?^-O\ T9C\0/\ ON^_^5M 'W_17P!_P\?^-O\ T9C\0/\
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MTI?L2?W<_A6%\1M:\2^'O"-_J'A+PW;^+M=@4-!H]QJ0T\7/JHF:-U5L=-P
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MA!;RLX?YL<9S@;?FKNOV-?AC/\.?A#INE:A9FUOYD6[N2WF?/+("23Y@R#C
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M[:[>9(Y$"B>*.#9;;D8DLTI4,!&&9G7(!]J4F::Y/X4Y2#TH 6BBB@ HHHH
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MY#C('0-U%?2WQ \(R^.O"]UHL6OZQX:%SM#ZAH,Z0784')5)&1BF>A9<,.S
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M?/MOZT?'+_@G5X#_ &@O%-QX@\4^+O'/]H&X6>S6UUE!#IP"@&.VC>%UC1B
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MLWCCQ+H]OJ>I6J:5822W]JJW3"21+6VB,;;7E$*(OEC+Y1@PWAJ\3_X*#?\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "/ Q@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBD- "T4W^&C^&E?2X"YHW#UIO>DD'RFE!\VX,>>E12-F
M,A"-W;FFJ[=*AN(]T; 2>6?[V[&*B_[SE0]+:E+6=>M]#MY;F[GA@@3&9)7"
MJ,D#J2.Y%?,OAGQ9=^./C#::D]@;FXM8VAMKO9(QC5HB6"'<0,E>2*3]J+XL
M.MC?6VD7,/EVL9#"1QY<LCK&T0X;#'<#P:U/V4_!^HV>FVMQJC237UJ@:6:1
M,%FD$N0#R#C..#7V%+!QHX.5>;LWH>34J7K*"5SZ5L_-^R(SDE^<@DYZU9$F
MYE&T_7%"+A:<G2OE#U1U%%% !1110 4444 %%%% !1136;:I-(!<T9'K4*R%
MCTXI&E"_+WJ5+N2Y)$^:-U0^</6G(VYJ?,BEJKDM%%%4 4444 %%%% !1124
M +2;@.IQ2=J;)G8<#)],4,!^1ZT;A5=I%;Y2S(?8XJ/SU0[,N?\ :;I2BI2Z
M$RDHEP,#1D>M0(YQD<TJRY/W<'U(I-\NC&M5<GI-PJ!IB, #-*L@:0+U)[T^
M9!%J1/1113&%%%(W2@!:*3^&D/>D]$ NX8SD8HW#&<\57F;;&%]:\]^+GBZX
M\/Z6T%G+Y,[_ '7#%2,,A/((/0FM\/2EB)**ZF<Y<JN>D^8#T-"R+(N58,/4
M&O(_@OXNU/7UU!K^5IU7R]C,S-_?SC)/H*]7CPK;$&%7KQ3Q-&>&J.#Z"IS<
MU=DV:-P]:;2=6QTKFYD:/0>&S2TS[M-:0U5G;0I)LDW"@-FH=VZE5B&[5,>;
MJ)W1+FC-,W4C.<'BG<"3-%1>91OQSD#ZT7#0FI*A\R3L8Z4R%1DE"?:G9@34
M5"9-PY)!_P!FH?,VN"OG$^C?=HLP+=%5S=;/OX%+YP=2P90/4FG9BN3YHR/6
MH/.7_GI'_P!]4]&##JI/M4Z@29HS3:*90[-&:;2CK0(=1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UF"J23
M@>]+FHYI%$9R-P],9J9; /% ->:_%;X[>&?A+-I]IJD]U<:QJ88:?I=C:R3S
M7;*5&Q-HVAB6&-S*.>M>;M^T+?6OB:Q.IHNDVT["-;>Z/ELTC1Y$8'F%6;/8
M$^V:]"E@:TJ:GRZ/;S]#F>(A=I/8^DMPV[LC%1R/M7KS4%E=)=VL;#H^?T-3
M, S8QG;7'R\CU.J#4M2%91C).,],UYM\:O$VKZ?X9FL/#VY=:OF%O%.K;1;
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M.V60+G\/6O=Q&7QP^%C4DK29PT9MS:N>L4F:1::>U?/GH#\T'I3-U(S8&:3
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MKYTUSX]:EI,PL98$,K]$V-G@ ]#)Z&NVTW6/$^HK:L;<PQMNZ)*I[^_M6];
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MM&/>H7-U+#\J!G/;%&*#\M7J(6D/'-)OI&8!23TI^H6'?C14>-ASEB/2@-N
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MX/YEQC[;&>4%^+/2%58%"JO'L*\M^*GB)YKJSTFQ)G:Y=O/EBEVBVC50V\D
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MO-)=ZF@M#<6\XB:VRS .3G=WQ@ _@.:ZK1_!W]O^/;.)996:W22.$1R,$ =
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MT^;ZY)/I8]AC5I%Y&T#MTI\>^20%N .U.7I3E'S"OSZ-3F;3/J5\*'T4M%6
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****0!12-323CCK3Z
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M/>%]%@\-Z3%:Q' ;/3'9B?0>M?$__!0"Y>;XJ?#RV-O*D47W;AF0I)NE0D*
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M6R2"/:I:2FK(I:"4U2<]*DI*6HK"T444QA1110 4444 %%%% !1110 4444
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M!CDDGI[U\Y_MZ?$"7P?\&;G3X'FBN-:G6S5TC1E\O&Z0-NZ9 Z@9^E?2',:
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M@)\1M8^'GC*Y>PM);DQP/<+(L<5QG'\1&Q7&#G;R>IKZ[7-\OOO5H_>X_P#
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M); ^M,9)13% [-G\:5CP<G ]: '4E-"YZ,3^-&6SC'% #LTM-_"EH 6BBB@
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MPH':>5G!^[Y@92/F+_-D;?F_1*QM?L\0&/\ /-?6YUB*>&IPRVAM#?SE^O\
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MJPJ*:O%W1\!_\.Y?CC_T>=X^_P"^+[_Y95'+_P $YOC@OWOVS/'S#_KG>_\
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M+M4]J=QGYUW_ /P3E^-.IWEY<W'[67BU'NG9Y4M[*YBC.[.0(TOE55YQM4
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M^ _[3QX_X:I=A_V3C3O_ (NOK[RT]!1Y:>@H ^0%^ _[3R]/VJ7'_=.-._\
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M5",$NI^4:7P7_;;T#XB?$Z?X4^+O#VH?#KXN6O$_AFZE34('_=-/^YO+?,;
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MN-C. >Z^)?%&F>#].AO]7NOLEI->VFGI)Y;/F>YN([:!,*"?FFFC7/0;LD@
MD:M?FI_P4._;2^(GPQUCX76$GPTU#PMX0FUJUUZ\CUR^L'O-9?3KRWN?LD9M
M9KE;>,,(&,I^=F90 %1Q)]_^!?&FJ^+_ +=_:?@77_!?V?9Y?]N3Z?)]IW;L
7^7]DNY\;=HSOV_?&-W. #K**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362058736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,464,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525361554256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,541,538<span></span>
</td>
<td class="nump">$ 27,040,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">15,232,697<span></span>
</td>
<td class="nump">6,877,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">10,647,529<span></span>
</td>
<td class="nump">8,429,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">3,738,842<span></span>
</td>
<td class="nump">3,339,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">49,160,606<span></span>
</td>
<td class="nump">45,688,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">7,497,356<span></span>
</td>
<td class="nump">9,048,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">490,826<span></span>
</td>
<td class="nump">442,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">29,048,043<span></span>
</td>
<td class="nump">23,954,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,932,876<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">219,850<span></span>
</td>
<td class="nump">1,024,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,426,996<span></span>
</td>
<td class="nump">3,419,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">90,776,553<span></span>
</td>
<td class="nump">84,459,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,510,756<span></span>
</td>
<td class="nump">9,640,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">229,605<span></span>
</td>
<td class="nump">969,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">13,565,862<span></span>
</td>
<td class="nump">8,668,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,306,223<span></span>
</td>
<td class="nump">19,278,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">17,700,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">9,279,208<span></span>
</td>
<td class="nump">7,488,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,285,431<span></span>
</td>
<td class="nump">41,857,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">47,532,375<span></span>
</td>
<td class="nump">48,452,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(8,768,112)<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">38,764,263<span></span>
</td>
<td class="nump">42,814,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(273,141)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">38,491,122<span></span>
</td>
<td class="nump">42,601,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 90,776,553<span></span>
</td>
<td class="nump">$ 84,459,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525361963104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,436,583<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,436,583<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362862176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 32,887,269<span></span>
</td>
<td class="nump">$ 27,665,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">2,224,443<span></span>
</td>
<td class="nump">1,328,027<span></span>
</td>
<td class="nump">6,468,212<span></span>
</td>
<td class="nump">5,486,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">4,110,397<span></span>
</td>
<td class="nump">3,800,288<span></span>
</td>
<td class="nump">13,281,511<span></span>
</td>
<td class="nump">11,709,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,714,254<span></span>
</td>
<td class="nump">1,453,873<span></span>
</td>
<td class="nump">5,283,083<span></span>
</td>
<td class="nump">4,071,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,166,118<span></span>
</td>
<td class="nump">2,039,799<span></span>
</td>
<td class="nump">6,672,442<span></span>
</td>
<td class="nump">6,367,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,486,448<span></span>
</td>
<td class="nump">1,013,948<span></span>
</td>
<td class="nump">4,609,146<span></span>
</td>
<td class="nump">3,354,080<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">11,701,660<span></span>
</td>
<td class="nump">9,635,935<span></span>
</td>
<td class="nump">36,314,394<span></span>
</td>
<td class="nump">30,988,606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(288,588)<span></span>
</td>
<td class="num">(1,563,395)<span></span>
</td>
<td class="num">(3,427,125)<span></span>
</td>
<td class="num">(3,323,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">21,602<span></span>
</td>
<td class="nump">7,394<span></span>
</td>
<td class="nump">52,709<span></span>
</td>
<td class="nump">19,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,187,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Other income - gain on insurance proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">611,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(149,340)<span></span>
</td>
<td class="num">(20,021)<span></span>
</td>
<td class="num">(406,539)<span></span>
</td>
<td class="num">(70,297)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(416,326)<span></span>
</td>
<td class="num">(1,576,022)<span></span>
</td>
<td class="num">(3,169,625)<span></span>
</td>
<td class="num">(1,187,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(6,900)<span></span>
</td>
<td class="num">(7,458)<span></span>
</td>
<td class="num">(20,700)<span></span>
</td>
<td class="num">(22,375)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(423,226)<span></span>
</td>
<td class="num">(1,583,480)<span></span>
</td>
<td class="num">(3,190,325)<span></span>
</td>
<td class="num">(1,209,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">496,787<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(423,226)<span></span>
</td>
<td class="num">(1,086,693)<span></span>
</td>
<td class="num">(3,190,325)<span></span>
</td>
<td class="nump">281,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">14,587<span></span>
</td>
<td class="nump">31,415<span></span>
</td>
<td class="nump">60,813<span></span>
</td>
<td class="nump">58,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="num">$ (1,055,278)<span></span>
</td>
<td class="num">$ (3,129,512)<span></span>
</td>
<td class="nump">$ 340,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.21)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(0.21)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">14,477,478<span></span>
</td>
<td class="nump">14,880,887<span></span>
</td>
<td class="nump">14,618,975<span></span>
</td>
<td class="nump">14,939,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">14,477,478<span></span>
</td>
<td class="nump">14,880,887<span></span>
</td>
<td class="nump">14,618,975<span></span>
</td>
<td class="nump">15,139,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362808592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (3,190,325)<span></span>
</td>
<td class="nump">$ 281,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(3,190,325)<span></span>
</td>
<td class="num">(1,209,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">4,816,630<span></span>
</td>
<td class="nump">3,529,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">320,598<span></span>
</td>
<td class="nump">517,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(1,051,908)<span></span>
</td>
<td class="num">(632,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</a></td>
<td class="nump">708,293<span></span>
</td>
<td class="num">(52,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Increase in noncash interest expense</a></td>
<td class="nump">7,608<span></span>
</td>
<td class="nump">33,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,187,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Gain on receivable of life insurance policy proceeds</a></td>
<td class="num">(611,330)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(8,184,656)<span></span>
</td>
<td class="nump">2,527,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,338,881<span></span>
</td>
<td class="nump">2,555,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">4,355,396<span></span>
</td>
<td class="nump">1,627,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">8,778,631<span></span>
</td>
<td class="num">(2,873,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(2,472,453)<span></span>
</td>
<td class="num">(943,439)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="nump">4,815,365<span></span>
</td>
<td class="nump">2,891,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,815,365<span></span>
</td>
<td class="nump">4,382,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(255,676)<span></span>
</td>
<td class="num">(94,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromSettlementOfPatentLitigation', window );">Settlement of patent litigation</a></td>
<td class="nump">21,757<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLifeInsurancePolicies', window );">Life insurance policy proceeds received</a></td>
<td class="nump">877,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Note receivable investment funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisitions</a></td>
<td class="num">(13,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(177,362)<span></span>
</td>
<td class="num">(180,613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(13,033,684)<span></span>
</td>
<td class="num">(475,098)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">46,700,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(44,000,000)<span></span>
</td>
<td class="num">(45,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(1,117,576)<span></span>
</td>
<td class="num">(1,792,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(863,383)<span></span>
</td>
<td class="num">(1,025,657)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">719,041<span></span>
</td>
<td class="num">(2,818,230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(7,499,278)<span></span>
</td>
<td class="nump">1,089,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">27,040,816<span></span>
</td>
<td class="nump">24,753,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 19,541,538<span></span>
</td>
<td class="nump">$ 25,843,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSettlementOfPatentLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Settlement of Patent Litigation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSettlementOfPatentLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLifeInsurancePolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21C<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080552-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLifeInsurancePolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525356499680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings (deficit)</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">$ (2,131,013)<span></span>
</td>
<td class="num">$ (117,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">162,960<span></span>
</td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(303,088)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,828<span></span>
</td>
<td class="num">(22,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2021</a></td>
<td class="nump">46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">281,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,850,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2021</a></td>
<td class="nump">46,646,265<span></span>
</td>
<td class="nump">$ 48,612,935<span></span>
</td>
<td class="num">(1,790,903)<span></span>
</td>
<td class="num">(175,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2021</a></td>
<td class="nump">46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">191,954<span></span>
</td>
<td class="nump">$ 191,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(484,965)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,223,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,560<span></span>
</td>
<td class="num">(5,069)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,926,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2021</a></td>
<td class="nump">47,808,407<span></span>
</td>
<td class="nump">$ 48,688,384<span></span>
</td>
<td class="num">(735,625)<span></span>
</td>
<td class="num">(144,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">162,167<span></span>
</td>
<td class="nump">$ 162,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(237,616)<span></span>
</td>
<td class="num">$ (237,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,086,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,278)<span></span>
</td>
<td class="num">(31,415)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,850,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2021</a></td>
<td class="nump">$ 46,646,265<span></span>
</td>
<td class="nump">$ 48,612,935<span></span>
</td>
<td class="num">(1,790,903)<span></span>
</td>
<td class="num">(175,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">14,742,754<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2021</a></td>
<td class="nump">$ 42,601,978<span></span>
</td>
<td class="nump">$ 48,452,906<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">159,901<span></span>
</td>
<td class="nump">$ 159,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(566,043)<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,385,253)<span></span>
</td>
<td class="num">(17,180)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,730,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2022</a></td>
<td class="nump">$ 40,793,403<span></span>
</td>
<td class="nump">$ 48,046,764<span></span>
</td>
<td class="num">(7,023,853)<span></span>
</td>
<td class="num">(229,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">14,742,754<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2021</a></td>
<td class="nump">$ 42,601,978<span></span>
</td>
<td class="nump">$ 48,452,906<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (3,190,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2022</a></td>
<td class="nump">14,436,583<span></span>
</td>
<td class="nump">14,436,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2022</a></td>
<td class="nump">$ 38,491,122<span></span>
</td>
<td class="nump">$ 47,532,375<span></span>
</td>
<td class="num">(8,768,112)<span></span>
</td>
<td class="num">(273,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,730,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2022</a></td>
<td class="nump">40,793,403<span></span>
</td>
<td class="nump">$ 48,046,764<span></span>
</td>
<td class="num">(7,023,853)<span></span>
</td>
<td class="num">(229,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(27,753)<span></span>
</td>
<td class="num">$ (27,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(196,692)<span></span>
</td>
<td class="num">$ (196,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,364,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,335,620)<span></span>
</td>
<td class="num">(29,046)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,649,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2022</a></td>
<td class="nump">39,204,292<span></span>
</td>
<td class="nump">$ 47,822,319<span></span>
</td>
<td class="num">(8,359,473)<span></span>
</td>
<td class="num">(258,554)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,730,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2022</a></td>
<td class="nump">$ 40,793,403<span></span>
</td>
<td class="nump">$ 48,046,764<span></span>
</td>
<td class="num">(7,023,853)<span></span>
</td>
<td class="num">(229,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2022</a></td>
<td class="nump">14,436,583<span></span>
</td>
<td class="nump">14,436,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2022</a></td>
<td class="nump">$ 38,491,122<span></span>
</td>
<td class="nump">$ 47,532,375<span></span>
</td>
<td class="num">(8,768,112)<span></span>
</td>
<td class="num">(273,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,649,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Jun. 30, 2022</a></td>
<td class="nump">39,204,292<span></span>
</td>
<td class="nump">$ 47,822,319<span></span>
</td>
<td class="num">(8,359,473)<span></span>
</td>
<td class="num">(258,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">188,449<span></span>
</td>
<td class="nump">$ 188,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Return of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of common shares</a></td>
<td class="num">(399,600)<span></span>
</td>
<td class="num">$ (399,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(78,793)<span></span>
</td>
<td class="num">$ (78,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (423,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(408,639)<span></span>
</td>
<td class="num">(14,587)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Sep. 30, 2022</a></td>
<td class="nump">14,436,583<span></span>
</td>
<td class="nump">14,436,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Sep. 30, 2022</a></td>
<td class="nump">$ 38,491,122<span></span>
</td>
<td class="nump">$ 47,532,375<span></span>
</td>
<td class="num">$ (8,768,112)<span></span>
</td>
<td class="num">$ (273,141)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364505008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its hospital, field and oncology sales teams and its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Annual Report on Form 10-K&#8221;). The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 10, for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, 2021 and the nine months ended September 30, 2022,  we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364530480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086,693)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408,639)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055,278)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,477,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,477,478&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,190,325)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,190,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,129,512)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,618,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,618,975&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,139,904&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, restricted stock awards and options to purchase 233,750 and 158,900 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364473200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903,305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,286,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,756,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,008,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,075,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,774&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,059)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,789&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,887,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the third quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the third quarter of 2022, the amounts noted were normal adjustments by channel partners.  Net revenue was positively impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022.  Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval.  Net revenue was negatively impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, we recorded $0.1 million and $0.6 million, respectively, for milestone and international licensee payments as part of other revenue.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant  programs totaled approximately $0.2&#160;million and $0.02 million for the three months ended September 30, 2022 and 2021, respectively, and approximately $0.3 million each for the nine months ended September 30, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525367620352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $1.8 million and $1.4 million, respectively.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2022 and December 31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory.  At September 30, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $7.5 million and $9.0 million, respectively. The Company had no Vibativ finished goods included in non-current inventory at September 30, 2022, and $0.5 million included at December 31, 2021.  The Company also has obtained $0.2 million and $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,738,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,277,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,144,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,497,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,647,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525453103808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease expired in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at September 30, 2022 is 0.4 years.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the &#8220;Leased Premise&#8221;) at the new Broadwest development located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each.  The Broadwest lease calls for monthly base rent, operating expense and parking payments. In year 1, the base rent starts at $33.06 per square foot of rentable area. The lease also provides for several months of free rent plus a tenant improvement allowance.  Cumberland received approval for its building permit and began construction on the Leased Premise in June 2022.  On October 25, 2022,  Cumberland received final building approval and a certificate of occupancy for the Leased Premise.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million and will be paid through the leases ending in October 2022 and April 2023. Excluding the Broadwest lease agreement, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364275616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2022 and September 30, 2021, the Company repurchased 290,576 shares and 326,537 shares of common stock for approximately $0.8 million and $1.0 million, respectively.  At September 30, 2022, approximately $3.9 million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  These purchases began in April 2022 and as of September 30, 2022, a total of 27,698 shares have been purchased through this trading plan.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the nine months ended September 30, 2022 or September 30, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and September 30, 2021, the Company issued 65,225 shares and 36,850 shares of restricted stock to employees, advisors and directors, respectively. Restricted stock issued to employees and advisors generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the nine months ended September 30, 2022 and 2021, the Company also issued 172,300 and 174,800 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in 2032 and 2031, respectively. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.  For the nine months ended September 30, 2022, we recorded a credit of $0.1&#160;million to share-based compensation related to the forfeiture of unvested restricted stock awards.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the quarter ended September 30, 2022, we were in compliance with the Funded Debt Ratio financial covenant.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15&#160;million to $20&#160;million. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement.  The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 5.25% at September 30, 2022.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company had $17.7 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525367620352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of September 30, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364473200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Income</a></td>
<td class="text">OTHER INCOMEThe Company realized a $0.6&#160;million gain in the second quarter of 2022 from insurance proceeds for a Company owned executive life insurance policy.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364266656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364326432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $4.8 million was accounted for as $1.9 million of other current liabilities and $3.0 million of other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2022.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 resulted in a $1.0&#160;million milestone payment due to Nordic.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after March 31, 2023. Cumberland will continue to distribute and support the product until then.  In accordance with the terms of the amendment, Nordic has agreed to return the 180,000 restricted Cumberland shares we previously issued to Nordic which will be cancelled, refund to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand's U.S. approval and issue a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Acquisition</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.  The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year.  The estimates of fair value for the more significant assets and liabilities assumed were as follows: prepaid expenses $0.3&#160;million, inventory $5.2&#160;million, goodwill $1.0&#160;million, intangible assets $12.1&#160;million, milestone payable $1.2&#160;million and contingent liability $3.9&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,721)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $4.5 million was accounted for as $1.9 million of current liabilities and $2.6 million of other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2022.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.658%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525361890048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364281136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086,693)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408,639)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055,278)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,477,478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,477,478&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,190,325)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,190,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,129,512)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,110&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,618,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939,919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,618,975&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,139,904&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364308032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three and nine months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903,305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,286,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,756,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,008,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,075,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,774&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,059)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,861,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(451,683)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,789&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,887,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,665,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525364361776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,738,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,277,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,144,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,497,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,647,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525365149952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text">Excluding the Broadwest lease agreement, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of Rent Expense and Sublease Income</a></td>
<td class="text">Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525361970496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,721)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Dissolution Payments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.658%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491,004&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525453103808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525358167472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (423,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,583,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,190,325)<span></span>
</td>
<td class="num">$ (1,209,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,491,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(423,226)<span></span>
</td>
<td class="num">$ (1,364,666)<span></span>
</td>
<td class="num">$ (1,402,433)<span></span>
</td>
<td class="num">(1,086,693)<span></span>
</td>
<td class="nump">$ 1,223,491<span></span>
</td>
<td class="nump">$ 144,661<span></span>
</td>
<td class="num">(3,190,325)<span></span>
</td>
<td class="nump">281,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">14,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,813<span></span>
</td>
<td class="nump">58,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,055,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,129,512)<span></span>
</td>
<td class="nump">$ 340,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">14,477,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,880,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,618,975<span></span>
</td>
<td class="nump">14,939,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">199,985<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">14,477,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,880,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,618,975<span></span>
</td>
<td class="nump">15,139,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362057824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">233,750<span></span>
</td>
<td class="nump">158,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362067504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Schedule of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 32,887,269<span></span>
</td>
<td class="nump">$ 27,665,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,903,305<span></span>
</td>
<td class="nump">4,012,746<span></span>
</td>
<td class="nump">11,418,673<span></span>
</td>
<td class="nump">12,286,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,960,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,756,411<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,909,750<span></span>
</td>
<td class="nump">1,896,584<span></span>
</td>
<td class="nump">6,008,005<span></span>
</td>
<td class="nump">8,799,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">921,811<span></span>
</td>
<td class="nump">1,255,669<span></span>
</td>
<td class="nump">3,075,355<span></span>
</td>
<td class="nump">3,734,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(436)<span></span>
</td>
<td class="nump">325,774<span></span>
</td>
<td class="num">(252,059)<span></span>
</td>
<td class="nump">1,861,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">99,792<span></span>
</td>
<td class="nump">368,733<span></span>
</td>
<td class="nump">337,685<span></span>
</td>
<td class="nump">638,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">35,600<span></span>
</td>
<td class="nump">22,689<span></span>
</td>
<td class="nump">31,925<span></span>
</td>
<td class="num">(451,683)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">85,809<span></span>
</td>
<td class="nump">11,459<span></span>
</td>
<td class="nump">238,712<span></span>
</td>
<td class="num">(13,291)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 496,789<span></span>
</td>
<td class="nump">$ 178,886<span></span>
</td>
<td class="nump">$ 1,272,562<span></span>
</td>
<td class="nump">$ 809,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525361448064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_RevenueRecognitionMilestonePayments', window );">Revenue Recognition, Milestone Payments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,413,072<span></span>
</td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">32,887,269<span></span>
</td>
<td class="nump">$ 27,665,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 20,000.00<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525361917216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence and discontinuance losses</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">7,497,356<span></span>
</td>
<td class="nump">9,048,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362038448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 11,738,972<span></span>
</td>
<td class="nump">$ 12,374,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">128,168<span></span>
</td>
<td class="nump">164,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,277,745<span></span>
</td>
<td class="nump">4,939,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">18,144,885<span></span>
</td>
<td class="nump">17,478,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(7,497,356)<span></span>
</td>
<td class="num">(9,048,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,647,529<span></span>
</td>
<td class="nump">$ 8,429,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362795504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>ft&#178; </div>
<div>renewalTerm </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum sublease income under noncancelable operating subleases | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLeasedArea', window );">Leased area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">157 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseBaseRent', window );">Base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space | Broadwest Lease, Five Year Renewal Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms | renewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:monetaryPerAreaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525358143424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Position (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 219,850<span></span>
</td>
<td class="nump">$ 1,024,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">229,605<span></span>
</td>
<td class="nump">969,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 229,605<span></span>
</td>
<td class="nump">$ 1,059,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525363993280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities at September 30, 2022</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 150,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">92,477<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">243,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">13,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 229,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362932816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Rent Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 861,398<span></span>
</td>
<td class="nump">$ 910,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 424,632<span></span>
</td>
<td class="nump">$ 526,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525356220496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2021</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78,793)<span></span>
</td>
<td class="num">$ (196,692)<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="num">$ (237,616)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,225<span></span>
</td>
<td class="nump">36,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,300<span></span>
</td>
<td class="nump">174,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,110<span></span>
</td>
<td class="nump">83,317<span></span>
</td>
<td class="nump">174,149<span></span>
</td>
<td class="nump">76,408<span></span>
</td>
<td class="nump">158,405<span></span>
</td>
<td class="nump">91,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,576<span></span>
</td>
<td class="nump">326,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78,793)<span></span>
</td>
<td class="num">$ (196,692)<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="num">$ (237,616)<span></span>
</td>
<td class="num">$ (484,965)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (800,000)<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Common shares left to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525357899520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Sep. 29, 2022 </div>
<div>USD ($) </div>
<div>qtr</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cpix_EightAmendmentMember', window );">Eight Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum', window );">Maximum funded debt ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cpix_EightAmendmentMember', window );">Eight Amendment | Revolving Credit Facility | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum', window );">Maximum funded debt ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember', window );">Ninth Amemdment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold', window );">Unrestricted cash threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantEvaluationFrequency', window );">Covenant evaluation frequency | qtr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Sixth Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantEvaluationFrequency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Evaluation Frequency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantEvaluationFrequency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantFundedDebtRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Funded Debt Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantFundedDebtRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Unrestricted Cash Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantUnrestrictedCashThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_EightAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_EightAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SixthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SixthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525357026800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525365959872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Gain on receivable of life insurance policy proceeds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 611,330<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525357240912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,932,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FinancialConsiderationPaymentPeriod', window );">Financial consideration, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FinancialConsiderationNumberOfInstallments', window );">Financial consideration, number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment', window );">Financial consideration received in exchange for product license rights, installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Sales milestone payments, maximum</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected', window );">Sales milestone payments, expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue', window );">Milestone payment credit due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Restricted Stock | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable', window );">Restricted shares receivable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsThreshold', window );">Tiered royalty payment, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,819,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,515,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="nump">3,946,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,535,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Number of Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Intangible Assets, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_KyowaKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362787680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">$ (1,051,908)<span></span>
</td>
<td class="num">$ (632,646)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">6,515,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(777,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(1,550,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">631,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 4,819,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362013792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,051,908)<span></span>
</td>
<td class="num">$ (632,646)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">$ (339,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="nump">498,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">$ 430,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,535,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140525362787872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Dissolution Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 496,787<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,491,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 496,787<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,491,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>cpix-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20220930.xsd" xlink:type="simple"/>
    <context id="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ecf59c7ee0f4ebf9430d47fc996630e_I20221107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="i16ada3ab868247dd9574797af517d567_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if626e02bae5647008aa9c24841ba535a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c72ce76653b4c67a43289e60f381b45_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifeb4adb610e0487da3f871d1774882a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31e37ca58de94c968783906ecbe91aed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i469879a126f645e6957c45bf0ffe9267_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id8364ff2b3c64c9ba02d2282288d872c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i816fdbe7cf00466da247a111463219bd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i984b30ad550c466bb44529cda7dd3e4a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd66a8cd08ad466a871a154c19ab33e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9f34225fa00b49d2886530446efba2bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic9bbe436ab9243bf9e8e1752ee7ba9c4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibd1d4b58df9742c4af8e0eb4e6838a85_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida381f36684e4a5eb6add6bc60925c59_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i700befe6d648426db6fbc40ee5dcc1a0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaedd290adc07485ca2c5f8e444d98b02_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9af4ea0922c24564a827d627f319505b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaa0144f9dc224850955f0f39892c50b7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib91da5e323af4228a5d518ae9dfabe2b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i218f7c05e38145d0a763437aa9f82a87_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i896ff8d34ff14381a728f65812de9237_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iefeac04e34504adc9b365fe4ab275dda_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4385acb51a744d36a58b40ca8fc87ed8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibbb9253827ae4d4893eafb5d816d8f8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife4e12a79e884084831efe27e493c0a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia91dfb736e2c42719050801c83e8a3c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0db23060227f4160ba28455c16b8b07f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3243bd8ec27a48e0af6fabfc07ac337c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35731f9de26c4c06af01f46bde90a9b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7c80483524e94ce385b64322c7e6ebab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1ca7aed0a270443ab090d05d1305fb08_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic47373afe83f4d06b32efc31992a4bbf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice6baec924b84624945c5bd58260a450_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4ace87a0492248878926a8f03cd4a851_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id04d0344712f4a1aafd6f9ba7a41df3c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd2da3c3015846d4942e467930489296_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i88ad4d2d8d8444fbbd7d930a0a59e68c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i49466fa28fb04d6cb5ce8a17a31d35a2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c1457746c76430098d4ceb9d629e6dc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic33219167c744508bf085d2ae2eba1dd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i753dd913f191471e8a379e7fa42a7892_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib81209df23984304bd9299e97be9d76a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idc8c19c661864883b36b04dc73597c1a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib40fb787c5304021af13e3f348f7983b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i61d1ae337b8241eaa014de1e9b8f7c07_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16e17b402c0f4e0288249a98d5c1ef67_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05d6b3e6fa3b44c390043374bd0da6ab_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf9a2d719ce448809401f919889d8f43_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ef2fd27ce9b4de6811b30262e109c4c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i96dba68919a94185be0f2caa4d19fbd6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81107b4b859c48379106d400c932111b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie672054973a54d8b96a1429d7893b153_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9c935e63cfe042c0b62e5ad1b3ffccc4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9de578808568412b98f4258ca2a140d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a5b9640c93e4f4787d4be2b043c3ae6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b2423acefd847a9a84fc30460b5526a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5aaf93c862d54ccb94779f62960f1d26_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iea3b5f2e4fb145d9951d563e234c5113_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0468ba36dc8c4f4e94efe1fce522a602_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i378e8f356b7d41ea99ef9c631175c257_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebdfd0073023463d9f73789defb1bc95_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28f0f1e915d743ea86de5bef24145fd2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icef1b02b27044b4a842a41c51f0dda36_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0a22798105d04ccf960042a44583bde5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibeb5fd089f1847c09d6b1565f351311b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8cc92d5aecc141899d9bbb33fece4352_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28345cf5e7864e4f88e1ad3783be1eb1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i393707a2f8e84e51aab9d9aa77ec97cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i15d6ec26dd9148f19ebaf571b61a2b1b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i474d3830aff24d969ed6a7730701fff4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34ea0bc96ecd4501a2dea5ae2bd2122b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57ccd958b6a845348dde9c5a826d3f1d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d2c178f155b4cd0a7df168033b61d35_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaeb4c673c94a4eebb2bb9cead80bf84a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87128d81de3b40f59ea5c6c5a4e7e490_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i029c4ae96e134c18bb123cde8e3f3b46_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5ff531cbef64ec99752b4a2832ce9b2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1eba1c1c7837438686f9bbe8a1d81821_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia65a4295cc5943d2bdca764eec17c7fc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ica03638cc07848c3ad90c3dc523f5a6f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5029ffaf4ba44d2ebd77cf036dcb3394_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaf738532e4694162b9ca0c676b7e2bfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i227ccd5f3c584c1f80be5a81980484aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a588281c96f412e8750a46d0cf78bff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f654c5250f1487a87a937cdbf000493_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie91cbfa298a24c6db40c5463641c9886_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i658044c887034a83bdb045b4fb42ca2b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie795a7e8b44749c2b64904584da6bf32_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i89ea0a5e1de9410b819fbb525f8f78e1_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i73e648d1756d4361ac4f73a357526bb6_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i9a5078dc2e454b1ba6c7f4e344e79a4b_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i0dfb60514b2a4bfba647a1772e5f8bad_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib2c5bbf3a46c412fbe0e400fa873a864_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f068611586b404c9e736da8397fb6d3_D20220401-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8b9a83dbeb504232888f1be955d3484a_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="icba3428fcf7b4d74a47c2ef785d2fa87_D20211227-20211227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-12-27</startDate>
            <endDate>2021-12-27</endDate>
        </period>
    </context>
    <context id="ia9a3f9de6fd74bcc977d7a494dfd0845_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if26fc6a73ecc488bbe41fa9905a8441a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c80572bb63c43f3a1049c338dfc7e8e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia41636d373054e1b8b162bc68c25ba1c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i94d70987e1124eccabfc3d8e4dec7545_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie71841d6d5c24f758fab7ac85872aa45_I20220929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:NinthAmemdmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-29</instant>
        </period>
    </context>
    <context id="i357c94714cfb4fd08c6fffaa13a6c200_D20220401-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i13f82082fed14f898c9cf04f1b98af86_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:EightAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie39e421790ed488e946469a82c5d37a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SixthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88065d8df8544ba4bf056f4d71ec695a_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ifedf271cc67e434abd3401e7acffd33c_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="iede01fe31ea346b4918f9f4d3d001891_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i31108d31c0b44f30a2b52b23201aea12_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iceae2fc3bfa449c5bb629a222d37c37f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i866dc2144f804589a64b1eb2c037834c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7a44e5571a0d436ca5db214ef0319e3e_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i319a720f5704435caf765b6497b99cd9_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i5877b735a5424506a5da1c44d8a26339_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iea269d83c37d448a868f5ac00213446b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if9529ac6603c4a1f9da2fbbe9d90afe8_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i767388330a25494b84c7b1f3f5e31ca9_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i1b15f1a6a0214d9db3c1f1b2e95e05e9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida016a3372fe4bd9999e6c19613c11af_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib33917577d8c413092ed9270c4c1e044_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba57519128a042e6bcc12053ad575901_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i14fe005a15a14d999173b7903bf4a67e_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="id20273d5a5164f0589d2524268988a2a_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="idfa76b73d21648f5a7205032b91c3205_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i134a7c60cd4344ffbbd3642de16ac052_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="i16021fcc1ba042c6952a72b0e414e233_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="ibbe5febaa0764ac187ee7a439033f2cb_D20220103-20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7092e7f4631046c394046d8e01666761_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2f1475f8cb974dc2b812258f6b108a91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d73c406eebd400ab792cf31e23c80e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0213cec992ab4b93b597378f304014b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id09c93443a82400e9a283705c01948ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b3b7c2e16664c71bf1bf299d2abd068_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb344f54d56f4e8fa0bcc0e5e31b52e9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50b37e261fb14120ab86fd7d766694c8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib806724dc82b467680c5d90135d516b1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i98818e47614047d287fd5c789ac7559e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewalterm">
        <measure>cpix:renewalTerm</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="q">
        <measure>utr:Q</measure>
    </unit>
    <unit id="installment">
        <measure>cpix:installment</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGFibGU6N2VkOTMxZDJlOWRjNDQwMWFkODg1YjRlYjEzZTAzMmQvdGFibGVyYW5nZTo3ZWQ5MzFkMmU5ZGM0NDAxYWQ4ODViNGViMTNlMDMyZF81LTEtMS0xLTMxMjEz_9f06ffe2-3e9b-4e2c-baf5-4e15e3750758">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGFibGU6N2VkOTMxZDJlOWRjNDQwMWFkODg1YjRlYjEzZTAzMmQvdGFibGVyYW5nZTo3ZWQ5MzFkMmU5ZGM0NDAxYWQ4ODViNGViMTNlMDMyZF82LTEtMS0xLTMxMjEz_c5040bd2-93d8-4032-8119-15e940b94a2b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGFibGU6N2VkOTMxZDJlOWRjNDQwMWFkODg1YjRlYjEzZTAzMmQvdGFibGVyYW5nZTo3ZWQ5MzFkMmU5ZGM0NDAxYWQ4ODViNGViMTNlMDMyZF83LTEtMS0xLTMxMjEz_bfb2e8ad-b5b8-43d2-ba60-afe5e35e7aeb">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGV4dHJlZ2lvbjo3NTM1ZjY0NWY0MDQ0YmM2YjZkM2RiMjZiNzEzM2MzN183OA_c5c8ec39-3772-4644-baf3-748dce59d30f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80L2ZyYWc6NzUzNWY2NDVmNDA0NGJjNmI2ZDNkYjI2YjcxMzNjMzcvdGV4dHJlZ2lvbjo3NTM1ZjY0NWY0MDQ0YmM2YjZkM2RiMjZiNzEzM2MzN183OQ_7d5f4636-7a87-495c-b4ba-d7694be2d487">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTcy_6de4c893-3bc6-4408-a42a-a90924f4ad92">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6NzlhM2M2NGM1NGZkNGZlOGJkNGMwZDcyYmY5OTdhOWIvdGFibGVyYW5nZTo3OWEzYzY0YzU0ZmQ0ZmU4YmQ0YzBkNzJiZjk5N2E5Yl8wLTAtMS0xLTMxMjEz_fe5203ec-16dd-41eb-9a08-2685c96fc560">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xMzA_a36d5c86-0329-429c-a830-7059184ec4e9">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MDFlYmYwZDYxM2YwNDAwNzllYzY1OTc4MzFiYzIwMDYvdGFibGVyYW5nZTowMWViZjBkNjEzZjA0MDA3OWVjNjU5NzgzMWJjMjAwNl8wLTAtMS0xLTMxMjEz_e5646a37-b084-496d-8032-234fd04b485a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTgw_4bfa1fac-f1be-49e2-b07e-0277af6b5d79">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc0_31cfd354-36b9-4b07-b09f-bdc409ec9a6c">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8wLTAtMS0xLTMxMjEz_2d460f6f-5e3a-460b-b1c5-6dcb92280ebe">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8wLTItMS0xLTMxMjEz_240d3379-39ef-4d8d-a5cc-424d5401154c">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfNQ_32087906-6314-498b-b743-bd87553815e9">1600 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfOQ_24743d02-8951-4f94-9874-77a9919964c8">Suite 1300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfMTM_c58b8b0a-0851-474e-8571-b5c5d04c693e">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTAtMS0xLTMxMjEzL3RleHRyZWdpb246NDU4YzA4ZDk2ODcyNDQ0NWEwODgwNzIxMWUzMDk1NzRfMTc_2565528f-3f69-45a6-a59d-cd3d044cb44e">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MGUwMTgwNWQxOWIxNGRmMWJjOWIxMjUxNWVjNTQwNTAvdGFibGVyYW5nZTowZTAxODA1ZDE5YjE0ZGYxYmM5YjEyNTE1ZWM1NDA1MF8zLTItMS0xLTMxMjEz_80882c03-c41d-4e38-9512-381e23740b64">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTgx_93791a6c-70bb-4eb4-9a82-1a2586e3333f">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc2_cf2d5c63-2ed8-40c3-be31-61ffa5f29eb2">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6OWQ3MWM1NDA3YThiNDExNjk5Y2Y2MjZiZWQwOTY4ODgvdGFibGVyYW5nZTo5ZDcxYzU0MDdhOGI0MTE2OTljZjYyNmJlZDA5Njg4OF8yLTAtMS0xLTMxMjEz_28990051-4028-4982-8808-1fbf93f7da0e">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6OWQ3MWM1NDA3YThiNDExNjk5Y2Y2MjZiZWQwOTY4ODgvdGFibGVyYW5nZTo5ZDcxYzU0MDdhOGI0MTE2OTljZjYyNmJlZDA5Njg4OF8yLTItMS0xLTMxMjEz_8159dcfa-a0e6-4af5-be2e-5913a8cfac02">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6OWQ3MWM1NDA3YThiNDExNjk5Y2Y2MjZiZWQwOTY4ODgvdGFibGVyYW5nZTo5ZDcxYzU0MDdhOGI0MTE2OTljZjYyNmJlZDA5Njg4OF8yLTQtMS0xLTMxMjEz_69fa5967-b507-48cd-975d-6754c5ba09d0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc1_ddda0194-eb14-4c57-abac-a68f9d919124">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTcx_6db48c1b-ff30-446e-9328-ce79aff991b7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MzVmZDgyZTQ0ZmEyNDc3Njk2YTk3ZTJhNjc5NmI3ZDQvdGFibGVyYW5nZTozNWZkODJlNDRmYTI0Nzc2OTZhOTdlMmE2Nzk2YjdkNF8xLTAtMS0xLTMxMjEz_a479840f-5f0b-42c1-9d2a-9febe8e2bbd7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MzVmZDgyZTQ0ZmEyNDc3Njk2YTk3ZTJhNjc5NmI3ZDQvdGFibGVyYW5nZTozNWZkODJlNDRmYTI0Nzc2OTZhOTdlMmE2Nzk2YjdkNF8xLTUtMS0xLTMxMjEz_1334a4b8-a384-4891-9b5e-335f802033b8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGFibGU6MzVmZDgyZTQ0ZmEyNDc3Njk2YTk3ZTJhNjc5NmI3ZDQvdGFibGVyYW5nZTozNWZkODJlNDRmYTI0Nzc2OTZhOTdlMmE2Nzk2YjdkNF8yLTItMS0xLTMxMjEz_04b2b157-9397-479f-b818-92cdb3b1cc1b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTc3_dbbbed63-77ac-4252-bf68-ba4368a1681f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1ecf59c7ee0f4ebf9430d47fc996630e_I20221107"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xL2ZyYWc6NTc3ZGIyOWJhZWI2NGRiYmJiYTdiODUzNWViNjY2ZDkvdGV4dHJlZ2lvbjo1NzdkYjI5YmFlYjY0ZGJiYmJhN2I4NTM1ZWI2NjZkOV8xOTM2_8ab2c15a-2b6b-4fe2-99b6-b15dc9f70e88"
      unitRef="shares">14464127</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMy0xLTEtMS0zMTIxMw_8b3603a6-17ca-449c-aa35-2eab55ddeb93"
      unitRef="usd">19541538</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMy0zLTEtMS0zMTIxMw_737c8e4b-4108-446a-bd13-640ddc06134d"
      unitRef="usd">27040816</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNS0xLTEtMS0zMTIxMw_89c3d149-ce76-4582-aba5-27648e7e2eb9"
      unitRef="usd">15232697</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNS0zLTEtMS0zMTIxMw_7cb42750-1855-4f86-b896-7814f4ba2bab"
      unitRef="usd">6877346</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNi0xLTEtMS0zMTIxMw_ff3e1113-a4ef-4ab9-8264-b513705217f6"
      unitRef="usd">10647529</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNi0zLTEtMS0zMTIxMw_a2872ab2-943e-474e-bf6e-56e684a2c66c"
      unitRef="usd">8429882</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNy0xLTEtMS0zMTIxMw_29bf0ab7-b91d-437f-a92d-0bd0a05ad871"
      unitRef="usd">3738842</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfNy0zLTEtMS0zMTIxMw_0b9ca854-1aff-4870-a14e-5236e424a999"
      unitRef="usd">3339969</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOC0xLTEtMS0zMTIxMw_edc26c8b-371d-4859-9fa9-4793a7d383c1"
      unitRef="usd">49160606</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOC0zLTEtMS0zMTIxMw_4dd92d48-c7a4-4c4f-9ef6-7276619df6cf"
      unitRef="usd">45688013</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOS0xLTEtMS0zMTIxMw_3d90b762-e145-4a78-818e-f74730e40560"
      unitRef="usd">7497356</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfOS0zLTEtMS0zMTIxMw_408534c3-d479-419e-8bd4-bcd0d6b8d8ba"
      unitRef="usd">9048567</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTAtMS0xLTEtMzEyMTM_0761a11d-ea1b-4a19-9d89-77c43878dbea"
      unitRef="usd">490826</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTAtMy0xLTEtMzEyMTM_e085838b-0f5f-47be-89ad-182fbd8db378"
      unitRef="usd">442635</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTEtMS0xLTEtMzEyMTM_cae56555-5d70-415d-80dd-e9a93a80f903"
      unitRef="usd">29048043</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTEtMy0xLTEtMzEyMTM_74bd2fdf-fae4-4988-bb32-b25093ca089f"
      unitRef="usd">23954475</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTItMS0xLTEtMzEyMTM_e201672a-68f1-449f-9811-18a41cb5c167"
      unitRef="usd">1932876</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTItMy0xLTEtMzEyMTM_95ee6bdd-bd90-4049-b25b-177618847c43"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTMtMS0xLTEtMzEyMTM_4c6be4f7-8d44-44c1-88f4-0f811571e047"
      unitRef="usd">219850</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTMtMy0xLTEtMzEyMTM_50a1a127-27ab-4c27-869f-edb8da782546"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTMtMy0xLTEtMzEyMTM_94b25b70-349e-4dfc-91c4-a65aa019399b"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTQtMS0xLTEtMzEyMTM_45ccec88-644d-4fcc-b692-a4d2a6df64d0"
      unitRef="usd">2426996</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTQtMy0xLTEtMzEyMTM_00f61da9-6425-4f57-89d4-c11f080e2c37"
      unitRef="usd">3419908</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTUtMS0xLTEtMzEyMTM_f5266faf-7607-49a2-a300-b01aeff82a7c"
      unitRef="usd">90776553</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTUtMy0xLTEtMzEyMTM_1b2e901a-0115-4d8b-892b-385c82ba1096"
      unitRef="usd">84459798</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTgtMS0xLTEtMzEyMTM_b923590e-cca9-4942-91a2-0367c2ec7ed2"
      unitRef="usd">11510756</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTgtMy0xLTEtMzEyMTM_da25132a-17a1-416f-8b11-f9693d27fa0e"
      unitRef="usd">9640980</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTktMS0xLTEtMzEyMTM_fae870b7-88c0-4e2d-bccd-696b7b365908"
      unitRef="usd">229605</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTktMy0xLTEtMzEyMTM_6bd4c061-9d46-4a31-9335-8006051693ec"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMTktMy0xLTEtMzEyMTM_e4791503-bad7-4c73-a3ca-c6b9c40b6ef2"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjAtMS0xLTEtMzEyMTM_90301c5c-f980-45d7-9549-d1b3fa1cac22"
      unitRef="usd">13565862</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjAtMy0xLTEtMzEyMTM_2e842492-62b7-4e11-951d-99724f9d5f21"
      unitRef="usd">8668303</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjEtMS0xLTEtMzEyMTM_9d506153-8c7a-40bd-8c3b-8b5fd48a0f0f"
      unitRef="usd">25306223</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjEtMy0xLTEtMzEyMTM_e5b0dee3-66f7-46e6-a88f-a2b0f5cda2ad"
      unitRef="usd">19278960</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjItMS0xLTEtMzEyMTM_b08109a5-5b88-4ba5-a6aa-7e7ad4a5d047"
      unitRef="usd">17700000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjItMy0xLTEtMzEyMTM_acfbc7f5-e226-449b-97d0-e56df4b673d3"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjMtMS0xLTEtMzEyMTM_ee46a639-e498-4589-8366-1ec35f9fada5"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjMtMy0xLTEtMzEyMTM_1bc6210e-fc2d-42ee-8bda-a97c92ca1368"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjMtMy0xLTEtMzEyMTM_2c34c072-4e86-43b8-ae5c-e6132f1201b6"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjQtMS0xLTEtMzEyMTM_dfbb948d-9170-48d0-8847-08434d21f7a4"
      unitRef="usd">9279208</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjQtMy0xLTEtMzEyMTM_e7ea173e-e22b-445e-8d54-8700c33c555a"
      unitRef="usd">7488844</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjUtMS0xLTEtMzEyMTM_bbfa6b2b-0df5-48af-8d11-b48d6fba4549"
      unitRef="usd">52285431</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjUtMy0xLTEtMzEyMTM_7c2b3807-855d-4552-bd45-23d45b8b21f3"
      unitRef="usd">41857820</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjYtMS0xLTEtMzEyMTM_fc2cf6cc-d378-4047-a2b0-a522f8cd5f11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjYtMy0xLTEtMzEyMTM_bc3f7db0-576b-4604-80d6-511b301bd984"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8xNw_349115dc-d89f-459f-a68f-c56f2a6eb466"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8xNw_988af9e0-12dc-4193-b44c-80696c973b3b"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8zMQ_4f075ace-919d-4c37-ab95-910d0df2f9a3"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV8zMQ_a2875bb7-2d5a-4771-9c9e-4daf06e4e4d0"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV81Mw_0a2abd35-a62a-40d6-aa79-ab29daea019d"
      unitRef="shares">14436583</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV81Mw_49ecae3a-b411-4e24-b516-a67846bbe251"
      unitRef="shares">14436583</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV82MA_47b99124-932a-418d-9c8e-b71c3576d086"
      unitRef="shares">14742754</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMC0xLTEtMzEyMTMvdGV4dHJlZ2lvbjowOTY5MjRhYjFlNzI0MDhmOTM0ZDJkN2UxOGU0ZTQ1NV82MA_d64ea13d-e69e-4b87-85ff-00db6b706f7e"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMS0xLTEtMzEyMTM_905ffc9d-ac45-461a-ac76-83c7429bb48f"
      unitRef="usd">47532375</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMjktMy0xLTEtMzEyMTM_7ec6a86d-0bb5-4e5d-8687-639def58c69e"
      unitRef="usd">48452906</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzAtMS0xLTEtMzEyMTM_dcd139c5-1cae-47e2-b33a-de3e08897874"
      unitRef="usd">-8768112</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzAtMy0xLTEtMzEyMTM_0a4f52dc-6fb2-4201-adf5-a916a360e347"
      unitRef="usd">-5638600</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzEtMS0xLTEtMzEyMTM_4add7444-0d44-48f4-8723-8149c978ff4e"
      unitRef="usd">38764263</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzEtMy0xLTEtMzEyMTM_e707cf2f-749d-4121-a8f0-1b55a78bd1e3"
      unitRef="usd">42814306</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzItMS0xLTEtMzEyMTM_88570669-1b2f-4659-88cd-0677fe908c51"
      unitRef="usd">-273141</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzItMy0xLTEtMzEyMTM_62c5e4dd-9d81-40c6-b4cf-7e0b04282979"
      unitRef="usd">-212328</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzMtMS0xLTEtMzEyMTM_f90ccf94-bbf2-42ad-8e09-5df53a15db58"
      unitRef="usd">38491122</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzMtMy0xLTEtMzEyMTM_be7ebb33-f774-4cb0-8c75-a87b2edb87e0"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzQtMS0xLTEtMzEyMTM_7def717d-3b6b-4688-b028-13cb401afb90"
      unitRef="usd">90776553</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xNi9mcmFnOjY0ZTI0NDZlMDIwODRhOTZiYTgwYWM0Y2JkNmViNGVkL3RhYmxlOjUzNWZjZDFmZDc5YzRjMmFiODBmNmFmNjU4MDIxM2YzL3RhYmxlcmFuZ2U6NTM1ZmNkMWZkNzljNGMyYWI4MGY2YWY2NTgwMjEzZjNfMzQtMy0xLTEtMzEyMTM_e81b5c55-b315-4f3b-a7f2-714a65c8a072"
      unitRef="usd">84459798</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi0xLTEtMS0zMTIxMw_bb0475f5-adaf-439b-88a0-44176133d5dd"
      unitRef="usd">11413072</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi0zLTEtMS0zMTIxMw_e4a41170-d550-4947-a909-4aac9c2d9470"
      unitRef="usd">8072540</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi01LTEtMS0zMTIxMw_4254774e-c408-48ee-a908-1426a180cc05"
      unitRef="usd">32887269</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMi03LTEtMS0zMTIxMw_e9f13c54-1aeb-40df-844a-fd7dd5e6f519"
      unitRef="usd">27665182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC0xLTEtMS0zMTIxMw_22180e6f-13d4-40c3-b67a-42733b9eee57"
      unitRef="usd">2224443</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC0zLTEtMS0zMTIxMw_4038b2ae-1de2-470a-8551-0a53f91e2b8d"
      unitRef="usd">1328027</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC01LTEtMS0zMTIxMw_dc59c857-0c0c-4035-b957-7f49567bb5a3"
      unitRef="usd">6468212</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNC03LTEtMS0zMTIxMw_f9e5548e-d04f-4dae-9512-78b202b5d4af"
      unitRef="usd">5486005</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS0xLTEtMS0zMTIxMw_d49acac3-7ced-49b4-a6fe-9beb6fba9f7a"
      unitRef="usd">4110397</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS0zLTEtMS0zMTIxMw_1e2aa132-9dde-461c-9c27-9ab3868b0ca5"
      unitRef="usd">3800288</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS01LTEtMS0zMTIxMw_e9ef9260-a542-4101-a0b2-f1f41277134f"
      unitRef="usd">13281511</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNS03LTEtMS0zMTIxMw_7cd21c80-cd7e-4dc4-96b6-d44aed57a96b"
      unitRef="usd">11709445</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi0xLTEtMS0zMTIxMw_dcdb02a8-309e-4e49-8578-f232ff143ee5"
      unitRef="usd">1714254</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi0zLTEtMS0zMTIxMw_699c90f9-563a-4eb1-9c15-7bb05642d1df"
      unitRef="usd">1453873</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi01LTEtMS0zMTIxMw_6e8e862f-4372-4c59-915e-e78dcf4771d8"
      unitRef="usd">5283083</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNi03LTEtMS0zMTIxMw_0630a397-019f-4e7b-93a6-6957fa933321"
      unitRef="usd">4071638</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy0xLTEtMS0zMTIxMw_93263af4-413d-4e74-81cf-0f6a4ee4669d"
      unitRef="usd">2166118</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy0zLTEtMS0zMTIxMw_f9ea06c6-220b-4d32-9b85-13991684cf34"
      unitRef="usd">2039799</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy01LTEtMS0zMTIxMw_438d6d24-2dfb-4f47-b37a-525258c06297"
      unitRef="usd">6672442</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfNy03LTEtMS0zMTIxMw_930ef420-6239-4f36-af3e-d1a1bc536bfa"
      unitRef="usd">6367438</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC0xLTEtMS0zMTIxMw_69663639-a706-486d-bcbe-1c96585c6efa"
      unitRef="usd">1486448</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC0zLTEtMS0zMTIxMw_74271984-4634-4271-b7d0-beef5ef8c01a"
      unitRef="usd">1013948</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC01LTEtMS0zMTIxMw_958aac80-21b2-4c63-9ef2-003fa252a049"
      unitRef="usd">4609146</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOC03LTEtMS0zMTIxMw_2ef616b2-f957-4d83-a65c-5b9126aca798"
      unitRef="usd">3354080</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS0xLTEtMS0zMTIxMw_420d6843-41e8-4b6f-b432-e3b412824950"
      unitRef="usd">11701660</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS0zLTEtMS0zMTIxMw_aac2f0e2-aede-4f8c-8ac7-2ba002b22f44"
      unitRef="usd">9635935</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS01LTEtMS0zMTIxMw_226c4698-2c7c-491f-b77f-cabe2b2a7d68"
      unitRef="usd">36314394</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfOS03LTEtMS0zMTIxMw_f2c4e284-44fd-4e93-a30f-11b0a6363d6b"
      unitRef="usd">30988606</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtMS0xLTEtMzEyMTM_de53ceff-adcc-4409-a5f0-edb35209d27c"
      unitRef="usd">-288588</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtMy0xLTEtMzEyMTM_20620874-e9f0-4e2f-a93b-85880e1db080"
      unitRef="usd">-1563395</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtNS0xLTEtMzEyMTM_98919d7c-e82e-425c-8db4-9a29e8a6c002"
      unitRef="usd">-3427125</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTAtNy0xLTEtMzEyMTM_edd4dc68-fd2f-4683-973a-4a972284eb65"
      unitRef="usd">-3323424</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtMS0xLTEtMzEyMTM_8e2aef15-4af0-4d8b-b765-30f52f609785"
      unitRef="usd">21602</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtMy0xLTEtMzEyMTM_029a9688-7672-41d3-9ceb-5861456eb9fa"
      unitRef="usd">7394</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtNS0xLTEtMzEyMTM_ab5eccca-5786-46b8-a077-b8441e93c634"
      unitRef="usd">52709</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTEtNy0xLTEtMzEyMTM_64872455-d976-4b85-bf85-aac12865cc50"
      unitRef="usd">19411</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItMS0xLTEtMzEyMTM_f3bbaacf-f773-4dc8-b2ad-11ba1771f757"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItMy0xLTEtMzEyMTM_e84add83-13d2-4be2-88c5-039a1331a1ed"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItNS0xLTEtMzEyMTM_a618a3f9-5030-4c04-8303-52423af12c72"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTItNy0xLTEtMzEyMTM_598a33cc-0221-4b39-86cd-2cb0c65c8abf"
      unitRef="usd">2187140</us-gaap:OtherIncome>
    <us-gaap:InsuredEventGainLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtMS0xLTEtMzEyMTM_72171565-6586-442c-9c79-6c91537dbb3d"
      unitRef="usd">0</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtMy0xLTEtMzEyMTM_feb7fb8f-ebc6-4432-a3ec-c8205de199ad"
      unitRef="usd">0</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtNS0xLTEtMzEyMTM_72779df9-8b03-413b-b09d-ac1620195f75"
      unitRef="usd">611330</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTMtNy0xLTEtMzEyMTM_083aead9-1556-427a-949d-a6cf5b4520ab"
      unitRef="usd">0</us-gaap:InsuredEventGainLoss>
    <us-gaap:InterestExpense
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtMS0xLTEtMzEyMTM_5cbab2e4-1e26-44eb-b8a3-c632bb34f929"
      unitRef="usd">149340</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtMy0xLTEtMzEyMTM_e05f6d72-6faa-49b1-ab08-b8c6871bf937"
      unitRef="usd">20021</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtNS0xLTEtMzEyMTM_6d1e050c-1844-40d9-8f81-8eed50dbcc4c"
      unitRef="usd">406539</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTQtNy0xLTEtMzEyMTM_6a9a5323-04b5-4082-80ec-30bbab30b275"
      unitRef="usd">70297</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtMS0xLTEtMzEyMTM_04296c8a-ff8a-417d-8ad7-bd38799e0a1a"
      unitRef="usd">-416326</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtMy0xLTEtMzEyMTM_06acfc8a-c659-4f3d-af26-8fa916ad8692"
      unitRef="usd">-1576022</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtNS0xLTEtMzEyMTM_2878eb96-8827-4752-ba34-ed350be64243"
      unitRef="usd">-3169625</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTUtNy0xLTEtMzEyMTM_4017e317-73e1-4f2f-ae1b-d9fba298a76b"
      unitRef="usd">-1187170</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtMS0xLTEtMzEyMTM_71230639-eb4e-41a1-abf2-266d481fc7fe"
      unitRef="usd">6900</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtMy0xLTEtMzEyMTM_c90df69e-5c4d-445a-9dd6-aed29b05d0b4"
      unitRef="usd">7458</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtNS0xLTEtMzEyMTM_c4c31589-55a7-4adb-8494-fe458e3ae612"
      unitRef="usd">20700</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTYtNy0xLTEtMzEyMTM_29215c70-7a7c-4d23-9a07-a6e5e1dc2d14"
      unitRef="usd">22375</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctMS0xLTEtMzEyMTM_cd306f8d-7a23-4447-b7b8-fd1ed163ebe6"
      unitRef="usd">-423226</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctMy0xLTEtMzEyMTM_a42c9fc0-5fd8-493d-91db-9bf0dc7eda56"
      unitRef="usd">-1583480</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctNS0xLTEtMzEyMTM_0845a259-2c09-4f78-84dd-d140ff304e97"
      unitRef="usd">-3190325</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTctNy0xLTEtMzEyMTM_d20ec557-09a0-4330-b526-f582b79a03c1"
      unitRef="usd">-1209545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtMS0xLTEtMzEyMTM_a366bf5a-6c37-4c1d-9d11-3a1aa767af75"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtMy0xLTEtMzEyMTM_fb028702-2690-4ef2-bee4-8184ef6fc3c4"
      unitRef="usd">496787</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtNS0xLTEtMzEyMTM_5ceaead0-f754-4cc5-afe8-90c915a6320f"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTgtNy0xLTEtMzEyMTM_e6c4ce79-b1ed-43e7-9e29-5b9a601883b9"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktMS0xLTEtMzEyMTM_d3412bce-2f41-4b65-b8ae-ac4c5c1ca3c2"
      unitRef="usd">-423226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktMy0xLTEtMzEyMTM_29feac07-dd66-4e8f-a0f1-698a89fa4c55"
      unitRef="usd">-1086693</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktNS0xLTEtMzEyMTM_9816b8c3-83b7-4ef3-8b55-3b904b8d3e27"
      unitRef="usd">-3190325</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMTktNy0xLTEtMzEyMTM_34daef80-f076-4020-b559-5f998325dfe3"
      unitRef="usd">281459</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtMS0xLTEtMzEyMTM_eff198a1-5c67-4bcf-b459-92c3cb42f19d"
      unitRef="usd">-14587</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtMy0xLTEtMzEyMTM_0f71b9d1-df41-4bd8-a060-2a9c06c3021f"
      unitRef="usd">-31415</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtNS0xLTEtMzEyMTM_3556da5d-f8ce-4ed1-a523-271022aeb086"
      unitRef="usd">-60813</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjAtNy0xLTEtMzEyMTM_c2cd2dda-1d4a-4fd8-b5a7-cc6db09e1b1f"
      unitRef="usd">-58651</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtMS0xLTEtMzEyMTM_9ba2e104-59ca-4a7b-aaaa-ef9261e93f1d"
      unitRef="usd">-408639</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtMy0xLTEtMzEyMTM_1989e941-bd1f-49f8-b313-fd904fcdfa69"
      unitRef="usd">-1055278</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtNS0xLTEtMzEyMTM_0c77e351-abc9-47d1-a10d-1e1a793bfd6b"
      unitRef="usd">-3129512</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjEtNy0xLTEtMzEyMTM_e57038d3-13c0-4d1a-9270-9f0f2e05a65b"
      unitRef="usd">340110</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtMS0xLTEtMzEyMTM_360fd5f1-051f-4ecd-b206-babf78f3fb56"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtMy0xLTEtMzEyMTM_d4146cf7-1d2c-4562-9d60-7cacbc2aedbb"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtNS0xLTEtMzEyMTM_7ccaa803-c69d-4bd1-b377-d637be6ae3eb"
      unitRef="usdPerShare">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjMtNy0xLTEtMzEyMTM_e9939922-d47a-4565-a407-ef22ac2df6f8"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtMS0xLTEtMzEyMTM_9fa8ae8d-6744-49c4-83c9-6c9b3dee2c99"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtMy0xLTEtMzEyMTM_1ec8f047-b20d-407a-8a9f-8e22cb25d3ec"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtNS0xLTEtMzEyMTM_6f7ac40e-5028-4cd4-bfdd-040a6cd54bab"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjQtNy0xLTEtMzEyMTM_d4be1b70-a454-4e01-84b5-7493f50930d9"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtMS0xLTEtMzEyMTM_f574c2ad-0ec4-4411-8b0c-8e1a935fc3dc"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtMy0xLTEtMzEyMTM_be0b5fd7-e4fb-407d-bf5b-ea118d5335c4"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtNS0xLTEtMzEyMTM_9fe99f2d-ab42-44a9-97fb-156434fa172d"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjUtNy0xLTEtMzEyMTM_309013cb-fa34-4635-9ecf-1ad335b6cb35"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctMS0xLTEtMzEyMTM_28640a1c-6842-433c-88f7-8cd308a8b5d0"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctMy0xLTEtMzEyMTM_45b187fa-82ab-43ea-8949-137f8582b31b"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctNS0xLTEtMzEyMTM_63f385ad-a0d9-4241-b9f7-535bf369ced2"
      unitRef="usdPerShare">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjctNy0xLTEtMzEyMTM_e9b7d2cd-ebf0-4bca-8227-c488119d069a"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtMS0xLTEtMzEyMTM_f7f4cede-c4e3-4aa9-9298-37b3638e006b"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtMy0xLTEtMzEyMTM_d8d3fe42-d17a-45f8-aef7-0a1e46eea1f5"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtNS0xLTEtMzEyMTM_bc4e876a-50e8-4c2f-8a63-4cbf28e9bf38"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjgtNy0xLTEtMzEyMTM_8fca3c1b-7a61-4098-965c-f2c0a7faca98"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktMS0xLTEtMzEyMTM_53f3ff8a-99e9-4388-b9d4-98c9e3e6d61b"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktMy0xLTEtMzEyMTM_130f7f61-b18f-42b8-ad8e-616e5b27a7ef"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktNS0xLTEtMzEyMTM_fb53d72f-5489-49c8-a384-5f52bbae9286"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMjktNy0xLTEtMzEyMTM_6ed0e09e-f3a3-425c-82d5-bc1e5ce0be74"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtMS0xLTEtMzEyMTM_e1a1f4d8-f81d-440d-9872-1a42f4ddf3b7"
      unitRef="shares">14477478</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtMy0xLTEtMzEyMTM_554afac6-e827-4b81-a7d9-18a391f6ffce"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtNS0xLTEtMzEyMTM_6d99a7e9-647b-4d61-ad56-13ccbbc226b9"
      unitRef="shares">14618975</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzEtNy0xLTEtMzEyMTM_b89fbfa8-61f9-43b7-9b98-54351347df72"
      unitRef="shares">14939919</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItMS0xLTEtMzEyMTM_4ded4125-9700-4ad7-8826-967d5c1c164d"
      unitRef="shares">14477478</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItMy0xLTEtMzEyMTM_daf4f1d3-863b-4d08-8948-0d7cb971ca51"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItNS0xLTEtMzEyMTM_0b230d13-d390-4094-8abb-06e6aab4e27a"
      unitRef="shares">14618975</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8xOS9mcmFnOjdlMWNlNzNhNDNkOTRjMmZhN2NmNzQ3YzgzNjIzYmRlL3RhYmxlOjRiNjI4MzhlNjk4MzQ2NDBhMmNlYjA2ZjBjM2M2NmM5L3RhYmxlcmFuZ2U6NGI2MjgzOGU2OTgzNDY0MGEyY2ViMDZmMGMzYzY2YzlfMzItNy0xLTEtMzEyMTM_4ce3dc71-5705-43d4-9194-c3cb7ddd1298"
      unitRef="shares">15139904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMy0xLTEtMS0zMTIxMw_41a57610-f6d6-4fd1-bdfd-52f3192e7d46"
      unitRef="usd">-3190325</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMy0zLTEtMS0zMTIxMw_58fde146-01d1-4d6d-8af6-5df0b7a59869"
      unitRef="usd">281459</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNC0xLTEtMS0zMTIxMw_665159ac-f879-4356-ae53-1a26e0337e27"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNC0zLTEtMS0zMTIxMw_1e9b1438-513b-429e-8463-f90e4f39819d"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNS0xLTEtMS0zMTIxMw_35b98dda-78f6-4a4b-bc0d-ebc89646976e"
      unitRef="usd">-3190325</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNS0zLTEtMS0zMTIxMw_6c3e40fa-dbf2-4a95-93e4-281902c2965a"
      unitRef="usd">-1209545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNy0xLTEtMS0zMTIxMw_3517ce5f-2b74-4048-8d96-333a044d8cd5"
      unitRef="usd">4816630</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNy0zLTEtMS0zMTIxMw_a2d0cb15-38fe-4f5d-8ec3-f4d13bb7d83b"
      unitRef="usd">3529245</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOC0xLTEtMS0zMTIxMw_e0b4c639-ec56-4a33-b0ed-c0858a91a55b"
      unitRef="usd">320598</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOC0zLTEtMS0zMTIxMw_dc905ef3-1572-40be-8afe-201c79422930"
      unitRef="usd">517081</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOS0xLTEtMS0zMTIxMw_9669b089-1049-4c3b-b659-3049d8a33204"
      unitRef="usd">-1051908</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfOS0zLTEtMS0zMTIxMw_82e6d69f-7708-4c4b-ae7c-ddbf3f9635f7"
      unitRef="usd">-632646</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTAtMS0xLTEtMzEyMTM_cf02051f-ad94-444c-99e4-5ebbc375a84f"
      unitRef="usd">-708293</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTAtMy0xLTEtMzEyMTM_1e30dd35-1619-4982-8ef6-823198279faa"
      unitRef="usd">52070</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTItMS0xLTEtMzEyMTM_9175560c-47b2-427d-a972-b9959f152a84"
      unitRef="usd">7608</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTItMy0xLTEtMzEyMTM_eb13cdf3-25c0-4448-a7e7-7df30f569196"
      unitRef="usd">33943</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMS0xLTEtMzEyMTM_a5bda9ca-1914-4ec0-bbfd-aefb254b625c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMy0xLTEtMzEyMTM_fb83ad2e-990d-4b2a-a01d-49832610b597"
      unitRef="usd">2187140</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InsuredEventGainLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMS0xLTEtMzM2MjQ_728f5a8e-c460-4e13-927f-ad06d3bb631d"
      unitRef="usd">611330</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTMtMy0xLTEtMzM2MjQ_ebae8bfa-4b00-4fe2-8450-140212bb98f7"
      unitRef="usd">0</us-gaap:InsuredEventGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTUtMS0xLTEtMzEyMTM_7947b9ac-2760-4103-b105-b9d902beb625"
      unitRef="usd">8184656</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTUtMy0xLTEtMzEyMTM_f5fc9a35-e8e4-4c7b-be62-73ae7942eacb"
      unitRef="usd">-2527183</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTYtMS0xLTEtMzEyMTM_0f09e1b1-d7c9-4c84-a9a1-6018a55e7181"
      unitRef="usd">-1338881</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTYtMy0xLTEtMzEyMTM_5f99c2bf-c382-4c11-b6be-2494f8fb82f3"
      unitRef="usd">-2555393</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTctMS0xLTEtMzEyMTM_eac338d3-aa6b-4e90-a9a5-48e98b8157df"
      unitRef="usd">-4355396</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTctMy0xLTEtMzEyMTM_5f2a5935-c506-44ab-a8da-354c5ceb061e"
      unitRef="usd">-1627350</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTgtMS0xLTEtMzEyMTM_f5c590b2-2aea-4efd-b76b-09193c04366a"
      unitRef="usd">8778631</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTgtMy0xLTEtMzEyMTM_646966e0-86ce-4e99-b407-9f8952180f33"
      unitRef="usd">-2873596</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTktMS0xLTEtMzEyMTM_5b3a8be6-e651-45e6-8d48-3d67667b6592"
      unitRef="usd">-2472453</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMTktMy0xLTEtMzEyMTM_7f7c8336-ebdb-4036-bed3-7fa1711741bd"
      unitRef="usd">-943439</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjAtMS0xLTEtMzEyMTM_86354614-3369-42dd-ab64-8cec51d1f351"
      unitRef="usd">4815365</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjAtMy0xLTEtMzEyMTM_160a372c-c6cf-45c7-bad7-59bca06d2b11"
      unitRef="usd">2891759</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjEtMS0xLTEtMzEyMTM_f2e9fa97-32c2-4a2f-b108-a0d6e956548e"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjEtMy0xLTEtMzEyMTM_49e45a55-fa92-4355-8f45-7dc6ca8482a4"
      unitRef="usd">1491004</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjItMS0xLTEtMzEyMTM_85a26056-ba37-4818-81bf-c24cbebd318b"
      unitRef="usd">4815365</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjItMy0xLTEtMzEyMTM_01a18a75-aad0-4f5a-85f6-3ef728853e95"
      unitRef="usd">4382763</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjQtMS0xLTEtMzEyMTM_d340075a-d5ce-4eeb-83a0-41e7119a81e1"
      unitRef="usd">255676</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjQtMy0xLTEtMzEyMTM_e47d31e5-a6c6-4a67-aa48-77ec8ec6de24"
      unitRef="usd">94485</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cpix:ProceedsFromSettlementOfPatentLitigation
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjUtMS0xLTEtMzEyMTM_da3239b1-1255-42d6-9911-80e9999da698"
      unitRef="usd">21757</cpix:ProceedsFromSettlementOfPatentLitigation>
    <cpix:ProceedsFromSettlementOfPatentLitigation
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjUtMy0xLTEtMzEyMTM_a4c1345c-3586-4b8c-a04b-62bc11529a70"
      unitRef="usd">0</cpix:ProceedsFromSettlementOfPatentLitigation>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjYtMS0xLTEtMzEyMTM_048d17bd-5329-48e5-b11e-16cf3f0c6e32"
      unitRef="usd">877597</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjUtMy0xLTEtMzM1NTA_824cfa09-c0e8-45eb-b42e-78701c4ffaae"
      unitRef="usd">0</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjctMS0xLTEtMzEyMTM_e7f1dd3f-7950-4d28-88d2-0ba9d237a8c0"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjctMy0xLTEtMzEyMTM_3897ea1b-e0bb-4098-a71e-d9fd267ebd60"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjgtMS0xLTEtMzEyMTM_692fb8be-02d3-4883-83a8-9be4a5c06418"
      unitRef="usd">13500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjgtMy0xLTEtMzEyMTM_879753eb-ce36-41c4-b6fa-d66e97dce70b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjktMS0xLTEtMzEyMTM_9eb64414-0250-46a3-bf74-6faf5ae3f27c"
      unitRef="usd">177362</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMjktMy0xLTEtMzEyMTM_a4c2c386-2d44-400a-ae53-a8139deae466"
      unitRef="usd">180613</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzAtMS0xLTEtMzEyMTM_e4670111-77f6-4ff3-8553-5a71b78b9568"
      unitRef="usd">-13033684</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzAtMy0xLTEtMzEyMTM_5bde2286-d17d-4e5c-94a9-b6e0c1227670"
      unitRef="usd">-475098</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzMtMS0xLTEtMzEyMTM_332a6517-b716-4066-92c3-0d40b66100da"
      unitRef="usd">46700000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzMtMy0xLTEtMzEyMTM_5693e1d4-7ca1-4d04-9737-58c7f2b9168e"
      unitRef="usd">45000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzQtMS0xLTEtMzEyMTM_36ed24bc-16ae-40a9-a1fc-e3abbfb606cd"
      unitRef="usd">44000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzQtMy0xLTEtMzEyMTM_91e1e686-7a0f-44bb-8c87-a94b99824d66"
      unitRef="usd">45000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzUtMS0xLTEtMzEyMTM_b1dcd068-9325-4735-a9ea-e9827fb2f36a"
      unitRef="usd">1117576</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzUtMy0xLTEtMzEyMTM_ca5adf20-4fc5-463b-85ad-3573058ea265"
      unitRef="usd">1792573</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzYtMS0xLTEtMzEyMTM_7852a3be-77f8-4fa6-9371-0ef2139b89d1"
      unitRef="usd">863383</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzYtMy0xLTEtMzEyMTM_a9b056ee-c90a-4992-81b5-4178f8db6109"
      unitRef="usd">1025657</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzctMS0xLTEtMzEyMTM_94da312e-c0be-44d7-942b-a8b13445e05d"
      unitRef="usd">719041</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzctMy0xLTEtMzEyMTM_87ef5fe1-7f99-41f9-b612-b8c1a7dc5ac8"
      unitRef="usd">-2818230</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzgtMS0xLTEtMzEyMTM_1e9ff420-25e7-4ed1-b2d2-c764b640bfea"
      unitRef="usd">-7499278</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzgtMy0xLTEtMzEyMTM_ef3703ff-89e8-40c6-99a6-636104f58915"
      unitRef="usd">1089435</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzktMS0xLTEtMzEyMTM_8db953d3-27f0-4a5c-b114-c3a9b88f0b50"
      unitRef="usd">27040816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if626e02bae5647008aa9c24841ba535a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfMzktMy0xLTEtMzEyMTM_58891743-b0e4-4c36-ad7d-39a49a4dea68"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNDAtMS0xLTEtMzEyMTM_35e59e1a-1c2f-4376-bebb-94052f4d4b5d"
      unitRef="usd">19541538</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c72ce76653b4c67a43289e60f381b45_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yMi9mcmFnOmUyMThhODY4MmI5MjQxMmNhMzU3NDU3Y2I1NTczNWEzL3RhYmxlOjc1ZGQ3ODMxYTRhNTQ2NmU5ZDVmYzgzODczNWI0MzQ0L3RhYmxlcmFuZ2U6NzVkZDc4MzFhNGE1NDY2ZTlkNWZjODM4NzM1YjQzNDRfNDAtMy0xLTEtMzEyMTM_94d6a797-c2b6-46dc-8f3c-f1adec249273"
      unitRef="usd">25843231</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifeb4adb610e0487da3f871d1774882a5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi0xLTEtMS0zMTIxMw_80ffaca0-87bf-4d9a-95b4-9b58b1e1b36f"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifeb4adb610e0487da3f871d1774882a5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi0zLTEtMS0zMTIxMw_7948ff11-1dc3-4527-8546-2504bd59f513"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31e37ca58de94c968783906ecbe91aed_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi01LTEtMS0zMTIxMw_220cfd94-0d50-4c07-9aaf-009bcdae1f1b"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i469879a126f645e6957c45bf0ffe9267_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi03LTEtMS0zMTIxMw_ae070f0c-81d9-4020-9c5c-d5ff07dc6f1a"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if626e02bae5647008aa9c24841ba535a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMi05LTEtMS0zMTIxMw_b32bfd5c-b178-40e6-bc97-871da0b3e6b2"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMy0xLTEtMS0zMTIxMw_efda9f4f-bc8a-45f2-9b33-e1580956f580"
      unitRef="shares">187759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMy0zLTEtMS0zMTIxMw_449fa34b-05ed-4653-a41d-3f7d7f5d2243"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfMy05LTEtMS0zMTIxMw_8130a0a7-f3dc-4663-ac63-aa5939ab6d50"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNC0xLTEtMS0zMTIxMw_575fcaa2-0084-4460-8a6b-f4b2e26c78a0"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNC0zLTEtMS0zMTIxMw_408ddf9a-3d7c-4342-9c9b-b85f0717087c"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNC05LTEtMS0zMTIxMw_1f892adf-b9fd-4681-bd8c-6873e0a0907c"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="id8364ff2b3c64c9ba02d2282288d872c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNS01LTEtMS0zMTIxMw_65df64b3-d5d4-4f2d-a1c0-646c1c466042"
      unitRef="usd">166828</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i816fdbe7cf00466da247a111463219bd_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNS03LTEtMS0zMTIxMw_4e9f07b9-4d2a-4df8-847c-be1db1498ed2"
      unitRef="usd">-22167</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7bcfa1fb92d641899331f83d0fde7540_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNS05LTEtMS0zMTIxMw_71a9e48e-148f-4258-9af8-9f56680861ae"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi0xLTEtMS0zMTIxMw_8c74aefa-b018-490c-8015-38317ad11bd1"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi0zLTEtMS0zMTIxMw_db03e667-98c3-4d57-a576-57399155d904"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd66a8cd08ad466a871a154c19ab33e0_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi01LTEtMS0zMTIxMw_bad0dde3-8535-4d65-a36e-6e9ed73d8a73"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f34225fa00b49d2886530446efba2bd_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi03LTEtMS0zMTIxMw_73737f9f-1e52-408e-bda8-f1b77175985d"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9bbe436ab9243bf9e8e1752ee7ba9c4_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjEwZWQ5OGFiMjljMzQwNzk4NzE1MWViN2YwMmE5ZDVmL3RhYmxlcmFuZ2U6MTBlZDk4YWIyOWMzNDA3OTg3MTUxZWI3ZjAyYTlkNWZfNi05LTEtMS0zMTIxMw_cd233151-0f5f-4fb7-b436-437f64255800"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS0xLTEtMS0zMTIxMw_ba8f70db-aa99-43d3-aa2b-a2d60e0f7098"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i984b30ad550c466bb44529cda7dd3e4a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS0zLTEtMS0zMTIxMw_c9e2d578-d795-423c-b34a-615cb0c2bba4"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd66a8cd08ad466a871a154c19ab33e0_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS01LTEtMS0zMTIxMw_0b1c6ef1-d684-4f16-97d2-d6e492ee61f8"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f34225fa00b49d2886530446efba2bd_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS03LTEtMS0zMTIxMw_0d632786-0aa3-4c16-8b4f-5c4f4d3e2800"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9bbe436ab9243bf9e8e1752ee7ba9c4_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMS05LTEtMS0zMTIxMw_dad57672-c970-465d-8ca2-c3021367b6bc"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMi0zLTEtMS0zMzY4Mw_9e7c4877-5a24-4a4d-b9a5-7cbb3db5a8f1"
      unitRef="usd">191954</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMi05LTEtMS0zMzY4Mw_5be51635-2c67-48ae-9f49-396d82ed2076"
      unitRef="usd">191954</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMy0xLTEtMS0zMzY4NQ_572759b4-456a-4336-beab-092d542dc349"
      unitRef="shares">158405</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic23d2e41827c415d98a9779dd9e5a587_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMy0zLTEtMS0zMzY4Mw_afd63585-ae9f-438e-bb49-7d786a4c5270"
      unitRef="usd">484965</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfMy05LTEtMS0zMzY4Mw_03b70ac5-bc73-472f-af67-2ea524eb6853"
      unitRef="usd">484965</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ibd1d4b58df9742c4af8e0eb4e6838a85_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNC01LTEtMS0zMzY4Mw_d5101416-1ff3-4684-a3bc-e7ea81c9ecb8"
      unitRef="usd">1228560</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ida381f36684e4a5eb6add6bc60925c59_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNC03LTEtMS0zMzY4Mw_246e5e4a-2791-4358-8969-932a02b4d1d0"
      unitRef="usd">-5069</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2f4be4fc8c446d9b9844093057ebc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNC05LTEtMS0zMzY4Mw_f3fae1dc-8781-46de-b211-488fefa7f3f7"
      unitRef="usd">1223491</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS0xLTEtMS0zMTIxMw_22a7c590-ecc5-46bf-b4c1-e85ebdf837a0"
      unitRef="shares">14926059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS0zLTEtMS0zMTIxMw_c57f1803-48f2-4a0b-81e5-5b8f8868f218"
      unitRef="usd">48688384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaedd290adc07485ca2c5f8e444d98b02_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS01LTEtMS0zMTIxMw_8882e4ec-44da-493c-abb5-93db7a9ce3a4"
      unitRef="usd">-735625</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9af4ea0922c24564a827d627f319505b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS03LTEtMS0zMTIxMw_061ed500-2497-4250-bbbe-7a6c76664d13"
      unitRef="usd">-144352</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa0144f9dc224850955f0f39892c50b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjdhMWI5MGNhYTA4NTRmZGViY2E4NTBjOTAzYjE4ZTgzL3RhYmxlcmFuZ2U6N2ExYjkwY2FhMDg1NGZkZWJjYTg1MGM5MDNiMThlODNfNS05LTEtMS0zMTIxMw_a2aa6911-42af-4c4f-894a-b4f8ff292502"
      unitRef="usd">47808407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS0xLTEtMS0zMTYwNg_2983a7bc-ac6b-4a16-a3b0-800e358e3566"
      unitRef="shares">14926059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i700befe6d648426db6fbc40ee5dcc1a0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS0zLTEtMS0zMTYwNg_a98a6170-1bea-42d7-ba69-0d361e3ffc69"
      unitRef="usd">48688384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaedd290adc07485ca2c5f8e444d98b02_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS01LTEtMS0zMTYwNg_890f2b3e-bb50-407e-b0bb-2bbb9d128abb"
      unitRef="usd">-735625</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9af4ea0922c24564a827d627f319505b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS03LTEtMS0zMTYwNg_8b0ecd16-f775-4f77-a516-96d7e10c5af5"
      unitRef="usd">-144352</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa0144f9dc224850955f0f39892c50b7_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMS05LTEtMS0zMTYwNg_9830a122-1741-4e6f-81f2-0bf2683b7ed4"
      unitRef="usd">47808407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMi0xLTEtMS0zMTYxNA_0e013ef5-97c7-42e4-a414-70cc5cbac868"
      unitRef="shares">875</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMi0zLTEtMS0zMTYxNA_d10ba79f-4a6e-4c56-8a64-3276b06db7fc"
      unitRef="usd">162167</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfMi05LTEtMS0zMTYxNA_3e67bfcf-2643-40bd-8770-b9fa0bb8e351"
      unitRef="usd">162167</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNS0xLTEtMS0zMTYyMg_b61e421a-b083-43d9-aa2d-a073dd39c3f5"
      unitRef="shares">76408</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i92d10dd09a414c6b8c740480ae7acd11_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNS0zLTEtMS0zMTYyMg_2063a4a0-9d54-495d-9f9d-fbafa2fbc16c"
      unitRef="usd">237616</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNS05LTEtMS0zMTYyMg_f0c84711-03da-4856-96a4-f39733c28a8a"
      unitRef="usd">237616</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ib91da5e323af4228a5d518ae9dfabe2b_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNi01LTEtMS0zMTYzMg_034d1d0c-2c9c-462b-b43e-b7dbf8f7aae5"
      unitRef="usd">-1055278</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i218f7c05e38145d0a763437aa9f82a87_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNi03LTEtMS0zMTYzMg_977686b9-85d6-4f55-b00e-ab72decc4274"
      unitRef="usd">-31415</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNi05LTEtMS0zMTYzMg_71383744-a59e-4a1d-b40c-807eeefd736f"
      unitRef="usd">-1086693</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i896ff8d34ff14381a728f65812de9237_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy0xLTEtMS0zMTIxMw_02754412-d258-4f5a-ad54-1989eb37110f"
      unitRef="shares">14850526</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i896ff8d34ff14381a728f65812de9237_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy0zLTEtMS0zMTIxMw_d2257290-7592-42f2-97ff-05a5ede95d58"
      unitRef="usd">48612935</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefeac04e34504adc9b365fe4ab275dda_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy01LTEtMS0zMTIxMw_4606c2e9-32e9-4363-88c2-36ce3b204b12"
      unitRef="usd">-1790903</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4385acb51a744d36a58b40ca8fc87ed8_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy03LTEtMS0zMTIxMw_f80abcba-83af-4ca3-aa60-37fd29fbf889"
      unitRef="usd">-175767</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c72ce76653b4c67a43289e60f381b45_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjY4YWM2NTQ4NWFhZjQ0MzY4NmM3ZjVmNDc4MGMyMTgxL3RhYmxlcmFuZ2U6NjhhYzY1NDg1YWFmNDQzNjg2YzdmNWY0NzgwYzIxODFfNy05LTEtMS0zMTIxMw_5160cd19-6b38-431e-b1af-5f6c9ae91f9a"
      unitRef="usd">46646265</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibbb9253827ae4d4893eafb5d816d8f8d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi0xLTEtMS0zMTIxMw_62e7583e-3ae0-4d29-8dc9-2374ba4d6057"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbb9253827ae4d4893eafb5d816d8f8d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi0zLTEtMS0zMTIxMw_36f3dc96-006a-4bee-8e7e-19274fbab3a5"
      unitRef="usd">48452906</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife4e12a79e884084831efe27e493c0a7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi01LTEtMS0zMTIxMw_71009273-7e1f-4de3-9245-b079da2c8131"
      unitRef="usd">-5638600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia91dfb736e2c42719050801c83e8a3c7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi03LTEtMS0zMTIxMw_2be5e9bd-56d0-4dff-8cff-99a113c0b5d4"
      unitRef="usd">-212328</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMi05LTEtMS0zMTIxMw_d6bd1b0e-8406-4995-beb1-6a480f5bf07e"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMy0xLTEtMS0zMTIxMw_c1476b6f-6c77-4e0b-a93f-aa685cba4f9c"
      unitRef="shares">162155</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMy0zLTEtMS0zMTIxMw_436d7044-4cb8-4527-b8b3-45afe6016769"
      unitRef="usd">159901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfMy05LTEtMS0zMTIxMw_e3a632b8-4312-4c57-b409-6cefd3f2a4ad"
      unitRef="usd">159901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNC0xLTEtMS0zMTIxMw_ed323c90-c2e2-41ca-a33b-0cd7a947057a"
      unitRef="shares">174149</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if1c2864b87974b8d87e746dcd718194c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNC0zLTEtMS0zMTIxMw_85e82730-7e9f-43f1-a44a-06538ea31ca9"
      unitRef="usd">566043</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNC05LTEtMS0zMTIxMw_6c5d2e13-f6c3-4c1a-a8e9-a81f8f2f9695"
      unitRef="usd">566043</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i0db23060227f4160ba28455c16b8b07f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNS01LTEtMS0zMTIxMw_b0ff0265-943c-42e1-807c-6ea4e6850d8a"
      unitRef="usd">-1385253</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3243bd8ec27a48e0af6fabfc07ac337c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNS03LTEtMS0zMTIxMw_b922b8a4-15a1-4c5c-a1f1-41cc028186af"
      unitRef="usd">-17180</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i64f020de384d4409bf839f7aaf0f3596_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNS05LTEtMS0zMTIxMw_f03cbaaa-4ba7-49b1-bd5f-0b9a2343b76d"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi0xLTEtMS0zMTIxMw_4d82762e-9e3f-4f16-96f7-38d21260762c"
      unitRef="shares">14730760</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi0zLTEtMS0zMTIxMw_081e60a1-3b45-4bf7-9601-3dff5442f471"
      unitRef="usd">48046764</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c80483524e94ce385b64322c7e6ebab_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi01LTEtMS0zMTIxMw_e85b8cec-f9d9-4863-a8e5-a695f59219ea"
      unitRef="usd">-7023853</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ca7aed0a270443ab090d05d1305fb08_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi03LTEtMS0zMTIxMw_be8ca2c1-46e8-4b9f-9389-73574436b4b3"
      unitRef="usd">-229508</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic47373afe83f4d06b32efc31992a4bbf_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOjQ3ZDA3Mzk2NWQ4ZDRjMjhiODRiYTViNThiMzZlYmYzL3RhYmxlcmFuZ2U6NDdkMDczOTY1ZDhkNGMyOGI4NGJhNWI1OGIzNmViZjNfNi05LTEtMS0zMTIxMw_d0a0ad74-ecc5-4d84-ae4c-8b459fdcf80d"
      unitRef="usd">40793403</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS0xLTEtMS0zMTIxMw_4d82762e-9e3f-4f16-96f7-38d21260762c"
      unitRef="shares">14730760</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35731f9de26c4c06af01f46bde90a9b3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS0zLTEtMS0zMTIxMw_081e60a1-3b45-4bf7-9601-3dff5442f471"
      unitRef="usd">48046764</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c80483524e94ce385b64322c7e6ebab_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS01LTEtMS0zMTIxMw_e85b8cec-f9d9-4863-a8e5-a695f59219ea"
      unitRef="usd">-7023853</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ca7aed0a270443ab090d05d1305fb08_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS03LTEtMS0zMTIxMw_be8ca2c1-46e8-4b9f-9389-73574436b4b3"
      unitRef="usd">-229508</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic47373afe83f4d06b32efc31992a4bbf_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMS05LTEtMS0zMTIxMw_d0a0ad74-ecc5-4d84-ae4c-8b459fdcf80d"
      unitRef="usd">40793403</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMi0xLTEtMS0zMTIxMw_d476bd77-d5c5-40f1-b0ab-14478ac84234"
      unitRef="shares">2250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMi0zLTEtMS0zMTIxMw_d96b83f4-5cb6-43a2-a131-e504585f574a"
      unitRef="usd">-27753</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMi05LTEtMS0zMTIxMw_5a79871c-f6ae-4960-b6de-da3fe9f000e6"
      unitRef="usd">-27753</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMy0xLTEtMS0zMTIxMw_1bad1df8-50eb-4270-a2c8-2f9087344f41"
      unitRef="shares">83317</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic0fac4b40c80412e99a0b519775d931a_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMy0zLTEtMS0zMTIxMw_ad18fda6-1cf5-4255-a165-92e90683b291"
      unitRef="usd">196692</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfMy05LTEtMS0zMTIxMw_c60f308c-0c07-404c-aeeb-1bf2fd19cf81"
      unitRef="usd">196692</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ice6baec924b84624945c5bd58260a450_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNC01LTEtMS0zMTIxMw_f66b0bc8-82c8-42cc-bdd3-0865fb041438"
      unitRef="usd">-1335620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ace87a0492248878926a8f03cd4a851_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNC03LTEtMS0zMTIxMw_c7a06006-cd90-497c-bb77-d48737bbbe97"
      unitRef="usd">-29046</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNC05LTEtMS0zMTIxMw_8747594e-01e5-40ea-8b86-1b3c8fff9fd4"
      unitRef="usd">-1364666</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS0xLTEtMS0zMTIxMw_4715eb16-62bc-4834-955d-dcb63259e5c4"
      unitRef="shares">14649693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS0zLTEtMS0zMTIxMw_372b3bf4-2130-43e8-a826-08a3fbc6f0ae"
      unitRef="usd">47822319</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id04d0344712f4a1aafd6f9ba7a41df3c_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS01LTEtMS0zMTIxMw_6f1e5908-da81-48c9-aa2f-9580125faa0f"
      unitRef="usd">-8359473</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd2da3c3015846d4942e467930489296_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS03LTEtMS0zMTIxMw_61c56c3c-0f95-40bd-a135-63eb3170460e"
      unitRef="usd">-258554</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88ad4d2d8d8444fbbd7d930a0a59e68c_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmQ1MzYyOTMyNWRjYTRlN2RiOTBmNzVkNTY0ODAxZGFjL3RhYmxlcmFuZ2U6ZDUzNjI5MzI1ZGNhNGU3ZGI5MGY3NWQ1NjQ4MDFkYWNfNS05LTEtMS0zMTIxMw_4bade462-f624-4dc2-9958-f474c7de1078"
      unitRef="usd">39204292</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS0xLTEtMS0zMTIxMw_a26b0352-fcc9-476e-9bb2-9ce3f5445232"
      unitRef="shares">14649693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bd0a5627bf041b7aeafb537bc2f59b2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS0zLTEtMS0zMTIxMw_f0bc2b41-f471-43d9-a000-89bab5a0fd09"
      unitRef="usd">47822319</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id04d0344712f4a1aafd6f9ba7a41df3c_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS01LTEtMS0zMTIxMw_6e94a865-ee49-4af2-983f-3635fa9e34e9"
      unitRef="usd">-8359473</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd2da3c3015846d4942e467930489296_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS03LTEtMS0zMTIxMw_f89659be-f81f-4973-b773-a130178bca97"
      unitRef="usd">-258554</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88ad4d2d8d8444fbbd7d930a0a59e68c_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMS05LTEtMS0zMTIxMw_78851de5-8d5a-4b74-bd3e-4cfec85ddd24"
      unitRef="usd">39204292</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi0xLTEtMS0zMjM2MA_909f969e-1e6a-4cce-b2ad-5ae08817697b"
      unitRef="shares">180000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi0zLTEtMS0zMjM2MA_9a94138d-163b-41c7-b215-908952b2aebc"
      unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi05LTEtMS0zMjM2MA_785ab2a7-eae1-4f0e-937d-2deac30b4736"
      unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi0zLTEtMS0zMTIxMw_178c1f9c-2a8f-4eb1-beba-358375f2f633"
      unitRef="usd">188449</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMi05LTEtMS0zMTIxMw_130536a3-4aa4-495b-a461-177fc8bafea6"
      unitRef="usd">188449</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMy0xLTEtMS0zMTIxMw_ed45258a-b2b7-4347-8264-4fb0e20f425f"
      unitRef="shares">33110</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib322f4a368ff4366a01ef5cafb399245_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMy0zLTEtMS0zMTIxMw_a11a9c09-208e-4491-8303-e4c5d666dae3"
      unitRef="usd">78793</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfMy05LTEtMS0zMTIxMw_a60d7bcb-1e98-487a-b3a2-b4813d4de0ae"
      unitRef="usd">78793</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i49466fa28fb04d6cb5ce8a17a31d35a2_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNC01LTEtMS0zMTIxMw_507bd996-2ee6-405b-b5bc-e6b58de70bf0"
      unitRef="usd">-408639</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c1457746c76430098d4ceb9d629e6dc_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNC03LTEtMS0zMTIxMw_cdfc10e0-56d6-4bac-a409-98d70257bd77"
      unitRef="usd">-14587</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNC05LTEtMS0zMTIxMw_5b58e695-2218-43cf-9039-f1c929c45d7c"
      unitRef="usd">-423226</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic33219167c744508bf085d2ae2eba1dd_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS0xLTEtMS0zMTIxMw_121de7e3-9bf1-4211-9fcd-e60c9d2c4372"
      unitRef="shares">14436583</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic33219167c744508bf085d2ae2eba1dd_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS0zLTEtMS0zMTIxMw_8a8b9149-9b05-4fa1-98f6-665acefbc19a"
      unitRef="usd">47532375</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i753dd913f191471e8a379e7fa42a7892_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS01LTEtMS0zMTIxMw_de7cfafe-fc9f-4f2b-a83f-b98e068ab955"
      unitRef="usd">-8768112</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib81209df23984304bd9299e97be9d76a_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS03LTEtMS0zMTIxMw_3e0b29f5-6f1d-4146-a5de-d7eb14e25d27"
      unitRef="usd">-273141</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8yNS9mcmFnOjE2NGY2NzkxMTEzZjQzYWNhNjQxODMwMDMxYzMzOTVmL3RhYmxlOmE0ZmU1MjlkMWRlYjRjMGFiOWY1NmYwMzg5ZjNiNjVlL3RhYmxlcmFuZ2U6YTRmZTUyOWQxZGViNGMwYWI5ZjU2ZjAzODlmM2I2NWVfNS05LTEtMS0zMTIxMw_92266611-e39e-4cfe-8117-1c745c93bdbd"
      unitRef="usd">38491122</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUyMQ_a4a9d187-bcba-4e2e-b45a-d9d119bca9cd">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its hospital, field and oncology sales teams and its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#x201c;2021 Annual Report on Form 10-K&#x201d;). The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 10, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, 2021 and the nine months ended September 30, 2022,  we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUyMw_712a490d-d2e7-4597-8789-7246527fc5a6">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings (deficit) as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUxNw_6582bed1-f92d-4f4a-9457-72e174270f84">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfOTUxOA_0762b239-417d-4120-b29d-723aa1834a1b">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zMS9mcmFnOjAzYWRmNThlNmYzYzQ5Zjc5OTY2MTJiMWU5MTA2OGNjL3RleHRyZWdpb246MDNhZGY1OGU2ZjNjNDlmNzk5NjYxMmIxZTkxMDY4Y2NfODcxMQ_4fe877b9-b30c-4f9a-b581-2d38d7f66a80"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfNDE1_d14aef8b-cf3a-49dd-9f3d-449ad10522e8">EARNINGS (LOSS) PER SHARE&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,583,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,477,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,477,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,190,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,209,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,190,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,129,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,618,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,939,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,618,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,139,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and 2021, restricted stock awards and options to purchase 233,750 and 158,900 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfNDE3_66a1d82d-d9ac-4ce5-92ce-9eb511bace04">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,583,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(408,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,477,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,477,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,190,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,209,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,190,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,129,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,618,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,939,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,618,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,139,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNC0xLTEtMS0zMTIxMw_cd306f8d-7a23-4447-b7b8-fd1ed163ebe6"
      unitRef="usd">-423226</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNC0zLTEtMS0zMTIxMw_a42c9fc0-5fd8-493d-91db-9bf0dc7eda56"
      unitRef="usd">-1583480</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNS0xLTEtMS0zMTIxMw_a366bf5a-6c37-4c1d-9d11-3a1aa767af75"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNS0zLTEtMS0zMTIxMw_fb028702-2690-4ef2-bee4-8184ef6fc3c4"
      unitRef="usd">496787</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNi0xLTEtMS0zMTIxMw_1f19ad60-40f5-4905-b627-517a854d4eec"
      unitRef="usd">-423226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNi0zLTEtMS0zMTIxMw_269e53c2-3bd4-4661-8558-77ffa6a4cb7c"
      unitRef="usd">-1086693</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNy0xLTEtMS0zMTIxMw_eff198a1-5c67-4bcf-b459-92c3cb42f19d"
      unitRef="usd">-14587</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfNy0zLTEtMS0zMTIxMw_0f71b9d1-df41-4bd8-a060-2a9c06c3021f"
      unitRef="usd">-31415</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfOC0xLTEtMS0zMTIxMw_9ba2e104-59ca-4a7b-aaaa-ef9261e93f1d"
      unitRef="usd">-408639</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfOC0zLTEtMS0zMTIxMw_1989e941-bd1f-49f8-b313-fd904fcdfa69"
      unitRef="usd">-1055278</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTAtMS0xLTEtMzEyMTM_e1a1f4d8-f81d-440d-9872-1a42f4ddf3b7"
      unitRef="shares">14477478</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTAtMy0xLTEtMzEyMTM_554afac6-e827-4b81-a7d9-18a391f6ffce"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTEtMS0xLTEtMzEyMTM_3dfabb03-1010-4ee7-a086-e506e13a9446"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTEtMy0xLTEtMzEyMTM_bcec73c9-f789-4d7b-b19e-13a30fd2663f"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTItMS0xLTEtMzEyMTM_4ded4125-9700-4ad7-8826-967d5c1c164d"
      unitRef="shares">14477478</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmIzYTM1OTJjMmU0MjRjYjg5ZmJhNDg2MmVhZWMzOGRhL3RhYmxlcmFuZ2U6YjNhMzU5MmMyZTQyNGNiODlmYmE0ODYyZWFlYzM4ZGFfMTItMy0xLTEtMzEyMTM_daf4f1d3-863b-4d08-8948-0d7cb971ca51"
      unitRef="shares">14880887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNC0xLTEtMS0zMTIxMw_0845a259-2c09-4f78-84dd-d140ff304e97"
      unitRef="usd">-3190325</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNC0zLTEtMS0zMTIxMw_d20ec557-09a0-4330-b526-f582b79a03c1"
      unitRef="usd">-1209545</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNS0xLTEtMS0zMTIxMw_5ceaead0-f754-4cc5-afe8-90c915a6320f"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNS0zLTEtMS0zMTIxMw_e6c4ce79-b1ed-43e7-9e29-5b9a601883b9"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNi0xLTEtMS0zMTIxMw_b168c6ff-209c-4019-9743-2bab2dc85742"
      unitRef="usd">-3190325</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNi0zLTEtMS0zMTIxMw_95940213-cb76-4546-9974-fe4a1c98f04e"
      unitRef="usd">281459</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNy0xLTEtMS0zMTIxMw_3556da5d-f8ce-4ed1-a523-271022aeb086"
      unitRef="usd">-60813</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfNy0zLTEtMS0zMTIxMw_c2cd2dda-1d4a-4fd8-b5a7-cc6db09e1b1f"
      unitRef="usd">-58651</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfOC0xLTEtMS0zMTIxMw_0c77e351-abc9-47d1-a10d-1e1a793bfd6b"
      unitRef="usd">-3129512</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfOC0zLTEtMS0zMTIxMw_e57038d3-13c0-4d1a-9270-9f0f2e05a65b"
      unitRef="usd">340110</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTAtMS0xLTEtMzEyMTM_6d99a7e9-647b-4d61-ad56-13ccbbc226b9"
      unitRef="shares">14618975</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTAtMy0xLTEtMzEyMTM_b89fbfa8-61f9-43b7-9b98-54351347df72"
      unitRef="shares">14939919</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTEtMS0xLTEtMzEyMTM_910272fa-cf8a-4d36-98b1-dad4aabe54b8"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTEtMy0xLTEtMzEyMTM_5aa9a374-70a5-44f1-9eaa-c591cdafda56"
      unitRef="shares">199985</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTItMS0xLTEtMzEyMTM_0b230d13-d390-4094-8abb-06e6aab4e27a"
      unitRef="shares">14618975</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RhYmxlOmM5OTA5MDI1ZGVkYzQ3ZjRiNzdhYWQ0YTMwMDFkNDRkL3RhYmxlcmFuZ2U6Yzk5MDkwMjVkZWRjNDdmNGI3N2FhZDRhMzAwMWQ0NGRfMTItMy0xLTEtMzEyMTM_4ce3dc71-5705-43d4-9194-c3cb7ddd1298"
      unitRef="shares">15139904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfMjM5_859ce511-e81d-40b5-bd9c-8a4d7558f6db"
      unitRef="shares">233750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNC9mcmFnOmJmNWQ0ZDM3ZThmMTQ3MDk4Nzc4NTYyMzk2YjkwM2VlL3RleHRyZWdpb246YmY1ZDRkMzdlOGYxNDcwOTg3Nzg1NjIzOTZiOTAzZWVfMjQ2_93e22efd-7f4a-46fa-930c-3e988c1bf7b2"
      unitRef="shares">158900</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzI0MQ_59555243-6f34-4e29-9e7c-1780a8844897">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,903,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,418,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,286,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,756,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,909,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,008,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,799,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,075,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,861,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(451,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,413,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,072,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,887,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Omeclamox-Pak revenue for the third quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the third quarter of 2022, the amounts noted were normal adjustments by channel partners.  Net revenue was positively impacted by product return adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With regard to Vaprisol, we are in the process of transitioning to a new manufacturer, who was issued an FDA Form 483 in the second quarter of 2022.  Once these 483 related issues are satisfactorily resolved by the manufacturing plant, we will then resubmit our application to the FDA for approval.  Net revenue was negatively impacted by product return adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2022, we recorded $0.1 million and $0.6 million, respectively, for milestone and international licensee payments as part of other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues also include funding from federal grant programs including those secured from the FDA and from those secured by Cumberland Emerging Technologies Inc. ("CET") through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these federal grant  programs totaled approximately $0.2&#160;million and $0.02 million for the three months ended September 30, 2022 and 2021, respectively, and approximately $0.3 million each for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzI0Mg_336ac9dc-1b87-4bc2-a602-ea2b5bcdf7f1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,903,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,418,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,286,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,756,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,909,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,008,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,799,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,075,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,734,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,861,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(451,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,413,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,072,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,887,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,665,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc8c19c661864883b36b04dc73597c1a_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy0xLTEtMS0zMTIxMw_efb08e05-14b8-4cd4-a786-af0d7cbcff39"
      unitRef="usd">3903305</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib40fb787c5304021af13e3f348f7983b_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy0zLTEtMS0zMTIxMw_7983ab91-8b1d-4c28-adbe-827e96601836"
      unitRef="usd">4012746</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61d1ae337b8241eaa014de1e9b8f7c07_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy01LTEtMS0zMTIxMw_53afaf62-9c0f-44fe-9e10-a67ec8b561b7"
      unitRef="usd">11418673</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16e17b402c0f4e0288249a98d5c1ef67_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMy03LTEtMS0zMTIxMw_3934238d-5ab0-46e6-9856-200403fd8cb5"
      unitRef="usd">12286729</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05d6b3e6fa3b44c390043374bd0da6ab_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC0xLTEtMS0zMTIxMw_731bde77-7e49-40b1-9fc2-2b3e746967a7"
      unitRef="usd">3960652</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf9a2d719ce448809401f919889d8f43_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC0zLTEtMS0zMTIxMw_c4408ac3-8e63-4460-a71a-67cdbf1fb5bb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ef2fd27ce9b4de6811b30262e109c4c_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC01LTEtMS0zMTIxMw_3cf00b1c-17e5-4bd0-8829-14d779254635"
      unitRef="usd">10756411</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96dba68919a94185be0f2caa4d19fbd6_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNC03LTEtMS0zMTIxMw_9c1b844a-d6f5-4522-ad5a-5dd7d2d9d03b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81107b4b859c48379106d400c932111b_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS0xLTEtMS0zMTIxMw_c81b168a-c54f-4b97-86e9-f8d30c671a3b"
      unitRef="usd">1909750</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie672054973a54d8b96a1429d7893b153_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS0zLTEtMS0zMTIxMw_d2b311db-dfa8-4681-a8a7-ad2e5f92c906"
      unitRef="usd">1896584</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c935e63cfe042c0b62e5ad1b3ffccc4_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS01LTEtMS0zMTIxMw_dec601e0-ad53-4390-a283-4c9523b16f2a"
      unitRef="usd">6008005</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9de578808568412b98f4258ca2a140d4_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNS03LTEtMS0zMTIxMw_1ef19ab5-e9dd-46cc-b156-b69574833d41"
      unitRef="usd">8799891</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a5b9640c93e4f4787d4be2b043c3ae6_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi0xLTEtMS0zMTIxMw_8c3c3f9e-3fb7-4d03-ac2a-79d7f3dfb927"
      unitRef="usd">921811</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b2423acefd847a9a84fc30460b5526a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi0zLTEtMS0zMTIxMw_a3b40028-3ee2-43c5-a29d-9a3af6726784"
      unitRef="usd">1255669</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aaf93c862d54ccb94779f62960f1d26_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi01LTEtMS0zMTIxMw_b66ab6ce-eea5-436f-9344-071d2eff2d34"
      unitRef="usd">3075355</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea3b5f2e4fb145d9951d563e234c5113_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNi03LTEtMS0zMTIxMw_c74bf698-1791-454e-8945-abab0dbb1fc0"
      unitRef="usd">3734273</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0468ba36dc8c4f4e94efe1fce522a602_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy0xLTEtMS0zMTIxMw_45084d6b-be77-4bab-940c-68bfbd3aecae"
      unitRef="usd">-436</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i378e8f356b7d41ea99ef9c631175c257_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy0zLTEtMS0zMTIxMw_f32b8943-6aa4-4b79-ae4e-5995c5b61900"
      unitRef="usd">325774</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebdfd0073023463d9f73789defb1bc95_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy01LTEtMS0zMTIxMw_0bdf5053-816e-4bf8-adfd-761c17fd112a"
      unitRef="usd">-252059</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28f0f1e915d743ea86de5bef24145fd2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfNy03LTEtMS0zMTIxMw_5be112bc-a292-485e-aa11-6d6c33900734"
      unitRef="usd">1861130</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icef1b02b27044b4a842a41c51f0dda36_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC0xLTEtMS0zMTIxMw_19a3baeb-3bbc-4a06-9439-3b5a5560007b"
      unitRef="usd">99792</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a22798105d04ccf960042a44583bde5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC0zLTEtMS0zMTIxMw_0d42ba93-a71e-4b37-a4cc-329a4296ef12"
      unitRef="usd">368733</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb5fd089f1847c09d6b1565f351311b_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC01LTEtMS0zMTIxMw_22210f34-1f85-4fbf-95d2-e017edd9dc6e"
      unitRef="usd">337685</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cc92d5aecc141899d9bbb33fece4352_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOC03LTEtMS0zMTIxMw_060dc9ca-0961-4772-809f-b6f0bb81696f"
      unitRef="usd">638704</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28345cf5e7864e4f88e1ad3783be1eb1_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS0xLTEtMS0zMTIxMw_0f8104b9-bfc1-4d86-925f-1ae58d07af3c"
      unitRef="usd">35600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i393707a2f8e84e51aab9d9aa77ec97cd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS0zLTEtMS0zMTIxMw_8fb8c6f4-2686-4a57-87ed-4cadb21faef5"
      unitRef="usd">22689</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15d6ec26dd9148f19ebaf571b61a2b1b_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS01LTEtMS0zMTIxMw_be275c9c-c0b3-48c6-8394-c94c4eeda862"
      unitRef="usd">31925</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i474d3830aff24d969ed6a7730701fff4_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfOS03LTEtMS0zMTIxMw_06386565-34a2-4a91-acb0-ffd767c1a410"
      unitRef="usd">-451683</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34ea0bc96ecd4501a2dea5ae2bd2122b_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtMS0xLTEtMzEyMTM_bc4a6fa1-1eb9-47d7-9448-6c2b4a8c51e8"
      unitRef="usd">85809</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57ccd958b6a845348dde9c5a826d3f1d_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtMy0xLTEtMzEyMTM_f78adffe-4ca8-4d4e-8f9b-e5fa027fc7c4"
      unitRef="usd">11459</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d2c178f155b4cd0a7df168033b61d35_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtNS0xLTEtMzEyMTM_d6d35946-ad0a-46cb-8ce1-51bdc287f168"
      unitRef="usd">238712</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeb4c673c94a4eebb2bb9cead80bf84a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTAtNy0xLTEtMzEyMTM_b3573952-f8fe-4612-bf14-81fde9a90ed1"
      unitRef="usd">-13291</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87128d81de3b40f59ea5c6c5a4e7e490_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtMS0xLTEtMzEyMTM_2467f835-f79e-42a3-a634-3c5cd77dac41"
      unitRef="usd">496789</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i029c4ae96e134c18bb123cde8e3f3b46_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtMy0xLTEtMzEyMTM_1a104261-53aa-4e38-b04e-62db4cef1b9c"
      unitRef="usd">178886</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5ff531cbef64ec99752b4a2832ce9b2_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtNS0xLTEtMzEyMTM_2f8d968d-99d7-497e-a651-41da92cadfc8"
      unitRef="usd">1272562</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eba1c1c7837438686f9bbe8a1d81821_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTEtNy0xLTEtMzEyMTM_5f9bb108-c13e-4d09-a47e-7427431d23e5"
      unitRef="usd">809429</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItMS0xLTEtMzEyMTM_1c12680d-70f2-4c66-8e62-f3fcae53334a"
      unitRef="usd">11413072</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItMy0xLTEtMzEyMTM_a30704b4-14c8-4df0-a7e9-d339aed842b0"
      unitRef="usd">8072540</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItNS0xLTEtMzEyMTM_3854177d-6b96-484f-b502-b67586be803d"
      unitRef="usd">32887269</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RhYmxlOjg5YWUwYTQ3NTAwZjQzZjlhMTgwODcxNTdhMDRjNzQwL3RhYmxlcmFuZ2U6ODlhZTBhNDc1MDBmNDNmOWExODA4NzE1N2EwNGM3NDBfMTItNy0xLTEtMzEyMTM_bb7a3f1f-86c7-488e-9892-d11da5858be0"
      unitRef="usd">27665182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cpix:RevenueRecognitionMilestonePayments
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMjU0Mg_c3cc3dbf-6ee7-4006-82ba-438d65850bfc"
      unitRef="usd">100000</cpix:RevenueRecognitionMilestonePayments>
    <cpix:RevenueRecognitionMilestonePayments
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMjU0OQ_4ccef4d7-72ed-46eb-bca0-6ac4ba5cfbfe"
      unitRef="usd">600000</cpix:RevenueRecognitionMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia65a4295cc5943d2bdca764eec17c7fc_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzE1MQ_3eec6faa-e982-47d4-8e35-535eeb649025"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica03638cc07848c3ad90c3dc523f5a6f_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfNTQ5NzU1ODE3NDMy_20780b03-fc2a-4522-ad2b-37f41d8f5277"
      unitRef="usd">20000.00</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5029ffaf4ba44d2ebd77cf036dcb3394_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF8zNy9mcmFnOjIzZTBiMmVhY2IxZjQzMWViYjk4ODRjYzk2NTE2NzY4L3RleHRyZWdpb246MjNlMGIyZWFjYjFmNDMxZWJiOTg4NGNjOTY1MTY3NjhfMzE5OA_54e15a53-0eb8-42d7-9d9d-ae8a5fb38208"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjMxMA_b1175a78-8938-4bb0-9202-658665858fae">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At September 30, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $1.8 million and $1.4 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory.  At September 30, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $7.5 million and $9.0 million, respectively. The Company had no Vibativ finished goods included in non-current inventory at September 30, 2022, and $0.5 million included at December 31, 2021.  The Company also has obtained $0.2 million and $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022 and December 31, 2021 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,738,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,374,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,277,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,144,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,478,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,497,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,048,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,647,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,429,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTAzOQ_9c8b4c6a-3c58-402b-a6e7-47b3ea64c2d4"
      unitRef="usd">1800000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTA0Ng_fbd0241b-87ed-43b2-b082-f3a29182f9ec"
      unitRef="usd">1400000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="iaf738532e4694162b9ca0c676b7e2bfe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTYzOQ_40d93cb4-f979-451d-b4a2-1d53bd014124"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i227ccd5f3c584c1f80be5a81980484aa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTc4Mg_3b8d3b79-a16d-4be3-8db9-1632a67e939b"
      unitRef="usd">3000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTk0Mg_d75b9012-aff3-4e4e-bd33-a88b6047999b"
      unitRef="usd">7500000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMTk0OQ_3296865c-4403-48c1-8a72-6da692ac3804"
      unitRef="usd">9000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoods
      contextRef="iaf738532e4694162b9ca0c676b7e2bfe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjA1NA_529e2a1c-1d7c-4f15-a927-aa0c3525804d"
      unitRef="usd">500000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNoncurrent
      contextRef="i0a588281c96f412e8750a46d0cf78bff_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjEwNA_04404f34-f8bf-4555-aa0c-d17c22d69a07"
      unitRef="usd">200000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i1f654c5250f1487a87a937cdbf000493_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjExMQ_a66b7dc5-06d5-445d-af6c-3cef9fb7a94c"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RleHRyZWdpb246NTczMGQ4MjUwZmY2NGYzNjg2MDE3NDU5YjQ4OTZmNjhfMjMxMw_931f64a2-5c55-4aa5-b8a8-7e08b1a9bdcc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022 and December 31, 2021 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,738,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,374,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,277,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,144,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,478,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,497,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,048,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,647,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,429,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMi0yLTEtMS0zMTIxMw_69c0c450-f24d-4689-8a6e-321da92f2fdd"
      unitRef="usd">11738972</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMi00LTEtMS0zMTIxMw_06849e8d-5d40-4f5a-a8fd-1bcc780a6a14"
      unitRef="usd">12374983</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMi00LTEtMS0zMTIxMw_3220e695-4e04-41eb-b175-6e5702651c14"
      unitRef="usd">12374983</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMy0yLTEtMS0zMTIxMw_ddd102f3-9b39-4f74-85e1-5ffab49dde50"
      unitRef="usd">128168</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMy00LTEtMS0zMTIxMw_8d3493e1-c881-450f-80b0-fca7e76df105"
      unitRef="usd">164378</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfMy00LTEtMS0zMTIxMw_d4fc08c7-5f48-4dc2-82b6-0b145294eff8"
      unitRef="usd">164378</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNC0yLTEtMS0zMTIxMw_51331cbf-5c91-440a-9dcb-ea07a77597c8"
      unitRef="usd">6277745</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNC00LTEtMS0zMTIxMw_2f65b052-e3d0-4f80-8e62-411c350814ff"
      unitRef="usd">4939088</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNC00LTEtMS0zMTIxMw_ebbf2965-409e-4c5c-afef-24f690e2cb07"
      unitRef="usd">4939088</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNS0yLTEtMS0zMTIxMw_c310ebb0-043a-4fc1-8964-33f3f3594725"
      unitRef="usd">18144885</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNS00LTEtMS0zMTIxMw_fae64f53-db61-4798-8e1b-3706edef91af"
      unitRef="usd">17478449</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNi0yLTEtMS0zMTIxMw_08de56f8-9996-4fd9-a325-107aa5392ed9"
      unitRef="usd">7497356</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNi00LTEtMS0zMTIxMw_d19a1ca9-b20b-41bd-9864-d4ca7040761f"
      unitRef="usd">9048567</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNy0yLTEtMS0zMTIxMw_aa2cbf65-e907-4da6-9d41-512a24f06971"
      unitRef="usd">10647529</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80MC9mcmFnOjU3MzBkODI1MGZmNjRmMzY4NjAxNzQ1OWI0ODk2ZjY4L3RhYmxlOjJmYzA2M2UzMDg4ZDRhZjJhMGE4MGIxNWYxZDg0MmYzL3RhYmxlcmFuZ2U6MmZjMDYzZTMwODhkNGFmMmEwYTgwYjE1ZjFkODQyZjNfNy00LTEtMS0zMTIxMw_2396e96f-a9ea-438d-ac18-eba96e55b0ca"
      unitRef="usd">8429882</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg1MA_9530b94a-65b8-42d2-9ce5-b3d049a38843">LEASES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease expired in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at September 30, 2022 is 0.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the &#x201c;Leased Premise&#x201d;) at the new Broadwest development located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each.  The Broadwest lease calls for monthly base rent, operating expense and parking payments. In year 1, the base rent starts at $33.06 per square foot of rentable area. The lease also provides for several months of free rent plus a tenant improvement allowance.  Cumberland received approval for its building permit and began construction on the Leased Premise in June 2022.  On October 25, 2022,  Cumberland received final building approval and a certificate of occupancy for the Leased Premise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million and will be paid through the leases ending in October 2022 and April 2023. Excluding the Broadwest lease agreement, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ie91cbfa298a24c6db40c5463641c9886_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfOTQ_efede379-9dda-4d19-b140-095137968688"
      unitRef="sqft">25500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i658044c887034a83bdb045b4fb42ca2b_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMzAw_cf004c99-389e-4c83-a355-13e335396e10"
      unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTI0OA_d2b69b16-8a66-44a6-b82e-12ed283f88eb"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTMwMw_395dc84a-67f8-4ce1-a1a9-9aa10db9b672">P0Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:LesseeOperatingLeaseLeasedArea
      contextRef="ie795a7e8b44749c2b64904584da6bf32_I20211115"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTQxNw_76fa705a-a887-4468-9507-92f5565259a1"
      unitRef="sqft">16631</cpix:LesseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie795a7e8b44749c2b64904584da6bf32_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTcxMg_e458e5a3-46dc-4aed-a39d-18afba9dd828">P157M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cpix:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="i89ea0a5e1de9410b819fbb525f8f78e1_I20211115"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTcyOQ_9166e799-d06e-497d-82af-2d5a14a76c8e"
      unitRef="renewalterm">2</cpix:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i89ea0a5e1de9410b819fbb525f8f78e1_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTc3Nw_3ee98b6d-992f-4bc9-b790-16672ab54213">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cpix:LesseeOperatingLeaseBaseRent
      contextRef="ie795a7e8b44749c2b64904584da6bf32_I20211115"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMTA5OTUxMTYzMTc5OA_9cff46b2-2337-40dd-9d99-6effbe9ef0f3"
      unitRef="usdPerSqft">33.06</cpix:LesseeOperatingLeaseBaseRent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg1MQ_041c233f-60b3-47b2-a237-3c90f400dd3c">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjMzNzgzM2UxYTkxNTQ5MDNiMjA4NjQxZjNjYTMxY2NkL3RhYmxlcmFuZ2U6MzM3ODMzZTFhOTE1NDkwM2IyMDg2NDFmM2NhMzFjY2RfMS0yLTEtMS0zMTIxMw_4c6be4f7-8d44-44c1-88f4-0f811571e047"
      unitRef="usd">219850</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjMzNzgzM2UxYTkxNTQ5MDNiMjA4NjQxZjNjYTMxY2NkL3RhYmxlcmFuZ2U6MzM3ODMzZTFhOTE1NDkwM2IyMDg2NDFmM2NhMzFjY2RfMS00LTEtMS0zMTIxMw_50a1a127-27ab-4c27-869f-edb8da782546"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjMzNzgzM2UxYTkxNTQ5MDNiMjA4NjQxZjNjYTMxY2NkL3RhYmxlcmFuZ2U6MzM3ODMzZTFhOTE1NDkwM2IyMDg2NDFmM2NhMzFjY2RfMS00LTEtMS0zMTIxMw_94b25b70-349e-4dfc-91c4-a65aa019399b"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMS0yLTEtMS0zMTIxMw_fae870b7-88c0-4e2d-bccd-696b7b365908"
      unitRef="usd">229605</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMS00LTEtMS0zMTIxMw_6bd4c061-9d46-4a31-9335-8006051693ec"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMS00LTEtMS0zMTIxMw_e4791503-bad7-4c73-a3ca-c6b9c40b6ef2"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMy0yLTEtMS0zMTIxMw_ee46a639-e498-4589-8366-1ec35f9fada5"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMy00LTEtMS0zMTIxMw_1bc6210e-fc2d-42ee-8bda-a97c92ca1368"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfMy00LTEtMS0zMTIxMw_2c34c072-4e86-43b8-ae5c-e6132f1201b6"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfNC0yLTEtMS0zMTIxMw_aec57555-ef44-4ded-8f53-79eab4436262"
      unitRef="usd">229605</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOmY1YWQyNTVmMjRiZjQ1ZDdhZGRhMjY4MGRiYjFhZmQyL3RhYmxlcmFuZ2U6ZjVhZDI1NWYyNGJmNDVkN2FkZGEyNjgwZGJiMWFmZDJfNC00LTEtMS0zMTIxMw_4afedfdc-3433-4aa2-a25c-363312b22c0c"
      unitRef="usd">1059693</cpix:LeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjM0Ng_8519010c-8647-4dd8-9b3b-24e649891526"
      unitRef="usd">200000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg1Mg_0289bf2f-d2c4-447d-be8d-c5a66ed84ec6">Excluding the Broadwest lease agreement, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfMS0yLTEtMS0zMTIxMw_bfe6192f-1904-4467-b73a-33c84db78d22"
      unitRef="usd">150533</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfMi0yLTEtMS0zMTIxMw_f1659c70-368b-42ff-936d-8552f7ea29ee"
      unitRef="usd">92477</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfMy0yLTEtMS0zMTIxMw_0826d265-5071-415c-86b2-2c8e0edefa60"
      unitRef="usd">243010</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfNC0yLTEtMS0zMTIxMw_3e5d16f3-765c-46b5-bda4-9ceead9babe0"
      unitRef="usd">13405</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjJiMjQ1ZTZhODk4NjRhZmQ4NzQ0NDU5NDdkNzNkYjVmL3RhYmxlcmFuZ2U6MmIyNDVlNmE4OTg2NGFmZDg3NDQ0NTk0N2Q3M2RiNWZfNS0yLTEtMS0zMTIxMw_6863efc4-1646-4636-8d03-7243b08685ec"
      unitRef="usd">229605</us-gaap:OperatingLeaseLiability>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RleHRyZWdpb246NWYwNzM2OGUyODMwNDFhYjliYTQ2YjdiMTBkZjhjMzBfMjg0OQ_13cde049-ec10-4323-9b1d-ce2a6fbcdca9">Rent expense and sublease income were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfMi0yLTEtMS0zMTIxMw_6a8fbbee-7dd0-4471-9a15-d62bdd7e9845"
      unitRef="usd">861398</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfMi00LTEtMS0zMTIxMw_d880fbe6-552f-4a0c-bacc-3743dc018383"
      unitRef="usd">910975</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfNC0yLTEtMS0zMTIxMw_5f20ad41-3915-4fd2-b929-315e4f73618b"
      unitRef="usd">424632</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80My9mcmFnOjVmMDczNjhlMjgzMDQxYWI5YmE0NmI3YjEwZGY4YzMwL3RhYmxlOjg1YjhjN2FiNGQ0MTQxOTZhYmYwOTQ5OGMxNWIyYzNiL3RhYmxlcmFuZ2U6ODViOGM3YWI0ZDQxNDE5NmFiZjA5NDk4YzE1YjJjM2JfNC00LTEtMS0zMTIxMw_f259dfcc-6bbe-4561-b5f1-cc430ac18025"
      unitRef="usd">526868</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNjE3OQ_c9151383-0b52-478a-baa1-402ba9ced7f7">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the nine months ended September 30, 2022 and September 30, 2021, the Company repurchased 290,576 shares and 326,537 shares of common stock for approximately $0.8 million and $1.0 million, respectively.  At September 30, 2022, approximately $3.9 million of common shares was left to repurchase under this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  These purchases began in April 2022 and as of September 30, 2022, a total of 27,698 shares have been purchased through this trading plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the nine months ended September 30, 2022 or September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants and Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022 and September 30, 2021, the Company issued 65,225 shares and 36,850 shares of restricted stock to employees, advisors and directors, respectively. Restricted stock issued to employees and advisors generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the nine months ended September 30, 2022 and 2021, the Company also issued 172,300 and 174,800 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in 2032 and 2031, respectively. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.  For the nine months ended September 30, 2022, we recorded a credit of $0.1&#160;million to share-based compensation related to the forfeiture of unvested restricted stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the quarter ended September 30, 2022, we were in compliance with the Funded Debt Ratio financial covenant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15&#160;million to $20&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement.  The Fifth Amendment extends the maturity date three years through October 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 5.25% at September 30, 2022.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December 31, 2021, the Company had $17.7 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the line of credit are collateralized by substantially all of our assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i73e648d1756d4361ac4f73a357526bb6_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTMw_98901114-7c93-49e2-a7ff-997101cee93a"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i9a5078dc2e454b1ba6c7f4e344e79a4b_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjkx_d0b9dec1-f587-4f91-bbb1-62a7e8ca5767"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0dfb60514b2a4bfba647a1772e5f8bad_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzk3_8c503148-bb3d-4033-a5e2-7026ebe74f1f"
      unitRef="shares">290576</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib2c5bbf3a46c412fbe0e400fa873a864_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDEx_ec3392e4-920e-4c4a-8960-3a102ba999e7"
      unitRef="shares">326537</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0dfb60514b2a4bfba647a1772e5f8bad_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDcw_dde0d428-95ca-430f-a65c-e81fa305bbc9"
      unitRef="usd">800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib2c5bbf3a46c412fbe0e400fa873a864_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTQ5NzU1ODIxMDc4_808bdb6d-be9e-472b-8eb8-d281bf063f68"
      unitRef="usd">1000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ic33219167c744508bf085d2ae2eba1dd_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTA4_b006f79b-116b-4fd8-86b7-c9b9e847ecdf"
      unitRef="usd">3900000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i9f068611586b404c9e736da8397fb6d3_D20220401-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTQ5NzU1ODIxMDA5_3b07d29f-b743-45d7-871d-d7010ef5b7da"
      unitRef="shares">27698</us-gaap:StockRepurchasedDuringPeriodShares>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i8b9a83dbeb504232888f1be955d3484a_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTA4MA_0361aa11-8e23-4ee0-85ec-7ed1f63759b5"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="icba3428fcf7b4d74a47c2ef785d2fa87_D20211227-20211227"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTY1OA_c4568b81-0d37-4d1d-a784-4dd776fe7ad8"
      unitRef="usd">19000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia9a3f9de6fd74bcc977d7a494dfd0845_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTk2Nw_d1688aaa-e0bb-4097-af9d-6f0be357c6ec"
      unitRef="shares">65225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if26fc6a73ecc488bbe41fa9905a8441a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTk4MQ_5c459b8d-4c02-4045-948c-e323b5880054"
      unitRef="shares">36850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7c80572bb63c43f3a1049c338dfc7e8e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNjE3NA_cf0e0c1d-5a32-4cb5-958c-a186b560d7f1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia41636d373054e1b8b162bc68c25ba1c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjI5Ng_c82b8c9b-7eec-4885-a87e-f546dab37bbd"
      unitRef="shares">172300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i94d70987e1124eccabfc3d8e4dec7545_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjMwMw_cfe21664-29a3-446e-8d8d-6c33ddc23986"
      unitRef="shares">174800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia9a3f9de6fd74bcc977d7a494dfd0845_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMjY1NA_37dd7089-ef40-4676-b84b-eb7c322f82a5"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <cpix:DebtInstrumentCovenantUnrestrictedCashThreshold
      contextRef="ie71841d6d5c24f758fab7ac85872aa45_I20220929"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTA5OTUxMTYzNTE3Nw_58a6be3c-2d43-4323-a34c-486c3bd72b0c"
      unitRef="usd">8500000</cpix:DebtInstrumentCovenantUnrestrictedCashThreshold>
    <cpix:DebtInstrumentCovenantEvaluationFrequency
      contextRef="ie71841d6d5c24f758fab7ac85872aa45_I20220929"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMTA5OTUxMTYzNTE4OQ_73f34a73-997c-46fd-89c2-acfc9d400736"
      unitRef="q">4</cpix:DebtInstrumentCovenantEvaluationFrequency>
    <cpix:DebtInstrumentCovenantFundedDebtRatioMaximum
      contextRef="i357c94714cfb4fd08c6fffaa13a6c200_D20220401-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzAyMQ_50ed9649-9b8c-4045-9377-2e4c7a739abd"
      unitRef="number">3.00</cpix:DebtInstrumentCovenantFundedDebtRatioMaximum>
    <cpix:DebtInstrumentCovenantFundedDebtRatioMaximum
      contextRef="i13f82082fed14f898c9cf04f1b98af86_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzA3OA_884d1be7-eea6-459c-b6d4-267b53c94699"
      unitRef="number">2.50</cpix:DebtInstrumentCovenantFundedDebtRatioMaximum>
    <cpix:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="ie39e421790ed488e946469a82c5d37a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzg5NA_d1370502-95ed-45d2-ac53-3bc2e2805b9e"
      unitRef="usd">15000000</cpix:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="ie39e421790ed488e946469a82c5d37a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfMzkwMA_0d02bd45-8f6a-41eb-8f9a-0983407df914"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i88065d8df8544ba4bf056f4d71ec695a_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDY2Ng_5bfd8995-fd16-4476-96aa-dd2c4f04e0ee"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifedf271cc67e434abd3401e7acffd33c_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDY3Mg_d0850c94-e37c-4590-a85f-666a57e503e7"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iede01fe31ea346b4918f9f4d3d001891_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDcxMQ_f784b0c8-8bd7-431a-b248-c511bc83a216"
      unitRef="number">0.0090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i31108d31c0b44f30a2b52b23201aea12_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDc3Nw_2d96bbf0-68c4-4c52-b349-297b84feac52"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="iceae2fc3bfa449c5bb629a222d37c37f_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNDgxMA_22cfc065-f8bf-4753-93a5-61948ac4344a"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="i866dc2144f804589a64b1eb2c037834c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTEyOQ_47cb8fff-52a4-4f08-9541-5317bd9bbed2"
      unitRef="usd">17700000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="ib7b8b6a29c9c47378dff87ffe5a15a48_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTEzNg_acfbc7f5-e226-449b-97d0-e56df4b673d3"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i7a44e5571a0d436ca5db214ef0319e3e_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTc3Ng_bcf48797-9479-4ccf-bc56-4fc748920e23"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i319a720f5704435caf765b6497b99cd9_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80Ni9mcmFnOjI1MDdiOGViMWZmODQyYzE4YTRkNWZjYzhlMzg5ZjQ2L3RleHRyZWdpb246MjUwN2I4ZWIxZmY4NDJjMThhNGQ1ZmNjOGUzODlmNDZfNTg1OA_874892c2-7ff4-4350-b386-8a73b34ffa3b"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80OS9mcmFnOmI3MzRmMDRiNzQ5ODQyZTc4Zjk3MjQ4MDFlZTFkZDBmL3RleHRyZWdpb246YjczNGYwNGI3NDk4NDJlNzhmOTcyNDgwMWVlMWRkMGZfNjM1_17e4fe66-2526-442c-9b43-96aa068c4825">INCOME TAXESAs of September 30, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i5877b735a5424506a5da1c44d8a26339_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80OS9mcmFnOmI3MzRmMDRiNzQ5ODQyZTc4Zjk3MjQ4MDFlZTFkZDBmL3RleHRyZWdpb246YjczNGYwNGI3NDk4NDJlNzhmOTcyNDgwMWVlMWRkMGZfNjI_a5f207f4-f533-45a7-a848-4c8ec207f9b6"
      unitRef="usd">56600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i16ada3ab868247dd9574797af517d567_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF80OS9mcmFnOmI3MzRmMDRiNzQ5ODQyZTc4Zjk3MjQ4MDFlZTFkZDBmL3RleHRyZWdpb246YjczNGYwNGI3NDk4NDJlNzhmOTcyNDgwMWVlMWRkMGZfMTMz_978a6266-f197-4242-bec0-4595fa420c6f"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81Mi9mcmFnOjJiYjMyMzY3MzNhMzQxZDhiMjE5NDAyNDMwOTk1MmFiL3RleHRyZWdpb246MmJiMzIzNjczM2EzNDFkOGIyMTk0MDI0MzA5OTUyYWJfMTU4_e945900f-05f3-47a1-b97e-943f83b3fede">OTHER INCOMEThe Company realized a $0.6&#160;million gain in the second quarter of 2022 from insurance proceeds for a Company owned executive life insurance policy.</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:InsuredEventGainLoss
      contextRef="i59b5281c659f4863940553cc78d0c93d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81Mi9mcmFnOjJiYjMyMzY3MzNhMzQxZDhiMjE5NDAyNDMwOTk1MmFiL3RleHRyZWdpb246MmJiMzIzNjczM2EzNDFkOGIyMTk0MDI0MzA5OTUyYWJfNDU_ecc6cff7-f8f5-43f1-9f01-9ddd11a41636"
      unitRef="usd">600000</us-gaap:InsuredEventGainLoss>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81NS9mcmFnOmU5NzI3ZjYyMjU4MTQzODVhOTQyMWIyOTBjYjYzZjBjL3RleHRyZWdpb246ZTk3MjdmNjIyNTgxNDM4NWE5NDIxYjI5MGNiNjNmMGNfMTAyNw_36ffbcc6-49a6-4ff1-8d9c-955685de309d">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwOQ_5297fc34-efb1-47b0-ae0b-f4b0dd44e17d">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $4.8 million was accounted for as $1.9 million of other current liabilities and $3.0 million of other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 resulted in a $1.0&#160;million milestone payment due to Nordic.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after March 31, 2023. Cumberland will continue to distribute and support the product until then.  In accordance with the terms of the amendment, Nordic has agreed to return the 180,000 restricted Cumberland shares we previously issued to Nordic which will be cancelled, refund to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand's U.S. approval and issue a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sancuso Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#x2019;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#x201c;CINV&#x201d;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#x2013; including its marketing, promotion, distribution, manufacturing and medical support activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was funded by cash and the Company's revolving credit facility.  The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year.  The estimates of fair value for the more significant assets and liabilities assumed were as follows: prepaid expenses $0.3&#160;million, inventory $5.2&#160;million, goodwill $1.0&#160;million, intangible assets $12.1&#160;million, milestone payable $1.2&#160;million and contingent liability $3.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $4.5 million was accounted for as $1.9 million of current liabilities and $2.6 million of other long-term liabilities on the condensed consolidated balance sheet as of September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as discontinued operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTY5_342c9a25-d8e5-45a8-85e1-185a80c42713"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTAxMg_0197f4fd-4b51-4b8d-aac5-4ceec8b9838d"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTExNQ_1442895e-f619-457d-9811-80fca5a5d673"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <cpix:TieredRoyaltyPaymentsThreshold
      contextRef="i2989d3daeec84e4e958c640e75c18aa4_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTE2NQ_56d9ac58-a21f-4de8-b8c9-237e6370b435"
      unitRef="usd">2500000</cpix:TieredRoyaltyPaymentsThreshold>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwNA_c958c243-48b8-45f2-816c-9cb18dcca1ae">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,819,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iaf738532e4694162b9ca0c676b7e2bfe_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfOS0xLTEtMS0zMTIxMw_9230aaf3-68cc-4b9c-85bd-8eb287fd1dd9"
      unitRef="usd">6515627</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTAtMS0xLTEtMzEyMTM_ed5c7c8c-8e7c-4d00-bb49-b75a748669a0"
      unitRef="usd">777855</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTEtMS0xLTEtMzEyMTM_4c0da4f3-21b9-461f-8d62-24cc0206129b"
      unitRef="usd">-1550241</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i4341d8f4411f447b973347e506a3b6af_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTItMS0xLTEtMzEyMTM_c3a6a76b-ee18-4831-b7ca-a8ef191addcd"
      unitRef="usd">631608</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iea269d83c37d448a868f5ac00213446b_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmU3Y2U5YzQzMzQ2MjQ2N2U5YThmMmI1N2EyMjhkZjZkL3RhYmxlcmFuZ2U6ZTdjZTljNDMzNDYyNDY3ZTlhOGYyYjU3YTIyOGRmNmRfMTMtMS0xLTEtMzEyMTM_d47cd6da-87ac-4d32-a5b3-bfc3018cdc7e"
      unitRef="usd">4819139</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iea269d83c37d448a868f5ac00213446b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTg5MQ_4b8833d2-5db4-4aad-a335-b5c9136e5acb"
      unitRef="usd">4800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iea269d83c37d448a868f5ac00213446b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTkxNQ_b11f9444-770b-478f-b662-1743a3060e53"
      unitRef="usd">1900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iea269d83c37d448a868f5ac00213446b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMTk1MQ_2278b9aa-4861-42d5-a80b-8cc14a8547b8"
      unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if9529ac6603c4a1f9da2fbbe9d90afe8_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMjQ0MA_f4a01342-a274-4efd-bd5a-cee4a077fae3"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="if9529ac6603c4a1f9da2fbbe9d90afe8_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMjQ3Nw_68f265a4-9724-42c1-a719-cf3a7f72e03d"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i767388330a25494b84c7b1f3f5e31ca9_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMjUxNg_a437a9f0-e9f7-45ac-8905-21c3e1b7766c"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i767388330a25494b84c7b1f3f5e31ca9_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzEyNw_59e445d1-5e16-4da6-b202-ac2a5ad12904"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i1b15f1a6a0214d9db3c1f1b2e95e05e9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzI0NQ_216350a2-19be-4773-9581-db1c63da6697"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ida016a3372fe4bd9999e6c19613c11af_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzMwNQ_d2e924f1-2a26-44e9-9b31-78c7812d09db"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib33917577d8c413092ed9270c4c1e044_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzQ1Ng_0fee642f-d093-4f08-bf41-9a89e5a8bece"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable
      contextRef="iba57519128a042e6bcc12053ad575901_I20220712"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfMzkxMg_4e121989-9cf2-4d1e-9608-7221a12673c7"
      unitRef="shares">180000</cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable
      contextRef="i14fe005a15a14d999173b7903bf4a67e_I20220712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNDAyMA_3359400b-27f0-462f-94e7-8275b5133e9e"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue
      contextRef="i14fe005a15a14d999173b7903bf4a67e_I20220712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNDEzOA_828df07d-2e28-4ab6-a53d-c97cd636ca90"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue>
    <cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="id20273d5a5164f0589d2524268988a2a_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNTc1NQ_4456987f-5d44-4b61-a2c9-67a542d39e6c"
      unitRef="usd">13500000</cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="id20273d5a5164f0589d2524268988a2a_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNTg0NQ_6e87838f-953f-45fd-844f-c7f0d3a5074b"
      unitRef="usd">3500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected
      contextRef="idfa76b73d21648f5a7205032b91c3205_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNTk0Mg_939c8fb3-e9b6-48a2-bc8d-30bf790e6e6b"
      unitRef="usd">1500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected>
    <cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="i134a7c60cd4344ffbbd3642de16ac052_I20220103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjA1Nw_667844c6-aaf1-40d6-9703-f6a06e3b85d8"
      unitRef="number">0.10</cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjg3OA_f6a6df6e-d219-4ac8-98a9-8a26d3fc0dee"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjg5Mg_5573a9b1-a362-4ca1-bf94-a5a6d75ed128"
      unitRef="usd">5200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill
      contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjkwNQ_306d6aa5-0a48-4a43-8fef-f43c1d0bffee"
      unitRef="usd">1000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjkyNw_8f8117b0-2002-4bec-ba7f-fdc35790b48b"
      unitRef="usd">12100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="ibbe5febaa0764ac187ee7a439033f2cb_D20220103-20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjk0OQ_edbedcba-6698-4a6d-96be-427ae20aa6a0"
      unitRef="usd">1200000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNjk3Nw_38d185c1-b2df-41ee-a1ba-34c8c13307ec"
      unitRef="usd">3900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i16021fcc1ba042c6952a72b0e414e233_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfOS0xLTEtMS0zMTIxMw_4568b627-a815-4067-b405-d8524601216a"
      unitRef="usd">3946716</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTAtMS0xLTEtMzEyMTM_ba08683c-de08-4a9f-9ce3-e137f75f451f"
      unitRef="usd">339721</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTEtMS0xLTEtMzEyMTM_d9d7c436-bdfd-4186-bfa7-80e731173762"
      unitRef="usd">498333</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTItMS0xLTEtMzEyMTM_f9dbfaf4-3fff-495b-8ef7-e842f8e31753"
      unitRef="usd">430317</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7092e7f4631046c394046d8e01666761_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOmMyNWFmZjBlMzg2ZDRjZmZiM2M3NTdiNjdjYmQ3NDg5L3RhYmxlcmFuZ2U6YzI1YWZmMGUzODZkNGNmZmIzYzc1N2I2N2NiZDc0ODlfMTMtMS0xLTEtMzEyMTM_a64858d8-8c8f-4fe1-9397-f041cc4046bb"
      unitRef="usd">4535645</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7092e7f4631046c394046d8e01666761_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNzI4MQ_b1d4feb0-4c25-467a-a2f3-5e2ea127f21d"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7092e7f4631046c394046d8e01666761_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNzMwNQ_af430b14-f6da-49e1-b5c1-80e3362d8270"
      unitRef="usd">1900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7092e7f4631046c394046d8e01666761_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfNzMzNQ_35619baf-18b7-403e-8a55-da56c8711e65"
      unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i2f1475f8cb974dc2b812258f6b108a91_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODU3Nw_36e59a0a-e9ce-4649-a011-5c683d16f9ae"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <cpix:FinancialConsiderationPaymentPeriod
      contextRef="i5d73c406eebd400ab792cf31e23c80e5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwNg_46e6d26c-7dcb-48d1-bd96-bdac3e0b2557">P2Y</cpix:FinancialConsiderationPaymentPeriod>
    <cpix:FinancialConsiderationNumberOfInstallments
      contextRef="i0213cec992ab4b93b597378f304014b2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODcxNw_22fa8341-0f56-4bbc-a1e2-4c892f1ef838"
      unitRef="installment">4</cpix:FinancialConsiderationNumberOfInstallments>
    <cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment
      contextRef="i0213cec992ab4b93b597378f304014b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODc1Mg_6d3adfd4-1c6f-4d1f-a06d-759ec9d1ca22"
      unitRef="usd">3000000</cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment>
    <cpix:FinancialConsiderationNumberOfInstallments
      contextRef="id09c93443a82400e9a283705c01948ba_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODc4MQ_cd29ce93-b970-4cb3-8e34-f4f8badb32cc"
      unitRef="installment">4</cpix:FinancialConsiderationNumberOfInstallments>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i0b3b7c2e16664c71bf1bf299d2abd068_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfODgwNg_d6a9646e-499a-474b-969d-98f58c8a2b67"
      unitRef="usd">2000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RleHRyZWdpb246Yzc5NTBhZmQxMjc1NDgxYzkxMTNlNzE3YTgwZmFkMGJfOTUwNw_74a62f51-2dc5-4076-bb17-6494088cb006">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi0yLTEtMS0zMTIxMw_a366bf5a-6c37-4c1d-9d11-3a1aa767af75"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie05f749180e74d81bb559a43fbd2d9c7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi00LTEtMS0zMTIxMw_fb028702-2690-4ef2-bee4-8184ef6fc3c4"
      unitRef="usd">496787</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi01LTEtMS0zMTIxMw_5ceaead0-f754-4cc5-afe8-90c915a6320f"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i57ae8e07dfc9494cba9f1a7c04f4c592_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMi03LTEtMS0zMTIxMw_e6c4ce79-b1ed-43e7-9e29-5b9a601883b9"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="idb344f54d56f4e8fa0bcc0e5e31b52e9_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy0yLTEtMS0zMTIxMw_0c09155e-a4f9-4dd0-90ec-c5a86fca511d"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i50b37e261fb14120ab86fd7d766694c8_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy00LTEtMS0zMTIxMw_ce0b151a-08bc-4b95-8b41-a31c7b09650d"
      unitRef="usd">496787</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ib806724dc82b467680c5d90135d516b1_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy01LTEtMS0zMTIxMw_17ace65c-60cc-4926-a28f-2387c1c1f7f2"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i98818e47614047d287fd5c789ac7559e_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjlkOGI1MjI5Y2JlNTQ5Y2RiOTk0MjVmZmNmYzkwOWQwL3NlYzo5ZDhiNTIyOWNiZTU0OWNkYjk5NDI1ZmZjZmM5MDlkMF81OC9mcmFnOmM3OTUwYWZkMTI3NTQ4MWM5MTEzZTcxN2E4MGZhZDBiL3RhYmxlOjFjNGEzYzc4ZjMyODQ0OTVhNjc1ZWRkM2ExZTE4MGY2L3RhYmxlcmFuZ2U6MWM0YTNjNzhmMzI4NDQ5NWE2NzVlZGQzYTFlMTgwZjZfMy03LTEtMS0zMTIxMw_d21b0546-7c36-4218-9bce-b9a1b4290117"
      unitRef="usd">1491004</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M+/?PT-P?[6*UQPGG,#I>970\NT]YR[C?QZVE/"'W:%QZV(/:,E:FQ[-[E0D
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MZ_NHDE#H1(VM:$[5\G2K96!R[;T>]1?..$-C;M<.(Q*32?!!MG!8MSZWJU6
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MX];]B;C^PNA-=^3K7ANCU]W'E<J@;+8 ^'ZIM7F^:#O8GTN\^1-02P,$%
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MX/N5@':R_Z ?</@!QO(?4$L#!!0    ( ':);E7[[+%W(PP  '1N   8
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MPC.1"BK=/H]*?5AJ=EL8[B-A\!M.JD_[[T.7ID$N]=CLG@LYD%1+0G/F)=4
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M?_A^)(/V_*7Q*_Z9%J"J\35_7!HPUT +<)_FL/D+'=#];N_D?U!+ P04
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M*F&50FPJN.1-,%6A9,O.U(]?WK][F2R#,G"'E3T7:#391FBH#L3*OO!#I8,
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MMY_Q[OCE[+3[8'2[O?OL]H=@3#*(UC@:3^?YI&LYPX4WN_#Y:&6\-TU8;J5
M_'D#GJ\-IO#^@A6,WQ-/_@]02P,$%     @ =HEN55A4A$. !@  ] \  !D
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M\\LL'DP/09);D9G2"==M:86]FF5&P9<KDZQV*S7^-=55:B\52R7J2B[*:MQ
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M6LB\*5R*#:JVB8OWT8CFJ*JH<1"BK BC("U#&*<G\% O.6BQNPURT*% @/(
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MO8KD_6#OXTK(WJ-NFW9F.H,DB0DJFXD;-=?$UUS1\8\JL[C=&\'C81$AOKJ
M^MXF&E&9KIY3 )'6#1^MTASV)]85%F(QKG$1P[5K70KE5"69I#A1LUG,$Q+3
MXJ!CD%(0,O/LM*RDU ?6R"32!C'[&1W7R\[D[GWGE9@I&4I'E")I#CJEBI5J
MKU(LHG/9R"D,SJ,@N"]1'N[)+(<_C,9B3;S&)^<]<0,T'\5OYS< />FQV+*
MY0&_2"(IF-IX"K"*RT0<:DTJ?Q@ F3+"NUT ,"Y54OMTB/A9+C16^!KLAH.>
M^-B>?[2+$.O <"IC/4 ?3%FE9YNR: 7[UIBJ!UR/!@HO[2E?$[4RER*9XI3Q
M X!SBHHYA/N*A!CK=B@UK+>.%!@$C.]I#%0(VI2*(^#N?<O?,4':GNE6KJ%0
M6-HR2V- ;(8#*:Y:=+]94M=U274JC W5+'I2S8S\6ZF5?F/=0E'9+ELP!;45
M&)%38IK_[B1Q)N$-V^ 6<ODM$^;'@FOF_Z5DLK&I.!QWA\/Q6K$\[!Z/^RWP
MW$KCR., 6.5%9A\59U5ZKST5!YJ<UJ5BLTC>; JIUF_+BNQ:BYLK0^4)M3/)
M]&RV=P\)GFB-K)C9TG$:&\AWGE*C(G/*.[J>$ZPLD<I[HU<MP!JU]ZBD^Z\B
MOJ]AV<8[DETT>G T[([ L31R<'30/<:U;GP?\;'1]^LX=M?QXC18H?.-X'0K
M1G7$ZUR4U4,!G(@6AOU1;<AHL.G+&)S()VQ^?61]S,0UIA(#H(P:<C1WPC0,
M8$?.K'Q:.1H[MJINP.I&0K0!I)#2?4I7WF8Z\BGZTK!J,K#[=G5;":;]:A>!
M;ZDY1UWCPB/0-J2:%43C-VA*7]WC[$UE5*1E<$VL&!,A=S.EF;:(^PRY V^W
M4D<NT6I0$TS;JTE3@4#H*RV')[66[?A9:[WHQ0=<+<0$\U.643V^4?<V8XZ^
MB%:]LT1@Z\7NDS9&)F#Y<VD^BY?DJ)S!BFMVFO?-/-1A+!#+&H_YK61PV9 ;
MPH3>YTI&][%;"(J7^M7:4-0(SR-D;LL8%'^8%DP7TB\H!M1#0B/))<?=<;_?
M[>,_+?%20^+5^?7=Y:0KN%X"%T02.3*V#S"$YBF)BCK3/D&\?4'QQ#!*$-1$
M"_<"'TH3\?+@5?,6;M:M2*H?/QM%2Q43AH(CTUPLFSJZ#=%,&PS1DGJ5>V68
M7N#[MR5B=B7V6;=?T4G*_\;O!0$70DUN[R5V*V6^V[-3I*3,DC)&_1:.>VL8
M5A,, L+&QLV(40\DA^<#^IU5$*.?M$0%AAHZC=U&)88=OR+3WGA]*KNV7A%R
MT/7/<,E8Q@T/D=8VF"1L'8(U>-%'8TOT75G%^S84KM@WM=+D:5"W8R'B8!'2
M&8):S)S-6<9V-FZ%%V;=8<.DIQAU(0M-NY"G0R[N=.(6R\<0SF6J.(/)8;QU
M12<7MZY.S>B8D-?4 !*7C6JWD%VBL,GD2ZF]#MSGM=O3RA&;Q?!Y1[!U>O95
MCOA@@ZH"".KHA^_Q'O*72H%;VT16)QC KJ"*U= 5<Z^M_?-B,&[7BQ?#_JK?
M!0X?T70PIQ]_!PP25,25_!M0^%K8=L6O4<NG!\>6V3H]1T!ENV*2=R],#V_+
MC+=Y1SUQCKTA^A#( D"3<EZB31D<='D3V&6-J_:?A@!A;+1KS.+&IO^-D'GE
M=.Q;90V"C[T-;3@VT_-I(+?>-(9&)#:!CO)C;<MI T,GJ=4ZF"BHV?3-GJ:V
M,69'/-O@/1&50L%[[:J9VP$T"#9V)!CR[OK\XPTVIB5USQL2XI>(*+L^P:/]
M680Z'BWM7 #9?Z]3H,@G8[O%\K%,[VC\(X$[Y LY!<-4&L5=-AW*,_W%AYC2
M[YWT?XPJ@64RG4BBK/4%GM6-HFS<&])RN\[=^+13IBE3$9W(S)2*Z](45#QV
M!$$(^G/S""(M59J2(*6383Z?8Z>3M$JSFF+:XT@VGX')1S:C*DG4(Y.!!>YT
M??K#QPU5Y02^W-TPUU?M"QY3_JTC,54F6= I1MW;%%97[!\1Y5$PAKKGI.I'
M47E3M#W5KAI+WE=H&L2H& S980=5C]P3DR>.LZK/ ,_R^$+2T>A1[VCCL'3\
MU&EIE[AV:IVS2T0A5BX#6GJ3KD*2MNJNR;VJ,Y_)1&=(*/#):NXJ3-:=QBY)
MT)P &VPV]-_ 8(H]?3FEI8+F/27^\ X"+:#TV/X B+>,[9\(,FKC5Q%WW1!7
MI*/6^=LZ]VR=*?VES1LE,UQ=\XZ W[R\A?:R0)U])=Z%E)26W(/]]>9"G&M;
M("YSF:@R(#DR;  _!=6CD;L^F^RW/F[E"O%,G_#HK -4&K]S-4^;KX23^'%L
M-3Q^8D3C!*J.Y]"GG3XRNB-<_&P7;X(M^%/9U(9@<[Y<@ B4HP%X/[/@SNJ&
M%FB^G9[]!U!+ P04    " !VB6Y5_AM>P#D#   ?!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6R-5=MNXS80_96!6A0M$%B.[&33U#;@7(KF(=T@
MR5Z 11\H<201H3@*2<5VO[Y#RE;<;2Y]D7@[9\X9<4:S%=D'5R-Z6#?:N'E2
M>]^>IJDK:FR$&U&+AG=*LHWP/+55ZEJ+0D90H]-L/#Y.&Z%,LIC%M1N[F%'G
MM3)X8\%U32/LY@PUK>;)8;);N%55[<-"NIBUHL([])_:&\NS=&"1JD'C%!FP
M6,Z3Y>'IV32<CP<^*URYO3$$)SG10YA<R7DR#H)08^$#@^#7$YZCUH&(93QN
M.9,A9 #NCW?LOT?O["47#L])?U'2U_/D) &)I>BTOZ75'[CU<Q3X"M(N/F'5
MGYU,$B@ZYZG9@EE!HTS_%NMM'O8 )^-7 -D6D$7=?:"H\D)XL9A96H$-IYDM
M#*+5B&9QRH2/<N<M[RK&^<65*:A!N!=K=+/4,V-83XLM^JQ'9Z^@?X5K,KYV
M<&DDRG_C4U8RR,EV<LZR-PGOL!W!9'P V3C+WN";#/8FD6_RKCVX4*[0Y#J+
M\&V9.V_Y0OSUDN6><?HR8RB24]>* N<)5X%#^X3)XJ<?#H_'O[VA=SKHG;[%
MOKCZ\_SC]27<+[]>WKVD[?^CEPZH!,ZGQR9'.R3U 'R-<$Y-*\P&:N% M*VE
MM>(;CGH#/QX=CX[YIFD=BD89*%&B%1H,=PCN!59X92K@3#HHA+4;;@PK8:7C
MLX7N9-C\CG$Z'1T.C"SJ72;.*Q=5V"PM-5$PKM$6RF'$DWGLA%:E0@E<(<4#
MTX4:=R.XK_F;L*TG?BC>LZH0FD7DB 8ZQP!/X%1E&%T(XWF+RM*Q(M5?%<]7
MA7*M*O',.*0+URUW$[;JN4RUAH)OOS(=!M)6;$*!LFN]QX4.9&>#E9!\$$:R
ME T9&;Z#I:ZJH[T=D83.*ZW^CL&#5Q_]O)>Q P@-C@5R1)%KW FHT 00T\9$
M4F=W-/^Q)HFE&O+ Z:*",9&O);M3HKS;SU%(A6%I/^<<HU3^EY #R34V.-F+
M]%)EI'M-JT%;Q=;,OJ@SON]?P^K0_9=]TWL^WO\ZKH6ME'&@L63H>/3A* ';
MM^-^XJF-+3 GSPTU#FO^@Z$-!WB_)/*[20@P_!,7_P!02P,$%     @ =HEN
M5?-#W0== @  +@4  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULC53)
M;MLP$/V5@5KT5%B*["QU;0&QZR(Y9$&<MH>B!UH:642X*"05.?WZ#BE;=8'$
M*6!87.:]>4/RS:35YL%6B XV4B@[C2KGZG$<V[Q"R>Q UZAHI]1&,D=3LXYM
M;9 5 21%G";)22P95U$V"6NW)IOHQ@FN\-: ;:1DYGF&0K?3Z"C:+=SQ=>7\
M0IQ-:K;&);IO]:VA6=RS%%RBLEPK,%A.H_.C\6SDXT/ =XZMW1N#KV2E]8.?
M7!;3*/&"4&#N/ .CSQ/.40A/1#(>MYQ1G](#]\<[]J^A=JIEQ2S.M?C!"U=-
MH[,("BQ9(]R=;B]P6\^QY\NUL.$?VBYV>!I!WEBGY19,"B17W9=MMN>P!SA+
M7@&D6T :='>)@LHOS+%L8G0+QD<3FQ^$4@.:Q''E+V7I#.URPKGLQE5HX%+E
M6N(D=L3HU^-\BYYUZ/05]">XTLI5%A:JP.)??$Q*>CGI3LXL/4BXQ'H P^0C
MI$F:'N ;]N4- ]_P/\H#I@I8;.@Y6[3P\WQEG:%'\>NELCO6T<NLWBAC6[,<
MIQ$YP:)YPBC[\.[H)/E\0/.HUSPZQ/[FE;R!OK]8W,'E]?SF:G%?(<RUK)EZ
M)@,QP7]C 0S>)X.33JWD0GAOK,F]0#_*#!9S30?UV##C2(<NPUU :;2D$-L8
MIG*$VN@<L;! ?8$H=UETJR@%;C!OO-M \!+W45KP_'GPTB'%>V]8HED'IUK(
M=:-<]YS[U;X9G'<>^!O>=9(K9M:4$P26!$T&I\<1F,Z=W<3I.CABI1WY*PPK
M:FAH? #MEUJ[W<0GZ%MD]@=02P,$%     @ =HEN5; P@.@+!   S0@  !D
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&ULG59M;]LV$/XK!Q4H-B"P'"=M
ML]0V8'O.%J!9 MOK/@S[0$MGB2A%LB05Q_OUNR-E)>G28-@7FR]WSSWW\'C4
M>&_<%U\C!GAHE/:3K [!7N:Y+VILA!\8BYIV=L8U(M#45;FW#D49G1J5CX;#
M]WDCI,ZFX[AVYZ9CTP8E-=XY\&W3"'>8HS+[27::'1=6LJH#+^33L145KC'\
M;N\<S?(>I90-:B^-!H>[238[O9R?LWTT^"QQ[Y^,@3/9&O.%)]?E)!LR(518
M!$80]'>/"U2*@8C&UPXSZT.RX]/Q$?TJYDZY;(7'A5%_R#+4D^PB@Q)WHE5A
M9?:_8I?/.\8KC/+Q%_:=[3"#HO7!-)TS,6BD3O_BH=/AOSB,.H=1Y)T"198_
MBR"F8V?VX-B:T'@04XW>1$YJ/I1U<+0KR2],*1LEML8)%@=FE4,DR8,?YX'0
MV28O.J1Y0AI]!^DGN#$ZU!Z6NL3RN7].K'IJHR.U^>A5P#7: 9P-3V T'(U>
MP3OK4SV+>&??P;MUE=#R;\'5< (+H[U1LA2I.'0)=PX]I9X6S ZNI!:ZD$+!
MFA:3+/#G;.N#HUKZZR6%$H'SEPGP_;KT5A0XR2S'<O>83=^^.7T__/A*>N=]
M>N>OH4\7MY\^S>:WJ]GF^O,29K^LELN;Y6^;]4L\_Q\2+-IFBTZQ6-*# "M<
M.$ PX/$>'0E5/*LFX9S052?<7H8:.&OABAJD]D&&EJ7V#"!+,I*[0SP(VSK?
M(EAG&NFEKL#6@BY@@61?4!3:*-LB0$'&?(#H!["I$78MS<F<6A6$FD*Q9>5$
MXYFN=9+:CE0'7KVG@"49.=-6-5QA&>FO&Z$4S%L*BM[#K*0+)_FX8TG\L)Y?
MK_+U9K/Z,=(T%,,!X>L 8B]<V=%8F,8*?8!:>.H/ 1VAQ& B=+2^D:F_="=)
M)3("?"C0'BN1%Y[[6'%@#Q*T0)J7-% D1,E:KK"4&X</)U :T"9 P\T]8CA)
M=*2("HFB,"V)3H*1;I3);+V C;&R@(OA!5^0ESL#I"P?61_#>(N%W/$)D<8E
M>EEIH@0HZ+QCI;Q]<S$Z_?#1@^-6Z9.(6R4KT==!-$[")E+_3OUI50U@&76*
M"5F*1I)02Z8W@[T\*XH/EJ=4 KIHG2.)M@<P&KOB%0XC>8=?6^F2@%NDJ6RV
M5(;)G$DD4M&)HWX+VK-]Y7AC,/)0+1>?U(_7@94HZ0XI8^.Q]J1YXUC6_5GO
MZ&*DNDN0M&$<0U+!:>1<[E&WD5VG'Y'3G$O1-SV:^,>N1C5&SWRJ<S]XJ1GE
M3YZ8!ET5'U(/L832:].O]F_U+#U1C^;IH;\1KJ+[#PIWY#H<?'B7I8HX3H*Q
M\<':FD#/7QS6]+V!C@UH?V=,.$XX0/\%,_T'4$L#!!0    ( ':);E5Y])"%
M-0\  !LN   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;.5::7/;1A+]
M*U.*-G&J*(J'J,.'JG38B9/X*$G.?MC:#T-@2$X$8& ,0)KY]?NZ9P ,2$JV
M-ZG4;J4J%5/@''V^?MW@\Y4I[NU"J5)\2I/,OMA;E&7^]/#01@N52MLWN<KP
MS<P4J2SQ9S$_M'FA9,R;TN1P-!@<'Z929WOGS_G9^^+\N:G*1&?J?2%LE::R
M6%^JQ*Q>[ WWZ@<W>KXHZ<'A^?-<SM6M*C_D[PO\==B<$NM495:;3!1J]F+O
M8OCT\HC6\X)?M5K9X+,@3:;&W-,?K^,7>P,22"4J*ND$B7^6ZDHE"1T$,3[Z
M,_>:*VEC^+D^_17K#EVFTJHKD_Q3Q^7BQ=[IGHC53%9)>6-6/RJOSX3.BTQB
M^?]BY=8>#?9$5-G2I'XS)$AUYOZ5G[P=@@VG#VT8^0TCEMM=Q%)>RU*>/R_,
M2A2T&J?1!U:5=T,XG9%3;LL"WVKL*\\OXEB3>:R062QN5%D5^&QFXGUAXBHJ
M!;O)/C\L<1EM.8S\P9?NX-$#!Y^)-R8K%U:\S&(5=_<?0LA&TE$MZ>7HT0-O
M5=X7XT%/C :CT2/GC1O-QWS>^('S+BN+)]:**Y-.=2:=%?YU,;5E@5CY]RZ5
MW8E'NT^D_'EJ<QFI%WM($*N*I=H[__:;X?'@V2/R'C7R'CUV^OG%]?7KN]?O
MWMZ*B[?7XN;EW8>;M^+=*_'^YMWUAZL[<?/ZAQ_O;G=)_>BYNZ7^LLO$KWH*
MNRW%=57H;"[>FJ5*IZJ BX:G/5$N%!DWE]E:1(FQ*A:4A_AO7BB%S"X1[.5"
MW"U4(9<RBY2XU"9?2&2;>++7/M[[7I0&"?RQTH7B8^>)F<H$J&!S>$U/=:++
MM0!&-2+I+$JJF*2B]0"<>U7BKYZ(-1RLIQ7YNX<OLFH&=SL%* <*-:\269IB
M[2 #Z:&0'=::2,L2.K#,=.BTP/I^>R-6B1Q+,JSJB5?&Q'S@=5'-Q46,Y*6;
M.<Z@W:OK"Z@E\[R T6*(^QMP2DX3A3VE/M#93#%@L5)T6PG,+=EHR,Y(%240
M5\!=VE06P!25^ B3^(T4RZT)%L;FNI3)@;>A$VR)PS2K>A"HUQZ59ZI*3:8E
MKX[@R41'O,;>ZXP?\@=H59$%57!Y7[PNA8QC>,B2^01L-5<D^@^%3 ]R8S5K
M%]PFRX69 ^Y['=\A;/!_B<-P?D3.CA4I$.O93$? WH/2'+!M6* 43W0,BQ_@
M9M@;QNR+JXJB,J'O%Q+"1)&IR$F!;65FI:\3).VT!H>H!0=!.F-K$7.H<AA<
MW%Z)T\&$KZ:#<H^:5B:D-9N$=&$/\PJ(!1$98E%9"P\[MII:];$B[R+2:1U[
MRC(VBQA&[U.:-.F4RI@"153YK #,PGCK.C3V1X/^ *4B25B;DD^C]"-[XOLM
M?2&Z%/N38!/^5:@\F6K.A?!*%LE:7.2%3BB_S^#AC#RL72)MVIA2/"9E< 2Y
MWZQE@A2% %5.CT>#?[ -LH.Y(<DR55O-RUB;4LX0(/QD?]2?-#*6"UAR89*8
M\BY5I;//K.(XK&_SXENQ4O14^>#']5/Z,S+S3/].V<!6TD5H]0.RNIA)/%W*
MI%(N,!"!!"-DDSH877 D6CH4ZM'"7!9EK<B#6]@+,U44;73LBKM._ *B<;9R
MT49R^0#ZW%V-> + E^C?R>160WTD$7)$5)F9$O8S NDLKT#UQ 4G+@=LKWLA
M&3U*@!K83_:SXA>U5(D8AP9+E;3P!GG >\<D((&<UWP/UQMR#XN^((2PM26"
M<[Y<-P8*B$:7\MVNXI"KJX(1'@Q.6R?-@^<ATC,/D<CWHG+N\=F*,]0G4&)"
M-4V.UAQ/00W[6,'Y<->Z+RYEPH\@U;6*7&T<#YG"#,6^..Y-AI/>\>A$7$F[
M").X#N#8U27.!X+Z6#PY.3GIG4XFWXLK-AB)UK75@WJ%4+1#FR?#WF0RZ(V.
MACC[#]OF&'H>#TY#$X#!E=X&GL;!!D>]T^%9;S@^>]PGK8\)XH[ZIPT0K+80
M'0_VA_VS9@7!#"Q8" H".KH^C L[--D?!^#7K$Y,-C^ (]/.>I/5P1B3HC'+
M:1(=^^+IM'4-E>2\W%:[#Z(=Z[M"?2(,#5G3<9<UR2R#7A$;?),UT;JW*$8Z
M0DDU -7+_J]]$ OW;)LRJ4_POJ6:^Z%_VQ<%\WI:Y#9\^\WI:'CRS(9,!+"Z
M,*BMGP@):SPF_HB^A\"C4T$#=N):+5$LP!] +Y AR(A% 0.BN/]6@7=H0ID8
M9 ]%'PH$7UO@""3.K0$K*+O?,>-PWX/%042*.+>2L_K";D1-+1UX"SFK Z24
MN!**,!7AJ!H.!KW!8$"AZNMEM^@25=.4/_N#(+H0_ANPOH [Y@L</B^D,\CP
MU)T,O /WC)A"@>:Z8A<(!=0'X0*A,M&]KU)+;,'R*O>!!][H62,XDT?&F2YL
M60>#]U.G:LC$FK D.T7J'9)II!.FJ9BE=FN#4FQ]C'1DZ(E$(D07'A(6&O[9
M8JE<UQM6 4]]0/;XP$&"->6K"?$.GV! ]T0_:0EQ'9 @["VQKJVH"M!9U+F&
MN=$.#GRO](Y#ZP.W>P);Y3GA^;LP6T]ZS(,ZHJ+0*$U\ON.F6N*.GX(\:Z@.
MF;!"SA6UX'" :UUH?XHJ79NM 1!N0D0F4\\0ZU!KXRL(NH="#85X27U$$@1Y
M@PR=$&QTHC.857'=80K520L?KK27K-A2V(YE.# =PW"51!)T/\9$8Q2Y1K1^
MW7DVU17P.N@&3U:R=57<VJQFZSYRF364QL ."?I@$B,AQ.,J_4>$>SFKF[B?
M*IAV.'+PW\5X:A<= R3 QB4X*4Y])V"J8A/WO5-6*%%J2I1'43NPI@ZU2M6N
MEKC1N^F"-Z(L3(_:-B;/35%6&=,JT\DIU4F_SF;FZF]D :MZGC/N -$*IO-%
MWIFJZ<95DVBXMG-!15TJ/<E<R['1@FV#2&W 7FVK;D-2\)"+E^[ Y4!8GT(K
M%>:'AID[V;%" 5LXQ0#7$0F6)#0 *-2LRGAE<"8/([;BAJM/$%DKY3N\AZ8.
MWUEO\# =633J41!.*&F9*3T[7"((O''JJ/->DRGQIJW[:\"J,BZ3NP,=G2<0
MR?)BGTD;K1M1A9IKT[548WP$.,:HW$!H[5HAW2#X9L1X6(5N+2EK.DIW@O?&
MKA:R+V[AE0I(<Q$TU<#RGP#TLEB+<9V78<FL)R5-<+>,R=?A@V9Z8[+()&:^
M/O#Q2[)&U/VG\$1$A*F6@(WV\]JLI/A9 [IZ".FHWPM3:(;,9=/,(""L=D!3
MYSC<!"]BRR]EW&JF;5!A2'Z3(5@[0E*W%14Z9^U!O."OMI0J'@8Y^IO)RBHW
M]%F:5#-@:-ZBF1HX;]#3NL"7Z]Q9G=X9,'N6^;KEA"X&/"NDX0P=YR7O,4O2
M5@&F80V+!A&" Q9 JI=M.PB:2*B\5AS),EXHIK(,W:@PT7WC&"]FPV>;6157
M_$2Q,1EL7<L_38R)+<F:"MBI< P3*17+-3@GO51@51UH.1!@#L4FZVA\H#-7
M:799\ E)-!H\NWK]]E?^.'SV/4_):&X(>D%\:W1$1Q^=B@6 WP)/X" 5VCLT
M+U=Q%(Q:$CJ8/>H&+#,.0I0"]+[.\- ''!G%K*#! IX84K/Q$AA:A> !B)7R
M7F6-'4J=4G<82W=E1FG W46L$KWT?,0"=8633%5$VV-CB>CMRJB-;*I#F-=P
M$4-;43%*U#5G5U5[J :QXX?/@B&B)M7: 3 VP8@\M/K<+)C3%]?79:D="/_=
MAHK#<3![^^Q0T9U[T1 7V#!QA6*KE-AV)+@?WN% S[-(61+,U,(LI1MZU\7/
M-?'..M">WU3"F%WEI@A618#"D(%J-PD[_IUEV395/9AZ4$'\@Z//X1>./O\F
M(TVR63/6E/0QT2D6HC"W\\;_B_EFF%XTEB+^1T.A-1+ +II\]B'Y'=6C):H<
M([OC;( ?UJ(;NQ"F+D,,$,A1 P6HA2<K0'Q2$;4_=<"?M2R]!M<M2X;HM$%A
MZ46/(B2C+HBP#/>OD0).*&KH4GS!T1I8HX:]E$I6:'I8494N1SN#-P_U',=D
M+!X.VZ<N%L ZFU$B^LIQG:ST<HBJ';V>VY_T1^WS.<HXJQ R65H.X\RYQ_>"
M[ ]'_6&[H)/V'!XX8-1B'??*3=2U<0:T:KK=_[7Q=C!TW>"X8A^?SHZ.>R?#
MXZ^9.H_'9[V3T?#/GSH?G9WVQN/QGS!Q/AH/>N/AR1=,G"?C2>_X:/*E$^?_
MYGU R-:#%P)?->.>?-V,^\'I]JA__-=.MU^6B[5Q/>D=FE!0%]1+-]T.<']K
M\-&=<URA>]2P4@,LGC&Z,5M !Q]Z/;\]!H2X7K2:,&::MMR6A&=]+^7)H_,9
M9[V_1%9ON]VRON37L3K;GD$&+PT$ST75''R<)AAJM3$&0 GB<0+ZG BM9BVB
MF[3KS'<*)N/7\T69J8+?G3$$\7$.\OS[B2A">U6X2*F+?DQET^3^)3).Y\ZC
MYTM.=[C63J&#XF2;&=\;L*DM93O>(<VNN7-D1A\0T*Z7=%WR0C^[L9!O^-N7
M)6V?TAV!;<?X+C_Q],=?&TZ]N49WQU8[!>_H2BB0&<Y<'+-K)+[9SS3C/GYS
M[-L>NE!I#F.O!'9['0A9Z-<ZL(G;68_^_6AOXRVF_Q4 K.6J0A/^;L3F-+/A
M0,B]APG2@Y9GH*;N2N7FSS9\I_UYPS13]_U)^%J&C)QQ^]C%6<;H$)?QARW1
MHOA^I.YIRY4Y(-YCP\I>4Z>PB>J*@E[.1Y&;QLQHB/O 7:7!9SJW\PK2UU^:
M93<V<A'#9SUPPFCG"4/![!V148]=XZ!'])3N$U%/FDQM1W7JWCW4Y<=Q5<V_
MV6F:#NJ-'4M^\)JMP&&I=EBSQV'>:DQCAXT<>.1E4+<O_]SBYE7=EG1L@2F
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M GP_,P@;_P==T/P>_/P_4$L#!!0    ( ':);E5<_9SG80@  'P4   9
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M^G$D"EK)MO(?S/;OE/QYR?)R4[GP5VS3WOE(Y*WSIDZ'84&M=/PO/R<<ON7
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M( #3C:[.<+IIQ\5,.QH^[7))TQZ-#Z#]N=9N:_@$_?_']"]02P,$%     @
M=HEN52$OYN[. P  L0D  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
MG59M;]LV$/XK!S7H5D")WBS%3FT#29IA 9K-B-OMP[ /M'2VA4JD1E*Q_>]W
MI&39:51AV!>);_?<<\>'1TYW0GY36T0-^[+@:N9LM:YN/$^E6RR9NA(5<II9
M"UDR35VY\50ED676J"R\T/<3KV0Y=^93.[:0\ZFH=9%S7$A0=5DR>;C#0NQF
M3N <!Y[SS5:; 6\^K=@&EZB_5@M)/:]#R?(2N<H%!XGKF7,;W-PE9KU=\$>.
M.W76!A/)2HAOIO.8S1S?$,("4VT0&/U>\!Z+P@ 1C7]:3*=S:0S/VT?T7VSL
M%,N**;P7Q9]YIK<S9^Q AFM6%_I9['[%-I[8X*6B4/8+NV;M*'8@K94696M,
M#,J<-W^V;_-P9C#V?V 0M@:AY=TXLBP_,<WF4REV(,UJ0C,-&ZJU)G(Y-YNR
MU))F<[+3\\]((2GX^0M;%:@^3#U-H&;*2UN NP8@_ ' !)X$UUL%#SS#[+6]
M1V0Z1N&1T5TX"+C$Z@HBWX70#\,!O*B+,+)XT7"$?]VNE)8D@K_[8FP@1OT0
MYF#<J(JE.'-(^0KE"SKS]^^"Q/\X0'#4$1P-H3<$82%4;G3:QV[0OI_=K09*
MI,9RA;++)C">P2=,V]' CM)7;Q'N15DQ?OA)06'Y,*50*VM1Y&R5%\2.TKA#
M:>9@+0HZS^H&[#&^%.O+KV1TVQCU>'[C%7ZO4#*=\TWK4!Z!ZI/W"PB#B3N.
M?6H%KA^.7"HVT"3L\QFK_^4PK:5$KE^%1P[#B9OX,;4F";6NK]_8<<'[3-^_
M&X=!^!$FONL'"7P1FA6O\"B F-J3" 9$$W>BB0=%LZ3JG-4%@EC#$].US/7!
MM-_DID]/@]#]>GK8IT6=F208L=Q)P;(=*GT4RT8B4JG6+JQK(H.F5.5E7;;S
M%3N8604U%0EI,GB9,IYB8:H.B-<)IFJTR_46"$'GE$,AJ?J;^^6T!1IEJ6@!
MX#Y%I4S@@B,<D,D/P+Y3Z&!Z@/4>E-.>M^7#C@:Q[\919#H13$)W1.IH]OF[
M,,-11"(P2E5$X)$37Y.L(')')(6%R2JIYX45M=W QKI?AP-:23JM)/]9*\_&
M\<.>[G2S;72XE_6J<?_(4U%BGUP&T?OE8MW@F1MU=)-;-V_KR&\$"V5SE:"Y
M2OJVQ9[C5]@7,$X"-YJ,S8$-?'=R'9]":GU=P(@J1Q*%U(K#Q!TGX]ZT>F?7
M:(ER8Q\+"E)1<]W<J-UH]QZY;:[AT_+F,?/$Y";GII:NR=2_NJ8C)YL'0M/1
MHK*7\DIHNN)M<TMO*I1F <VOA=#'CG'0O=+F_P)02P,$%     @ =HEN51*O
M96H,!    PL  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULS5;;;N,V
M$/V5@;989 $ANEF^9&T#L=-BM\ 609*V#T4?:&EL$4N1#DG%\=]W2"F*4]C&
M;K$/?;%YF3ESYL+13'=*?S45HH7G6D@S"RIKMU=19(H*:V8NU18EW:R5KIFE
MK=Y$9JN1E5ZI%E$:Q\.H9EP&\ZD_N]7SJ6JLX!)O-9BFKIG>+U"HW2Q(@I>#
M.[ZIK#N(YM,MV^ ]VM^WMYIV48]2\AJEX4J"QO4LN$ZN%KF3]P)_<-R9@S4X
M3U9*?76;S^4LB!TA%%A8A\#H[PF7*(0#(AJ/'6;0FW2*A^L7]%^\[^3+BAE<
M*O$G+VTU"\8!E+AFC;!W:O<).W\\P4()XW]AU\J.\@"*QEA5=\K$H.:R_6?/
M71P.%,;Q"86T4T@][]:09WG#+)M/M=J!=M*$YA;>5:]-Y+AT2;FWFFXYZ=GY
M=5ER%QX#3)9PA[;1M%9KN-6J; H+/DT&+A[82J#Y,(TL676Z4=%96+06TA,6
M)O!%25L9^%F66+[5CXAM3SE]H;Q(SP+>X_82LCB$-$[3,WA9'X+,XV4G\!:-
MH1-C8*GJ%9>L#<=?URMC-17-W\=<;A$'QQ'=0[HR6U;@+*"78E _83!__RX9
MQA_/\!WT? ?GT.?W]##+1J#+4L_]NGALN.E2N=H?[D-R3%HN-RBM6QI>HO9>
M'O/LK.WCGCU4"&LEZ'V3$;"N4,#?2BH<2Y=%Q<BZ 2[]=LVXAB<F&N^"%W@E
M6!P2!,'9B@MN]R3&+'!#C:!&9AJ-);A'3?NBT=H9IL?)S24\G,-#IB5INEIG
M1:$;6A,I:G'NGC#PF;J=<50-;!DOP2H'J-D3DP7"8\.T12WVE[!@PA\1JQLL
ML%ZAABSQ19G 3S ,\R0/A^D(ELQ4A+6O'1OR5ZL]$^10V7C6SGTRSU4)%Z/1
M*!SG^0=8^H Y:F]C==(O+@O1E">]N4C"/(_#=)!\."R&_QB;(?DYC,>'(: W
M:;L8= ^38C (Q\DD3+()_+\JY(#WKTQ22O>0]:2S<#(8AJ-D^#V)R[)).$J3
M'Y^XP60<9EGV Y(VH,1DR>@;DI9G5+B#',ZTJKQO5?DWMZH;;HP2C6=]VT;5
M'&M 9Q%/-Z#R +Y+FH&U5C4L"8-3Z(!I='.$&PA<R%RE/*&D!'DQ FBSY&+8
M!9!"W384^C1LF:3<4TN0RKJT-?HUN(QL%YPYV!VWE:L-@R=H.$"-"'7[543W
M5?Q7*GXCI\_=^U3Y1O.ZNFM],93"]^_&:9)^=,F<4"F/1V_.DG P2<(X'L!G
M6:CZO/??@7:L7**#P:1&O?'CEZ$2;J1M9Y3^M)_PKMO!YE6\'0^_,+WA1$C@
MFE3C2S=0Z7;D:C=6;?V8LU*6AB:_K&A*1>T$Z'ZME'W9. /]W#O_!U!+ P04
M    " !VB6Y5S18MO$("  #N!   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6R-5&UOTS 0_BN6D1!(4Y.FW8"11&H[)O9A4*T"/B ^N,DEL>:78#O-
MX-?CES1KI:[B2^,[W_/<<]<[I[U4C[H!,.B),Z$SW!C37D>1+AK@1$]D"\+>
M5%)Q8JRIZDBW"DCI09Q%21Q?19Q0@?/4^]8J3V5G&!6P5DAWG!/U9PE,]AF>
MXKWC@=:-<8XH3UM2PP;,MW:MK!6-+"7E(#25 BFH,KR87B_G+MX'?*?0ZX,S
M<I5LI7QTQEV9X=@) @:%<0S$?G:P L8<D97Q>^#$8TH'/#SOV6]][;:6+=&P
MDNP'+4V3X?<8E5"1CID'V7^&H9Y+QU=(IOTOZH?8&*.BTT;R 6P5<"K"ESP-
M?3@ ),D+@&0 )%YW2.15WA!#\E3)'BD7;=G<P9?JT58<%>Y/V1AE;ZG%F?RK
MJHF@?TEHD2C1DFBJD:S06H$&8<+-4=B;&S"$,OTVC8R5X(BB8DBW#.F2%])]
M0/=2F$:C3Z*$\A@?6>FC_F2O?YF<)=Q .T&S^ (E<9*@#=1V8,P9WMG8EYGG
MG?U'7R[02@HM&2V?VW34'=NM6RJ(*"AA:&.=X%1H]'.QU4;9P?MUJE-!P/RT
M +>,U[HE!62X=;G4#G#^^M7T*OYXIKSY6-[\''O^I>-;4$ZX76]EJQ UTJ%Y
M^I36P';IV=R>[_)I&NT.!40',\A!U7[3-"ID)TP8Q]$[+O,BS/!S>'@)[HFJ
MJ="(066A\>2=S:O"=@7#R-9/]%8:NQ_^V-@'"90+L/>5E&9ON 3C$Y?_ U!+
M P04    " !VB6Y5B#P:#"T%  #^'0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6RM66MOXC@4_2L6LQIUI&V)G7<'D*8E$%;;4375['P.Q( U2<S:
MILS^^[63-(5@ NSZ"R3./>?>:Y_<^#'84?:3KS$6X%>>%7S86PNQN>_W^6*-
M\X3?T0TNY),E97DBY"U;]?F&X20M07G61Y;E]?.$%+W1H&Q[9J,!W8J,%/B9
M ;[-\X3]\X SNAOV8.^MX1M9K85JZ(\&FV2%7[#XOGEF\J[?L*0DQP4GM  ,
M+X>]+_!^!I$"E!9_$;SC>]= I3*G]*>ZF:7#GJ4BPAE>"$61R+]7_(BS3#')
M./ZN27N-3P7<OWYCGY3)RV3F"<>/-/M!4K$>]H(>2/$RV6;B&]W%N$[(57P+
MFO'R%^PJ6\_I@<66"YK78!E!3HKJ/_E5=\0>0/+H :@&H#;@E >[!MB7 IP:
MX%P*<&N >RG JP'>I0"_!OB7]E)0 X)+/80U("SE4(U?.?CC1"2C :,[P)2U
M9%,7I8)*M!QS4BBQOP@FGQ*)$Z,H804I5AS<_$DY_P2>,0,OZX1A<#/&(B&9
M;+L%WU_&X.:W3X.^D"X5L+^HZ1\J>G2"W@9/M!!K#J(BQ:D&'W?CPPY\7Z;:
MY(O>\GU G80O>',';.MW@"R$-/$\=L/_V!:=\'$W_"EA$@Y/PJ/+@X<:^.3R
MX'7PZ>7!Z^#Q_^OYV7_._4 (=B-\N^2S3_!]W>:8)8*R>YVJ*ZRCQZH/T#W?
M) L\[,DO#,?L%?=&'S] S_JLDY1)LK%)LL@DV<0DV=0D66R2;&:([$"T3B-:
MIXM]]%7.?DBQH+DLSUE9KY>,YF A:R0IMK*. SD+DJJ6TPBNDW7%[I7L:AKT
M.KIUD(V0-^B_[BNV,XIK%6N2+-)D -W =@+K,(6)2:]3DV2Q)@4;AI:-W,,4
M9KI<D16ZSKOA@8K<1D5NIXK&A->*P>D9P51$[EX(K7Y^['1UK51,DD7'L3NA
MYP=^2R@F?4Y-DL5G.W]V; &=$%J6HQ>(UPC$NZ[,Z*3A'?G6UQ)/HV+;<SRO
M93C6&3H6<FS[T##2>(96X'EARW!RS @1LF4/'=I--7:.#+!E%FO\ZE_<8T,4
M0,<-]:/B-Z/BGQT5-1H@$7)M.N<D)7)Y*N\$(_.M2.89!H*"@A;J[68TR]0'
M@10"2ZT)[>OM:_3CMM^0Q\ZPKGW%39)%Q_';T(&MX9B8=#DU218?Q^]9 6S)
M>'9LY0:>"_5J"AHU!5=.)=I"DL]R6@"N5H-KFJ68:344:.84\FVTPY:*.L.Y
M5D4FR2)-!M!R7>0'+2&9]#HU219K4K A"EV(6EHZ-K0="T)++Z:P$5/8N9@:
MXX+FI#BYG I-+J=,DHU-DD4FR28FR:8FR6*39#-#9 >RA=;[[I?5605_E)NA
M.+U-7N4T>(6K:L<!W0HNDB)57]"/'P($X6>UITH6X(;4)5$_*ZK]'7Y2'=]W
MVL7DL3NR:W5LE"W29A$$5G T>S;J=VJ4+=9FX<$@]-L3-JUE:(<A/#%G@WO[
MJ_#,8BO;JOU\@)=+O!" +@$5:\P QXLM(X)(M9W3%#R["NL.XFHQF62+SH<_
M,>IP:I0M/A_^3&,"PS ,3JS3(7H7#S)6GE(E-+F@/R<F='&!ZHSM:DV99(NT
M6>@+E$F_4Z-LL38+?8'26+I0%JBCI7Y_[RPHQVQ5'B1R.9G?%J+:'6]:F\/*
M+^417:O] =Y/H:8]5H>;Y=G3.WUU,OJ4L!4I.,CP4KJR[GP9+JL.&ZL;03?E
M2=2<"D'S\G*-$[FP4 ;R^9)2\7:C'#1'OJ-_ 5!+ P04    " !VB6Y5T(6'
M7'\"  #K!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RM5,ENVS 0
M_15"!8H$:"U9LK-5%A [*5J@ 8RXRZ'H@9;&$A$N*DE9Z=]W2,F*DSII#[U8
M7.:]>6_,F;15^LY4 );<"R[-+*BLK2_"T.05"&I&J@:)-QNE!;6XU65H:@VT
M\"#!PSB*3D)!F0RRU)\M=9:JQG(F8:F):82@^M<<N&IGP3C8'=RRLK+N(,S2
MFI:P ONE7FK<A0-+P01(PY0D&C:SX')\L9BX>!_PE4%K]M;$.5DK=><V'XM9
M$#E!P"&WCH'B9PL+X-P1H8R?/6<PI'3 _?6._;WWCE[6U,!"\6^LL-4L. M(
M 1O:<'NKV@_0^YDZOEQQXW])V\=& <D;8Y7HP:A ,-E]Z7U?AST \AP&Q#T@
M?@J8/ -(>D#BC7;*O*TK:FF6:M42[:*1S2U\;3P:W3#I_L65U7C+$&>S:ZHE
MDZ4A1Y^4,<=D"9JL*JJ!'%V!I8P;\AGN;4/Y,7E+C+LQ:6@QL\.'>9]EWF6)
MG\ER3FZ4M)4AU[* XC$^1,6#['@G>QZ_2+B">D22Z V)HS@^H&?Q[_#Q"W*2
MH8J)YTO^5L6'\GV_7!NK\97^.%2NCFYRF,YU[H6I:0ZS %O3@-Y"D+U^-3Z)
MWAWR^I_('CF?#,XG+[%G"R4$=B.^T_R.T"T^&+KF0'"\D+K1>84=1FRE55-6
MV/18$99;*';Q+=6%(5061-6NJ_$9,MF_LN-#=>O$3+T8-Z"V69PDI],H#;?[
M%?DS;#P].X\>PCJOX5[?"-"E'R>&Y*J1MGN+P^DPL2Y]HSXYG^,DZP;/ TTW
M!F^H+AGZXK!!RFATBJ)T-UJZC56U[\ZULMCK?EGA- ;M O!^HY3=;5R"8;YG
MOP%02P,$%     @ =HEN53COVVS-!0  42L  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&ULK9KO;Z,V&,?_%91-TYVT7K -!KHVTC7FM&DZ7=7N;J]I
M<!MT@#-PVNZ_G_E1B,'QKNGSI@WD>3[.8_N+^8(OGD3UO=YR+IWG(B_KR\56
MRMWY<EEOMKQ(Z@]BQTOUS;VHBD2JP^IA6>\JGJ1M4I$OL>O299%DY6)UT9Z[
MKE878B_SK.37E5/OBR*I_KWBN7BZ7*#%RXF;[&$KFQ/+U<4N>>"W7'[=75?J
M:#E0TJS@99V)TJGX_>7B(SJ/29O01GS+^%-]\-EI2KD3XGMS\$=ZN7";7\1S
MOI$-(E'_'OF:YWE#4K_CGQZZ&-IL$@\_O] _M<6K8NZ2FJ]%_G>6RNWE(EPX
M*;]/]KF\$4^_\[X@O^%M1%ZW?YVG+M97+6[VM11%GZR.BZSL_B?/?4<<)"B.
M.0'W"7B:X!U)('T"^=$6O#[!^]$6_#ZA+7W9U=YV'$MDLKJHQ)-3-=&*UGQH
M>[_-5OV5E<U$N965^C93>7)UPQ]YN>>U<^;<JDF8[G/NB'NG/^V\8UPF65Z_
M5]]_O67.NY_?7RRE:K?)7F[Z-JZZ-O"1-HCS691R6SMQF?+4D,_L^9$E?ZGJ
M'8K&+T5?82OPEN\^.,3]U<$NQH;?L_[Q=&0JYVVMQR>WKG4&&68 :7GD".^Z
M$NE^(^MST\!VJ9XYM;F(G=>[9,,O%^HJ5?/JD2]6O_R$J/N;J5<A80P2%@/!
MM/[WAO[W;/1!@:;N[S)IF]E<\A]7"'F(N(&:-X^'73L/#%60[[EZ')O'$1R&
M ::1'AC/ W% J8_"L66M6G^HUK=6^V>5U3+)1<U-]5IS7SO=(&$,$A8#P;0!
MH,, T-/E3B'['Q+&(&$Q$$SK_V#H_^!DN7>9_J$Z(Y<0UY^H?1[GN0@''IVH
M?1[77#Y"&I")V@V!&*LX')G5'@[%AM9B;Y-2W<,(4ZW6Q-=.-4@8@X3%0#"M
M]Z.A]Z/3I1Y!]C\DC$'"8B"8UO_('6^NW9/%WJ?J:J<N]:=KNR%PNJP;0I ;
M^-1#:*)T*TRO\L!"(&N5W[*[1-D]8Y'6S-=.,U : Z7%4#1]#/ X!OATK?>Y
M4*, 26.@M!B*IH_":*60U2G8]4[F&HW<*/#=J=X-@6%$_=";JGX>2%TW=*?W
M"[$A, RB*(S0$>F/W@79S<LZR5.1B\I8L#7UU;,.DL9 :3$431^$T5(A_PW:
M!_54H#0&2HNA:/HHC+X*66V#7?MT)L (HW"Z.J\-<0C[/IW:<V8()&K!)_Y,
M^H; @'CXP +H]8X^!MF-S+=DI[R\R(WU6E-?/>D@:0R4%D/1]$$8_14*WR!]
M4(\%2F.@M!B*IH_"Z+.0U4;8I1_-!'CF$3H5_CR*8#\(9DN^@89][/K3YW>&
M0&7\$2)'[O;QZ&FPW=-\W'"9I$(:'^#9<U\[Y4!I#)060]'T41@]%T:G"Q^#
MNBY0&@.EQ5 T?11&UX6M?L(J_#Y56_.C()JZ>T,8H6% )H_HF"F.!#2<+OB&
M.$K"P/6.Z'[T-MCN;;X4?),GA7@^NTZ^&PL&?5D$2F.@M!B*IH_$:+JP]P;M
M@[HN4!H#I<50-'T41M>%[6^RK-KWYV+UE3>?:G\>AC$-IS?[)AJ*\$SY\[ S
MST<T/'*KCT=K@__/VJ397Q5_-I8*^LX(E,9 :3$431^$T6_AX VJ!S5<H#0&
M2HNA:/HHC(8+V]]H654?SA^S^:$;354_#T/(F][!,T,85@LYPE/9S^/.$,''
MGNWAT=5@NZOY(K>\<JJN8&.]H.^00&D,E!9#T?0-.J/E(N[ITB>@E@N4QD!I
M,11-'X71<A'[:RZ;]/O4P_TR7D2#Z5*^-L2A( S#Z9M[4QP.L$^GZC<$JBN.
M-WMQOSS8(ECPZJ'=FUD[&[$O9;=7;#@[[/_\V.YZG)R_0N=K9#C/T'G<[>X<
M\=UFT\])]9"5M9/S>]64^R%0EZJJV[_9'4BQ:S<HW@DI1=%^W/(DY543H+Z_
M%T*^'#0-#+MH5_\!4$L#!!0    ( ':);E5XA44((P,  $H-   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;+5776^;,!3]*Q:;ID[JRC>A68+4AFRK
MM$I1HFX/TQY<N$E0 3/;2=I_/]L0F@^*TH[E(<'FGG-\SS4W9K A]($M 3AZ
MS-*<#;4EYT5?UUFTA RS"U) +N[,"<TP%T.ZT%E! <<*E*6Z91B>GN$DUX*!
MFIO08$!6/$URF%#$5EF&Z=,UI&0SU$QM.S%-%DLN)_1@4. %S(#?%1,J1GK-
M$B<9Y"PA.:(P'VI79G_LRW@5\".!#=NY1C*3>T(>Y. F'FJ&7!"D$'')@,7/
M&D:0II)(+.-/Q:G5DA*X>[UE_Z)R%[G<8P8CDOY,8KX<:KZ&8ICC5<JG9/,-
MJGQ<R1>1E*EOM"EC74=#T8IQDE5@L8(LR<M?_%CYL ,0/,T JP)8AX"7%.P*
M8)^JX%0 YU0%MP*HU/4R=V5<B#D.!I1L$)71@DU>*/<56OB5Y'*?S#@5=Q.!
MX\$4UI"O@*%/Z"J.$UD\G**;O-R!LI1G(7"<I.RC"+F;A>CL_<>!SH6T)-"C
M2N:ZE+%>D+'1+<GYDJ%Q'D/<@ _;\9<M>%VD7.=M;?.^MEH)9U!<(-LX1Y9A
M60WK&9T.-YO2^3?U\9O5]\RPZTU@*SZ[?1.@.249&C]RH'(3C-3N XI^?1?Q
MZ(9#QGXWE;XD=YK)9:/KLP)',-1$)V- UZ %']Z9GO&YR?<NR<(NR<8=D>U5
MR*DKY+2QUQ6:0D06N7I,S]%MDH(HD:C-!#^)WLU94W5*8D\1RW^-=6 :\C/0
MU[N^M^J_UO=C3:]!<]R1YIZC;NVH>XJCC9:52'?7,M,Q;:-G'9CF'N7IBR#7
M.4@T/":T+=_O6=[E@2/'A%;/\US3?U;>R]:KL_5:L_U*<<Z;4FV%O?;9[9(L
M[))LW!'9GO>]VOO>_^RNO2XKU"59V"79N".RO0KY=87\-_<"__B);&J?+X0=
M]('C*+NI+[:N]K5>Z#N'0['?%NI4SE!$5CDOCPCU;'WPOU+GW8/Y:[,_,AOF
M0_&B4)[KG^G+MXQ;3!=)SE *<R%E7/1$>Z/ER;T<<%*HH^D]X>)A4)=+\;(#
M5 :(^W-"^'8@!>K7I^ O4$L#!!0    ( ':);E719+%N*0,  %\.   9
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M]/8B.UWK'2 (,T#W+SE7KPVSQRCWE.$?4$L#!!0    ( ':);E614(F@X@(
M %D(   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;*V674_;,!2&_XJ5
M31-(@WPG+FLCC2(T+B8A.K9KDYRV%HZ=V6X+_W['28E*&\HF[::QX_.>\[R.
M/SK>*/UHE@"6/-5"FHFWM+:Y\'U3+J%FYEPU('%DKG3-+';UPC>-!E:UHEKX
M41!D?LVX](IQ^^Y6%V.ULH)+N-7$K.J:Z>=+$&HS\4+OY<4=7RRM>^$7XX8M
M8 ;VOKG5V//[+!6O01JN)-$PGWA?PXLI=?%MP$\.&[/3)L[)@U*/KG-33;S
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M$RB;@.L+*<U38)M?>]=E_P!02P,$%     @ =HEN5:*12E1_ @  0@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULA95A;]HP$(;_BI5-4RM-37!(
MLK(0:6U5K5(KH;)NGPTYP*H=9_8%RK^?[:09&H%](3[;=\_[XOB2[Y1^-1L
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MQ?,/:<HW=\H-;'\+9/)_4$L#!!0    ( ':);E4NU-7N?0@  "1D   9
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M16)ZFZ^#N;SNZ<R3RVPK>[-__L,9#_[=IBPDS$?"*!+&D#".A D0S%#@<*?
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M 2T>7",WL4P6I7GP-^F64Z$^ I3F0VD42F-0&H?2!(IF*K(Q'9SI>7(JU'Z
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MK'HE136CTG7Y@H/'5*DT+B=7,EC(K%A!+U^FJ7J9*0K8O1AD]G]02P,$%
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MO9LQYJ*J:Z?ZPLAM54T\28.U2=7,L=X$90?@_;64YGAA']!6L,F_4$L#!!0
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MJ#X'#\ZCL#VGPNVO6]/?4$L#!!0    ( '>);E67BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ =XEN50^.X6JA P
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MG[>_+Q^;O8=PQ]G!+XW5+U!+ P04    " !WB6Y5B(RI-Z4!   O&0  $P
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M5HE"5HE"5HE"UC$*6<?_2=9WK5=__0F_79-:E<W1GW7_2>:?4$L! A0#%
M  @ =HEN50=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " !VB6Y59PE!(>T    K @  $0
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M=#(N>&UL4$L! A0#%     @ =HEN52 16OFC @  :@<  !@
M ("!M10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ':)
M;E5R#Z\[!@@  *,H   8              " @8X7  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " !VB6Y5CB56%<D'  ",(0  &
M        @('*'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ =HEN5?OLL7<C#   =&X  !@              ("!R2<  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ':);E7#:4!UU \  ,,G   8
M              " @2(T  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " !VB6Y5Z(KL;U $  #P"@  &               @($L1   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ =HEN52#PP2&Y"
M6Q0  !@              ("!LD@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( ':);E585(1#@ 8  /0/   9              " @:%1
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ =HEN56PL
MCN#'!P  ^1(  !D              ("!6%@  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " !VB6Y5VL6;'N$*  !''0  &0
M    @(%68   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M ':);E7^&U[ .0,  !\'   9              " @6YK  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ =HEN5?-#W0== @  +@4  !D
M             ("!WFX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " !VB6Y5L#" Z L$  #-"   &0              @(%R<0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ':);E5Y])"%-0\
M !LN   9              " @;1U  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ =HEN55S]G.=A"   ?!0  !D              ("!
M((4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !VB6Y5
M)+76*=<#  #X"0  &0              @(&XC0  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( ':);E6T:;BWG ,  &H'   9
M      " @<:1  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ =HEN53&V<^CG @  2P8  !D              ("!F94  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !VB6Y5(2_F[LX#  "Q"0
M&0              @(&WF   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( ':);E42KV5J# 0   ,+   9              " @;R<  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ =HEN5<T6+;Q"
M @  [@0  !D              ("!_Z   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " !VB6Y5B#P:#"T%  #^'0  &0
M@(%XHP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ':)
M;E70A8=<?P(  .L%   9              " @=RH  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ =HEN53COVVS-!0  42L  !D
M         ("!DJL  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " !VB6Y5>(5%"",#  !*#0  &0              @(&6L0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ':);E719+%N*0,  %\.
M   9              " @?"T  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ =HEN59%0B:#B @  60@  !D              ("!4+@
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !VB6Y5,[C@
MD4\$  !T$P  &0              @(%INP  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( ':);E7CR,".@@(  /<&   9
M  " @>^_  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M=HEN5:*12E1_ @  0@8  !D              ("!J,(  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " !VB6Y5%:FX\&H"   E!@  &0
M            @(%>Q0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( ':);E6X"T2+@ @  !=D   9              " @?_'  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ =HEN52[4U>Y]"
M)&0  !D              ("!MM   'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " !WB6Y5/N+=$3<"  #X!0  &0              @(%J
MV0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( '>);E5R
M,SW.JP(  *P(   9              " @=C;  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ =XEN55]1[6F##0  /KH  !D
M     ("!NMX  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M  #J$@  #0              @ $T]P  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( '>);E67BKL<P    !,"   +              "  8SZ  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( '>);E4/CN%JH0,  ( ;   /              "
M 77[  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !WB6Y5*5V(H),!  #B
M&   &@              @ %#_P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !WB6Y5B(RI-Z4!   O&0  $P              @ $.
L 0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,0 Q $X-  #D @$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>157</ContextCount>
  <ElementCount>214</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Revenues - Schedule of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails</Role>
      <ShortName>Revenues - Schedule of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Revenues - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails</Role>
      <ShortName>Revenues - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Leases - Lease Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases - Lease Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Leases - Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails</Role>
      <ShortName>Leases - Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Shareholders' Equity and Debt - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherIncomeDetails</Role>
      <ShortName>Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherIncome</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cpix-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Dissolution Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20220930.htm">cpix-20220930.htm</File>
    <File>a2022q3-exhibit311.htm</File>
    <File>a2022q3-exhibit312.htm</File>
    <File>a2022q3-exhibit321.htm</File>
    <File>cpix-20220930.xsd</File>
    <File>cpix-20220930_cal.xml</File>
    <File>cpix-20220930_def.xml</File>
    <File>cpix-20220930_lab.xml</File>
    <File>cpix-20220930_pre.xml</File>
    <File>pinnaclebank-cpiamend9tolo.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="558">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 157,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 342,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 29,
   "keyStandard": 185,
   "memberCustom": 21,
   "memberStandard": 17,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Other Income",
     "role": "http://www.cumberlandpharma.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Revenues - Schedule of Revenue (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails",
     "shortName": "Revenues - Schedule of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "idc8c19c661864883b36b04dc73597c1a_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:RevenueRecognitionMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Revenues - Additional Information (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
     "shortName": "Revenues - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:RevenueRecognitionMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Leases - Lease Position (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases - Lease Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Leases - Rent Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails",
     "shortName": "Leases - Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "icba3428fcf7b4d74a47c2ef785d2fa87_D20211227-20211227",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Shareholders' Equity and Debt - Debt (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt - Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7a44e5571a0d436ca5db214ef0319e3e_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i16ada3ab868247dd9574797af517d567_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuredEventGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Other Income (Details)",
     "role": "http://www.cumberlandpharma.com/role/OtherIncomeDetails",
     "shortName": "Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i59b5281c659f4863940553cc78d0c93d_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InsuredEventGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i5d73c406eebd400ab792cf31e23c80e5_D20190101-20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "cpix:FinancialConsiderationPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration, Vibativ (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i4341d8f4411f447b973347e506a3b6af_D20220101-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration, Sancuso Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "ibc14356f78484679af24ba6aef97f3f8_D20220103-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i7e8eb2790a704ccb9b25a602bc10494e_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
     "shortName": "Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "idb344f54d56f4e8fa0bcc0e5e31b52e9_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "ifeb4adb610e0487da3f871d1774882a5_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i0ac845d9fd47441189f4a42b63c54170_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220930.htm",
      "contextRef": "i52f679c926174dd8ac8c70cf1e660ca5_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BroadwestLeaseFiveYearRenewalOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broadwest Lease, Five Year Renewal Option",
        "label": "Broadwest Lease, Five Year Renewal Option [Member]",
        "terseLabel": "Broadwest Lease, Five Year Renewal Option"
       }
      }
     },
     "localname": "BroadwestLeaseFiveYearRenewalOptionMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due",
        "terseLabel": "Milestone payment credit due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable",
        "terseLabel": "Restricted shares receivable (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "terseLabel": "Sales milestone payments, expected"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Sales milestone payments, maximum"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DebtInstrumentCovenantEvaluationFrequency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Evaluation Frequency",
        "label": "Debt Instrument, Covenant, Evaluation Frequency",
        "terseLabel": "Covenant evaluation frequency"
       }
      }
     },
     "localname": "DebtInstrumentCovenantEvaluationFrequency",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_DebtInstrumentCovenantFundedDebtRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Funded Debt Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Funded Debt Ratio, Maximum",
        "terseLabel": "Maximum funded debt ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantFundedDebtRatioMaximum",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cpix_DebtInstrumentCovenantUnrestrictedCashThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Unrestricted Cash Threshold",
        "label": "Debt Instrument, Covenant, Unrestricted Cash Threshold",
        "terseLabel": "Unrestricted cash threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantUnrestrictedCashThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EightAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eight Amendment",
        "label": "Eight Amendment [Member]",
        "terseLabel": "Eight Amendment"
       }
      }
     },
     "localname": "EightAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cpix_FinancialConsiderationNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Number of Installments",
        "label": "Financial Consideration, Number of Installments",
        "terseLabel": "Financial consideration, number of installments"
       }
      }
     },
     "localname": "FinancialConsiderationNumberOfInstallments",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_FinancialConsiderationPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Payment Period",
        "label": "Financial Consideration, Payment Period",
        "terseLabel": "Financial consideration, payment period"
       }
      }
     },
     "localname": "FinancialConsiderationPaymentPeriod",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Decrease (increase) in cash surrender value of life insurance policies over premiums paid"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_KyowaKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin",
        "label": "Kyowa Kirin [Member]",
        "terseLabel": "Kyowa Kirin"
       }
      }
     },
     "localname": "KyowaKirinMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Base Rent",
        "label": "Lessee, Operating Lease, Base Rent",
        "terseLabel": "Base rent per square foot"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRent",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryPerAreaItemType"
    },
    "cpix_LesseeOperatingLeaseLeasedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Leased Area",
        "label": "Lessee, Operating Lease, Leased Area",
        "terseLabel": "Leased area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeasedArea",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "cpix_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Borrowing Capacity",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity",
        "terseLabel": "Additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NinthAmemdmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ninth Amemdment",
        "label": "Ninth Amemdment [Member]",
        "terseLabel": "Ninth Amemdment"
       }
      }
     },
     "localname": "NinthAmemdmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicGroupBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "terseLabel": "Nordic Group B.V."
       }
      }
     },
     "localname": "NordicGroupBVMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "label": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "terseLabel": "Financial consideration received in exchange for product license rights, installment payments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProceedsFromSettlementOfPatentLitigation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Settlement of Patent Litigation",
        "label": "Proceeds from Settlement of Patent Litigation",
        "terseLabel": "Settlement of patent litigation"
       }
      }
     },
     "localname": "ProceedsFromSettlementOfPatentLitigation",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_RevenueRecognitionMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Payments",
        "label": "Revenue Recognition, Milestone Payments",
        "terseLabel": "Revenue Recognition, Milestone Payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestonePayments",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SancusoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sancuso",
        "label": "Sancuso [Member]",
        "terseLabel": "Sancuso"
       }
      }
     },
     "localname": "SancusoMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of Rent Expense and Sublease Income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SixthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth Amendment",
        "label": "Sixth Amendment [Member]",
        "terseLabel": "Sixth Amendment"
       }
      }
     },
     "localname": "SixthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_TieredRoyaltyPaymentsThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Threshold",
        "label": "Tiered Royalty Payments, Threshold",
        "terseLabel": "Tiered royalty payment, threshold"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20220930",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r58",
      "r60",
      "r100",
      "r101",
      "r220",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r219",
      "r240",
      "r262",
      "r265",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r433",
      "r435",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r219",
      "r240",
      "r262",
      "r265",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r433",
      "r435",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Wet Laboratory and Office Space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r169",
      "r197",
      "r198",
      "r257",
      "r258",
      "r399",
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r169",
      "r197",
      "r198",
      "r257",
      "r258",
      "r399",
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r219",
      "r240",
      "r260",
      "r262",
      "r265",
      "r290",
      "r291",
      "r292",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r433",
      "r435",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r219",
      "r240",
      "r260",
      "r262",
      "r265",
      "r290",
      "r291",
      "r292",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r433",
      "r435",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r59",
      "r60",
      "r100",
      "r101",
      "r220",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r111",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r111",
      "r116",
      "r195",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r111",
      "r116",
      "r195",
      "r263",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r174",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "negatedTerseLabel": "Share-based compensation credit"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r72",
      "r91",
      "r232",
      "r370"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Increase in noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r91",
      "r187",
      "r189"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet of office space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r30",
      "r97",
      "r149",
      "r159",
      "r165",
      "r178",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r344",
      "r349",
      "r360",
      "r387",
      "r389",
      "r403",
      "r418"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r24",
      "r47",
      "r97",
      "r178",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r344",
      "r349",
      "r360",
      "r387",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r261",
      "r264",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r261",
      "r264",
      "r320",
      "r321",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r326",
      "r328",
      "r329",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r90",
      "r335"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses",
        "verboseLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r327",
      "r330",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r327",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r327",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r325",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22",
      "r27",
      "r93"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r93",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r361"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r408",
      "r423"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74",
      "r399"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r96",
      "r102",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r371",
      "r404",
      "r405",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r216",
      "r233",
      "r234",
      "r369",
      "r371",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r53",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r54",
      "r96",
      "r102",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r91",
      "r147"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r69",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r117",
      "r119",
      "r122",
      "r123",
      "r124",
      "r128",
      "r129",
      "r358",
      "r359",
      "r413",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r119",
      "r122",
      "r123",
      "r124",
      "r128",
      "r129",
      "r358",
      "r359",
      "r413",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r115",
      "r131",
      "r179",
      "r253",
      "r254",
      "r295",
      "r296",
      "r297",
      "r310",
      "r311",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r385",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r188",
      "r400"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r91",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain on forgiveness of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r28",
      "r183",
      "r184",
      "r185",
      "r186",
      "r389",
      "r402"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r149",
      "r158",
      "r161",
      "r164",
      "r167",
      "r401",
      "r410",
      "r415",
      "r429"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r97",
      "r106",
      "r149",
      "r158",
      "r161",
      "r164",
      "r167",
      "r178",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r343",
      "r359",
      "r360"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Net income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r66",
      "r71",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r119",
      "r122",
      "r123",
      "r359",
      "r409",
      "r411",
      "r413",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r66",
      "r71",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r119",
      "r122",
      "r123",
      "r124",
      "r359",
      "r413",
      "r424",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r17",
      "r20",
      "r316",
      "r425"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r17",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r69",
      "r71",
      "r120",
      "r122",
      "r123",
      "r413",
      "r425",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r120",
      "r122",
      "r123",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r301",
      "r305",
      "r307",
      "r312",
      "r314",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r114",
      "r115",
      "r148",
      "r300",
      "r313",
      "r315",
      "r430"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuredEventGainLoss": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.",
        "label": "Insured Event, Gain (Loss)",
        "negatedTerseLabel": "Gain on receivable of life insurance policy proceeds",
        "terseLabel": "Gain on receivable of life insurance policy proceeds",
        "verboseLabel": "Other income - gain on insurance proceeds"
       }
      }
     },
     "localname": "InsuredEventGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/OtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r67",
      "r146",
      "r368",
      "r370",
      "r414"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r181"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r23",
      "r45",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "less non-current inventories",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r41",
      "r181"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r45",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Obsolescence and discontinuance losses"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r76",
      "r145"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r50",
      "r97",
      "r160",
      "r178",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r345",
      "r349",
      "r350",
      "r360",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r97",
      "r178",
      "r360",
      "r389",
      "r407",
      "r421"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r52",
      "r97",
      "r178",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r345",
      "r349",
      "r350",
      "r360",
      "r387",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r49",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r49",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r49",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r54",
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r54",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r57",
      "r97",
      "r178",
      "r204",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r360",
      "r406",
      "r420"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r87",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r61",
      "r62",
      "r65",
      "r70",
      "r92",
      "r97",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r121",
      "r149",
      "r158",
      "r161",
      "r164",
      "r167",
      "r178",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r359",
      "r360",
      "r412",
      "r426"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r62",
      "r65",
      "r114",
      "r115",
      "r347",
      "r352"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r254",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r158",
      "r161",
      "r164",
      "r167"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities at September 30, 2022"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r379",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r21",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Other Payments to Acquire Businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period",
        "negatedTerseLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r332"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for acquisitions",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Note receivable investment funding"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLifeInsurancePolicies": {
     "auth_ref": [
      "r78",
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.",
        "label": "Proceeds from Life Insurance Policy",
        "terseLabel": "Life insurance policy proceeds received"
       }
      }
     },
     "localname": "ProceedsFromLifeInsurancePolicies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r20",
      "r61",
      "r62",
      "r65",
      "r85",
      "r97",
      "r106",
      "r114",
      "r115",
      "r149",
      "r158",
      "r161",
      "r164",
      "r167",
      "r178",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r343",
      "r346",
      "r348",
      "r352",
      "r353",
      "r359",
      "r360",
      "r415"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r191",
      "r389",
      "r416",
      "r422"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r299",
      "r398",
      "r445"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r254",
      "r389",
      "r419",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r115",
      "r179",
      "r295",
      "r296",
      "r297",
      "r310",
      "r311",
      "r357",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r143",
      "r144",
      "r157",
      "r162",
      "r163",
      "r169",
      "r170",
      "r172",
      "r256",
      "r257",
      "r399"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r320",
      "r321",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationSancusoAcquisitionDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationVibativDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r16",
      "r18",
      "r19",
      "r20",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Dissolution Payments"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesAdditionalInformationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r26",
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r141",
      "r142",
      "r149",
      "r150",
      "r161",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r56",
      "r63",
      "r64",
      "r65",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r115",
      "r131",
      "r179",
      "r253",
      "r254",
      "r295",
      "r296",
      "r297",
      "r310",
      "r311",
      "r357",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r385",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r131",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r34",
      "r35",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r56",
      "r253",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r254",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Shares",
        "negatedTerseLabel": "Return of common shares (in shares)"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Value",
        "negatedTerseLabel": "Return of common shares"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Common shares left to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r34",
      "r35",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r34",
      "r35",
      "r253",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r37",
      "r38",
      "r97",
      "r177",
      "r178",
      "r360",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r64",
      "r97",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r178",
      "r179",
      "r254",
      "r295",
      "r296",
      "r297",
      "r310",
      "r311",
      "r341",
      "r342",
      "r351",
      "r357",
      "r360",
      "r362",
      "r363",
      "r367",
      "r385",
      "r437",
      "r438"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r239",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r378",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r118",
      "r124"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r117",
      "r124"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r447": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r448": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r449": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r451": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080552-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001628280-22-029906-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-029906-xbrl.zip
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M9D(#OELVKQ^.>5U&_,]&^L=[G8-!4?YBVPC;OO%:+O@(V#HRY"8 L4+!8Q9
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M#FON-\CA\0&&ZW%C\PT^.&G ^8>?&M#.QO%AT;S:NFI0N)IHMK,.QNAU],P
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M1@^ 45$?E92".>ZE F.CVD2)$P/SXV+@H>9$86YXJ"?X^YLZ$!VWP4F"(X;
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M\?CMQ=*5V8S]<R*!U#'%L."1..WR!  OM:<B3XE; %UY0(B#P;.VSS<^CZ4
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M@Q< @R:R#LA'&VGRS"7+N<FSD"0UEE(*(9]G*BW0($:EAS/PA;,IO2ME\)0
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M!OY_RP_@]\'5WY^:5_\4A[F]=$L<M/3G5_OK_<8>OGBUW[AH'&]=?4A14,R
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MBS:G.G!=TWF:*E]-S)A/0E%9\M0L^?*F)4>@%IIIAW 2"7'E@%H8&Q#1-+D
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MH<CR0*T,2?* @6G6.95U8ZK,U1(;\?A7)5=&/"$COD4H,$Z2!&O B&DNE":
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M#T9GG.,ZK3SGJBX8K3-5U4=?8@,>T^2NRH G:L"W9WA%+ZV6 6'GP("C" @
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M*[)"K'5CR^:%;G]\+D+_: 0KUZX:"AU_O<0Z:,)9_^%+H"L\ I%DI5OKG9U
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M#ZT:.X^-9>Q1M_U.IO&[0Q'FSJGWQ'<#^YQ1'','809YQZ,NT* 3..^H5XN
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M!4U2&6^H) "(05NOO<(^D2@E]E8,*2*I*.)B "*Y!8B<"JX4C\ASK!'7,69
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M P,-U4M#=3\NX)0EJI7(@OM:/J EN)0%,"8S"26H&%\UTZB9ZSCJANHU1O7
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MN259%[ PR0"+IP96,@E*H)"4N0A&-/!N G@'=MVO!6_SUN=$<$_]*E< +$.
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M%X?@?LZ^"$]'(T!G(D#G.9!GML X:&NXSTZ:[1W!NB*Y!N#U!/#P[GP#\,(
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MQV+6+H$*& %1$;@8==V"*9QG*C*/=2 CJ@&VPS0<CQ''PU>$-!PO',?]B$3
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MRW*#^-I ?#%U(DV!+Q7=_3B&"JE.%610%#46!1X44$X6'*O3NDE+P7)3X)N
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MM?Z, 2CLU6SIHRE:)\54."M)0*KI=.$L2..EED5/,=WZ,S8)]'?<:MGLDWG
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MHG'10KCHK,=%RN:8.&I@O- 01AW!4M:@8F;>D')6NV* 6]ZA:M6-=X'!:U8
MM%K'Q9E'MQ\6.O:1P"M!4WOW9TPFK157C@)D:VH=MM) 24G@)'1B4IHD3)L(
MO G@'MC,N#VXFR$R%\+[A@A/SG.4%A2O58W");"H)63'$F;I+'>U@KE#QSLV
MQN*'38PYG0<G+R#S^2+P>>8]S#%U:GSD-HK(SC]O52OOV']7K^W/1\?UB7NG
MI\<3_VZ:D'QVM'=T6 _T^&B_G."K1S5#D$Y.&R$.1HA/9TP>J;RS,1(86_PQ
M)/3@ ZM;VH)U&K4S.@T:)5J)@76-1I9B)#4:654:Z=M5.LB$+!-$GT6A$:?
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MUW*KR&+,8$TC,,4[QV:-FE6N66\<L?C,8N.(U>.(OJED1=UX[#(8PVSA"/1
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MH*F%,[DH-6P5,,M./WV:#7^<+\;Z';ZZ?W1RVCI[!^2HV9T CANEBLP C1>
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M?'D&;^E5 G^<Z ^@7$[P.]K_B]Z?;/_[\WNNW' 7!R3EMZ8*X[KK>'%[7DA
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M6*JQCJ00Y5<1-4NLO.;L JH-5LC1WP"'?3T=[Y;%7U<2ZV?Q@TLB*F,A&J<
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MX^[[<IZX]^/_O-[[[1$OC\_V#GZ=O'RSU]O+,2TDT2(9964"28D!1N' QN!
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M:!N^<KY2(*"T9SCB2@9M+EGG_4&C.P!T@?+AZZ"+EK #=6#'H$JBLI_]-E/
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MN"BQS I)1V?ZC#!71JDCK,.I ,O-)W*A#1DA*"(W.^E-2DN+E*F2<UDN,(&
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MF$97IBBEY4+-;^;W[I\F$LW4XJ6;:^H27+*7EC-;?YB-=84K:_Z8QK6B:6V
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MQ##=?ICM]G2S%ZH-8Z08*PZ?#89NY/OK4FSXX=EOUWYKO?O,@Y>PNXJ8-+&
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M78G8_=7\'&4T\[!;1"BK"=>Y(1K^(S[@,1ROTD !4?%$-K-4W=Q\7",_4"V
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M)_)I;P4^I&"H&I.DA"84\T!]3G0B05R))/,TU8KS;#TRO4N.V:RXY*9P^8,
MD)K+'X[+EU"(L=[FJ54D8$LV[G)##%6> (.G27 LR]*P=ES^'#T65:6HF^"1
MTOU354Q*88'=8(+AS>@">E*)H6N(6/;#==*L-J?N3I"]78$KW&'[72:(RA.
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M&7^ZWW<NU(?$_:G.=\:3G0\N81A*F)T1NG86*N U4.\W@*?Q!]IL8.KCL+#
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MHW/#.$NU]<%)GFNE)0\V37B6&"%8IFNK?;,8?=EJQYRJ)&&2I-XSL JL *M
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MXIMNQ'G<AD5"!,H9S*W(E"ZC? 1H...6BL@GI[@G4^KY__X?R6C^;WB*[11
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MM!(\& >+V4M@#L4TB"J $O<$'U<*\VK$U?73-)M9)&NH,7L4($F!"6H8PUD
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M/CRD ,-AE0&&"Q'I@SB:6\9<IG227YV6]]/ZAH9,< L$F 3*)09QM4ISZTP
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M95Z8B9!'OA*"Q7&:*N9F/$F<@,>,N?P6U_R6FIX>-;'^V[, I'.2QM)FPO&
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MJ^W/AT4*"C4F8H,<S4W&("HG9@D[$35=1H_9>3II$#5NDS/5@Q_&LXR+J9X
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M=W)N\]'$'!>D$<)C5O636X3/:\#U$4:F1MG#%ZJ<V*/95;C;\# T6X$X$$%
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M2PYX:@D?_@ZMP(DFX=J&T:*A%KN(0F9$[A)[W7ELL*LNEEUM[<[+M!9%2I?
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M096<7YZ \T6[RJ)TX@H35W"-N#:,0 1(@6!X"(,R_A#9XY@<-Q$8QP4V3'D
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M3>QGPHE)PF+B1.3RY H&R\=P>1G04(;)S4 P[(?(I</_=1,G#I#_VE[Y?U]
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M8:&U ()*9RFRR+<#H&DL#=(H @T$^CY,B1T@:F,W J+[0'+X4A)&S_A[00J
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M&*[ (PYX-2PVVMF6+YJ)-W$IM%'VE<-TGVB783->V [XD%Z<1$2B_2X<:?'
MMK0(D3NVX48\ PYB>!D*%G$>'(QRQQLNE(;OUXR570;9*0T-.0)!'[BXO691
M^2G3@=^%29';+B98$T6]LLD&SBT,:)5SI1 GL*;&XI="MVT>7D J]<-'W,@.
M?7? @@QYKPX6E.+;9AZ<S2"VW[;YAJHH+85%Q3?MOF%:+=/HODKGB5?HZ6&U
M=&.]SA,5&6QGEVTRJI6'40ZP_SF+^UW2^L"EM0I$;P/@B&[3#V0##/KC[/'0
MM [96>N0-\WB)O]B'QE2A9.G5_$WVRUSC7&4I >@3)WJK1(? #="^()W/TDG
MA?(Y=J+]]FF&QYY%6/LDP;:LFJNA8%].AGIDS3;B7'-Q7@][=W_BO%N'?\_F
ML_3PJ_3\J=J6]$1;WY >-L*=)ANZ+BOM!KKZ=:AK&IJL&\OQ3YHBS#5(><N/
MJ2BKA07P"N=>+^EW=Z1P#X9ER(JY9:E(A1R] V>3*G<T4[:L+:M&J^K"[(.4
M(JTZ*Q$!O^$%D<KIH%!YU=1Q%';O@@+57H6ZK!D*UF\O7X4[(,3;N%>-[!Z/
M[!JRJ:MRVUR!:[M'V7U!V:?Q)H?/9DM;X_1YT694:UE+-Z-Y5'>G@[;6*P>E
M')]B94^686Y+[U53D>'STL1^ILR8)"R6&D3NGRDE7[/4?LH+=J,Q';+;E#[C
M>P/TSUW)?HA<.H&O=)+!Z_)9VRN?,3-">$!Y$0AG=I8&Q1*Q\A /B_ 4DE%X
MFA>5!PPX^UEBE<=2;/O/11&!VZCPBB=B%%,0^4^L6(%_05-4:TL)L19)2&T2
M-#I6JZ/5*N>AW>0\[#3G82VB5/ T^0[4B"OU\L5]W$?+=8R(-T?+S5G<BW<:
MFJQUNK*B;8KWW1S&-8=QS6'<3ZHAMS5-UM7E8:;FO*@Y+]I'WE!7MV15V2/2
M?G,0T01SCSR8JRER1[7DMK+B/+#JT=PF=KN+F-Y5=<*VA\+0O09I#R!&>WPH
M>)W#0,%KBCO#L8!*:(H[F^+.IKAS]J"#+XZFN#-LBCN;XLYJ4^[(BSOK& 9O
M3N":$[@7GR"HLJJT94.M:CE<(\^-/&\P\;_]Q=)4[<>*"G-SG%Q%.]H<)V>E
M0ZINR.V.TM1V[DDU-2?US4G]/HJ55-V456/YNF]J._?.J!=Y-U5U8/9!R+GF
M7TU"19-0L6Y:DZ6WY;:R8L/<5'8VLELYV5W+?E0]$VC#:JX:I9)4N*Y3VWF"
M$._D]!XD<_TWV[Q50.1.$!H^2!@>=5,L6H5B4>%453@1J3;]G>B-ZZ/D]\;8
M-X%W0]MKL^#B2#(@?"]F7=ALEAZ3QGDC5WM"D_PO"4EB!P\>WF''L4L]%T33
M$2$PR$VN2R0R*-B!Q$:L?/@CB6S'Q1XGL6C=@ K%<8=T.PD?-IDHCG##QGGP
MUO6Z$R<AS J%=P(C_^Z-82C^,S;#R%N]X,O>ZSF"/W8 B"?N@#4VY+TL,PA^
M6A(SW5T6]&HY3!&_# ;A&*9M?\]C//N0\):4CV3+3@_4H Y4'68"V \N;TN*
M[SSQPSC^P%++>,L0ZIJ6YZCU7?B6*^XG:L@D'$JK\]>I[A J=J_>I*?VKNOH
MJR$WUPFVF67T*F]]]E:24^RW$;F#\"$@M6=+#S;81^JQ%*=@KP;4WV7@ND[,
M^^YE2F.>1<L[37O./]YY7<?JFYK6'?1=T^@.G'ZW:VCF<#@8#KI*UU'^K]-^
MMX6R6)(RNH_T7N#*X!3$,+('R<<X'<-@G^?3;O:5\VO5/.>WE+K32N#M<Y>(
MM%\N__GU\OSR_G^EWM6Y=-:[N;SO?9%N+^ZNO]Z>7=RM4X:PO\'_$4;43?J,
MN4%K#K8Z"=;7V)2*NL\]@R^?@D4CE>5[X(PX'I[1@*T:V/%(PGW<([A$Y*C1
M+T,_?!*=97/[)CK'V6/L%PSV+HRB\"G; *+/2!VPL$DQ&#HOH?9:?=@%P:X5
MGK03NH<W&?7!Z7J@1DW81RO_K R6VXOIW.B)LX![HED7W.FO2$^@@.$S$GB8
M?Z;8PA8;>5'.JYM]3'J H28C.;O03V-X2QQ/-0LK-/EB'B7U Q.?)X\"/IA&
MA;;.:/)A\TQ^WS#%:ZV5W;[>2K 79][G*?,\*Y[4!KPDY@3.A 3F/\<&$J1Y
M[XEN/G<'_%>5N2Y[RK_O=EN&:FZ9?M\QM=?(/3=,ZQ42Y2UMNUJ!58-MKS>@
MW:=&UR,Q=U[^CQDU:&[9E^4LSSB>'2+!VZ3)[R$S?^H]!Y_Y<88&W Z<.9?B
M)6?A-3^U6FN*U3Z64KNR::BRJ6\) U2A!)1&\.HD>%I'5A"F66WO/:5FQFRI
M^BO;K;<V6D=JL?Z8V=:<#-(HHM-/=L+AX^Y0_.9[=M_S87?HQA\:BU9KQ:++
MEFG(NJ4W%JT1O+<4O+9L*%U9,?<H>(>2)'K&U3*%)J63<>HGWL1G0<%I+9Z$
M:^GPPZAC4%O+H:2:^I MEVYK><.%/3F;V^?@U_T=M43G6% RXSZ&_B,ZHC/'
M&O:C[?E,8SUODQ!:].P/P /8:*H55R>RSC(KM\_VG9UQ=1+2&[&KJMB9*'+5
M$+L79).K:I5/3C%)>S"R@P<74R19,+PL*KY16AJ]83XIK#E9;4Y6&V"N79T^
M'Q9FU![0MK@.F7_585%VG9/M]DM."+K-,?-B'P9QP<B63J+PT4/=T'^63M*8
M:A0^?%Q'ZIL-[Q[Y=YV!0MA834'!N#6"*O7>1-1HCV#(EFK*>MNL6!RQD8E]
MRH1N:7*GO?S<HL''68.4E\&C&Z]0?P<.E'*BZK*BZW+;,EYTDM[ V;PJEXR.
M*2M=:R\L.A1GAP-O;[K::R@N';4K*\9RW)7F\''+I:B!3V;)FJXL6HPU,KU[
MI21N'K.J[1/'97]]6!JHW1*H=''X_"CP>EZ;.A5?L1W9Z'9EK;.Y^=P1@2J>
MF-8LDF:1J+)B=65#7QYIJ.I"6;LQ7J5J@O$ $T\HWW=:9@9V(NS@[LXK&>H%
M*SZ&2<R!H]#+><R6((GXEIB 88#H5!L<#H<Q#+7_/!_OS9%EJ4:WQ,MN2=+9
MDJ>R^PC$P6A9&3&F!T[(.&Z<^@F#RQ*DBL7 &982OD1MZ3E:3)&D(8%<\&Q$
M]CEC"FA&>"3T4GLP8,75$_N9R$4US_2*0OHBO<?*ATVX)4^N3[6Y5*+MP)1A
MZ>"-01B<,G9R&%[\T4&4KH%'E=TR5G3GN#OXQ7AD1^XI0E@Y!%P"STW#!A&(
M#M+RO=E2,P@,!,;Q8D;$$D9FDX-/NR!9.#\^>WP5W &3TO))C6TO@!=0'3J?
M588@)<!U&.B8*$W/O#L@I1\&#Z>(=39'.2V7_A:3DQ)AS&7DB1,UEX021"L^
MGI:$=?=E(IDC;LT.M*2DG8VRD\E)&37Q->^55C>[2:Q?F@PLL\B=I-%@A%\A
M?L89LE,XAA4,RB<$"9F1'!#DC)_L36+E"Q0X>$E$,,\>+X-G+("?1;M#2E?@
M]*@=;D*F(XN$*+)K)SI274M'KE)?\F)]6:Y>=Z KC6E=22 PB(K%F^^QYY<H
M2FT&9ZM,*<PLTGVJ-Z.E%-1;V?$5C"R"(?F@C*879]$*S.EU-L7N%"DXGL0#
MT).@*?ARO;FYD;Z$=L"?T0KCV49Y"2U*N?$YL)L --+FAE18^%/7.<S9'[^<
M2;_^"XFSEN:#=:7L7&59&Z@L^ RL\<A^)!R0,@6V!,&CP4RB-(ANS3&3*H$P
M=.[V$ZDG\%%K9RBO@X)9T[K"]<=U=X98=\&S1#+*X".9KKB"OT92#^;K"$19
M_#G/@3]C_@^INXPTTI,'3]UX06 /0'5^LH-OT@DB]8W)NK)OOLNN9\^]^X ?
M2"<.@0+!/9]3LL9$^%LJ'8+K8]<.! :FASI<.O$^3-U*E: Y\A'>\C4 Y006
MFPP>:6$/K<> J^WWEFRR7%O$FX07PALO/EW>G_?(ECDN^J5 43!_K(>MBV[^
M4'+MP0AT: S;3NG/%&P[XBJ!)@;UY9,]&J(R/#$^9%?!B'EHPJ7/7.>)"TLV
M9RXS6:A\@5'@':,B)!J7$VF8-1 =A&":[#5;B%=-6G]-P2W+R;!44"_PT=U(
MZ@19G20"1_=W^[LW3L?ELMA'2"Y_D/H$BC7'^=,IKO,' A!AQ)U,1C 2O:4H
M#&$2_E^803 E8>!P>^Y%CI 1$M4LP1@<KNE'21C%%W$+ZI(:1V&K(_M_M\&S
M$/@T,_S'^4]S;4HB;%A'Z,-N(1#DU#QZ,=O)%W318CF87VZ,=2'H#1\T1[XA
MGE=Y<RL8O1T!W<NA[!:O:G2,$(Z7)["3EAC;#FU(2,8(,Q<V+0PSM]B$FWG_
M^=#*P&]K*39SR$8;20ZQPQNN)3E78>)F3O>=]WT;<<-P0D1 [V&^:257.()_
M>A.$;\N,&%GD4 C4>]4LNO;OM<+&IXZ,NQXD(;DFUA9\L\&>IM%F;%N7SV4:
M H'X%][<JJ'"Q3!*&'DP-A"Y$CV%^U*'K-RO*:@235$[,,U/+CP0$*XRD"A]
M@"E(JH'\4RV&R%B 7@8I]OR,S1WBLK(AEW%V;.]G"[Z1704RNMQD%G3V8M[/
M7<EF2DIU3C;8^YE7.;:3-$*P1?X=>%!Z=NT(KT9A^C#*YL@TD%$_[XOAI2/E
M8RK:=Y&_"RP8.#8L,@.W?+G\='TK3?P40[PS;X@GH-T<1EY1X@]:;L!$0S2[
M*/D #W2Q>-V"UZ)$J*V.^5<4!HW^L/M@)OF(R,VS03\&9,/9C_"(TNHJ?V5#
M E/I>P,>XRY^8.G8<%F8+0T_EY0X[[!$+H,L@@,K0AJZ+OLP/@.N)DD.TA",
M>/3 J(C?2@.*C,P"M,+K^-B$X2G>B"]'F%@1M.+.8 :!3]%'(.3(?N3M0[C3
M2B#9<<Q\%K[7X>U&IHG1=X/!"/L"B(W0)/2X%\.(2G?!=# R1YLMYO0ZL$=B
MF@ _^<@)&H"\2ZHF$=,,'H)%?[5^^K.W$<CJM-8;@?R^!WW:F6YHH)IYY&VZ
MHX&,?@.#\X75@Y6,29S ,_E2\BA *W0</Z48V@.J3J^V?2H/OMS8SX.1._@F
MW42@PP<4_84_'R)[3#:WPA-:Z/'T0/WYDJ8(2SC5K >#ZSP$BZC&9&/Q3--'
M;X0<P&E#R?O"V ^PK!]P$>9^XWM-5JT.=J64)FD4IW;N["PCZPG>@'VN-.7'
MFYL;^DO]\4-!(7YVX2_P%\["* SL1R\"O=_S'!G,J^^Y0^8!7,#"#\?> !;'
M@-G-'FP\3MZ=]6XO[O#O=Q]DZ6GDP68/M2GL;$AOL.V?QMV$&KJT7^<;.!'%
M;VYD:>!&"78J$-#<_!KQ=FP_H\84!PN21]<8_G<6+0?-[L/4O$*W5A:HB@>1
MU\_;!&5$E@L=8 H/@Z7 @ 7KZ"+3SA*]+6:<630^%HX<NY0F_&CVE9KCK-/8
MZ=U/TE[;3Q06*CL)87SE:S-%1Y'.*5(6D)GE5$LZ3VF/;L>QAXI[P+=TXO0(
MWS-M(AS/D8(PD7R;3@[!58?O1#YYFQ00&T_\\-EE4F#/''V?7?_K\OQ4[0)'
M029A*=;/(;TL[ ]G=66<]C%@1_T_L,D9.BLBE(:4I%9]G1_CXEE=2Q(!1K74
M)&?ZU\:GQJ#C@/K>H!#+N?O48QCY3$/[LQMUD@54:.*K92ILS:8BW7<;HRXL
M/V!I3LAFY$M7:GY"MJRKR,HOO+4S=_WY\^FGWI?>U=F%=/?+Q<6]U+N][5W]
M?/'[Q=5]9?J,E$O*>=YB;VTL$)Y XF9JW T>L%L5>@ !*?33ONV3'8A'K@N;
MNRC"D"Z9WQ)EO9[:L+0RM5'=]C.70#J67*JWI'^BE^HEI(6(AO]$.\K_?0Z[
M23^,J;$';//3!+W%;T"W6R_^5A7Q63!)L9V^11]]@_%6QQ;_P8(,X,V$/ UD
MS*@?P6PD,AWLYP*PSE04(<:@ VM9&(\D2FDE,X(WCN!#_O,IZVB"BPL\7_[Z
M+"='])59LL&%,3HA+37R5_^+V3V1]\C$)S])\8(XB5(6102/@25N%F8#) I8
MPM34K33E %<P$2&-7)Z;4XB4\,FSX-*8VI+U_\,V\'G'1CJ'QBP@UL:UD()#
M'Z'.K-%C\30 -DH^ON^[-_;^BU//OBKZV/$8I!\^G1)#\@_$-=Q%+>Q(E!%Z
M5NHRRI;F_ %A42JPBV0$$L#8,_N*&6GESB2>"0H1? I3W^&M-%V6<)#1WP[R
MZ!=LWK@XS;[3]N'CGT3@5 1$I^]B-H/)L:#"T]SJBX%+WM ;X+;>"9] 8)WY
M*=E<(*<6(U^&"U99:4"S=@(T'\J>)4TAD+:H,];&0>YCBW)+B^*?),+S <Y5
M\<L5ZKW:-O[B.U]K-;;Q9&: =2RSV"UD/O/(TM? P_5SEV2*:D8M8:<UF A?
M!8-G6G>8 \M6!4:QG^:L=+EIAK>-7&?&W,Z]?^BG@R1ES>_@.P7+@=*T[J.X
MU&D%\<YIV):/Y[B2)S/W+#M,82895EWV'5@.745R8'^8JPZPQ2%&$5A$D*_7
M"68[YWVVLQ?T788R._:XHM)G7T=9RZG+#B+YX_P3+<HPFQZI*^02NZ0R-PJ;
MY(K,$6\LK.+F:(?4]%8"Z?-8^0PP\M$5C7GSS(8 WINE6;/6O%Q'9F-CYI'9
MUXRT?%CN<(CY*]QLY4GO+-Q%+EPQ2R9P%C5Q7G,#96ZZ@5K5X75_6RJC)9W!
M[5'H,\;?X(F?@SNHVNFF^SQ.EX7VF#N.VD+.,R/IN!/=YN+RFGWR;.2Y0^GB
MNSM(R3>_'H(KA2(,1&+7/F<BQ:_)()BP'L"E3)D/@:N61+-0"5#V+2?;MU)>
M1,:,2<8,RI.EN#%50GD8TA]2XBFHGML4\]Y5W3Y5S1/W SVJF@[_5V[!^4$+
M[B,R4X1G+N@]='6#=<UFN;CLD.==\;9W'S[(O&=D(=.5Z G\"O.3 "J;@!'^
M4YPR2[<NZC)<GZ![QI*JG/ZSX./2M#C5Z$AS1^Q@:@((FE4MV$G)#.CS; KE
MGUZ#.Z0G,U:S+1JY;1*JM#!@)8"QZ#U-.Q8OH @RR2"&I[UHZE3<)WO)2U!$
M^)G;V(CH&?/W@ /D4>%#Q$/><8'G4XSVJ#H'$\M@JOQL'__,P&]9I@Q[/5[
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M:KT6!66DSS#(,*J?F!522H7TL).+HJN)A<WPKV3$1 ;,;Y8-RHVGS,*,>#J
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M2E3P-GGVU,D+*(\X9)@)M&<&+UL<HN=B" .; H28/I2B3&3FLGM#>$DZ\6$
MW*;A@9@C/:"['M#A =S,(OLXXL<0OX!!?(JE9C1AAT^Q3/0=8B4/J3,>*71%
M"FD:\,S)A-6*,%%T WX\A_IJX[S$,UA&_<A[83[B/M,1>WXRHC/?^=-"$8'@
M:Q0%" ]C"C%5(<)LPY=S1.Q^<.^6Q5>'126'Q0+P%@KC(]M0%"//Q<#'%$82
MR_2W,6,QP>#*R;3\>#,:9$J*/<1[G(OW9EI"Q OHQ Z$6.@*%MV(7<HAQG\4
MO"_QM,,^$:>3B4_[7JJOQE,'E"]*AH5E\F>*$\*TRCA$@!(AZ%E.I:C#"(.'
MD(T-YN,-D 7)$ZJYVS2./9ON^_H-W^VRQ2NTU%3C.+KRQ'*#. FW]] ZVWAH
M>TP+RUTTK445^P]>S*J_[@3BQ\6?*5*I$.$DNL9D1OG685V';E^;O^PTJ6P^
MM7, _LC.N?WL+(RP8(K@,!->4H !4_%;.J&R535'ERG#CBD6+&#\&]S*_JEJ
MB=AN,>Q)YO17&WS1B H4NRR2]"G$71;<?^Z!-T*N+-@RN^][\8@'[\4A5'$P
MY:.'7WU[D)7HXE%]"LHWXFA%[/0^?S3#PRF><!?GMWXI3C5[J%')"4M;>I8Q
MBDUQ1U2NF\4C/\Y18<?3[:XUVVELRS?NTV:U+%W9ID^;WFE9BOD:K<_,CK'S
MUVHML[M=][>E@VVW-*7S"DWE3/U5FLJ9G?4&>T"=<V_H4&F-ED_;3JJ@.U\]
MTFNMU7_L'G'II"NJ56&Z)1PNU/<5&?,=!W*+:#.ZV"&IR'"%.^5D1809O-^-
M'67E.#<I&/P!N"B]( AQ&^E(-SY\%>?)"QYGIOJ2!@:'*,L]&"IL3"HO#Y$W
M<-E:N[$]I^K#G0C%0,NNZJ,]X5KA0[-4EI&)8T4QQC+M7P?.]C!S D9N)Y47
MQ'/TOB/I7[:?8H"H+D:5PG&_V\_2_[J)]*GR5,YL*Y-DJFBO^IC)V'/+7O6Q
M+G$\#KZU'L)(O:3]:RV[%)>3HBLK[?9KM,+=&0T/NW/+&O.O=F\6K?7"MBQK
MK:(:="AJ)+GFDJS+W:XIM[7EK0GW)\Z'TNJ2836^+!9704NJ:G)'U3>8UF&V
MH 1[\/K-GX^1L*">VFWPUIK6VB\F978&N O'MR;:297U0C9^T]UZ?7UF=+9S
M""KDPAXXCT UZI:L*EMN1!KG;.;4<!TUL75/S?K%2'1=5E5E%Y[=7FY=N_\H
MY9OR5YRB6'Y4R].]V$]>X "O/IZJ5H/WMU%1G+:+HCB8] %4Q54M^;/=DBZ^
MC[Q^(?G@;3.Q@ DM1=DJ%:O3:JO;92$M3YG2V]OE+RT=J][J*HLO;YW<I+8Z
MFK9)<M.,:E)-$L*]Z^Q-U?MA9&E=%7K [O58?Q^3/R?\[ D:N&V)4"[3W;J*
M]*',H_:; A44Y_^KQLHL/TA?688P'+X2>3I_94-W$/.$\O _$C *W@7#L4N]
M'Y>Y&#_N?8#2*'*'P P.N]>W@V^G@XE' #W=!$;7&B5 ]9)6G"LZ5<F\89,]
M \V7]_[LLWHC4:E4P%2_&=G1V!ZX*0E C/6 K?GN3& I[%F7LU$SM58SNKIO
M-</F7C4=HU1=QRP=(-<Q-B[[/_53/BX=7'72+6?( :Q]%D!IB["7;N:JL?13
MU3BQ/X@TZQ708ZB+>DXX0;54?-<=;SVC*UKV)CL"5>C&I]????=9O$13%*V:
M6J?=J))Y5:(UJN185(FV5)7,@_8UJJ11)>NK$@V\DD:7'(DNT=9U2QB0K6B-
ML%S'J);TM777.FME&D+5345>I4:Z2KNN:J39![THW**V+J_NWD[GB&.]RE#@
M\NK+Y=6%].]/MU\DH,0]=6LZOS[[BDV:I%/I_I>+DM_/KR_NI*OK>ZEW<W/1
M0U!#?N/]Q6WO[/[R7W!O[[XG?;[\<B%]NCCK?;V#J_=W[#OWO9_OI-[MA73Q
M^Z>+\_.+<^F/R_M?LG?D Q+?VSI6W:RWZJVWN[-?JF#C][W8[GO_OKZZ_OU_
MI8M_WU]<W5U>7TE F8O?>YG4-T)_.$)_UOO2"'VIT -ESKY^(3Q<"6[\[5/O
M[J)9 @>X!,XO/C=+H'0) &4NKRZ;%7#H*^!+[U.S DI7 %#FXDLC_(<L_#>W
M%XWPEPH_4.8.A+UQ@0X]Z4Y5C'T'FO8Z_[/K?UW<2C>]GQ=%BDY8:XS[BW.I
M=S<5">I=G4MGU[!(X)=S##==_/N7RT^7]Q*HE@^[72*J?JAKY,#2.#<Q)Y6W
M$9\]1%?'SB((//W2@.>Q2<)AB4(:!0RU>#?B,%>0M)]BG*:#UXIB)7TWQ4KZ
MNY]J7ZQ4E19>=Y<_7_7NOX*#7FW\[N*9-FLI2=T.61NJ]3)M9/X@HO%'^"KL
M(N&DV#3!3JG9\XB:^U'W'];8$INI\(['\)F^.[+]H>AQ2<?__ 9J0I@&V$D"
MWR>PU%UGONG!,>*!*]WN-D5H5DNS=H^PK1FMKK5=N=BR:UI+M78/,JZWVNU7
MP.W6MP897SY8I;->P5P%"&NV#+5]7-5]=;IU]VY^=6_MUL^#7U%B,^7-[WG]
M;)"%NKM;MX_I50\1Y=Q.W(^[WW[NN3KXD161J08K(JL3(D?EM<.GYTWDY9!F
M_D/\@_1K. JD7^SQN$P+'EG<JAQ$J<J+:XU;UX(CVM5[*B_R;R7NS:V5%X5%
M-5+H)IYC8*27!4;$M7FA68@NM2ADU@!%K1-[-1;'7G_HA\XS_-\H&?L__7]0
M2P,$%     @ =XEN56:XF&"T#   "X4  !$   !C<&EX+3(P,C(P.3,P+GAS
M9.U=;7/;-A+^GE_!TY=+9TK+DA(G]L2YL97X3E,[UDA.VOO4@<BEA D)J !H
MR_?K#P!)B1(I@M1+PY;.3&R)Q#X ]EDL%@N0_O"O1>!;C\ XIN2RU3DY;5E
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M]X?+ \&$./^OBQ^0.>DQ2$#F':CB)81"OTJ;A4_&:)WY?[W_ 8L5CH<"VJ
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M-/E_^XC3#_C+?+8\[">.%1YE,9!E(<_ 2ST*4W,P1AH9F2K*MU[@W!;KF&+
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M TB6M([=6C8^TJ8P6^EFFZ8PVPAVV[.HU8_+EX!C_.??_C]02P,$%     @
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M1$D$!8]II!6B.E$^=!P(]!Z9N7?(W9@Z+) =DW8I+-B2%E3B@DK>*U!)'([
MW=$)Q.4.$_9*Z^X [#.\QYU^9"]>BA^C6ZT6LREGDQMS12'8^"_JF:O9*%-2
M<:X09$B;'6:JC<671-H0?1Y%G$8)P8D+SS1-,C1F68L)5G*Z<4DCD,WL$0J>
MCOGB$!GP6R6DHS7<")&L??VEH[ISJ'9F&\3#Y,RF+A!4_&FO+$DQHFE4$F/C
MO;U0H8OT*_)SNK:=;?MMR<>%^'51C(VUK.:WDU?S,$QG;^6N+).499KD,,Z%
M@D@F"!(D)%0R52HF3.O$:[?;--G@Z&\E7#L/6A.LCJZS0&!U38:N./G[R!P
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M(T3<\&M^E4.@TO&K? !(FR#'8\CXQ!1=AE!?447.CXYG<-%I[9O#BX[<UV.
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M!2.(A/F#2(4A-B2AB/F?&*>CB3(TIN2C.V.<FL_IN:?5<W\P:W?OP$9<,)V
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M5=U)@.@Y) *QR\EI>J64<\KN\\C9Z]M7M)W.=G<8J]"EQ^D'554K47(4F=U
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M.H[MJM6V15#7\?,&B^:J5>,PC*O^@LZR=7Q/VYH>,:)WKB[SHI^C.!="^DN
MN-$QG8O2#ND(;8_P=CL;ZDO1)T]]L_L8\R^>[_2EVT?T/E<0HQW&7M[E:T1T
MM35W2<RPFVU7E#W;/KMV?=B[:^S[8EGLQ56[VR17F*,L!<8O,BLMH0C(60*!
MH,K6E48T2;UB-4\%C,TO.MF>GE8P/0,SSVATF_IMR+G!=O_P>_N7".K(%)P]
M?E 3<$FYTZE_\;K02 &V+CJ./.EWYDLX%U,VVU9H]?UT.3QJ5.]T!=>>(.X
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MX\_J[TY[@#;3T9$3<?+P01V(>L5.G8<+5W768^_M="7,"GNS/.QXRW3"-==
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M-6S^EX/29VE@+O>$]J]_, ]9LME[L\[\Z]_5SPG.:8Z4@""/$P1PK'/ "2<
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M!""=(B)Y'C.:;_E^\4DJZ)[TEP%,^C'S)>5WY:Y+U\R['D5T0>10QQ &:W0
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M_NV_;7]C_K!UP_[MO_U_4$L#!!0    ( '>);E7)94-,S%\  * F!  5
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M=F;KRW?#1?=IQL,%VP4^/G[&V>R">AL$;7C24;R4"--"$/4)+60=,F;)$9O
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M['QN5*"/ H8.EL11_M^G9_?(5Y\6'Y X2M,9WB@U^[1XJEIX*L8;PR 0NQ1
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MI/&9)%8TB!RD3S8F6P;H6+(C=>.V@^H0H8.HM8M=_"YO1RG5B&]%DL?IUWH
M,Y%6I5 'CW 1B2O!-#B73;WF8FTVP>3FM:B[T#7ZC+-!4/$H^ Y44!<=+.YR
M5;LLS^F7:-%.1'$N%1&!Z7H3U!EB!Q6#;'WT-KG,^0"GO/<3-/K$LW& MJ]*
M.D78ID/SU1YQ-EHB)2]XM!*2JUW1T$?PQG&0&)DK2B31?"K:;I2-WD=]',P=
MK*11P7=?1FJ3C5I?LG61-)UN1E;87+@UY-K*5$=4)G#"6"C12.Z8MD&IFP#<
M/9MX_VM'[[\^)+H&UD*G?MMFY=1*F3,VKW,GI.5,YP)6^U*G%1CP@1.S.JF2
MG4$S0."[.WVC]W@?T=0=KK .*IMVKY_95OLU,4(;ZV($J1*"8DK7 2P:)&.Z
MN.2]-:WWX,,H'A>PSURM](S*[:!YVHZL;B_6G=A,%D"CJ9WB%*@8&+AZ"Y#)
M)%Q!G35O7;!_$,'C9L.?&<C/I]H?RB1/!..*=C&*Y5PQH'(=EUXB!VT9\<4M
M;46MLSN[4S=NLKQ;4_LDI75@5N_A[&RTUG9!,H'225N@.$$;1_0.(J,_R!=W
M24;)3&S=2>OI5(Z;&7KN>W:MU-5%!/4^?#\_8SA*_SB=+I&XI86V_OY^%N;K
M.GV0OKN9ESS17BI):PPBUL6F<P9/X2&($D5VW#N>96,H[DY=E_?TFB'E]CV]
M890V?M*(^$B(>7-!YB.NU[/S=?V>'E]CP_7T^*R>M23RH[5'"-)ZDAYZ(%\$
M@;P3GTO&(..M@\-[\D6[OK'+*WFM\36<#CKP!:_S=;<0KGH33.O"G>60,450
M,G&(VDD03MA(8)>FM+[3_BA17=Z0&\RN-551#YB[;:BOIJBN)M('Y@6Y)CDI
MDI3-"8*W$KB3)<J2C)+-X?8 /5U>/GNV'71?Q?13=G.'I8N*=US]95FKB8HT
M7#(5((<LZ[PX<H7I.T!4L\1"J-=(A\;;+9JZ3"$^&^8.45#'N'M#*IP?3^,,
MSP\N@_$9D6<(@E>C+2V$VG<I2(Y.,938O$/EHT1UF?-[1FMW@(JZ*&S878(3
MK3,Z[P68Y#2H4"+Y##J"E$61CYICXJV+#'>GKLO,WE X'$AI_6;V+F\W;!&D
M*SR&HAT(5:U][2,;I S@?!T!$"A*U>IY8/D E>.&'\^=V6NEKCXR>]>"J0_X
MY7P+J)? R.<@@1)-T_6$2R&BMS4AI!FH9,CP.\,@"]1:H/%1MVXML!-A7>;S
MFN'C@;BWC:HZB'VO,_+;8HTK\D+.RG2S<Q[)E@N*LD )J\ IZZ%$E:*SOBCG
M&T/N/EJZS.H-A;(F"NDN[OAEL7SL4O86@4Z4#H8'E& 5.A)DR.!SLE#W#<6B
M3SJU+JX^B. N\X"#V<-G4VT7L<Q%>$;\TAH]7:;/886UU\#)R6+^<;U(?Y]D
M9PL+/H#%Z.JL"@[1N S%DK_MC52I>;O5QZGJ,F,X,"9;*:D+X.TNPDG(B*J>
M[C!MZU@RY'6H3X&$S"1T2J;R3-6)^QK'YTXC#@7$@93601!=V:K_U=/KKV&&
MF]M=)+%I(L#7'QS-\\UO7/OD>UQ.%_EN??%Y1\77W]*FE<L'6CRO2T%2@F')
MI4WG"U-HN3I6Y4]R,B8F:X5/@K<.?9Z7PRYSG$,MBX[!\Z,OK8E'5SR9#Q"6
MUYY&&,$[DT#Z(ID1B*GY:-N#".XRJ=HE\)^DVKUQ_&6SO#ZNPW+= 9J-U5Q3
MA ".4<RK JU:6KX%K+.1F5!XQJ[L_KA]"'XH-#]%M0>B^?7\N@\^RF271:F\
MK[_?Y*C%5)?+)S_C1)?MW+2?YK*)U3XO9K1L5F=OO#I28*R4; 44GA+!QT>(
M=0:"#ZK([+(3L74SR)T(.[B'Z\5+/FWR?2RC"9(S\ETP@V+.G TO5*&(X!AF
MEEM?=;A)03=S61IAX4X3UOWEW4'B_I+Z,XG4/K*+>36O1]^FJPD:)WQ(-5D<
MR&&H,Z=CT06"<$H(6PIKW@7E08(ZP=(>FKX/- >+O0,,W>+AU>(D3.>3Y+37
MT5G04I)CX+(%CU(!5R;H(&I!>NN9>5L)Z00SAROZ]K3:@Z7> 72N951_Q>I*
M3)B0 GG-8)%S5R=<2/(G?0$7,?.@R+G3S<//VT2,"YD&BKWM9Q\DY2X*'#[@
MFJ2 ^6)&\SD?.0FF0V&04R3+JS+MV1@,4)@;3;(RJ^;WZ+=3,N[A<GO(-)!W
M%[C9/D?GG)N8!%H7/&#.CKBAO=R3<* H'H7R*M,::7W.\0 ]XQ[[ML=0,]EW
M@:3+G9SB87Q#7]:Z14E"\ %XE+'V+/$0LJP-C(41FJ(&+5OW/KA+12?W<1OZ
MQ/L)N -OYNZ9PMV8\P.MAE\6RS_",D]<XJPX(4 G(VKQ H+3T8 I*BI6F"^\
M]27;)Y+8B?.\)R(>[4?43CT=H.^:EW=W"'9Q)0M1*,A04H.*SH$OB7C1F;M:
M0B-BZVL9#]'36Q_3AD"XW_<^3"O=',C<E=5>HPP%3R:&*(#7NFXE= 276(:H
MBR6G0[*@VF^>+2COK37J<-@=0=-]H?S-:G6*^=7ILG)\]H+-&KYG\):G55NB
M35"B)%ECS&?C@# Z89U03+)!(/TT,GMKLSHP?@?480>;_CTL;F8 W<.A$3QG
MD2B&,X8V'88.@A4*<L$<%5+$9UI?D7LZE;UU:WUVD+;28"\8_8 9R9?/[Y8O
MPVRV;4%.7,PA<X-@SLJL\N:&JJ3UYZSW(87V9:<[DM9;N]:!T=A85_U<(WF4
MN\VJFP0I!9,N@$?-0=5BJ2B4A<BR=EXJD_RS W%#V;A%GEWA\.F:Z@Z&%Q<+
MMJTOD4U6G"1&SG.F]24518;!0?+<ZH@DV= Z-?0X5>.66HX OU8:ZN("R$,\
MG:TF27&:XR5!5K79=R39^20D,"XR.B,2LZV/[!\E:MR"R%XP]W3]= &Y]\M%
MF:XWX\UTT$S+HD#G2)(QQA+M=?6HK)(02>O;3?Q:W#T_?_M.(/+_#"#:4^(=
M1 D/)DJCS=%;GH&+&O%H1LC/)!RNHO4."T?%&J/G\/0U^V< 5#.U-"W!'CU[
M;90G;HE5K!7O2G$#(=7*+4NF68?:&KTU()\Q>\W_*8Y>1E#UCW#/X-WR.,S/
M9S+3CU^$U72U*.^OO66?.P8[/+7I_8*G<M'H;L'UUU[=;*A0FN?K+[\<=AUF
MEZ?8U_IJN<B2E 4BK]UTN33U%)M!DM8Z7ETYT]K1;D+XH<;W("+JE(K9HD[.
M_43*?#&KM_#1J6Q*2L"L($%F86H=(P,T6:)FS)3<>LQ3:Q[&/0I_?CS?MM*C
M8J*9WSN0K;XHOZP./46"&P]L'^N\]3E-[?'CE#:RP!<ONGC)%0@S%F]R=144
MK]WO.434",4*+27CQ3?/7MQ'R\$W*FX]]PK<WA,SG+P/X0G2ROA0!X37>KO(
M-".W6\36C03O)6;D,OD6.+ASJ:*)X'NW*A_P*\Y/<;6/);G\W:;68SM%K>Z#
MXG'=+#[@E^KUSX\OD1+1:JDQ@1:LCL!,&H(0CE0L<E2:.^F:7P&]AY:#P]I;
MS]VV,6JK0W!<@9><8BF;)(3(&3",41E+L53S'O0[D#5RB6D+;-P)/!LKHW=[
M<GUN^!XFY<[8\596Y5ZZ&AF6B^=_OU+PU>!4Y5+!I""%>CR4,NDWE]HF02E1
M>*V%;S_0_5YR#J]LO_/H*R@+06Z_K5>!BG6@I!+@0S20T&<9DTA"M7:\'J)G
M[-KB-IBX6[S>2 .]&Y.W-2VXEQTY_\VF)F0;-8VLQ]FC+\'AF<E>%P-:,7);
MD2<(BA4(Q0D?#3JTK7?GFQ0<:B/>UND6>#5K?//P*XPZ*9-U08.-]:R@GF Z
M3G\4IB.YZ[ZXT/H&PL,4C6LG#M#^;=/04/"]&X=-4'8CI4\?>H5QO8^]N/]A
M34W(CC0?:%4VX]S.VYJ</?[*E;4L&V<-,%G(E>6T.P0;+93H1(A.%W%[K.@]
M\_.V/K[]@5SM5[UMETNIA#J.@G9.%D 51<XS6D%HMCD6ITH)K7MY[4S<.,:D
MD=(?/SAKH9+>;<N;.7V)G\*W?:.8JU]O',7<0U>S*.;\^5L\UA@\QIKK4D+4
M[FXJ0^0N 7>">Q<=\[Q]%',O.0WNY]Y^]+6 /">3141@(KEZAA'!11LA">DR
M3YDVRM:9U8?H&3N*:8.)+5=PVVB@=V/R;OT9EV?<[G6:?NW7VQZ;WT=7J_/Q
MJ^?7T<3?ZJ65:VYNT5;S8APDPPTHECWXJ$CC7F<CG+/8? [2PQ0=?*)]X^F;
M?YV_8BO"T>MDK((0:TE>K">FM$\#2L:*"5%GU[J?VI,('/DLNAUV[APR#Z:F
MW@W1R\6,8+NHH>%7/#I>XMG!^3Y&Z;Y'->X;N@.]717SE"*+X<5"%HEPZ6EG
M=#8(T(9+E8PNL7F+X2Z*>6YJ:KFL3=/K"[;&"9I%5ZR&4G*A."$[<$PP6EM6
M,W0R)-7:[C^!O'^&$IRGH/!NC>\PFNS=-A[E/*W/6H7:9WI]NIQO2@@7^32M
M/TR//^]G)G=X:E.+^50N&AG/BX'&+Q<GD7"YH> JG>D48P$]1$0-JK;6]5YQ
MR!)99B*C=:T[JSU$SZ&F;LNSMZV-$J5'+SFP6+M?&<XA,,L@6(XY2D?1S3-P
MW9V!:X:4VW9K +7T;K(>+WM^3_M'VO,D_@E/?^9B[NU<=>4'TNZ70AU IWVA
M_= Y :'ND1ASBDY;9IJ/NNS"#_P-_SA*:7&Z&=Y'^\Z<ODQGK]AH[?O9G]=*
MZ:S+"2-))A0/2AL-@5L$FY)GT6>=4NMZ@:?2^,_@$3X%CW?GC@VHTPXN&_Y>
MQ_F]7JVG)R2VU809)7QD%.LG*T&)R&@[BA%0EQ),$<:8UB'<30K&[2DV/MX.
MT$<?S6%O5?QM7R2,>::8S"#KA!R%-D%DY/6(Z -/2>KDAR[ W-_:#=81;'ST
MM==>0U ^X\V230_?O1S'!YXV^"V3;50/?==$"A480P4N%D-1BY$4M5@'B1<;
M' O6Z];WSH:Z:_(Q?<9\.JOV]]8;JAN>:EW!='9:^]]L;LE>+H>(M-H,BV"4
MKN?_IC:CD RR,HRE6!)GK=W=/4GM])[*4S!TQV(]@])Z#X4O[HSL;[5N/6&0
M&RT#6J=[[RXX\KH3]QD,VS1G*QQ<* 6\0BQ>6M+]#W.OY0KH%(NLO_]MFO'-
MO"Q(UE4WYU+^A5;=:Q+J<AYF+T]7Z\4)0?#%]_,DZ(J6PT=<?IVFZV61R-%S
MQR,(E<AA$-Y!T"D"TYP;IHSUS:>L#\9,IW=HGH+#!RS<B(KOW09>N^&ROQF\
M^Y"A;N$,: P?NG<1@]="!PG9TQ\JQ@(QA 22(5K:]+1LOM0'O(MSM3(N7_+R
M=%D7ZJW-7BOF,2L++@E;N\OS.IHUU2OQR68;C+'->]3L2-O8U6UML'*_S6JH
MF=Y-T/EU@[VMSXW?'^#NSH VY]8=CB*-"LAJ@D#5]GQ<@BNTYS'M W-&(PNM
M6]RUN<&S*2,_6JUPLV.^G88XG6VF/)_=++D%WD!A0\@R0/(UAN!83]*P]@#+
M#FUQSLKRF-*?],:N+NH\1<D7]F$X^7:02M]V^^B"Q>^_AO7IDOZ^Q6(A/XLS
MH2#6;EI*4^CK$MF_6CI,8DT"8^LZR#W('#<IWP!WSZ6B$5&X65H7^^ZB?"#!
MGA=VTH;P\918VC29.ZLZO\&@X,%)C@5*H.U7%:<@>*D HT;:BTF>,NYDQO9Y
M^[@9]U8F;7"Y]^[[/%YZM;]?M/.SG[F8;$!_ZL%"(9L(B)X,DB(W'%22#GS%
M:XK61DPL\N:#[(<L*;N*%2[><I3^<3I=G4G_Q?=K_WJYV!S#DV+K\=@T;\SX
M8G[MAF\QGK,<0(=,081##:$83JM8)?(D/"<!#1;H'4Q^Q\5I3\'<_<'@\RJX
M Y?PBG4*L+\L5F'VE^7B],OJLOUJC;LW/)]B/G=+B/&S[>+R;/=%( .5\.-G
MQ#6YS1>6*<RNHO9K63UO5%(AD4PR[2CDLU@(&%F-L+&H;*4;,-GQ;&R.ZY(^
MPUKI$S"]^R&/UT]>_\2K.MM[-E"!Z+87/7.MZ*.\=E4VJDQ,P3I/X7YMS\%Y
MA%"[=3!M'#<A89#-KT1V43:ZT?"[<AF6GA\CK2;"8RE83\)EEK5>FU:F1UZO
M!2N,)I32OC[T/F+^&0I!GX*P.X6@3;34N_W<5E9T@)5\Z'&#ET,-:?'NK67A
MBA?MD@;#&&W^F<)[[U@$+5P.UB>E6.O4=^MZJ$U&@^!><;Y87BV>F!U+Y!<(
MK#-WLL\063*@#8O$IV5!NL?PL/W1G98E/465-[)!A\FNBS+>,X>RKJ9:6' 6
MEIV2E&ZXG$^?("$E\]$&)->8!$EN)X.852+7N&0TT47A6P]S&X:3$;L<'8BN
MK7U(1E5T!W'Z32ELC[%^P_6[\BE\FQB+.E3?P5A+XO8Y@?,Q0')HDQ3,B=SZ
MCL13Z!LG,AX<F@V5T@'@KDTG<\&D;$L"&^N4AA(S.!X8*.TY22>BP)'GP34_
M?AD +'L*M ,H$(2OD+Z3<4U&QI1E!F8S&5<C/80J-F^9YE)YU+EUH/QD(L<9
M6SX L(953Q?#*6^P.*$@-G'T"F3$1/MW5A #E^"U*D9B9-JWWMYN$##.B/&A
MD?,DL8Y=1O *YXN3FM>^)@DIC8FU&V^46I(DN(9HE 2C2W"%,Y;X;L5.6QX^
M;C*_?0!XJ/RZ" '_AO64&_,1/30<XT7^Z\[LR\T]FTG21DHI"I3$Y'F53 @%
MLI*%<R5BUJU3E4\B<,2 [6 T+)Y+,1UX0UN9.[_"=8?#H_R_3U?KFH6=T)9;
M@HD>K#2Q-N0L$&,=P5983IZB &+G.?#W.*DCQF?/@L3&RNH5D_6$=CNC$U3>
MV<@]2&%IJT=A2:120!!6*!>SS;KU+8LGDCABV/=,UK")<O;'WF(=9J.>UM3C
M_=,P:WQH<_'4YSJ[V<K%T$<X67&'414P*9';YQ2AD04"9XA9*,FU:;Y\A[K2
M?C1?3W-="=.O^!%3+6^>XNKUMYK1Q7R6\3WY<GIQ=GJ'C)/:^&9BO%0Y2)(%
M"V2N*2""6&?L.%,$F>UZ5:=U[_,FA'=ZKO04?-VV=L^OT/X;>%Q<,+]>A+WY
MS@$'UX\^<Y K\KMQ,/2E>>M9S+3_@L^1T&&5!Q^X :8,@;4PZTWK].(/<VF^
M)OXF)7GFHG=0LJX31:H+P<F1U5Z;Q'A.@3<7T!",='I9_BGX&_RR_),5/F*\
MLEJN)^<\O%N><W#T;;J:!$5!/N<./!,<E$^13'UT('BDS8@",9MW:H-!+[@&
M5OK7%5#O>_?(&!L?#HN&NND#6]<%\FIQ$J;SB7%&!!XVXXYHR3)F:YLZ!5)J
M:[F.J--.7:!V ]A= L9!61N=W@7(@0(>^_3@OR^G%&W/R/?[%:O',]%&$O75
MPTTVU.XG=9R-1%#D9R9F<I2>/>:0;7WRZ&H_5%.+5F(;6^<?PSR=KA87E(>4
M7; &-/>E#EKD]<HL VFD\T&F$&\[2/?=*+W^V'$2IP-I>W^!C:WJO[YY<?3I
MS5_/*4]*%<4I=N2!,U#2D2@$)P%P-%K)I'W:[5CPQF/'R4\.I.K]!3:VJE^&
M65[,%LMSTDV*V?@ZM3E%\GN$*>#JO2'NG5(&-<NWQT[>H^N;SQVG5&0@91\@
MLK&U_=?PA;:@Q>R<="0>C989#*]=7ITG$01R=:5!E8H-R<B\V\J^\=QQRCN&
M6MK[BVQL;1\E7(>\6%]X&R40\5P2-&VI[:8=!T]4 WJ5E,FT0^U8WG_KP3OI
MV_P@^CY$:&,K_-T)IEDX67Q['_Y^3K[B*7LN+119:Y)X0 C%1S#>BRAC<B7O
MYIC???9.:K<_B-H/%-W8FO^ >?IIB=\N]B0K)/>64SBJ*9JH.8S@#8<<*,0(
MA&:[HV&_^=R=-.Y^$(T?(+*QM;V9Z7@AD@NT6H&,B 21C )E@@4?N8;D21JY
M4(R1Q&X+_>[#=]*[_T'T?JCP.JA6>6JF\^UTCF_6>+*:D%.JBXD6; U 54D2
MHF>.-C<6@C1:H&A=0[4WL>.6C/:35WY>K7< [XNSTJNF762AC,@&+,_L;$1*
MJ$+TG!8H9]S%YB-K;M,P<J'!\ZA^T5 /HQ8X;PS]Y2*\+/;V.6:G'616%Y_F
MM'DD%2$:YD7!E*7:+?ZY_>1QP7&8FA:M)-9%1?NU-5$ONE8F_C9=?[Y8%V=5
M-/4D>K6J?2)SO5?HO)2ET.I 9AVH$ MX+<G9)_?"61,#NQTBM;(N3R%SQ.KV
MPV"QW:@,IJ'>VV]<KM;+CDW73'J#<J8'GSM(2=/NG#0J:[KL:W4U?$%AS#QX
MJ TU*1A0Y%;98$!:94Q1.<?8^FK*'2+Z+&1*TBL,SH,[NY,6#05,!2$R9BS%
M.>A3ZS&]_X2%3(<A[GDJF)ZBZ3ZJ3&Y65$A5HE8F@?&U9M8H!\XX#LX*+WTL
M*NJ=&H?\GPJFI\/AL0JFI^BF#VQMR1CES'P)QD!BM6M)**%>S^6U+CH+'8VU
M8:>:SG^2"J8GZ72G"J:G"+B#-,-?EF&^/D\ 2LZP7L\&J>M(7^G)PPPA@\\Y
M61Z1W-K6,PZOO7YT9!RJS$4;R78 BOTS+<XPE$R5FLNK_9"JK47):W=8E%BB
MH3_^3VJUKPWO>;4^]K'1.4,?,"V.YYN0[=?I#(FC.;X/W\\Z76:T1;(L*,".
M 50F#]<I[H$8\[0[4!C.;L4+]YX</OJR'S6G^B2=+P940 ?V<I]TCE%)Y,WX
M#6-KSR;:%R*Q!3D81"P2E?Y1$F[#=2QY5G0^ES9[3\Y=&]_X6UC6!G1?#[EB
M^-#CAAH[^3#=SS" 4A=+>"N$OV!DG=\0P N-%%<$\O>X8CFU/F(>< #EUN&&
MDX1!Y")-G5-68R<?P&5.3BVMNUA\+IJWSC=N):3?T9)/0<'=KI"'RKR#C7'+
M()1-V.T2BTH8A&QJZSCFB0/M) 3F! 5*)@77^J;]/:1T I[]E;QH+_%.@5._
M7"*>A^:B4$CN*<B13M<=E^03"S/@56),1^D<-\\ H1M$]3'8Z"#5[P"G_?4P
M=NSWIN!ZN8AA_I)^/$WAHI[=!Q]%,!IXO<*HT N(AM=;2BD[DYD5=K=[7/>\
MH#]<'*##16.!C@V*F]>6O*_#++(AY3H$1=LWA& 5*"4E]XPL,G_4X]WSGM?@
M4YP& ,#^PAM;[3<O)N:D97'$MG I$V"Y A\*,8*,\$ID,RMW4OO3;W(.-O1S
M0+7O+[P.?(OWIW$V3;^OST<R7_I@F\T24;!-W;NK?KLR)4+@# $5\1:,\P);
M#YU\B)YQ#4=[][29[#O&T2?Z_?,%EB01GFCCX]D*4+8V_,NZ3L)%6]LC).]:
MGZ@]3M6XWD@[!.P(K3W5,?;^=)]K%306E\E(2S+=)"+F:?4Q!4)XRZ(QR47[
MX_JJK96XB[/Z%(EV8'8N97*5[49="C>* <9@0 6MP=D8P&8959'":-?ZU/4N
M%>,Z.^VWJ@/EW!-2_AIFI^=G)RM<?L75Q#JGG(\*;#&$^5SKECTZ2-$44[PD
MT+=V<^ZGII,<W)YZO@\VAPF])_C4^1]GJVHB;8DNU$'4R2>*ZY2IO7H4N""T
MBZ[0SP;+^5^1T8E7W!@P>XJY)Z3\0AOKZC/FORP6>37QCG'/%9E;7]N?A\J%
MK]<D+!,AT4I(MW,I[<!R@Y).MJ;&>-E?V#_0"?15J]AKWVQS&OW@HX<ZF=Z=
MGV<XI4XA!')Z:0?BV8%"R2!JZT!DZS1S28GLAUJ@ YY2UX%$=9EMAN:=[[Y'
MLTVI2*T)N&3?9^ZST@)DHD!31:L@1$[20,5<)->?^\'8WY'&3ERC [%S_Y8W
M@*:ZN()YR>&'\,>O@1B:AMD-+E>34$*QC-4!#8*1-Q@M>%42L:BC%^BTT.W'
M:SY&52=X&P07]X&PC8JZ@-VFK<<E8Y=<?3S]\F5&^\S1//^*R_2YC@A9X>^T
MNRSKD/GI\7PSKL:'DB5C&J)R 511"%Y8"2:&6(0I3N?6$SH/(KB3,. YP/I\
MBNTVG+BY-),PG+M:SQ!5+?#4 :(4#ISSSJILM(^MRV=W(*N30.-9S6<C)75A
M/R^9^LNRSK(T)KAHZWDV*@F*6Z28BD*L$F24CIL82VN#>)."<5J&CHNGIXN^
MV?BJMKDR)P+#C*F>3-3D,WG(WA<%-G@?HM=6W>X_-UJNK'D?TG$AM*<2NAA2
M?%UB$Z,B"2,ET)LF-C8H\*Y._"Z:_$^-QC3O5';]_>/T-!T9.T\4>^^YM+<8
M5FTN<MSSI*:9LEVH;908.WO5)7A"=*BBMY"%LJ"$+!"DB^ D,E$D$U:T#L=O
M4G"HX7A;+R/AYIFO<)66TR]5#6?GH%G+F-!KJ"-R0>F0P7%EP&LF4D;-M6]]
M0/P .>,F&0[0^VVCT4KD'<1<[Y>++[A<?W]/JW)-X>3K?YQ.O]3@\<6F]F)3
MG>.9C-D48BF&.B2><? ,?>VE%Y)V)0O>>HGL0-;8:&H$@=O53(WUT3/$KA7W
M6(?TZNAH#?H,2M)7,8@ LB1.2U.$%)N77SY.UL@U4:VAL"O4]M1+!U![<4H2
MG<Z/SRN\N)$FYJS!<V\H"-")@@"9@:E2(C*ON&Q]T'.3@DX!M*^"[UP2VEO:
M(_=)>E?*-.$M^I'1_[!0H&@E>039DE""T\!"4,$%77)H,45PV[O'S6@/A9,F
MDN[ JFQV^8N6 *=A]@F7)QOK:XC6R&FC]UA;<T9N@622(!J'D04,QK6NBKJ/
MEG$1-)0WU$3RG2+H?&%QQ9C* DG5ACA)R&F)10O(;0I9^VQ8Z_NL]U,SMD_=
M0ML[0&@/T8]]+>#%<A'R'[A:;_CY9?H5_Q>&Y0><XQ]A]FZSW,Z-JTW<B.PC
M,!YIO?%$ECHY =*'(IV5:':<1KGS*_M#S3X*7@PN[2X,T39#_?:R0)&V^&+1
MUGXVL3:^,V2L:^_\$@,+4FCBJ'7'W$=(&O=H=;B-K9T>.H#5T1)#3=&'V>L5
M*0<O/,I),%J;1"SD*,AM5'YSL6MSAR<)&0*MC]8GJ??1,K:5:JCPQ0#2[P!%
M[XAJ4LC\>".FO^'T^/,:\]%7^NXQUE+$Q>E\_:$RB,M4#_F8R3DZRX$"SUIG
M("GBM*:VI191VZ#J7-G6A4M/I+%'O[P-Z@;55N]H_(#5P;CX874Y^*0ZJ9IG
M"3)R0ZN-Z=KG551_@*)=YXW 9T7C%AI[W$R? 8V':FMLY_],<#=9W/R1J^F?
M"&TSA4<*)./AK.8JA,J*STE$)I/QNUT-?O@]XQ8E#0&>UL+MP&IMXZ8"_EVY
M")$F6EIK=<P@N".O@*,'[\B-Y=9IRRWG5K1N3O X5>.6*PUIF1IKI$=;]-NF
MKJ.ZH)L N7*WF@CT3BLL8$RH&>--=WV2G@NTB)+VT:?=IJGO^L9QJY:>U3X=
M+/!.+=4U?B;.EB2$<J!5G4E+BP!<KG=A5?8\^)2)V6<P4]=(&F?F\U@V:E]=
M]&B@7ISQ0S&(8'6:6FT=@O6,LHC:F94!Q1Y>61\LX_N[2A=O&6=2]"B&:"_!
M=F)\%LN;O%QTH?^T>%&[U./T*^8)AI("T0CT!0.%V4$]H 2M951,6.:;-SO>
ME;9Q!E,_ESEJKIT?HV#WC-?%6=N^@XMVMSYM@,+=QZD>IGB7&Q^S(&A97T>7
M:]J2R-QX"$5'RQ'1-D\ MBW>O;7EUJS%N_+["NN,@?5$A:2-31J2<QZ4BP*<
M8P:TE81Z4YA*S2]F/D30V"GTO77_<+;H$+%WL)?=2EU,0ZQ=U"X:8I&-U"PY
M%B $)&L<980H60&>"@O1R1ASZQWL88K&3HD/A**#!-\OC*[=J0IU+EX("5AT
MILI*0\@F@K%!JN@01?.^/H\2-79&>V@P[2G^\8.PZTQ,HN19,I'!E$RDR\T-
M+2E 1S0A!Q3E=ONP>\.NZ\\=.R-]L/(/E=6/X=->]3ZZP>H45[^&]>F2F*9?
M_>64OL1?I_/IR>G)>4W/R<ETO7'Z#W:$VY$P@/<\D'R&<;E]5EDQ0GA,FH-B
M,D&H$5Y(REJON+;-?=(A7>YKPKZ(,%^=7ETMI5W;.BXE,%TS\[9>$./. G<^
M,BYS<:7UO92GT->50_X49.RV^S502@>.U=8#Q@MS?\'?V1%UKDG]7Z:K%&:U
MX) XY8%;%0$Y8T!AAP#:8QQHVFMLYE+3SO ,.?#=J!T7C,,A:(=<^0#J_%&
M2V+]C7::3W_@["O^NIBO/Z\FR+1*N5[ML)XB'U?Y]+6]=A'(O"Y)^=:!PKZT
MCAN,]@7:0U7Y T%V$DIR!44$+8DE%0VC8"H6B)$G)4IFPC_'Z>(VVL8-:;N#
MY)-4U4%+H ?Y^KTV:MM41F)^_2W5*3TG]5^3PAQGWCD@;NJD^& @Z-K#Q.1H
MHB])V-975?<B=-R0NP]P-E%B%WW/[F%P$E+>7.D$H8H$5;R%8*4!1[Y\9I9G
M$8<]>'A:BF>PNK!GPUL+1?S_+!DTN56>.THZ:,*[3@C=EM%E2NCG-LJLI1^O
MOWW!^>KP!E-;GC6 :!^C>)BD62PY^D1>=$ 1:&.H_?E-W2*<#H(KH5'LU%J@
MDZ39N0 GADR;C3J"%26!,CE 5%8 C\H+[TQTI75[J:V$=)4&>XJN']X&]A%S
M!S'8Q],XJ^2_F=/:PPD%B5(R:\#:2-NBRPRB=!XDSU'4GB!"M8ZT;E+0U7GS
M(>@X0+"]^P8?Z=_X>3$C7:QJ^Y'-#O<*X_KN#P[8:/9X2],MZ% N#]R<-J>-
M9X\_.GOO)2QM9J9$B1"<TZ 8Q=B$(0-&2JD#%L^">TRZ]S_^8(MR[@^]*QM!
MU:+33,Y.M8[GZW@9YL>X\7Q>?+_ZS+F7?O1'6.:S.]O.!4]NLX?BM*HU&0:\
MK&UAN4&GD#%"?FMCU(KX<7:Y1J"Y8\M&46D/NV.]H5U9.)-IY7DQKUQN.IT0
MO;1#! <E(<5[R&I72MKTBQ1>NIPQI-:9\P<)&M>S&@DDMZ':3&,=P.\6#^>-
M4H*/W,EL(&--,_@0P-F<0"M/Z]NY;'+K#I];"1D9;NT4O6@M]0Z@4],+B_G'
M]2+]_;SY37%1<\4+6')I222U7W;.&1@J%#$9@\VO:-TA8ES(-%#LHJ641\TJ
MUWY_GZ;K:J_?S//TZS2?AMEF[013N'(\0RJ*@>*TBH(R 1*6G&A5\;(;4!YI
MK;CUY>.&?^-N86TT,G*SSCL,_&VZ_OP!9QOYK3Y/OWQ:O)ZO:\QTMOJ<%T9F
M9""EJ@647D"L?2:%*M9*8HU"[R' ]C!9X]BI1@!X"$X-M3$RT%Y-EYCHQQ?]
M;)4-&7T"3+7T(24%03@+GB463=3H<*=#L$=P=/.M'<&DI6(73:3<@1-T9I O
MVF]'S[)W0H),D8,2F>BVVD*,A1DAF'78.ER[0<"XI2)]A&?[:Z0#..TON"NV
MY[DV;OXMG%ST:C;H>>8Z0A+H0051;Q D#TE'AUEJH5WKTZ8A^!C7LS\ 5K?S
M!V/KN .<?\#5>CE-:\S7(YO$<D(A$R1'I"L=0^THD4"J['4QS@;3NA/15D)&
M3CN,CH]%:V6-??WLS;QV')Q^Q0T#9PU[5^=\R$!,I&0@N$!^"PD"'-8&OD9C
M"89'YF\UW+[GJ..!EXP<<_8"J*:ZZ,"*O9W.R=EY22^>KG\):5.BM=D>T(3@
MLA"0:]LN$@YQE&T$CE%PR9PHQC8V9/?1,FZ!9A\N81,]=8JWM_4$>'DQE<-D
MEU%D*#43K62,X++F$+A*Q44,1C6?[_8(32/7XC31_ YPVEL-8V^-[Z?S>4@S
M6G;SBYW=DV=+Z\M E)'5FI18+RU+$"Y)PX6G"%SNM"/>?79_:-A?<8MV4NS
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MA6QP<!HM4[9YR]Z[5/0$EGVU^X";LH>HQW9,/DZ_K3\?D3QRE<D% Z9$G40
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M#8V4",J7FD-@ :S"XC6*J'C?F9?3I1TW;IP20D\QWSR!^KI9I<-@)?H<G8A
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MP:EVY HM'M8.-C-+7O6MY&F"YO6.4ZS.A\TV7%_OCNL6M1.K3<Z#YJR6#&(
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M$M#MS[C#M_\[_*)^B>3/_/N__3]02P,$%     @ =XEN55!?+N_""   ABX
M !X   !P:6YN86-L96)A;FLM8W!I86UE;F0Y=&]L;RYH=&WM6N%3X[82__[^
M"C7T7;F9Q+&=!$+@F F)KZ0-@0F^8_JIH]ARHL.Q_"0E(?WKWTJR(2$! G1*
MX+W>E#ODE7:U^NUO=V4?_=0^;_E_7'AH),<QNOAVTNVT4*%4+E]56N5RVV^C
M4_^LBZJ6[2"?XT1025F"XW+9ZQ50821EVBB79[.9-:M8C _+?K^LEJJ68\8$
ML4(9%HZ/U C\)#@\_M?13Z42:K-@,B:)1 $G6)(0301-AN@J).(:E4J95(NE
M<TZ'(XE<VW71%>/7=(K-<TEE3([S=8[*YO>CLE9R-&#A_/@HI%-$PR\%&@:!
M>Q#:;K!7(U4<U?!^=0]'MH/W2-4-:X,_'3"R#.)FCI#SF'PIC&E2&A&EOW'@
M6O5Z*@]G-)2CAF/;_RXLBV(^!.D!DY*-&[;E.""<XC"$795B$DD8LUT8D^1&
MEG!,ATGCQT1(&LW-$$U"V 9(56JIA+4CEDC8!@>SS#^-=:LV+BEV:O?5.E9U
M<4Q[,Q]<L"4 Y80OF5*RK3M3<G4!BQEO[-CZOT/UI!3A,8WGC5]\.B8"]<@,
M]=D8)[\4!:"E) BGD1$4]"_2T([1O\Z,9ZNP3DP3DGO:<6O@VUZGYY^BYIG7
M:\/_/O+/4=_[?M[]WNG]BEI]K]WQ4?>\V4/-7_N>IT26_?2PAVS+73V:-3YR
MK;VGCZOR)A[2Z/-/.Y?H^6Y"NW)$!?JT4ZD>-B%R0A4]^K?/",8U#" <:2(9
MP@*Q"%V25)+Q@'#D'A1-( [F""<A&A Y(R1!K6]G)UZ_V^RUT<5ILW_6;'G?
M_$ZKV;U$G5[+*B*,?)(D1 A"4,!XRCA6+()VM>(3QCF;$6ZL*.JE+SJ]7K/5
M]=!)L_?[\@(#G%PKKEA:2(Z(V5,7MI0O96V.B>I*X+A6=0TFJML=-GVOU?'!
M[Y]V:O7#37?O6+65W;_+D,B!I!&D$&' L QJ.<*0=0B7F":H3Z8LGBHTM4"
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M(F2>AEX2()75WKA2LRI;%!^;YI"'H:?RI3"DI :5?W?I9[0H'4.CJ27PF$W
M>A#YEBC?<AHH[[:PT, E-X&2A,<_UXLUVR["KHHJW^Q26-$[Z?CMIJYK0J+R
MND[B4&6HE54^@GD$ _U%5 0X1D"*',008 XC#J>GLGH$Y2+:K7Z^?3K @HIG
M-+;U=\]XNK%UWXKQ0/LCC&>"3!W40D"&H8E C!)0OT"*@(PWW,56<YT^Y/5<
M]TP&6P4\4)C]4L2#1]Z6Q5:(9X'%BIHKDKGN/93S<IY9J+SP$/PX5,_OR S'
M,0H4AV7^7BJ@J13H<C* "HYB;BJO.$0S"KG:U-5%W9Z(R> 'H$97UV!!EQ)(
M^ASEQNI+.<6/J4[T^KFX)R 4AT9XJDK)J*@>TG'*A.['BIFRS>_P*A^EN*ML
M7W'75&2FKG8,CZ6JG ^SOEAGLRA2# )->I8/]1WS;?M<O$.8&"GPI7BNIF9]
MFAJ)2-98D)L4D$(4-H()YZ8YSP1-9Y)D9*7H5L%2=2Q!/%%F:YBR"61P.H:6
M6HMA]+.K$K,IE'3Q%!&2E4M8L$3W+#'$B+%B4\#5;.O@0^"MNGUX\]<6O(IV
M\FJ7&N(S+2AP2@J@>/CD[AW2_M_OZ_I&"<ZQ:WN5@U+%=N#/@]9F4VK[&CC
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M,2YH=&U02P$"% ,4    " !WB6Y5^>NWK'T(  #J,   %@
M@ &W"   83(P,C)Q,RUE>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( '>);E5-
M3YBM.P4  -$:   6              "  6@1  !A,C R,G$S+65X:&EB:70S
M,C$N:'1M4$L! A0#%     @ =XEN51_W8<HNA0$ #UX1 !$
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#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
